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ABSTRACT 
Background. This body of work is intended to serve as a proof of concept for the 
application of supramolecular chemistry in drug development. More specifically, 
this work is designed to evaluate crystal doping by recrystallization from 
supercritical media. The rapid nucleation and growth implicit to supercritical fluid 
based crystallizations were tested in doping drug crystals with structurally related 
impurities. The ultimate motive was to tailor the physicochemical properties of 
active pharmaceutical ingredients (APT) through crystal doping. This, in tum 
provides the ability to tie functionality to APl 's at early stages of drug discovery 
and synthesis. Methods. The rapid expansion of supercritical solution (RESS) 
process was evaluated for these purposes. Pure and co-solvent modified 
supercritical fluid C02 was used as the recrystallizing solvent. The supercritical 
region investigated for these studies included pressures from I 07 l-9000psi and 
temperatures ranging from 31-100°C. The pharmaceutical solids studied included 
a-naphthalene acetic acid, aspirin, benzoic acid, caffeine, chlorpropamide, 
indomethacin, naproxen, phenytoin, piroxicam, salicylic acid, theobromine, 
theophylline, tolbutamide and urea. For comparison purposes, model 
chlorpropamide+urea system was also recrystallized from three liquid organic 
solvents using evaporative crystallization. The composition, morphology and the 
energetics of the crystals thus produced are characterized utilizing techniques such 
as microscopy (polarizing optical, SEM), thennal analysis (DSC, mDSC, TGA and 
thennomicroscopy) and HPLC. Results. Selective extraction and a reduction in 
crystallinity were consistently seen in all of the drug-impurity mixtures co-
crystallized by RESS process. ln addition, a number of interesting phenomena were 
revealed. These include habit modification, solubility enhancement, particle size 
reduction, eutectic formation, amorphous conversion, hydrate formation and 
polymorph conversion. In viewing each of these phenomena from an application 
standpoint, this work serves as proof of concept for enhancing the physicochemical 
and mechanical attributes of APl's using supercritical fluid crystal doping. 
Comparative evaluation studies indicated RESS to be superior to organic so lvent-
based recrystallizations in crystal doping. In summary, RESS offers great promise 
as a hybrid technique to control both the crystalline and the particle morphologies 
of API's in a single stage. Conclusions. The presence of an impurity in the 
crystallization medium exhibits varied effects depending on the phase in which it is 
present prior to nucleation and its affinity to the host relative to the crystallizing 
solvent. This in turns dictates the rate at which it nucleates and grows in relation to 
that of the host. The domain of effects that these kinetics dictate on one extreme 
includes the fomrntion ofa solid solution or a solid dispersion of the impurity in the 
host lattice. On the other hand, selective extraction of each of the components with 
respect to time can also occur, the extent of which primarily depends on the 
resolution factor of the recrystallizing so lvent. While the former mechanism is 
largely aided by the rapid nucleation and growth implicit to supercritical fluid 
recrystallizations, the latter forms the scope of supercritical fluid chromatography. 
An optimal compromise between these extremes can be reached by utili zing the 
adjustable solvent power of supercritical fluids. 
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PREFACE 
This dissertation is written in the 'Standard Format' as described in the Guide to 
Dissertations Manual of the University of Rhode Island. The entire body of this 
dissertation is organized into five chapters. The dissertation work reported here 
serves as a proof of concept for using supercritical fluid aided crystal doping to 
alter the physicochemical properties of pharmaceutical actives. Chapter one 
reviews the current status of supercritical fluid particle formation in 
pharmaceuticals. The design and process aspects of laboratory scale SCF 
equipment are covered in chapter two. The main body of this dissertation can be 
found in chapters three to five. Investigative supercritical fluid co-crystallization 
studies involving twelve drug-impurity mixtures are excerpted from the appendix 
and reported in chapter three. A more rigorous evaluation of crystal doping was 
performed on chlorpropamide+urea system, which forms chapter four. In a parallel 
study, qualitative phase behavioral and solubility studies that aid in the supercritical 
recrystallizations were performed. Such studies are reported in chapter five. At the 
end of the dissertation, a bibliography, which cites all the sources used in this 
dissertation is included. 
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CHAPTER ONE 
Title: Supercritical Fluid Technologies in Pharmaceutical Material Processing. 
Abstract: Material processing using supercritical fluids (SCF) has been a subject 
of recent interest in pharmaceutical drug development. The potential to integrate 
the synthesis and delivery stages of drug development brought about a wide 
recognition to the technology. Particle formation using supercritical fluid 
technology offers the possibility to reduce the number of unit operations, while 
imparting favorable particle characteristics for downstream processing. Further, 
SCF technology involves minimal usage of solvents, moderate operating 
conditions and provides the ability to continuously process materials under cGMP 
conditions. The technology is rapidly evolving as reflected by the number of 
modified processes reported since its inception in the pharmaceutical realm. 
These include Rapid Expansion of Supercritical Solutions (RESS), Gas 
Antisolvent process (GAS), Particles from Gas Saturated Solutions (PGSS), 
Precipitation from Compressed antisolvent (PCA), Aerosol Solvent Extraction 
System (ASES), Supercritical Antisolvent process (SAS) and Solution Enhanced 
Dispersion by Supercritical fluids (SEDS). The evolution of these technologies 
chronologically with advances in SCF science is addressed in this article. 
Applications of supercritical fluid technology in the processing of pharmaceutical 
solids are also emphasized in this review. 
Key words: Supercritical fluids; Particle fomrntion; Review; SCF Technology; 
Material processing. 
/ 
\ 
I. INTRODUCTION 
While organic solvents are extensively used in the processing of pharmaceuticals, 
there has been a growing concern of late in view of the potential health hazards 
caused by their emissions and residues in the product. Research aimed at 
eliminating or reducing their use is an area of particular interest both to the 
industry and the regulatory agencies. Towards this goal, environmentally safe 
supercritical fluids (SCF's) appear to be logical alternatives to traditional organic 
solvents. 
While significant advances have been made in such fields as extraction, 
ceramics, separation science, polymer processing etc, it was not until the recent 
past [Krukonis I 984, McHugh I 994] that pharmaceutical SCF applications have 
been realized. Since then, the technology has rapidly progressed as reflected by 
the number of SCF related publications and patents in pharmaceutical literature. 
Supercritical fluids have not only established a place in the series of conventional 
GRAS solvents, but also possess other distinguishing features that make them 
attractive in a gamut of pharmaceutical applications. SCF technology accordingly 
holds an immense potential, although the progress to date is limited only to the 
research laboratories. Table I summarizes the various reported pharmaceutical 
applications of supercritical fluid technology. It is the purpose of this article to 
introduce the various SCF techniques evaluated to date primarily in 
pharmaceutical material processing. For purposes of clarity, each of these 
evolving techniques is dealt with in separate sections. 
Table 1. Potential Applications of SCF Processes in Solid Drug Processing 
Application 
Extraction 
Micronization 
Nanoparticles 
Microencapsulation 
Particle coating 
Crystal modification 
Solid dispersions 
Dissolution enhancement 
Amorphous conversion 
Infusion/Impregnation 
Liposomes 
Granulation 
Polymorph separation 
Extrusion 
Polymerization 
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A comprehensive review oforigin, theory, practice and applications is included in 
each section. 
2. BACKGROUND 
Critical point for any pure substance is defined by the temperature and pressure 
coordinates above which no physical distinction exists between the liquid and 
gaseous states. Substances in this region of the phase diagram are referred to as 
' supercritical fluids'. Many thermophysical properties change abruptly around the 
critical point. Due to the very high compressibilities of supercritical fluids, large 
changes in density and therefore solvent properties can be affected by fine 
adjustments of pressure. Supercritical fluids exhibit properties that are 
intermediate between liquids and gases [Tom 1991 b). These unique properties of 
SCF's are utilized in the material processing of pharmaceuticals. For example, 
liquid-like solvent strength can be continuously adjusted over a wide range from Ii 
= 0 to 9 (cal/cc)112 [Perry 1997] by changing the pressure and temperature while 
utilizing gas-like transport properties. Other properties of supercritical fluids as 
applicable to the various SCF techniques will be discussed in their respective 
sections. Supercritical carbon dioxide is the most commonly used SCF for 
pharmaceutical applications as it 1s considered non-toxic, nonflammable, 
inexpensive and has a moderately low critical point. Some of the physical 
properties of supercritical C02 are summarized in Table 2. 
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Table 2. Properties of C02 
Property Value Condition 
Molecular Weight 44.01 
-
Boiling point -78.4°C Atmospheric pressure 
Triple Point temperature -56.5°C 
-
Critical point [31.1 C, 1070.1 psi] 
Vapor pressure 838psi At21 °C 
Dipole moment 0 
-
Quadupole moment 
Acentric factor 0.224 
Compressibi lity factor 0.277 At Critical Point 
Thermal Conductivity 0.0166 W/m-K At 25°c 
Heat capacity J.66xl0' -5 J/Kmol-K At 25°c 
Density 0.47 g/cc At Critical Point 
Solubility parameters 0 to 9 (cal/cc)' 0.5 [3l-70°C, 14.7-14500psi] 
Dielectric constant 1.6 
Polarizability 26.Sx 10' -25 cm' 3 
Diffusivity I 0' -3 to 10' -4 cm2/s 
-
Viscosity 0.02-0.09 cps [37-77°C, 580-5800psi] 
Surface tension -0 
This section introduces the reader to the origin of SCF material processing and 
various modifications thereof. Various processes to be discussed hereunder (Table 
3) can be best envisioned as the different permutations of contacting the solvent, 
solute(s), cosolvent, antisolvent and precipitating the solute thereafter. The state 
of solute prior to the precipitation and the mechanism of solute precipitation is 
what distinguishes one process from the other. In principle, the basic advantages 
of supercritical fluid particle formation such as rapid and uniform nucleation 
remain the same in all the various processes, although the mechanism of particle 
precipitation varies with the process. From a processing standpoint, the simplest 
of the processes (Figure I) involves exposing the solute or a mixture of solutes to 
supercritical fluid for a fixed period of time. Rapid venting of the SCF leaves a 
solid product with enhanced attributes [Sand 1986]. In this process, SCF is used 
as a solvent or as a swelling agent, that may be rapidly removed via 
depressurization. An extension to this process that gives additional control over 
product morphology is called supercritical fluid nucleation [Krukonis 1984] or 
rapid expansion of supercritical solutions (RESS, Figure 2) [Matson 1987]. 
Herein, the solute(s) of interest is dissolved in a SCF at fixed extraction 
conditions. The solution is then rapidly depressurized through a restrictive device 
that is designed to tailor the product morphology. Solute interaction with SCF 
leading to its dissolution/swelling is a primary requirement to process solids using 
the above methods. However, the solubility of most drugs and pharmaceutical 
polymers [Alessi 1997, Subramaniam 1998] in SC C02 is prohibitively low, 
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Table 3. Distinguishing Various Supercritical Fluid Processes 
PROC ESS AC RONYM Solute(x I) Sol\'ent (x2) Antisolvcnt(AS} 
I llap id Expansion of Supercritica l Solu tions RESS Drug or Drug mixture Pure or modified SCF Absent 
2 Part icles from Gas Saturated Solutions PGSS Compressed gas/SCF Melt of Drug/ Drug mix Absent 
3 G as Antiso lvent System GAS Drug or Drug mixture Liquid Organic solvent $CF/Compressed gas 
4 Precip itation us ing Compressed Antisolvent PCA Drug or Drug mixture Liqu id Organic solvent SCF/Compressed gas 
4.a ·Aerosol So lven t Extraction System ASES Drug or Drug mixture Liquid Organic solvent SCF 
4.b ·Supe rcri tical Antiso lvent System SAS Drug or Drug mixture Liquid Organic solvent SCF 
5 Solut ion Enhanced Dispers ion by Supercritical fluids SEDS Drug or Drug mixture Liqu id Organic so lvent SCF, also acts as 
with/without water d ispersing nuid 
Method Mechanism of 1>article precipitation 
RESS Solution o f x I in x2 rapid ly expanded Loss of SCF so lvent power a fl.er rap id evaporation 
PGSS Solution/Dipserion ofx l in x2 rapidly expanded Phase change in x i +Jou le Thompson Cooling 
GAS AS bubbled through solution of x I +x2 Volumetric expansion of solvent by gas 
PCA, x I +x2 sprayed into AS (or) x2 evaporation into AS 
ASES Same as above Same as above 
SAS Sarne as above Same as above 
SEDS x I +x2 and AS nowed through coaxial nozzle Dispersion of x I by AS+x2 evaporation into AS 
Chiller 
Gas Tank 
Figure I. Schematic of Static Supercritical Fluid Process 
Throttling device 
Particle Collection 
Get Tank Eztractor 
Figure 2. Schematic of Rapid Expansion of Supercritical Solution Process 
resulting in poor yields. A further development involved the use of cosolvents that 
modify solubility behavior in supercritical fluids [Dobbs 1986]. The solubility 
enhancement factors although high (up to 500%) with certain cosolvents, still do 
not provide a realistic means to produce mass powders and mixtures on pilot 
scales. Further, the advantages of pure SCF crystallization may be compromised 
with the use of cosolvents. This stems from the fact that solute recrystallization 
occurs from the condensed cosolvent and not from the supercritical phase as 
observed by Larson &King [Larson 1986]. 
Another method of particle formation by recrystallization from pure SCF 
is particles from gas saturated solutions (PGSS, Figure 3) [Weidner 1995]. Unlike 
dissolving the solid in SCF (see RESS), PGSS involves dissolution of SCF in a 
solid melt and subsequent expansion through a restriction device. The process is 
based on the fact that gases have higher solubility and diffusivities in liquids than 
in solids. Thermal stability of drug compounds and significant solubility of SCF 
in the melt are the primary requirements for PGSS. 
However, the poor solubilities of many drug compounds in SC C02 
propelled research efforts towards the use of SCF's as antisolvents. This 
approach formed the basis for gas antisolvent precipitation [Gallagher 1989] 
(GAS, Figure 4), wherein a gas is bubbled through an organic drug solution. 
Large volumetric expansion of the organic solution as a result of dissolved gas 
coupled with solvent extraction by SCF leads to high supersaturation and hence 
solute precipitation. Solubility requirements in this case include (i) miscibility of 
Thr ling device 
Gas Tank 
Particle Collection 
Figure 3. Schematic of Particles From Gas Saturated Solution Process 
_Q - - -
-,·-CL. 
---v- o 
_.,,_ - 0- -
- -~ - - Particle formation 
Gas Tank 
Figure 4. Schematic of Gas AntiSolvent Process 
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organic solvent with the SCF, (ii) negligible interaction between drug & SCF and 
(iii) partial solubility of drug in the organic solvent. Realizing the fact that 
solvent-SCF mass transfer rates are higher from a fine spray than from the bulk 
solvent, modifications have been made that constitute processes like precipitation 
using compressed antisolvent (PCA) [Bodmeier 1995], supercritical antisolvent 
process (SAS) [Bertucco 1996] and aerosol solvent extraction system (ASES) 
[Bleich 1993]. These processes are schematically shown in Figure 5. Herein, an 
organic drug solution is sprayed into a compressed gas (PCA) or a supercritical 
fluid (SAS or ASES) that selectively extracts the solvent and thereby causes 
precipitation of solute. 
With the objective of improving extraction conditions, simultaneous 
introduction of the drug solution and SCF has also been evaluated. This formed 
the basis for continuous PCN AS ES/SAS processes [Figure 6] as well as solution 
enhanced dispersion by supercritical fluids process [York 1995] (SEDS, Figure 
7). In SEDS, the mechanical energy of rapidly expanding gases is streamlined into 
dispersing a drug solution by passing through a coaxial nozzle. This enhances the 
extractive capability of the SCF's, thereby precipitating microparticles with 
desired attributes. 
II 
Organic solution 
Gas Tank 
Figure 5. Schematic of Batch PCAJASES/SAS Processes 
Gas Tank 
0 0 
0 0 
0 0 ° 0 
Organic solution 
Figure 6. Schematic of Continuous PCAJASES/SAS Processes 
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( 
Organic solution 
Gas Tank 
Figure 7. Schematic of Solution Enhanced Dispersion bv Supercritical fluid 
Process 
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\ 3. STATIC SUPERCRJTICAL FLUID PROCESS 
3.1 Mechanism: 
Placing a solute or a mixture of solutes in contact with SCF or a near critical fluid 
for a fixed period of time is shown to affect the solute properties in different 
ways. If the solute(s) has some solubility in the SCF, the process is analogous to 
conventional solvent-based recrystallization with a compressed fluid or SCF 
replacing the organic solvent. Supercritical fluids exhibit a combination of the 
features of liquids and gases. Like liquid solvents, SCF' s allow intimate mixing of 
solutes at a molecular level during solubilization. At the same time, the 
supercritical fluid turns into a rarified gas when depressurized. Owing to the high 
diffusivities, low viscosities and zero surface tension of gases, easy solvent 
removal is implicit with SCF recrystallization. Thus, the process offers a means of 
producing solvent free drugs and drug mixtures. The solvating and swelling 
properties of SCF coupled with their high diffusivities form the basis for this 
process. 
Studies have shown that supercritical C02 has the ability to swell a 
number of glassy polymers [Wissinger 1987, Wissinger 1991, Shieh 1996b, 
Kazarian 1996). Sorption of C02 into an amorphous polymer matrix weakens the 
intermolecular forces that bind the polymer chains together, leading to an increase 
in the molecular motion. As a result, a depression in T g and plasticization of the 
polymer are observed upon C02 sorption. Theoretical and practical considerations 
of the sorption of supercritical fluids and gases in polymers have been extensively 
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dealt with by a number of authors. [McHugh 1994, Sefcik l 986a, Sefcik l 986b, 
Hirose 1986, Wissinger 1991; Wissinger 1987, Condo 1992, Shieh 1996a; Shieh 
l 996b, Kazarian 1997, Kazarian 1996] Pharmaceutical polymers that are relevant 
in this context include PLGA, Cross-linked PVP, Cross- linked PMMA, Cross-
linked sodium startch glycolate, Ammonium glycyrrhizinate, Polyacrylic acid, 
Gelucire 50/02, Compritol 888ATO, Lubrifiant Wl3284, Carbopol 974P etc. 
3. 2 Process: 
The solution of drug in SCF is brought into contact with the polymer for a time 
sufficient to permit sorption into the polymer. Rapid decompression of the 
system results in the loss of SCF's solvent power lead ing to solute deposition 
within the polymer matrix. Also, SCF becomes gaseous and rapidly diffuses out 
of the polymer, leaving a solute laden polymer. System requirements to carryout 
this process include a high pressured vessel capable of withstanding the operating 
pressure and temperature (Figure 1, p8). Mixing of the contents in the vessel 
while under pressure is shown to be important for homogenous infusion [Juvekar 
1994, Muth 2000]. Stirring of the contents in the pressurized vessels has an 
inherent difficulty arising from the moving parts that cause the leaks. This can be 
circumvented by the use of magnetic mixers. Typical operating conditions are T= 
-55 to 60°C, P=600-4300psi, t= l 5-300min, v=0.01-5 ft/sec [Lindsay 1992]. 
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3.3 Applications: 
Typical applications utilizing this process employ the impregnation/infusion of 
solutes in porous supports, forming intimate mixtures of actives & excipients, 
solid dispersions, polymerization and micronization. Reported applications of thi s 
technique are summarized in Table 4. As can be seen from the table, a number of 
small drug molecules have been impregnated into porous supports and polymers 
using the above technique. A preferred drug molecule is one that shows some 
degree of solubility (at least 0.1 wt%) in the SCF. Also, some degree of 
interaction between the SCF and the polymer is necessary for polymer dilation (at 
least 2 vol%) [Berens 1989]. Partitioning of the solute in a swollen polymer is 
controlled by adjusting the concentration of solute in SCF and the rate of venting. 
The degree of loading and the form of the resulting mixture therefore depend on 
the temperature (T), pressure (P), mixing conditions, time of exposure(t), and 
venting rate(v) as well as the properties of drug, SCF and polymer discussed 
above. 
The degree of success achieved using this technique is limited, 
considering the poor interaction of many pharmaceutical compounds and 
excip ients with SC C02. While a compound 's solubility in SC C02 limits the 
level of loading that may be achieved, it is not the only factor in determining the 
efficacy of the process. 
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Table 4. Applications of the Sta tic Supercritical Fluid Process 
Comlit io11s Conl flc f 
Rr rrrcncr Ai:rnl 
_J Subslrfltc{s) 
-f ,. :::r p Ti mr Appliu tion Cata lase l rLGA WC I 2940psi JO mm Solidd1spersionorcatalasc Howdle 1998 
in PLGA,, Drug loading• l-50-/e 
Dimenhydnnatr IOxyethyla1r lintaralc+ 20"C 1500psi lOmin Gnmula11onforiablc1m11 Liodsay 1992 
MCC+Cakium S1carn1c 
Dimenhydnnate IEh1ytene Glyeol+Copolymcr or 20"C 760psi 
'"' 
Tr111nsdcnnal applicaiion Lindsay1992 
E1hylcncandPropylencOx1dcs 
Nimesul1de Crou-linktdPVP 60'C 2350psi 
'"' 
lmp1egna1ion, Loading""25Y• Carli 1999 
Acyclovir Cross-hnked PMMA SO"C 3230psi 
""' 
Impregnation, Loadmg• 2 1% Carli 1999 
Ketoprofon Cross- lin\.. tdPVP 60'C 2350psi 025hr l1npregna1ion, Loading-25-Je Carli 1999 
Pirox1cam Cross-lin\..edsodium- 60'C 2350psi 
'"' 
lmp<cgnation, Loading• l5.,. Carli 1999 
:::; I st:m:hglycolate 
Cimcudine Acrylic acid cross-linked· 60'C 2350psi 
'"' 
Impregnation, Loadmg- 20-/e Carli 1999 
withallilictstersorsucros.e 
l'rogeslerone IPolyumhM<.Polyrnboo"' 4''C IOllps1 
'"" 
Controlled Rrlease, 8% Loadmg 
alpha- tocophcrolacct:uc Atrosi1972 40'C 4410psi Uhr lmprtgnationup102s•/o 
Piroxicarn btta-eyclode>Ctnn 150"C 2 175ps1 
'"' 
12.Smol/molinclusionor 
Berens 1989 
Magnan 1996 
Van Hecs 1999 
Piroxicam in Cyclodcxtrin 
Seopolan11nc NS NS NS NS Impregnation Sand 1987 
l'LGA 22°C 800ps1 72hr Porous sponges Moouty 1996 
rvc PMMA 40-80"C 3600psi 4h' llcterogenousPolymcrizauon Muth 2000 
•CO: is the SCF used m all the abo1 e reor1td studies 
Recent reports have shown that the technique is amenable to hydrophilic drug and 
polymer processing [Zia 1997, Lindsay 1992, Howdle 1998]. Specific 
intermolecular interactions that come into play need to be addressed for the 
system under study in evaluating this process. 
4. RAPID EXPANSION OF SUPERCRITICAL SOLUTIONS (RESS) 
4.1 Introduction : 
Supercritical fluids exhibit remarkable solvent properties compared to gases. In 
the vicinity of a fluid's critical point, solvent strength was found to be a very 
sensitive function of pressure and temperature. Increased solvent strengths of 
SCF's compared to gases are attributed to the liquid-like densities of the fluids 
[Kumar 1988]. C02 for example, has a density of 0.47 glee at its critical point, 
close to the density of Hexane (0.66g/cc at 25°C) [Dixon 1997]. On the other 
hand, SCF's also exhibit gas-l ike behavior (eg. high diffusivity, low viscosity and 
zero surface tension) [McHugh 1994]. These intermediate features of SCF's have 
been utilized in a variety of applications including RESS. 
4.2 Mechanism: 
In RESS, the solute of interest is dissolved in a supercritical fluid. The high 
solvent power of the SCF allows formation of a homogenous solution. Nucleation 
of solute is then induced by rapidly reducing the solution density through 
expansion to atmospheric conditions. A rapid decrease in solvent strength results 
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in high supersaturation that leads to very high nucleation rates [Mohamed l 989b). 
The time for crystal formation and growth is very limited (typically 10·5 to 10-6 
seconds) resulting in very small particles [Debenedetti l 993b, Turk 1999). In 
add ition, the rapid decompression of SCF generates mechanical perturbation 
within the solution that travels at the speed of sound. Consequently, very uniform 
conditions are reached within the nucleating media. Narrow size distributions 
typical of RESS processed materials is attributed to the above mentioned behavior 
[Tom 199lb). Thus, RESS provides a means of forming microparticles with a 
unimodal particle size distribution. 
The morphology of the particles formed essentially depends on the phase 
of solution from which the so lute is precipitated. The thermodynamic factors that 
control the phase behavior of solutions are pre-expansion temperature and 
pressure (T,P), solution composition(x) and post-expansion temperature and 
pressure. While solute vapor pressure behavior and chemical interaction dictate 
solid solubility in the SCF, solvent physicochemical/transport properties need to 
be considered for precipitation. Preliminary solid solubility studies in the SCF 
not only help to choose the extraction conditions, but also identify the conditions 
ideal for solid precipitation. Researchers have attempted to correlate product 
morphology with the T,P,x conditions of the system and form a theoretical basis 
for particle growth [Mohamed 1989a, Helfgen 2000, Tom JW 1991b). Most of 
such attempts to date have only resulted in qualitative models. To this end, 
density of the solution from which precipitation occurs, the time scale allowed for 
t9 
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precipitation and growth, as well as agglomeration were shown to have a major 
effect on particle morphology. A comprehensive model should take into account 
the combined effects ofT,P,x at each stage of RESS process on the above factors. 
Among the process variables that play an important role in particle 
tailoring, the geometry of the restriction device through which expansion occurs 
merits a special mention. A restriction device is designed to support the large 
pressure drop that occurs across it, while maintaining suitable conditions for 
precipitation. Various configurations have been evaluated to date, for example 
capillaries, nozzles, laser drilled discs and valves. The Joule-Thompson cooling 
effect, observed as a result of large volumetric expansion in tum produces a drop 
in the temperature of the nozzle. This leads to supersaturation and premature 
precipitation of the solute. Plugging of nozzles that is commonly observed in a 
continuous RESS process results from premature precipitation of solutes in the 
expansion line. The restriction devices are therefore heated to prevent clogging. 
Typical aspect ratios of the restriction devices evaluated to date are in the range of 
6 to 20, with orifices from 20 to 1600µ in diameter. The effects of different 
geometrical configurations of the restriction devices on the morphology of 
particles have also been investigated [Matson 1987, Mohamed 1989b, Kim 1996). 
As a result of these studies, theoretical models addressing the fluid dynamics 
during expansion and particle growth therein are developed [Matson 1987, Lele 
1992, Debenedetti l 993a]. 
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Poor yields owing to the low solubility of many pharmaceuticals in SCF' s 
is a major limitation of the RESS process. Use of co-solutes and co-solvents to 
improve the solubility of solutes in SCF' s have been investigated. Tavana and 
Randolph [Tavana 1990] have shown that the solubility of salicylic acid in SC 
C02 can be enhanced by an order of magnitude in the presence of a more volatile 
co-solute like benzoic acid . Similar observations were reported by Kurnik [Kurnik 
1982] and Pennisi [Pennisi 1986]. The enhancement of solubility has been 
attributed in all these cases to the vapor pressure effects of the more volatile co-
solute. For further details about solubility of mixtures in supercritical fluids, the 
reader is advised to refer to a recent review by Lucien and Foster [Lucien 2000]. 
Various research groups have evaluated the design and synthesis of COi-philic 
polymers and surfactants that aid in the solubility enhancement of solutes in SC 
C02 [McClain I 996, Ghenciu EG 1997, Ghenciu 1998, Yazdi AV 1997, Super 
1997]. To date, the success with such enhancement aids has been marginal, 
although the potential for such research using pharmaceutical polymers and 
surfactants is tremendous. 
The practical and theoretical aspects of using co-solvents to enhance solid 
solubility in SCF's (for the most part SC C02) have been extensively evaluated by 
a number of researchers [Dandge 1985, Wong 1986, Dobbs 1986, Larson 1986, 
Ting 1993]. Various mechanisms of solubility enhancement by co-solvents have 
been postulated (Ekart 1993]. A co-solvent may enhance solute solubility through 
specific chemical interactions like hydrogen bonding, complexation and charge 
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transfer. Physical interactions with the solute like dipole-dipole, dipole-induced 
dipole and induced dipole- induced dipole may also lead to solubility 
enhancement. Further, a co-solvent can modify the physical properties of the 
solvent such as dielectric strength, polarizability, density, etc and thereby cause 
solubility enhancement. Tavana et al have demonstrated a systematic approach 
for screening co-solvents with two model compounds griseofulvin and digoxin 
[Tavana 1989]. The co-solvents are ranked based on the GC retention time with 
SCF+co-solvent being the mobile phase and solute as the stationary phase. Given 
the restrictions on the choice of organic solvents in pharmaceutical processing, 
co-solvent use in RESS processing has been very limited. Jn addition, the 
presence of a co-solvent can sometimes adversely effect the product 
characteristics by condensing in the precipitation vessel [Larson 1986]. Jn such 
instances, recrystallization occurs from the condensed co-solvent and not from the 
supercritical phase, thereby losing the very attributes of RESS [Larson 1986, 
Mohamed 1989b]. It is therefore important to select pre-expansion conditions that 
allow precipitation from a single fluid phase. Also, pre-expansion temperature and 
conditions in the precipitation vessel should be chosen such that the co-solvent 
stays in vapor phase after expansion. With proper choice of conditions, the 
removal of SCF and co-solvent should leave solid dry particles within the 
precipitation vessel. This however, is not an easy task considering the complex 
phase behavior exhibited by a three component SCF-solute-cosolvent system. 
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RESS has been evaluated in many of the processing areas where organic 
solvents can be replaced by a SCF. The pivotal role of solvents in crystallization, 
forming intimate mixtures of different substances that requires mixing at a 
molecular level, coating, etc requires no special mention. SCF solvents not only 
aid in serving these objectives, but also possess other distinguishing features that 
make the RESS process unique. One of the major advantages in RESS is the ease 
of solvent removal, in contrast to solvent evaporation. While the former is 
triggered by the thermal perturbations, the latter occurs due to mechanical 
decompression at supersonic velocities [Debenedetti l 993b]. The primary 
requirement for a solute to be processed by RESS is a significant solubility in 
SCF (>0.5 wt%) [Alessi 1996). Among the pharmaceutical class of compounds, 
steroids with a basic perhydrocyclopentanophenanthrene ring have shown 
significant solubility in SC C02 and are particularly suitable for RESS processing. 
4.3 Process: 
The basic components of a RESS apparatus consist of a pump to deliver the SCF, 
preheater, extraction vessel, preexpansion chamber, throttling device and a 
precipitation vessel (Figure 2) . Liquid C02 from a tank is fed to the preheater at a 
controlled flow rate using the pump. Typically, an air driven pump is used to 
pressurize the C02 prior to delivery to the preheater. The function of the preheater 
is to bring the temperature of the pressurized liquid to the supercritical region. 
The preheater is typically a lengthy stainless steel tube immersed in a temperature 
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controlled bath. Pressure and temperature in the preheater are read using pressure 
transducers and resistive temperature devices (RTD) that have a sensitivity of 
0.05-0.1 %. SCF from the preheater then flows into the extraction vessel that 
contains the material to be processed. Packing the extractor with alternate layers 
of glass wool and solute has been shown to improve extraction efficiency by 
providing better fluid contact with solute. Alternatively, a mixing device may be 
used that agitates or stirs the contents of the vessel. The pressure and temperature 
in the extractor are recorded using a pressure transducer and RTD respectively. 
The saturated solution from the extractor flows into the pre-expansion chamber 
that has independent temperature control and a line connecting it to the preheater. 
The saturated supercritical fluid solution can be diluted with fresh solvent from 
the preheater, allowing control over the composition of the solution prior to 
expansion. Interfacing a HPLC system at this point helps determine the exact 
composition of solution prior to expansion. The fluid from the pre-expansion 
chamber is rapidly expanded through a heated restriction device into the 
precipitation vessel. For the most part, the effects of post expansion pressure and 
temperature on product morphology are inconclusive or relatively insignificant. 
Excepting situations where post expansion conditions have been shown 
significant [Mohamed 1989a], or where fluid recompression costs are a factor, the 
precipitation vessel in most instances is maintained at atmospheric conditions. 
Typical extraction conditions are T=40-80°C, P=2000-5000psi . The pre-
expansion temperature is generally maintained at about 50°C higher than the 
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extraction temperature to prevent premature precipitation, which in tum leads to 
plugging of lines. Solute throughput in a RESS process depends on its solubil ity 
in the supercritical fluid and is typically up to 1 g/hr with so lvent flow rates 
ranging between 20-80 standard liters per hour [Tom 1991 b). 
4.4 Applications: 
One of the potential applications of rapid expansion of supercritical solution 
process is in the area of particle size reduction. The RESS process, in principle, 
offers the advantage of growing the crystals to a desired size unlike most other 
high energy comminution techniques like wet milling, spray drying etc. Most of 
these processes commonly involve energizing the particles to bring about size 
reduction. The implications of imparting energy into the system are pronounced 
when dealing with proteins, peptides, and other unstable compounds. 
Accordingly, particles generated using RESS process frequently retain their 
crystallinity and do not carry static charge. Particles with various morphologies 
like microspheres, needles, fibres, dendrites, etc. were produced by changing the 
process conditions. Production of micron and submicron particles with a narrow 
size distribution has been demonstrated with a range of compounds (Table 5). A 
universal model relating process conditions to product morphology is yet to be 
developed, but definitive trends have been observed in each of these compound 
specific studies. Agglomeration of particles was prominent, as observed with 
cyclosporine [Henriksen 1997] and lovastatin [Mohamed l 989b ], when the 
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Table 5. Summary of RESS Studies 
[\gen I ]SCF Ex1rac1ion Pre-ex 1rnnsio n Application Average Additional Co mments Hcfcrcncc 
T("C) l'(psi) T("C) P(psi) Diameter 
rbeta-carotcnc l o, 70 4l00 NS NS Micronization 0.3u C02 reacted with drug & formed an cpoxide Chang 1989 
beta-carotene I C2H~+ 70 4l00 NS NS Micronization 0.5u Agglomeration reduced by Ch:mg 1989 
Toluene prc:cipitationintogclatin.'Twcen 80 
bc1a-cstradiol co, 55 5070 NS NS Micronization <I" McHugh 1994 
Griseofulvin CHF1 60 2600-3200 60-150 2600-3200 Micronization \.lu Long needles 10 quasispherical panicles Rcverchon 1995 
Mcdroxyprogcs- co, 30-40 2200 40-60 NS Micronization <S" Alessi 1996 
acetate 
Lovastaun CO!+ 40 5500 NS NS Micronization 10-SOu Recrytallized from cosolvent Larson 1986 
N I McOH °' 
Nifedipine co, 70 8700 NS NS Micronization I-Ju Stahl !987 
Progesterone co, J0-40 1800-3600 40-60 NS Micronization 4-8u Large dendriies 10 micron particles Alessi 1996 
Sa licylic acid co, 40-60 2940-3800 60-140 3800 Micronization 1- IOu Ncedles,Sphcrcs,Nctworl: Rcverchon 1993 
Testosterone co, 60 5150 NS NS Micronizallon 2-Ju McHugh 1994 
l-IYAFF-11 co, 60-80 2940 Micronizatmn < IOu Microsphcrcs to aggregates llencdeui 1997 
L· PLA 1co, 55 3675 70 NS Microniza11on 4-IOu Needles to Microsphcrcs Tom 1991a 
L·PLA ICOz"'" 55 2900-3400 75-120 NS Microniza1ion 10-25u Micropa.rticlestodcndritcs Tom 1991a 
Table 5. Summary of RESS Studies (Cont'd) 
A gen I SCF E:tlraclion l' rc-cx1rnn!iOn A11plicalio n Average Adlli1io1rnl Commcnis H.dcrcncc 
T(•C) 1'(11.s i) T(OC) P(psi) Diameter 
L-PLA CClF, 
" 
1700 70-83 NS Micronization 2-20u Needles to m1crosphcrcs Tom 1991:1 
!'GA co, 
" 
2650-3000 82 NS Microniza11on \0-20u Ovals&Rcctanglcs and Needles Tom 1991a 
Poly(mcthylmcthacrylatc) CICl-IF2 70- 100 2000-3000 11 0-130 NS M1cronizauon NS Powder to Fibre prcc1p1tatcs Lele 1992 
l'olycaprolacto11e CICl-IF1 100 2000-3000 90-145 NS Micronization 1-.Su Spherical particles to fibres Lele 1992 
l'olystyrcne/Poly(mcthyl CICHF2 75-100 1500-4000 110-130 NS Micronization NS Powder to Fibre precipitates Lele 1992 
mcthr1crylatc) copolymer 
"' ILov.Slot;o+DL- PLA C02 
" 
2900-3700 75-85 NS Microencapsulation 10-\00u Load1ng•27% ITom 1993 -.J 
Naproxcn+L-PLA co, 60 2750-3 100 90-140 NS Microencapsulation 1·15u Agglomerates,M1eroparticles,Microsphercs Kim 1996 
Carbamazcp1 ne co, 35-100 2000-SOOO NS NS Polymorph conversion <)" alpha 10 gamma form. Gosselin 2000 
11henacecin co, 60 8820 NS NS Disslnenhancement 
'" 
20-30fold1mprovemcnt Loth 1-11986 
Phenaceun CJ-IF1 80 7350 NS NS Disslncnhancement 10" Sameasabo"'e Loth 1986 
S11gmastcrol co, 3S 1450- 2030 I00-150 1450-2030 Amorphous Conversion O.OS·0.2u Amorphous globes to Whiskers Ohga\.:i 1990 
llenzo1c acid co, 45-70 1470-3700 NS NS Crystal modification I0-20u Change in crystal habit Robertson 1996 
Cyclosponne co, 3S 3000 40 NS Nanopanicles 80mn Prec1p11ated i1110 Twccn80+i'hospholipid. Henriksen 1997 
Lovasrnun co, 7S SS()() 105-135 NS Nanaopan1clcs 200nm Dcaggrega1ed by somcallon in Heptane !Mohamed 1989b 
particle size was in the nanometer range. Deaggregation of nanoparticles by 
precipitating into a surfactant is a solution, although it involves further 
downstream processing in an otherwise single-step RESS process. 
The potential of RESS micronization in dissolution rate enhancement has 
been verified by Loth and Hemgesberg [Loth 1986]. Twenty to thirty-fold 
enhancement in aqueous dissolution rate of RESS processed phenacetin is 
observed after it is blended with aerosol R972 or mannitol. The majority of the 
compounds produced by RESS have crystallinity unaltered as a result of 
processing. Exceptions are few where the process has resulted in a change of 
crystallinity of the solute. Ohgak.i et al produced stigmasterol particles with varied 
morphology from an10rphous globes to whisker-like crystals [Ohgaki 1990]. 
While a change in the crystal habit of benzoic acid is claimed in the study by 
Robertson J et al, further characterization remains to be done before any definitive 
conclusions can be made [Robertson 1996]. ln a more recent study, Gosselin PM 
et al have demonstrated the controlled polymorphic conversion of carbamazepine 
by RESS process (Gosselin 2000]. RESS as such can be potentially used in 
cleaning up polymorphs by utilizing the selective extraction capabilities of SCFs. 
Efforts to understand the mode of particle growth from supercritical fluid 
solutions are still ongoing and involve an interplay of the complex SCF phase 
behavior and the SCF fluid dynamics during expansion. 
Another area of potential RESS application is in the microencapsulation of 
drugs within polymeric matrices for controlled release applications. Polymers 
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studied in RESS include poly ((L+]-lactic acid) (L-PLA), poly(D,L-lactic acid) 
(DL-PLA), poly(glycolic acid) (PGA), polycaprolactone, poly(methyl 
methacrylate), styrene/methyl methacrylate and polystyrene/poly(methyl 
methacrylate) block copolymer. Polymers are selectively extracted by SCF's with 
the lower molecular weight fractions solubilizing faster than the higher end. It is 
therefore important that the polydispersity of the polymers is kept to a minimum 
to produce identical microspheres throughout the process. Initially, the polymer 
and the drug are screened independently to select appropriate conditions for 
microsphere format ion [Tom 1993, Kim 1996]. Coprecipitation of drug and 
polymer is then carried out with an optimal balance of process conditions to form 
microparticles or microspheres. A complete understanding of the 3-component 
phase behavior is necessary to prevent independent precipitation of solutes. 
Microcapsules (10-100µ) of lovastatin needles embedded in DL-PLA have been 
produced [Tom JW 1993]. The authors proposed that the readily so luble 
lovastatin was extracted first and then acted as a nucleating . site for the later 
precipitating polymer. Similar results with a better dispersion of drug within 
polymer were reported for pyrene and naproxen in L-PLA [Tom 1994, Kim 
1996]. 
In comparison with the conventional solvent evaporation and coacervation 
techniques of solid formation, RESS offers an effective means of producing 
micron and submicron particles with unimodal size distribution. However, the 
limited solubility of many pharmaceuticals in the most widely used SCF viz. C02 
29 
I' 
restricts its application to a few low molecular weight lipophilic compounds. 
Also, theoretical understanding of the process is limited and further complicated 
by the introduction of a third component such as a co-solvent or a polymer. Future 
research should aim at identifying potential approaches to improve solute 
solubility in SCF and generalize the effect of process conditions on RESS product 
morphology. 
5. PARTICLES FROM GAS SATURATED SOLUTIONS (PGSS) 
5.1 fntroduction : 
The solubility of solid solutes in SCFs and vice versa have been explored in RESS 
and the basic supercritical fluid processes discussed above. Considering the 
scarcity of interaction observed leading to low solubilities and poor yields, a 
logical alternative is to exploit the solubility of SCFs in solid melts (liquids). This 
approach forms the basis for yet another particle formation process called PGSS. 
The solubility of SCFs in liquids is about three to four orders of magnitude higher 
than the typical solid solubilities in SCF [Weidner 1996]. Accordingly, the 
product yield of PGSS process is significantly high in comparison to poor RESS 
throughputs. Also, the fluid consumption in PGSS is considerably reduced 
compared to RESS. A distinguishing feature of PGSS, in contrast to the other 
SCF techniques of particle formation is the complete absence of co-solvent use. 
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5.2 Mechanism: 
The schematic of a typical POSS process is shown in Figure 3. In POSS, the 
solid(s) to be processed is melted to form a single liquid phase prior to saturation 
with a compressed gas or a supercritical fluid. The pressure and temperature 
conditions of the SCF are chosen such that solid melt is highly saturated with 
SCF. The highly saturated solution of SCF-solid melt is then rapidly expanded 
through a restriction device, similar to the one described in RESS section. Rapid 
expansion causes precipitation of a dry powder via two different mechanisms. 
Due to the temperature drop of the solid melt and the high supersaturation caused 
as a result of rapid expansion, solid micron particles precipitate in the collection 
chamber. Compounds with negligible solubility in SCF, a low melting point, 
thermal stability and sufficient solvent strength for the SCF are reported to be 
most suitable for POSS processing. 
The solubility of a compressed gas in a liquid (or a solid melt) depends on 
the pressure, temperature and physicochemical interactions between the gas and 
the liquid [Martin 1993). With proper choice of pressure and temperature 
conditions for the system under study, up to 50% by weight of compressed gas 
can be dissolved in the solid melt [Weidner 1996] . Preliminary solubility and 
phase behavior studies of the compressed gas in drug or drug-excipient mixtures 
are critical to the selection of proper conditions. A general rule of thumb is to 
start at the liquefaction conditions of the drug/ drug mixture that result in the 
fonnation of solid drug particles, devoid of gas after expansion. The pressure of 
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the compressed gas has varied effects on the liquefaction temperature of the 
compound(s). While static pressure overhead causes melting point elevation, 
dissolved gas in the solid leads to a drop in its melting point. The combined 
effects of these competing factors on the liquefaction temperature should be 
evaluated as a function of pressure, prior to choosing the saturation conditions. 
To date, studies on the solubility of compressed gases/SCFs in 
pharmaceutical solids are very limited. Also, understanding of the relation 
between the physicochemical properties of compounds and their solvation power 
for compressed gases is rather primitive. Within the same chemical class of 
polyethylene glycol polymers, Weidner et al have shown that the solubility of 
compressed C02 is practically independent of the polymer molecular weight 
[Weidner 1996]. Reported studies using a divergent class of chemical compounds 
(Table 6) support the theory that the properties of a compound have a weak 
influence on the SCF solubility, often outweighed by the P,T effects of the 
process. The PGSS process involving dispersion of a compressed gas in a solid 
melt is also shown to form powder particles [Mura G 1995]. A clear 
understanding of the solubility influence on product morphology remains to be 
established. 
5.3 Process: 
The basic components used in producing particles from gas saturated solutions are 
a pump to pressurize carbon dioxide, a saturation vessel capable of withstanding 
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Table 6. Summary of PGSS Studies 
Agcnl SCF Co nditions Measured A ppli ca tio n Mean lncma rks 
T('C) P, psi particle size 
Felod ipi ne co, ISO 2940 Dissolution Enhancement 42u Improved after mixing with lac1osc 
Fclodipine+PEG4000 1co, 60-150 2575-2800 Solid dispersion NS Dissolution rate improved 13 .5 times 
Fcnofibratc lco, 65-80 2800 Dissolut ion Enhancement 7-32u Agglomeration 
t3 I Fcnofibratc+PEG4000 co, 65-80 2800 Solid dispersion NS Agglomeration 
Nifcdipine 1co, 175-185 1470-2940 Dissolution Enhancement I Su Porous pan iclcs;Dissln rate increased 
Nifcdipinc+PEG4000 1co, 50-70 1750-2800 Solid dispersion <IOOu Dissolution rate improved 9 times 
PEG's 1500-35000 ICO, 45-70 1470-3700 Miconization 170-370u Fibrcs,Spheres,Spongcs 
Phenacetin ICIF3C 141 600 Micronization Su Homogcnous powder 
high pressures and temperatures, a restriction device and a collection vessel that is 
temperature controlled. Pure drugs and drug mixtures are melted by maintaining 
the saturation vessel at the liquefaction conditions of the solids. Addition of a low 
melting component may reduce the melting temperature of the other 
components(s), which allows use of milder PGSS conditions. Sencar-Bozic et al 
demonstrated this phenomena using PEG 4000 to reduce the melting temperature 
of nifedipine [Sencar-Bozic 1997]. The saturation vessel is maintained at the 
liquefaction conditions of the solids, corrected for the effects of compressed gas 
and other components on melting temperature. Compressed C02 is pumped into 
the saturation vessel, which dissolves or disperses in the solid melt. The gas 
saturated solution in the saturation vessel is rapidly expanded through a restriction 
device into the collection vessel. The drop in temperature and the supersaturation 
caused as a result of rapid expansion allows the formation of sol id drug particles. 
The morphology of the particles formed depends on the location and time scale 
over which particle congealing occurs. Particle growth and agglomeration occurs 
if the decrease in temperature across the restriction device is insufficient to 
congeal the particles at the tip of restriction device. In such instances, the pre-
expansion conditions may be modified by the introduction of fresh SCF to the gas 
saturated solution. 
Typical operating conditions of the PGSS process are: Saturation 
temperature= 40-200°C, Saturation pressure= 1500-4000 psi, C02 consumption 
=O. l-0.8Kg gas/ Kg of solids processed. Powder processing using PGSS has been 
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demonstrated both in a lab scale setup processing 200-400g of solids [Weidner 
1996] to pilot scale designs producing 1000 Kg solids/hr [Mura 1995]. 
5.4 Applications: 
Reported applications of PGSS process are in the grinding of difficult-to-
comminute PEG polymers, micronization of drugs, formation of solid dispersions 
aimed at improving aqueous dissolution rate of hydrophobic drugs, etc. (Table 6) . 
Weidner et al have processed polyethylene glycols with molecular weights 
ranging between 1500 to 35,000 and formed unimodal microparticles with 
different morphologies, such as fibers, spheres and sponges by varying the 
process conditions [Weidner 1996]. Micronization of phenacetin to produce 
homogenous 5µ particles has been demonstrated by Mura and Pozzoli using a 
pilot scale PGSS process with product yields up to 1000 kg/hr [Mura 1995]. 
PGSS, as a means of forming solid dispersions has been evaluated using a number 
of hydrophobic drugs. Improving the aqueous dissolution rate of a series of drugs 
has been evaluated in view of the micronization and solid dispersion capabilities 
of particles from gas saturated solution process. Up to a 15 fold enhancement in 
dissolution rate is achieved with felodipine and nifedipine when the 
agglomeration of produced particles is kept to minimum [Kerc 1999]. Another 
feature of PGSS that aids in aqueous dissolution enhancement is the morphology 
of particles produced, which in most instances are porous microparticles with 
rough surfaces [Sencar-Bozic 1997, Mura 1995]. Of the various process 
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conditions evaluated, the pre-expansion temperature and geometry of the 
restriction device have been found to have a significant influence on the 
morphology of the particles. 
Compressed gases have zero surface tension, high diffusivity and 
significant solubility in liquids and solid melts. They can be dissolved or 
dispersed in the molten solids easily under pressure. The ease of processing such 
gas saturated solutions owing to their reduced viscosity, makes PGSS unique in 
comparison to other methods like fusion, melt granulation, melt extrusion etc. 
Further, the milling step associated with all the latter methods of solid processing 
is avoided in the single-step PGSS process. In comparison to other SCF 
techniques of powder processing, PGSS operates at much higher energy 
conditions. The feasibility of the PGSS process for the compounds under 
consideration should be critically evaluated along the lines described above, prior 
to selecting the process. 
6. SUPERCRITICAL ANTISOLVENT PROCESSES 
6.1 Introduction: 
Poor solubilities of many pharmaceutical compounds and polymers in SC C02, 
coupled with the high-energy requirements associated with RESS and PGSS 
processes prompted the use of SC C02 as an antisolvent. lnitial experiments using 
supercritical antisolvents were perfom1ed on thermo-sensitive materials like 
explosives [Gallagher 1989], proteins & peptides [Yeo 1993] and other 
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biologicals [Tom 1993]. Since then, the technique has been extended to the 
processing of a variety of pharmaceutical actives & polymers. Also, several 
modifications of the technique have been made with the objective of achieving 
better particle morphology with low residual organic content. These constitute 
Gas AntiSolvent process {GAS), Precipitation using Compressed Antisolvent 
(PCA), Aerosol Solvent Extraction System {ASES) and Supercritical Antisolvent 
System (SAS). 
Review of literature reveals that some of these terms are loosely and 
interchangeably used, with no rigid definitions distinguishing one from the other. 
A general conception of the terminology is stated unambiguously by 
Subramaniam et al and is followed here [Subramaniam 1997]. GAS is generall y 
used for a batch process (Figure 4) wherein a gas/subcritical or supercritical fluid 
is bubbled through a stationary bulk of solute laden organic solvent. Decrease in 
solvent density as a result of large volumetric expansion leads to a rapid loss of 
solvent power and therefore the solute precipitates out instantly. Particle 
formation occurs in the liquid phase and a secondary solvent removal process is 
required to produce dry particles. A modification of this process with the 
objective of enhancing mass transfer by spraying organic solution into 
compressed fluid is broadly called PCA. Due to the improved transfer rates of 
organic solvent into the compressed fluid and vice versa, rapid evaporation of 
organic solvent and droplet expansion take place respectively, leading to the 
precipitation of fine particles. The process is tem1ed ASES or SAS when the state 
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of compressed fluid used as the antisolvent is supercritical. The PCA process has 
been investigated both under batch and continuous modes. The former involves 
spraying organic solution into a vessel containing compressed fluid (Figure 5) 
[Bodmeier 1995), whi le concurrent administration of compressed fluid and 
organic so lution at predetermined flow rates in a continuous manner constitutes 
the latter process (Figure 6) [Yeo 1993) . 
6.2 Mechanism of particle formation: 
The mechanism of particle formation is by solvent-antisolvent precipitation. The 
solute(s) to be processed is dissolved or dispersed in an organic solvent that has 
preferential affinity to the compressed fluid rather than the solute. When brought 
in contact with the compressed fluid , the organic solvent instantly throws out the 
solute owing to the loss of its solvent power. Particle precipitation is postulated to 
occur through two different mechanisms [Tom 1993). The influx of compressed 
fluid into the bulk of organic solution or the spray droplets brings about a large 
volumetric expansion of the solvent. This is followed by a loss of solvent power 
and very high supersaturation within the organic solution. The degree of 
supersaturation in the organic solution and particle growth are controlled by the 
rate and extent of antisolvent addition. Preliminary studies to determine the nature 
of solvent expansion caused by a compressed gas, as a function of pressure and 
temperature allows selection of appropriate process conditions [Gallagher 1989, 
Yeo 1993). 
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On the other hand, solvent flux into the compressed fluid causes rapid 
evaporation of the solvent, thereby supersaturating the solution. This is influenced 
by the relative affinity of solvent to the compressed fluid versus the solute. Also, 
other conditions such as the solute concentration in the organic solvent, relative 
rates of flow of organic solution and compressed fluid , pressure and temperature 
conditions of the compressed fluid etc. affect solvent evaporation. The rate of 
solvent evaporation and the degree of antisolvent penetration in the droplets have 
been shown to have a major effect on the porosity of the particles formed [Dixon 
1993, Werling 1999] . 
While solvent expansion by the gas is shown to potentially influence 
particle morphology in the GAS process, solvent evaporation and other spraying 
conditions mostly affect particle formation and growth in spray processes. Mass 
transport rates and the dynamics of jet breakup dictate particle morphology in 
spray processes. The former is found to have greater influence on particle 
morphology compared to the latter. Werling and Debenedetti have developed an 
integrated model of the effects of these mechanisms on particle morphology 
[Werling 1999]. The choice of process conditions should take into account the 
effects of these two different mechanisms on optimal particle formation. In 
addition, the phase of the medium where particle formation occurs is another 
factor affecting particle morphology. Particle formation in the GAS process 
occurs in the liquid organic phase and involves secondary solvent removal and 
drying steps. On the other hand, spray processes offer particle formation in the 
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supercritical phase in which the solvent is instantly extracted, leaving dry 
microparticles. In a recent development, spraying organic solution into a two 
phase vapor over a liquid antisolvent has also been evaluated [Young 1999]. It is 
postulated that particles formed in the vapor phase are later solidified in the liquid 
antisolvent beneath it. Preliminary phase behavior studies of the ternary system 
will form a basis for understanding the site of particle formation and thereby 
allow control of particle morphology. 
Compounds most suitable for antisolvent processing should have 
negligible interaction with the SCF and sparing solubility in the solvent used. In 
the presence of interactions between the compounds and the antisolvent, the 
solute is extracted along with the solvent. These interactions not only effect the 
ease of solvent removal, but also result in low overall yields. While visual 
inspection of compound behavior in SCF is one way of determining compound 
suitability for antisolvent processing [Bodmeier 1995], Steckel et al. have 
attempted to rationalize it based on partition coefficients of compounds [Steckel 
1997]. The authors have shown for glucocorticoids that a log P (octanol/water) 
value of less than four eliminates the possibility of compound extraction by SC 
C02. Ideal solvents for use in supercritical antisolvent processes should have a 
significant affinity for SCF and a high vapor pressure. Most common solvents 
used to date with C02 as the antisolvent include methylene chloride, dimethyl 
sulfoxide, methanol and ethanol. Minimal solvent residues that are an order of 
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magnitude below the pem1itted levels have been achieved through proper choice 
of operating conditions. 
6.3 Process: 
The basic components of a GAS system (Figure 4) are a precipitator with ends 
fitted with filters, pumps to precisely deliver compressed gas and organic solution 
into the precipitator and optionally, a post expansion vessel to separate the 
compressed gas from organic solvent for reuse. The solute(s) to be processed is 
dissolved in the organic solvent, typically in the concentration range of 0.1-5 
mg/ml and is introduced into the precipitator using a pump. In the particle 
fomiation step, a predetemiined amount of compressed gas flows through the 
organic solution at a regulated rate. Owing to the volumetric expansion of the 
solvent, particle precipitation occurs. The morphology of particles fomied 
depends on expansion path followed, regulated by the rate of addition of 
compressed gas and the solute concentration in the organic solution. Particle 
precipitation is followed by an extended drying step where generous amounts of 
compressed gas are bubbled through the precipitator. During this process, 
particles are restored in the precipitator using filters at both ends. The pressure 
and temperature conditions within the precipitator are controlled and recorded 
using a pressure transducer and a RTD. Typical operating conditions are 30-40°C 
and l OOO-l 500psi and antisolvent flow rates of 17-18 SLPM. In comparison to 
RESS, the gas antisolvent process operates at milder conditions and produces 
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higher yields. On the other hand, particle agglomeration and the additional drying 
step in the GAS process owing to low rates of mass transfer prompted spraying 
organic solution into the compressed fluid. 
Spray processes require an atomizing device in addition to the components 
described above. Various spray devices that range from simple capillaries and 
nozzles to vibrating, energized nozzles have been evaluated. The influence of 
nozzle configuration on the final particle morphology has been found to be rather 
insignificant compared to other operating conditions like relative rates of flow of 
organic solution and antisolvent, pressure, temperature, etc. This is explained by 
the fact that mass transport rates between the solvent and SCF have greater 
influence on particle size relative to the dynamics of jet break up and initial 
droplet size [Werling 1999]. 
In a batch spray process (Figure 5), organic solution is sprayed into the 
precipitator containing a compressed fluid where the particles are formed. 
Additional compressed antisolvent is then swept through the precipitator to 
remove the organic solvent completely. Typical flow rates of organic solution are 
between 0.1 -1 ml/min. ln the continuous mode (Figure 6), organic solution and the 
compressed fluid are simultaneously administered at predetermined flow rates 
into the precipitator. Typical flow rates of organic solvent and compressed fluid 
during particle precipitation are 0. l-3ml/min and 6-20 SLPM respectively. At the 
end of particle precipitation, spraying of organic solution is stopped while 
additional amounts of compressed fluid is passed through the precipitator to 
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remove the organic solvent. With proper choice of operating conditions, dry 
particles containing very low levels of residual volatile organic content can be 
produced. 
6.4 Applications: 
The advantages of using supercritical antisolvent crystallization in the 
micronization of drugs and pharmaceutical excipients are numerous. Energy 
requirements for the process are low and the technique offers the ability to 
process compounds under mild conditions. As summarized in Table 7, a number 
of pharmaceutical actives and excipients have been processed and various particle 
morphologies have been achieved. While the process has mostly been evaluated 
in the production of dry particles for nasal administration, it can also be extended 
to tailor particle morphology for any desired situation. Schmitt patented the 
miconization of a number of API's including alprazolam, triazolam, ibuprofen, 
erythromycin, penicillin, ampicillin, glyburide, dexamethasone, hydrocortisone 
etc. [Schmitt 1990]. The technique offers the ability to form discrete 
microparticles with a tight size distribution using mild process conditions while 
preserving the activity of sensitive molecules [Yeo 1993, Young 1999]. Other 
aerodynamic attributes for the particles such as flowability, surface roughness, 
charge, density, porosity can also be tailored specific to the end use. With the 
proper choice of process conditions, low residual solvent content that are an order 
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Table 7 . Pharmaceutical Studies using SuQercritical C02 as an Antisolven t 
Agent Procc:i:s Solvcnl l'ercent Conditions A 11 plica tion P:trliclc Htrcrcncc 
Solute T(°CJ f'(psi) char11c1eris1ics 
Ascorbic acid PCA EtOll NS NS 650-2200 Micronizat1on 1- IOu Weber 1997 
Ascorbic acid+Asp1nn PCA EtOH NS NS 650-2200 Amorphous Conversion Weber 1997 
Bctnmethasone-17-valcratc ASES McCl2+ Mc01-I lwt% 40 1230 Microniuation Steckel 1997 
b-poly-L-lac11de-co-D,L-lactidc- ASES McOH+MeCl1+ 3% 
" 
1450 Microcncapsulation Micropaniclcs with drug pmnaril)' on surface Engwich1 1999 
co-Glycolidc +Estnol TFE 
Budesomde ASES MeCl2-..MeOH lwt% 40 1230 Micronization Spherical, nonporous particles Muller 1997 
Bucleson1dc+Lcc1thm-t ASES NS NS NS NS Micronization Spherical microparticlcs, Muller 1997 
l-IP-bctt1-cyclodcxtrin Improved aerodynamic behavior 
.... 1Camptothes1n SAS DMSO o.scw. 
" 
1850 M1cronizauon O.Su Subramar11am 1998 
.... 
Cata lase GAS EtOll/H?O O.O lo/e JS 1320 M1croniza11on 1 u,Spherical or Rectangular Tom 1992 
Ch loramphcnicol-t-Urca l'CA DMSO NS 40 14 50- 1740 Solid solution Weber 1997 
Clonidine MCl..- L-PLA !'CA MeCt2 0.02o/.&.20'h 60 1470 M1croencapsula11on <\OOu,Spherical particles, Controlled release Fischer 1991 
CPM+L-l'LA PCA MeC12 0.4&4% 23 1015 Microencapsulation \-Su Microsphcres; Drug 1oading-3.73o/e llodmc1cr 1995 
Dexamclhasonc-21-acel:nc ASES McCl1+Mc01 I twt% 40 1230 Micronizauon Steckel 1997 
Flumsol1de ASES Ml.!Cl1-t-MeOM \wt% 40 1230 Crys1al modification Reducedcrystal lmity Steele! 1997 
Fluticasone-17-propionate ASES MeCl1 .. MeOH ]wt% 40 1230 Crystal modification Reduced crystalhnity Steclel 1997 
Gentamyc1n sulfntc~L-PLA PCA McCl i O.lo/e&0.9% 35 1250 Microencapsulation tonpaircd Micropaniclcs Steckel 1997 
llYAFF-11 SAS DMSO 0.5-1 S\\1% 35-50 1470 Micromza11on O.l-0.7u Bt:rtucco 1996 
-.., 
Table 7. Pharmaceutical Studies using SuQercritica l CO, as an Antisolvent (Cont'd 
A gen I lProcw i so tvent Percent Conti it ions A1111lica1ion Par1icle Hcfercncc 
Solute T(oq l'(11si) ch• rac1er is1ics 
l-IYAFF·ll SAS DMSO 0.05-1% 35-60 1250-1470 Nanopa11iclcs Nanospheres(400nm) 10 Aggrcgates(5-30u) 13encdctti 1997 
HYAFF-1 l+Modcl Drugs SAS DMSO lwt% <O 1470 Microcncapsulation Nanosphercs(320-400nm) ;Drug Loadmg• 20-86o/1; Bcrtucco 1996 
l-lydrocomsone SAS DMSO 0.5-3% 3l llOO Micronizauon Agglomcra1cd, Sphencal, 0.5-1 u par1iclcs to whiskers Submmaniam 1998 
Mydrocort1sonc SAS OMSO 0.5-3% ll 1850 Nanoparticlcs Discrete spherical particles <SOOnm Subramaniarn 1998 
1-lyoscmc Butyl Brom1de+L-PLA ASES McCl1 2w1% 40 1320-2940 Microcncapsulation Spherical microparticlcs(8-80u), Loadmg-97,5% Bleich 1996 
Ibuprofen SAS DMSO 3% 3l 1500 N11nopanicles Discrete microm size particles <0.6u Subramaniam 1998 
lndomethacm PCA Acetone 99\\1•;. 25 Upto4000 Nanopanicles 143nm, prccip1tatcd mto phospholipid Henriksen 1997 
... 
llndomc1h11cin+L-PLA V> l'CA MeCl1 0.4'11&4% 23 1015 Microenc11psula1ion 1-Su Microsphcrcs, drug loadings0.73% Oodmeier 1995 
lndomethacin +L-PLA ASES MeCl1 2\\1% <O 1320-2940 Microencapsulation Spherical m1cropan1ctes(2-40u), Loading- 25"1 Bleich 1996 
lnsulm GAS E101-VH10 3l 1320 Micromzauon Microspheres{< I u) & Thick needles - Sul Tom 1993 
lnsulm GAS DMSO 05-1.5% 25-35 1275 Micronizaiion 1-4u powders Yeo 1993 
Insulin GAS DMFA 0.50'1. 3S 1275 Microniza11on 2.Su Yeo 1993 
L-PLA PCA MeCl1 OJ-1 wt% 31 800-1400 M1cronizat1on 0.3-2u Bodmeier 1995 
L-l'LA l l'CA MeCI! 1-6°/iw\/v 0-32 1200 Spherical,free Oow1ng,Non-agglomerated&<Su Oodmeier 1995 
L-PLA rCA MeCl1 IM'lo 20 1515 Micronization J-4u Young 1999 
L-PLA ASES MeCI! 15-3'·· <O 1230-2940 M1cronization Spherical m1cropan1cles(6-50u) Thies 1998 
Table 7. Pharmaceutical Studies using Supercri tica l CO, as an Antisolvent (Cont'd) 
A gen I Procc.n Soh·cnl l'errenl Co nd itions Ap11lic1uion l'a rtic:Jc Rdcrcnce 
So lute T(•C) P(psi) ch arac1cristics 
Lysozymc+L-PLA PCA McCli O.W.&5'/, 24 1515 M1crot:ncapsula11on 250-SOOu m1crocncapsulcd Paniclcs Young 1999 
Lysozymc+PGLA PCA MeCl1 O.S'l.&5% ·20 1515 Microcncapsulation I0-60u microencapsuled paniclcs Young 1999 
POLA ASES McCl1 I.SO'/. 40 1320-2940 Micronizntion Bleich 1993 
PGLA PCA MeC11 l-J0\\1o/e 24 to -20 \SIS Micronizauon 0.S-SOu Young 1999 
PGLA ASES MeCl1 1.50% 40 1320-2940 Micronization Polymer film Bleich 1993 
Pl-IB IASES MeCli 1.50% 40 1320-2940 M1croni:iation Porous micropaniclcs Bleich 1993 
... 
ll'irox1cam+L-PLA ASES McCl 1 2v.1% 40 1320-2940 Microencapsulation Spherical m1croparticlcs( l -14u), Loading• 2.5% Bleich 1996 
°' 
Prednisolone ASES McClr• MeOH lwt% 40 1230 Amorphous Conversion Nearly amorphous part1clcs,rcsidual solvent""5 \ppm Steckel 1997 
Prcdnisoloncuceiatc PCA Acetone 0.5-0.6o/.w/Y 40-80 1470-2940 M1croniz1111on 0.5-Ju particlcs,polyd1spersny<4 Kulshreshtha 1998 
Tc1raca111e lll PCA Acetone 0.97% 25-45 Upto 4500psi Nanopartides JO- J 70nm, Prcc1p11atcd into tween 80 Hcnnksen 1997 
Th)mOpcntin ~ L-PLA ASES McCl2+MeOH 2"1% 40 1320-2940 M1crocncapsulauon Spherical microparticles(l-JOu), Load111gz96'1<t Bleich 1996 
Triamcinolone ace1on1de GAS THF 4.50".4 49 1620 M1c1oniumon 5-JOu Schmin 1990 
Triamcinolone aceton1dc ASES McCl2+Me0H ]\\1o/. 40 1230 Crystal mochfic:111on Mierospheres with reduced crystallimty Steckel 1997 
Uoc' l'CA EtOH 2.5-4.2% 35-40 1015-1450 M1croniZ11tion Caked aggregines(>SOu) Weber 1997 
Urea PCA DMSO 5·30o/• 35-75 101 5- 1450 M1cronization Micronp:irtides,2-8u Weber 1997 
of magnitude lower than FDA regulated limits have been achieved [Ruchatz 1997, 
Steckel 1997]. Compared to solvent based crystallization, the levels of solvent 
waste can be significantly reduced by reusing the solvent. Removal of C02 from 
the solvent after particle formation can be affected by simple depressuri zation and 
both the solvent and antisolvent can be recirculated for reuse. 
Another potential pharmaceutical application in the area of controlled 
release by microencapsulation of drugs is reflected in a number of reported 
publications. The efficiency of encapsulation can be improved by mixing at the 
molecular level, which is only possible with solvent based microencapsulation 
techniques. Supercritical microencapsulation, in principle, combines the 
advantages of solvent based techniques while providing a number of other 
advantages. These include the ability of controlling particle morphology and the 
ease of solvent removal. As can be seen in the Table 7, a number of 
pharmaceutical actives have been microencapsulated in various polymers using 
supercritical microencapsulation. The effect of the lipophilicity of drugs on the 
efficiency of loading into L-PLA has been investigated by Bleich et al. [Bleich 
1996]. The least hydrophilic among the compounds studied showed maximum 
loading in L-PLA, while lipophilic piroxicam was found to be extracted by the 
antisolvent. Preliminary studies of the ternary phase behavior for the selected 
system should help in choosing appropriate solvent and process conditions to 
form the desired microcapsules. 
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Typical polymers evaluated to date include L-PLA, HYAFF-11, PGLA, etc. The 
thermal and crystal attributes of these polymers that make them particularly 
suitable for particle formation using the antisolvent process was reported recently 
by Engwicht et al. [Engwicht 1999]. Due to the fact that the thermodynamic and 
phase behavior of only a few polymers in supercritical C02 are well documented, 
a majority of the supercritical microencapsulation studies are restricted to a 
selective few polymers. It remains to be seen how other pharmaceutical polymers 
will perform in supercritical microencapsulation. 
Rapid dissolution and absorption of actives of thermodynamically unstable 
forms of drugs has been a subject of interest in the recent past. In this direction, a 
nearly amorphous form of prednisolone has been produced by Steckel et al. 
[Steckel 1997]. The processing of drug mixtures to alter crystallinity has been 
reported by Weber et al. [Weber A 1997]. Varying degrees of crystallinity of 
aspirin and chloramphenicol were achieved by coprecipitation with ascorbic acid 
and urea using supercritical conditions. Although the technique in principle seems 
to offer the ability to alter crystallinity, more investigation needs to be performed 
before definitive conclusions can be made. 
Utilizing this technique, Subramaniam et al patented the process of 
coating actives with excipients and forming free flowing microparticles in a single 
step [Subramaniam 1998] . Possible applications are in the taste masking, 
controlled release and enhancing dissolution rates of pharmaceutical actives. With 
the objective of improving wetting and thereby dissolution, Steckel et al. [Steckel 
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1997) have coprecipitated a series of steroids with phosphitidyl choline and 
observed a significant decrease in contact angle with water. If this study could be 
extended to other poorly soluble pharmaceutical actives, this approach may 
provide a convenient way to forn1 free flowing discrete microparticles with 
enhanced solubility attributes in a single stage processing. 
The supercritical antisolvent technique has the potential for use in a 
multitude of applications for particle formation . However, the current level of 
understanding of a ternary phased supercritical mixture is rather primitive, 
restricting its application to a few excipients and actives. Pharmaceutical 
applications utilizing this technique have mostly been restricted to processing 
drugs with a few excipients. Extension of the technique to new molecules requires 
better understanding of the physicochemical properties of compounds that make 
them amenable to antisolvent processing as well as the phase behavior of ternary 
system under consideration. 
7. SOLUTION ENHANCED DISPERSION BY SUPERCRITICAL FLUIDS 
7.1. Introduction: 
With an ever-increasing need to tailor the particle morphology of pharmaceutical 
powders and to overcome the limitations of above described particle formation 
methods, alternate combinations of particle precipitation techniques have been 
explored. A more recent development among these supercritical fluid processes is 
what is known as ' Solution enhanced dispersion by supercritical fluids' (SEDS) 
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[York 1995]. ln SEDS, the solute(s) of interest is dissolved or suspended in an 
organic and/or aqueous solvent that is brought into contact with pure or modified 
SCF (antisolvent) using a coaxial nozzle. Mixing of the two fluids takes place in 
the nozzle just prior to the expansion through a restriction. The efficiency of 
particle precipitation by SCF is enhanced in SEDS by utilizing the energy of the 
rapidly expanding gas in dispersing the solvent. This feature of SCF's coupled 
with their solvent-extraction capability is believed to enhance the mass transport 
between fluids . Improved mass transfer between the solvent and the SCF assists 
in complete removal of solvent, which in tum aids in the formation of non-
agglomerated powders [York 1999]. Among the several SCF particle formation 
methods evaluated to date, SEDS offers a convenient means of forming non-
agglomerated powders under mild processing conditions while placing fewer 
restrictions on the solubility properties of the compounds. 
7.2 Mechanism of Particle Formation: 
Similar to the supercritical antisolvent processes, antisolvent-induced 
precipitation of solute from a solution or a suspension forms the basis for particle 
formation in SEDS. Refer to Section 4.2 for details about precipitation by 
supercritical antisolvents. A major limitation to the processes discussed in Section 
4 arises from poor mass transfer between the fluids, leading to incomplete solvent 
removal and hence agglomerated particles. While the morphology of newly 
formed primary particles depends on such factors as pressure, temperature, 
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density of SCF, initial droplet size, nucleation rates, spray velocities etc, 
incomplete solvent removal leads to growth and agglomeration of primary 
particles. To retain the characteristics of the primary particles, it is therefore 
important to remove the solvent immediately upon particle formation . From a 
theoretical standpoint, so lvent flux from the droplet into the SCF is higher from a 
finely dispersed mist of solution. Dispersing the solution in SEDS is brought 
about by the use of a coaxial nozzle. In principle, SEDS is an extension of the 
supercritical antisolvent spray process and operates similar to the continuous PCA 
process. The major difference from the PCA process lies in the use of a coaxial 
nozzle with multiple passages for different fluids. The nozzle not only helps in 
reproducibly contacting the fluids at a specific site of interest, but also helps in 
streamlining the mechanical energy of the rapidly expanding SCF to disperse the 
solvent. 
The solute of interest is dissolved or suspended in a solvent, which can be 
organic or aqueous. Precipitation of solute from its solution is caused by contact 
with pure or modified supercritical fluid. A multi-channeled nozzle with a mixing 
chamber allows convenient contact between the fluids at the site of interest, prior 
to dispersion and extraction of solvent and particle formation. Complete 
understanding of the mode of particle growth and the effects of process variables 
on particle morphology requires knowledge of the phase behavior of the system 
under study. The importance of fluid phase behavior is addressed in a recent 
review by Palakodaty and York, in which the authors addressed U1e fundamentals 
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of binary and ternary phase behavior involving SCFs [Palakodaty 1999]. The 
literature on the phase behavior of solvents and solutes that are routinely used in 
pharmaceuticals, however is scarce and therefore are limited to predictive 
calculations to date. One such study, characterizing the crystallization 
mechanisms of paracetamol by SEDS was recently published by Shekunov et al. 
[Shekunov 1999] . With rapidly increasing SCF applications in the field of 
pharmaceutics, it remains to be seen how new developments would aid m 
understanding the process better. 
7.3 Process: 
A general schematic of the SEDS process is shown in Figure 7. The basic 
components of SEDS process include pumps to deliver the fluids at desired rates, 
a co-axial nozzle, and a particle formation vessel. Solute(s) to be processed is 
dissolved or suspended in the solvent, typically in the concentration range of 0.5-
3% w/v and is fed to the coaxial nozzle using a liquid pump. Typical flow rates of 
the solute laden solution or suspension are in the range of 0.2-3 ml/min. Pulse-
dampened supercritical fluid is delivered to the coaxial nozzle at flow rates of 9-
45ml/min. Preferably, the ratio of flow rates of the solution and SCF are 
maintained between 0.01 and 0.07 [York 1995] . The T,P conditions of the 
supercritical fluid are fairly mild, generally ranging between 40-80°C and l l 50-
2940psi respectively. The fluids are brought into contact within the mixing 
chamber of the nozzle. A coaxial nozzle has multiple passages for different fluids . 
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Specific designs of various coaxial nozzles can be found in York' s patent [York 
1995]. In the particle formation step, the fluids are expanded through the nozzle 
where solvent dispersion and extraction take place instantly. Particles are retained 
by frits placed at the outlet end of particle formation vessel. Temperature and 
pressure of the particle formation vessel are controlled using an oven and a back 
pressure regulator respectively. At the end of the run, pure SCF is flowed through 
the system for 10-15 min to remove any remaining solvent. 
The solvent of choice should have a preferential affinity for the SCF 
compared to the solute. It can be a pure organic solvent that is miscible with the 
SCF of choice or it can be an aqueous solvent which can be extracted by a 
modified SCF. A modified SCF is one that is doped with traces of a polar co-
solvent like methanol or ethanol and offers the ability to extract aqueous 
components of the solution. SEDS thus offers the ability to process a wide variety 
of pharmaceutical compounds while placing fewer restrictions on their solubility 
attributes. Much of the development in SEDS process has been brought about by 
Bradford Particle Design Ltd., VK and it is proposed that the process has the 
capability to be scaled up to the tune of producing 1 ton/year [Bonner 2000]. 
7.4 Applications: 
One of the potential areas of SEDS application is in the crystallization of pure 
drugs. Compared to conventional crystallization, SEDS has been shown to 
generate particles that have better attributes such as crystallographic purity, 
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uniformity in size and size distribution, lower solvent residues, etc. For delivery 
purposes, conventional crystallization methods often require secondary processing 
of the material that may effect the activity of the molecules, besides adding to the 
economics of production. SEDS, on the other hand offers the ability to combine 
the processes such as crystallization, purification, micronization, etc. into one unit 
operation, while providing better control over particle morphology [York P 1999]. 
As can be seen from Table 8, the technique is particularly attractive in producing 
dry particles (pure, 1-5µ, static free, non-cohesive, free flowing, freely 
dispersible) intended for insufflation. Pulmonary delivery of such compounds 
places demanding requirements on the particle size, size distribution and other 
aerodynamic properties of the powders. Studies involving comparative evaluation 
of various processes in producing such powders have revealed that SEDS 
generated particles have better attributes [York 1996, Palakodaty 1997]. 
Utilizing the selective nature of supercritical fluids and the rapidity of 
extraction in the SEDS process, it is possible to separate polymorphs [Beach 
1999] and enantiomers [Koordikowski I 999]. This provides a convenient way of 
cleaning up active phannaceutical ingredients (AP!s) and thereby producing pure 
drug substances. To the same objective, the amorphous and metastable domains in 
AP!s that would otherwise compromise their stability can be removed by selective 
SEDS based crystallization. Highly crystalline forms of salmeterol xinafoate, 
lactose and fluticasone propionate have been produced using SEDS process. 
Conversely, crystal to amorphous conversion of pharmaceutical actives can be 
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Table 8 . Summary of SEDS studies 
A gen I I So lvrnl J Antisoh·enll Percen l Conditions Applica t io n l'arlicle 1 Refcre11cl!' 
Dispersing So lute(s) T I' C harnclc ris tiCll 
Agen t [w/vl l' Ci h1sil 
Lysozymc DMSO co, O.S-1 40-50 1150-2940 M1cronizauon Spherical microparticlcs(l-8u) Moshashaec2000 
Lysozyme Watcr+EtOl-I CO: J 40-50 1470-2940 M1cronizauon Spherical micropamclcs(l-12u) Moshashace 2000 
Salmc1crol Xinufoatc Ethanol co, 0.5 60 4410 Microniza11on 1- IOu, Improved aerodynamic propcrlies York 1995 
Salmctcrol Xinafoa1c Acetone co, 05 50 2940 API Clcanup. I-I Ou, Separated polymorphs I and II Hanna 1998 
:alpha-Lactose monohydnue Water+Mt..-OH co, 0.25 90 2200 Microniz.a11on Juwarcr-likccrystals Palakodaty 1997 
alpha-Lactose monohydrale Water C01+Me011 10 50-90 2200-4410 Micronization l-20u wi1h<2 5% water content Palakodaty 1998 
"' I 
"' alpha-Lactose monohydratc Water C02+EtOH 10 50 2200 M1cronizat1on 11 - 15ucrystals,watcrcontenl""2.5·5% 
P:ilakodaty 1998 
DL-PLG EtAc +-Acctonc+ co, 2.3 33-38 1900-2700 M1croniz.a1ion Discrete spherical part1cles(20-200u) Gh:ideri 1999 
lsoprop.inol 
DL-PLG I McCJ2+MeOH co, 2.3 33-38 1900-2700 M1cronizat1on Spherical beads connected Ghaderi 1999 
by solid bridges 
L· l'LA IMcCl2+Acctonc+ co, 23 35-40 1900-2700 Micronizat1on O. l-50u M1cropanicles Ghadcri 1999 
lsopropanol 
DL·PLA IAcetonc+ElAc+ co, 2.J 35-40 1900-2700 M1cronizat1on Discrete particles t aggregates (30-200u) Ghadcn 1999 
Hexane 
Polyc:iprotactonc IAcc1one+McCl2+ C02 2.3 35-40 1900-2700 Micronizat1on Large irregular shaped pamclcs(5 -1 000u) Gh:idcri 1999 
lsopropanol 
Table 8. Summary ofSEDS studies (Cont'd) 
Agent I Solven1 I Anlisoh•cnl/ Pcrcen1 Co ndilions A11plie11 1ion r a r1 iclc I Reference 
Uis11crsin g Sol u1c(s) T ,. Cl111rl\cleristics 
Agent lw/vl l'Ci I psi I 
Budesomdc Acetone co, 1-2.5 60-80 1470 Micronizat1on Smooth crystalline powdcr<Su Bisrat 1998 
Salmcterol Xinafo:ne+ MeOH co, NS 45 4410 Crystal Free flowing partlclcs,altcred crystallinity York 1995 
Fumed Silica modification 
Salmcterol Xinafoate+ ACCIOl\C co, 0.45&0.05 60 1750 Coprec1p1tat1on Fluffywhiteintimatem1xture York 1995 
l lPC 
Nicotmicacid Ethanol co, 0.625 70-90 1320 Micronization Non-charged, free flowing 5.75u IYork 1997 
Paracetamol Ethanol co, 0.0 1 40-60 1320-3625 Micronization Non.charged, free flowing 5.75u IYook 1997 
V> 
Ltbuterolsulfatc 
°' 
Water+ Acetone+ co, 50 2200 Smooth surfaced, free no1Vmg crystals York 1997 
MeOl-1 
Salbutamol Sulfate 
Ibuprofen DMSO lco, 1003 
I"' 1"00 IM"""'"''ioo 106" "'""'" Sodium Cromoglycaie MeOl-1 co, 0.25·0.75 :0-73 1470-2940 Amorphous 0.1·20usphcrical particles, IJaarmo 1997 
Conversion Amorphous 10 moderately crystalline 
achieved by SEDS as demonstrated by Jarmao et al [Jaarrno 1997]. The study 
reports a controlled crystal to amorphous conversion of sodium cromoglycate by 
antisolvent recrystallization using methanol and SC C02. A stable amorphous 
form of sodium cromoglycate was produced that did not exhibit crystallinity for 
five months. The authors attributed the conversion and the stability of the product 
to the residual levels of methyl alcohol. However, a major limitation of this 
approach stems from the fact that the drug may revert back to the 
thermodynamically favored crystalline form, compromising drug stability. The 
likelihood of such conversion is less when dealing with the pure drug, as seen in 
Jaarrno et al's study. A theoretical basis for this phenomenon, if consolidated, 
may have implications in improving the biopharmaceutical properties of 
crystallographic origin. It would also enable to extend these observations for any 
compound in general. 
Processing mixtures of drugs and excipients by SEDS has also been 
shown to be effective in a variety of situations. Coprecipitation and surface 
adsorption ofsalmeterol xinafoate on to different excipients was reported by York 
and Hanna [York 1995] to control the release and enhance the fluidi zation 
efficiency of the drug. Polyn1er processing using SEDS technology has recently 
been reported by Ghaderi el al. Various morphologies of polymers like L-PLA, 
DL-PLA, polycaprolactone have been produced using the SEDS process. 
Processing of pharmaceutical sol ids frequently involves optimizing 
particle size, purity, crysta!linity, flow, static charge, cohesiveness, solvent-
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content, stability besides other features specific to the delivery system. A particle 
formation process that effectively combines all these steps into one unit operation 
is of particular interest in the context of integrating chemical synthesis and 
formulation development. With increasing emphasis on reducing the time scales 
of different phases of drug development, there is a growing attention to such 
techniques with feasibility for scale up. Understanding the basic mechanism of 
particle nucleation and growth is essential in reproducibly producing the powders 
and in scale-up. Such understanding to date is limited and future work in this field 
should aim at forming a general basis for processing a wider variety of 
compounds. It is noteworthy that SEDS and PGSS are the only two processes, 
among several SCF particle formation methods that approached 
commercialization on a pilot scale. 
8.SUMMARY: 
In the reality of growing competition and emphasis on reducing the drug 
development time, search for new technologies continues to be a part of 
pharmaceutical research. Supercritical fluid technology, among other 
contemporary technologies has been gaining increased focus owing to its potential 
to integrate the synthesis and delivery stages of drug development. Other 
advantages include minimizing the usage of solvents, reducing the number of unit 
operations while offering the ability to continuously process materials under 
cGMP conditions. The technology is rapidly evolving while continuing research 
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efforts aimed at maximizing the benefits of supercritical fluids are in progress in 
order to process a wider variety of compounds on a pilot scale. Consequently, a 
number of supercritical fluid techniques have been reported to date. Each of these 
techniques discussed in this review utilize the remarkable properties of 
supercritical fluids in producing pure drugs and drug composites of various 
particle and crystallographic morphologies. In providing a comprehensive 
summary of various supercritical fluid techniques, this review presents the scope 
for supercritical fluid technology in pharmaceutical material processing. A large 
domain of supercritical fluid research still remains unexplored, considering the 
number of supercritical fluids and pharmaceuticals investigated to date, the extent 
of supercritical region evaluated, current process throughputs and the present 
level of understanding of the SC C02 based material processing. While exploring 
the other potential applications of the technology in pharmaceutical material 
processing, future research should also aim at theoretical understanding of the 
different processes. Such an understanding will then form a basis for processing a 
wider variety of pharmaceuticals and achieving better efficiency for process 
scaleup. 
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CHAPTER TWO 
Title: Design and Process Engineering of Laboratory Scale Supercritical Fluid 
Equipment. 
Abstract: Consistent production of solid drug materials of desired particle and 
crystallographic morphologies under cGMP conditions is a challenge often faced 
by pharmaceutical researchers. Supercritical fluid (SCF) technology gained 
significant attention in the pharmaceutical arena by not only showing a promise in 
this regard, but also accommodating the principles of green chemistry. Given that 
this technology attained commercialization in food industry, a majority of the off-
the-shelf SCF instrumentation is designed for extraction purposes. Only a 
selective few vendors are in the early stages of manufacturing equipment 
designed for particle formation. The scarcity of information on the design and 
process engineering of laboratory scale equipment is recognized as a significant 
shortcoming to the technological progress. It is therefore the purpose of this 
article to provide the information and resources necessary for startup research 
involving particle formation using supercritical fluids. The various stages of 
supercritical particle formation can be broadly classified into Delivery, Reaction, 
Pre-expansion, Expansion and Collection. The importance of each of these 
processes from the standpoint of tailoring the particle morphology is discussed in 
this article, while also providing various alternatives to perform these operations. 
Key words: Supercritical fluid Equipment; Particle formation; Design; Vendors 
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1. INTRODUCTION 
The central role of solvents m the processing of pharmaceutical materials is 
widely accepted since the origin of modem pharmaceutical processing. It is only 
in the recent past that the adverse effects of the residual solvents from both 
processing and environmental standpoints have been recognized. Strict 
regulations on the use of organic solvents and their content in the end products 
forms a major limitation to the traditional techniques. In an effort to eliminate or 
reduce the use of volatile organics, search for alternative techniques of material 
processing developed as a new facet to pharmaceutical research. Supercritical 
fluid (SCF) technology is a recent outcome of such research with particular 
emphasis in the green synthesis and particle formation. Particle formation using 
supercritical fluids involves negligible or no use of organic solvents, while the 
processing conditions are relatively mild. ln contrast to the conventional particle 
formation methods where a larger particle is originally formed and then 
comminuted to the desired size, SCF technology involves growing the particles in 
a controlled fashion to attain the desired morphology. The adverse effects 
originating from the energy imparted to the system to bring about size reduction 
can thus be circumvented. This feature makes supercritical fluid technology 
amenable to processing biomolecules and other sensitive compounds. 
Particle engineering using supercritical fluids is a relatively recent 
development in the pharmaceutical arena. Growing demands on the particle and 
crystalline morphologies of pharmaceutical actives and excipients, coupled with 
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the limitations of current methods, brought wide attention to this technology 
[York 1999]. The technology is rapidly evolving, as reflected by the number of 
modified processes reported since its inception. These include Static Supercritical 
Fluid process [Lindsay 1992], Rapid Expansion of Supercritical Solutions (RESS) 
[Matson 1987], Particles from Gas Saturated Solutions (PGSS) [Weidner 1995], 
Gas Antisolvent process (GAS) [Gallagher 1989], Precipitation from Compressed 
antisolvent (PCA) [Bodmeier 1995], Aerosol Solvent Extraction System (ASES) 
[Bleich 1993], Supercritical Antisolvent process (SAS) [Bertucco 1996] and 
Solution Enhanced Dispersion by Supercritical fluids (SEDS) [York 1995]. Refer 
Table 3 and Figures I through 7 (Chapter- I) to distinguish the various processes 
from a mechanistic standpoint and to identify the critical attributes controlling the 
particle morphology. Solubilization, plasticization and diffusion properties of 
supercritical fluids are utilized in Static supercritical fluid process, RESS and 
PGSS processes. On the other hand, mass transport, dispersion and antisolvent 
properties of SCF's are of interest while dealing with the other processes. In 
principle, the supercritical fluids are used as recrystallizing aids in pharmaceutical 
particle formation. The basic advantages like rapid and uniform nucleation of 
solute(s) remain the same in all the processes, although the mechanism of particle 
precipitation varies with the process. 
Carbon dioxide is regarded as an ideal processing medium [Subramaniam 
1997] for a number of reasons. It is generally regarded as safe (GRAS), non-
flammable, inexpensive; has a low critical temperature and pressure and exhibits 
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solubilization and plasticization effects that can be varied continuously by 
moderate changes in pressure and temperature. The solvent properties of 
supercritical carbon dioxide are reported to resemble those of hexane, toluene, 
isopentane and methylene chloride depending on the pressure and temperature 
conditions of the fluid (Hyatt 1984, Dandge 1985, Dobbs 1987, Ting 1993]. From 
a feasibility standpoint, compounds exhibiting significant solubility behavior in 
the SCF of interest (for example- lipophilic compouds with low molecular weight 
and high vapor pressure for SC C02) are most suitable for RESS process. PGSS is 
ideal for processing low melting compounds that exhibit negligible interaction 
with the SCF and more importantly, significant thermal stability. Antisolvent 
processes, on the other hand provide more flexibility in choosing the precipitation 
conditions through the use of solvents and solvent mixtures and by manipulating 
the solvent extraction conditions of SCF. Excepting PGSS [Mura 1995] and 
SEDS [Bonner 2000] processes which have been scaled up to the tune of 
producing I ton per year, the progress with other techniques is by far only limited 
to the research laboratories. The potential for SCF technology however is 
immense, as reflected by the wide gamut of pharmaceutical applications reported 
to date. Table 1 (Chapter- I) summarizes the various applications of supercritical 
fluid technologies in pharmaceutical material processing. 
The majority of the off-the-shelf SCF instrumentation currently available 
is designed for extraction purposes. Only a selective few vendors are in the early 
stages of manufacturing equipment specific to particle formation (Table 9) . 
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Table 9. Vendor Information of Supercritical Fluid Equipment And 
Accessories 
ITEM REPRESENTATIVE VENDORS 
Gas suppliers Air Products, PA; BOC Gases, NJ; Matheson, PA 
Gas Pumps Haskel, CA; lsco, NE; Jasco, MD 
Liquid metering Pumps Eldex, CA; lvek, CA 
Heat Exchanger/Chiller Lytron, MA; Polyscience, IL 
Tubing/Fittings Vici Valeo, TX; High Pressure Equipment Company, PA 
Reaction Vessels Thar Designs, PA; Pressure Products Industries, PA 
Valves High Pressure Equipment Company, PA; Vici Valeo, TX 
Back Pressure Regulators Tescom, MN; Thar Designs, PA; Jasco, MD 
Mixing loops 
Whole units 
Phase monitors 
Pressure Transducers 
RTDrfheromcouples 
Flow meters 
Nozzles 
Sapphire windows 
Toll processing 
Technical Consultants 
Thar Designs, PA; Autoclave Engineers, PA 
Supercritical Fluid Technologies, DE; Thar Designs, PA 
Supercritical Fluid Technologies, DE; Thar Designs, PA 
Texas Instruments, TX; Omega, CT 
Omega Engineering, CT 
Dwyer, fN; Porter Instruments, CA; Coriolis Liquid Controls, IL 
Thar Designs, PA; Applied Surface Technologies, NJ; BPD, UK 
Thermo Oriel, CT; Mindrum Precision, CA; Insaco, PA 
Thar Designs, PA; Lavipharm, NJ; Bradford Particle Design, UK 
Phasex, MA; Supercritical fluid technology Consultants, PA 
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A general practice however, as reflected from the reported publications and 
patents, is to reconfigure a commercially available system speci fie to the end use. 
It is the purpose of this article to provide the information and resources necessary 
for startup research involving particle fonnation using supercri tical fluids. The 
various stages of supercritical particle formation can be broadly classified into 
Delivery, Reaction, Pre-expansion, Expansion and Collection. The importance of 
each of these processes from the standpoint of tailoring the particle morphology is 
discussed in the following sections while also providing various alternatives to 
perform these operations. 
2. SUPERCRITICAL FLUID DELIVERY 
The critical point for any pure substance is defined by the temperature and 
pressure coordinates above which no physical distinction exists between the liquid 
and gaseous states. Substances above the critical point are referred to as 
' supercritical fluids'. In contrast to the other transitions of state, the phase change 
from the liquid or gaseous state to the supercritical fluid state is not a first order 
phenomenon, although most physical and transport properties change abruptly 
around the fluid ' s critical point. Accurate determination of the solvent critical 
point is therefore not a straight forward task and often relies on a number of 
complimentary techniques involving the study of critical opalescence, mixture 
phase behavior and theoretical equations of state [McHugh 1994]. The binary 
critical phase behavior, however for a number of frequently used supercritical 
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fluids and fluid mixtures can be readily obtained from scientific literature [Walas 
1985, Mc Hugh 1994, Perry 1997] . 
Among the various possible pathways, the most common and economic 
route of reaching the supercritical region is from a gas through the liquid state into 
the SCF phase. Compressed gases are readily availab le in large quantities and 
purity and are reasonably inexpensive. These gases are liquefied by passing 
through cooling lines prior to charging the pump (Figures l to 7) . Delivering the 
fluid to the pump in a liquid state ensures effective pressurization without any 
cavitation problems. Frictional forces from the pump and the heat of compression 
can raise the temperature of the fluid, thereby inducing phase change and needs to 
be compensated using a heat exchanger. While circulating a coolant in an external 
chill-can surrounding the pump head can be an option, more sophisticated pumps 
rely on improving efficiency by internal circulation. Refer to Table 9 for details of 
major gas suppliers and pump vendors. Given that C02 is the SCF of choice in a 
number of reported pharmaceutical applications, pumps that efficiently perform 
up to l O,OOOpsi are most commonly used. For applications that do not require 
high pressures or situations where the difference between the properties of fluids 
at sub and supercritical states is not distinctive, liquid tanks with a dip tube can be 
readily obtained from a number of gas suppliers that can be directly connected to 
a preheater. 
Pressurized liquid from the pump is then brought to the supercrit ical state 
by it passing through a heat exchanger (preheater). Given the high thermal 
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conductivities of these fluids [Perry 1997), supercritical temperatures are easily 
reached although the residence time of fluids in the preheater is not long. A 
lengthy piece of coiled tubing up to 5 meters in length is typically used as a heat 
exchanger. The temperature of the coi l is controlled using either a temperature 
bath/oven or a heating tape, and is chosen such that equilibrium supercritical 
temperatures are attained by the time the fluids reach the end of the coil. The flow 
of the SCF at this point is pulsed depending on the efficiency of the pump and 
exacerbated by the high kinetic energies of the fluids. Steady flow rates of SCFs 
assist in creating uniform conditions for nucleation in a number of supercritical 
fluid processes and is therefore of interest in the context of particle formation. 
Wherever uniformity in flow rates is considered important, pulse dampeners or 
snubbers can be used to buffer these pulsations. Alternatively, an additional vessel 
can be placed upstream of the reaction vessel that delays the frequency of 
pulsation and thereby stabilizes the flow rates. Flow measurement of the fluid in 
supercritical state is relatively difficult considering the high pressures and 
temperatures that the flow meters need to handle. Gas flow meters are typically 
used to monitor the supercritical fluid flow rates and are placed down stream of 
the particle collection vessel where the fluid is in gaseous state. Allowing the gas 
to flow through a lengthy tubing would not only assist in dropping any residual 
solutes or solvents well before the gas enters the flow meter, but also helps in the 
equilibration of temperature. Various flow meters are currently available and the 
choice of the meter should take into account such factors as the operating range, 
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sensitivity, type of fluid , moisture levels of the gas, inlet temperature and 
pressure, etc. While applications requiring accurate measurement such as the 
measurement of solute solubility in supercritical fluids require sensitive meters 
(eg. Thermo mass flow meter) with the totalizing function , other applications can 
function as well with inexpensive rotameters . 
In operations involving the use of co-solvents, the phase behavior of the 
resulting supercritical mixture needs to developed. A liquid metering pump is 
additionally required to deliver the co-solvent and can be purchased off the shelf 
from vendors dealing with the liquid chromatographic systems. It is noteworthy 
that such a metering pump should be capable of pumping the cosolvent against 
the head pressure of the compressed fluid . Mixing of the fluids can then be 
affected at the junction where they meet in T-configuration or more effectively, 
through the use of a sampling loop. The fluid mixture can then be delivered to the 
preheater that raises the temperature of the resulting mixture to the supercritical 
state. 
3. REACTION 
A reaction vessel is where the supercritical fluid is brought in contact with the 
material(s) to be processed. Essential requirements for a reaction vessel are 
chemical inertness, ability to withstand the operating temperature and pressure 
conditions and ASME specified design. Several designs of the pressure vessels 
are currently available and in general are distinguished by the type of closures. 
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Different closures vary in the nature and site of formation of the seal to contain 
the supercritical pressures. Finger tight closures with a ' c'cup seal formed of a 
graphite reinforced teflon ring containing an energized spring (Thar Designs, PA) 
can withstand pressures up to I 0,000psi and are most suitable for pharmaceutical 
applications. Refer to Table 9 for particulars of some of the vendors of pressure 
vessels and reactors. 
Reaction vessels made for pharmaceutical applications are typically made 
of stainless steel (316 SS) due to the sturdiness and chemical inertness of the 
material. The temperature of the vessel can be controlled either by using a heating 
mantle or a temperature controlled bath or oven. Controlled conditions of 
temperature and pressure in the reaction vessel are important to attain 
reproducible results and can be achieved through the use of sensitive pressure 
transducers and temperature measuring devices. Through a proper choice of the 
heaters and temperature controller and by an appropriate placement of the 
thermocouple(s), the temperature of the contents in the vessel can be accurately 
controlled. 
Intimate mixing of the supercritical fluid with the material to be processed 
is critical in SCF material processing [Juvekar 1994, Muth 2000). The effects are 
particularly pronounced in rapid expansion of supercritical solution (RESS) and 
particles from gas saturated solutions (PGSS) processes. Channeling of the 
supercritical fluid in continuous operations of RESS and PGSS processes limits 
the contact of the fluid with the material(s) of interest. Packing of solute(s) in the 
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reaction vessel is therefore critical in these processes and should maximize the 
interaction while limiting the entrainment of solute. Mixing the material with 
glass beads and glass wool prior to loading it to the reaction vessel is frequently 
used to improve the degree of interaction. The glass beads not only help in 
improving the contact of materials with SCF's, but also assist in buffering the 
flow pulsations by reducing the free volume in the reaction vessel. Alternatively, 
stirring or agitation in the reaction vessel can be provided using an impeller and a 
motor. Extrusion of the commonly used seals in mixing devices due to the 
sorption of gases into the polymers at relatively high temperatures forms a major 
limitation to using ordinary devices. Moreover, the wear and tear of the moving 
parts of the mixing device is exacerbated by the high pressures of the SCF 
process. To compensate for these limitations, magnetic mixing devices have been 
designed that effectively provide a leak proof agitation in a pressure vessel 
without the use of polymeric seals and other moving parts. Patented devices for 
mixing in pressure vessels such as PP! Dyna Magnetic Mixers and Ferro Micron 
Mixers are available as off-the-shelf items (Table 9). 
For investigative studies requiring the physical observation of events 
occurring in the reaction vessel, view cells can be fitted in the vessel caps. 
Commonly used view cells are made of such materials as quartz, sapphire, 
polycarbonate etc. The compatibility of the cells and the seals with supercritical 
fluids needs to be verified prior to their use. Sorption of SCF' s into the o-rings 
combined with the leaching capability of the fluids is a frequent cause of leakages 
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inherent in supercritical systems. Preventive maintenance of the system should 
therefore include replacing the seals at frequent intervals of time. For studies 
involving milder operating conditions, a Jerguson gauge (Clark-Reliance 
Corporation, OH) can be used as a reaction vessel and also to qualitatively view 
the events of the reaction. Solubility and phase behavioral events of the 
pharmaceutical materials in supercritical fluids can be developed using the above 
mentioned designs, although special devices called phase monitors are 
specifically designed and frequently used for such studies. 
4. PRE-EXPANSION 
The composition and phase of the supercritical solution from which particles are 
precipitated is found to have a major effect on the morphology of particles in 
RESS and PGSS processes and is controlled during the pre-expansion stage 
[Helfgen 2000, Weidner 1996]. Independent control of the temperature and 
pressure during the pre-expansion stage is therefore critical in these processes. 
Additionally, the phase changes in the supercritical solutions, which often lead to 
plugging of the lines, can be eliminated through the use of a controlled pre-
expansion line. While one end of the pre-expansion line is connected to the 
reaction vessel, the other end feeds the supercritical solution through a back 
pressure regulator to the expansion device (Figures 2,3). The composition of the 
solution in this line may not only be controlled by changes in temperature, but 
also by adding fresh SCF solvent to the line. Typically, the pre-expansion line is a 
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lengthy coiled tubing having the same dimensions as the other lines with a port 
for the addition of fresh solvent. It is usually maintained at approximately 50°C 
higher than the temperature of the reaction vessel using a heating tape or a 
temperature bath/oven. Premature precipitation of solutes in the lines can thus be 
avoided unless the solute exhibits retrograde behavior in the operating 
temperature regime. ln such instances, plugging can be prevented by the addition 
of fresh supercritical solvent to dilute the supersaturated solution. The fluids can 
be effectively mixed through the use of mixing loops that are most commonly 
used in pre-column reactions ofHPLC analysis. 
S. SPRAY CONFIGURATIONS 
In supercritical fluid particle formation, the fluids are expanded through a 
restriction device in a controlled fashion. A restriction device is designed to 
support the large pressure drop that occurs across it, while maintaining suitable 
conditions for precipitation. The geometry of the restriction device has been 
shown to influence the morphology of the particles to varying degrees and by 
different mechanisms [Matson 1987, Debenedetti 1993a, Subrahmaniam 1998]. In 
RESS and PGSS processes, the device controls the growth of particle after the 
nucleation process by affecting the dynamics of jet expansion. On the other hand, 
the restriction device in antisolvent processes affects particle morphology by 
controlling the initial droplet size and also the rate of solvent extraction by the 
SCF. Various configurations have been used to date, namely capillaries, nozzles, 
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laser-drilled discs and valves. For investigative purposes, capillaries are preferred 
to other specialized designs owing to their availability, cost and the ease of 
changing the geometry of the device in house [Kim 1996]. Typical aspect ratios of 
the restriction devices evaluated to date are in the range of 6 to 20, with orifices 
from 20 to 1600µ in diameter. Joule-Thompson cooling, resulting from the large 
volumetric expansion across the restriction device, causes a drop in temperature, 
thereby affecting a phase change and subsequently leads to plugging of the 
device. The restriction devices are therefore heated to compensate for such 
effects. While stainless steel nozzles are most frequently used owing to their 
strength to withstand the large pressure differential, they are limited by their poor 
thermal conductivities. Wherever necessary, they can be replaced with sapphire 
nozzles that provide better heat transfer to the fluid while also maintaining the 
material strength. The devices for the most part are custom designed according to 
the specific needs of the researcher. Off the shelf devices with standard 
configurations can also be obtained from selective supercritical fluid vendors 
(Table 9). Other coaxial nozzles that are specific to the SEDS process are 
regulated by the stringent patent protection and can be purchased for purposes 
notwithstanding the claims of the patent [Hanna 1999]. 
6. PARTICLE COLLECTION 
Retaining the original characteristics of the particles produced by supercritical 
fluid process is as critical as forming the particles and constitutes the particle 
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collection step. This step is critical in that the distinct characteristics of the 
particles can be completely lost owing to a poor collection technique [Turk 1999] . 
In rapid expansion of supercritical solution and particles from gas saturated 
solution processes, the rapid ly expanding supercritical fluids impart high kinetic 
energies to the particles produced. Insufficient path for expansion can therefore 
result in the agglomeration of particles. The agglomeration is even worse in the 
presence of residual amounts of co-solvent in RESS process or uncongealed 
portions in PGSS process. Design of particle collection vessel in these processes 
should be such that agglomeration is kept to a minimum by providing a sufficient 
path of expansion for the supercritical fluids. While a logical solution is to make 
the collection vessel very large, the collection of small amounts of material from a 
relatively larger vessel can be difficult, resulting in low yields. This problem can 
be circumvented in part by inserting detachable baskets inside the vessel. The 
baskets can be taken apart at the end of the process to collect the particles. While 
precipitating the solutes into a non-solvent containing a surfactant is another 
solution to agglomeration, it adds one more step to an otherwise continuous unit 
operation. An optimum balance between the ease of collection and the expansion 
path of the SCFs should be reached in designing the particle collection vessel. 
Other design factors that merit consideration include: surface finish of the inside 
of the baskets/vessel, shape of the vessel, alignment etc. [Matson 1987, 
Debenedetti l 993b, Turk 1999]. The role of post expansion conditions on the 
morphology of particles has been found to be inconclusive or relatively 
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insignificant. Excepting situations where post expansion conditions have been 
shown significant [Mohamed l 989a], or where fluid recompression costs are a 
factor, the collection vessel in RESS and PGSS processes is for the most part, 
maintained at atmospheric conditions. 
The collection of particles in the antisolvent processes occurs in the same vessel 
where solvent extraction talces place. The particles are retained in the vessel by 
placing frits at either ends of the vessel while the solvents are extracted out with 
the flowing supercritical fluid . Particle agglomeration and solvent removal from 
the vessel in these processes are less dependent on the design of the vessel and are 
outweighed by other thermodynamic effects. The design of collection vessels 
used for antisolvent applications should however talce into account the interaction 
between the materials and the supercritical fluids without plugging the lines 
[Hanna 1999]. 
7. SUMMARY 
Current advances in pharmaceutical research have not only contributed to the 
discovery of various new technologies, but also identified the potential limitations 
of the conventional techniques of material processing (York 1999] . Among the 
different nascent technologies currently under investigation, supercritical fluid 
aided particle formation is reported to operate under relatively mild conditions 
making the process amenable to sensitive molecules, enzymes, proteins and other 
macromolecules [Yeo 1993, Moshashaee 2000] . Volatile organic solvents can be 
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reused making their usage minimal. Different SCF processes have been 
demonstrated to produce particles with residual organic content of an order below 
the permitted levels [Steckel 1997]. Further, control over the morphology and 
crystallographic purity of the particles is shown to be better than several other 
conventionally used processes [Beach 1999]. The potential for SCF technology in 
the pharmaceutical realm manifests from all the above-mentioned features 
combined with the feasibility of producing particles under cGMP conditions in a 
unit operation. The information provided in this article is intended to assist 
investigative researchers in evaluating such potential either through setting up a 
particle formation system in house or by contracting the work to established 
supercritical fluid consultants. 
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CHAPTER THREE 
Title: Co-Crystallization of Pharmaceutical Actives and Their Structurally 
Related Impurities By RESS Process. 
Abstract: Pharmaceutical research in the area of crystal doping to date has mostly 
been focussed towards understanding the impurity-induced effects on the host 
molecules. From an application standpoint, doping crystalline active 
pharmaceutical ingredients (APD can provide the ability to tie functionality to 
API's at early stages of drug discovery and synthesis. It is with this objective that 
a number of drugs were recrystallized in the presence of impurities from 
supercritical media. The rapid expansion of supercritical solution (RESS) process 
was evaluated for these purposes. Results of RESS aided crystal doping studies 
involving twelve drug-impurity mixtures are reported in this manuscript. It was 
concluded from these studies that RESS offers great promise as a hybrid 
technique to control both the crystalline and the particle morphologies of API's in 
a single stage. In addition, a number of interesting phenomena were revealed. 
These include habit modification, solubility enhancement, particle size reduction, 
eutectic formation, reduction in crystallinity, amorphous conversion, hydrate 
formation, polymorph conversion and selective extraction. In viewing each of 
these phenomena from an application standpoint, this manuscript serves as proof 
of concept for enhancing the physicochemical and mechanical attributes of API's 
using supercritical fluid crystal doping. 
Key words: Co-Crystallization; Crystal Doping; RESS; Rapid Expansion. 
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I. INTRODUCTION 
Imperfections prevai l in virtually all solids to varying degrees, resulting in a wide 
range of materials from almost-perfect crystals to amorphous substances. While 
the nature of these imperfections can be studied in crystalline substances, the 
effects on an already disordered amorphous state are rather difficult to isolate 
[Suga 1997, Suga 1999]. The extent and nature of imperfections largely depend 
on the structural properties of solids, kinetics of crystallization and impurity 
levels, as well as other crystallization conditions [Weissbuch 2001]. The defects 
in crystals impart higher localized energies as a result of the elastic strain arising 
from the reduction in symmetry [Burt 1981 , Weisinger 1989] . The higher energy 
of the system contributed by such pockets, although slightly compensated by 
increased entropy, is what renders higher free energy to imperfect crystals. 
Increased chemical potential and thermodynamic instability of such crystals can 
have profound implications in a wide variety of pharmaceutical applications. 
The utility of impurities in causing crystal disruption is evaluated in this 
work by controlled co-crystallization of AP! and impurity from supercritical 
media. Besides modifying the energy of crystals, impurities are also reported to 
elicit a broad range of effects on the polymorphism, habit, size, true density and 
surface area of host crystals [Zhang 1999] . The combined effects on the 
morphology and energetics of the host crystals can be advantageously used in 
tailoring crystals to pharmaceutical needs and forms the scope of this research. 
Such research is of both fundamental and practical relevance. From a theoretical 
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standpoint, the role of impurities on crystal disruption can be studied and can be 
extended to tailoring additives for specific purposes. From an application 
perspective, the bulk properties of crystalline pharmaceutical actives can be 
modified according to their functional utility at early stages of chemical synthesis. 
2.BACKGROUND 
2.A. THEORY OF CRYSTAL DOPING: 
Doping is defined as the deliberate addition of an impurity (guest) into the 
crystallizing medium of the host drug substance. Depending on molecular size 
and shape, stereochemistry, solubility and chemical affinity towards the host, 
impurities can profoundly alter the kinetics of nucleation and growth of the host 
crystals [Rauls 2000, Weissbuch 2001]. To date, various mechanisms have been 
proposed that typify the impurity-induced effects on the host crystals at both 
molecular and bulk levels. Firstly, the impurity can function as a co-solute in 
either enhancing or reducing the solubility of host crystals in the crystallization 
media. As a consequence of altered supersaturation, the induction time for 
nucleation and the metastable zone width are modified leading to changes in 
crystal size, size distribution and habit as observed with acetaminophen doped 
with p-acetoxyacetanilide [Prasad 2001]. 
Other means of crystal modification by impurities involves stereoselective 
adsorption of impurity onto specific faces of a crystal, causing differential 
inhibition of growth [Addadi l 982]. Inhibition of growth in a specific direction 
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manifests in increased surface area of the face perpendicular to that direction. 
Such selective inhibition might lead to modified aspect ratios, a change in habit 
and in some instances, crystallization of selective isomers and polymorphs. This 
phenomenon has been illustrated in several host-guest systems such as racemic 
glutamic acid mixtures, adipic acid+n-alkanoic acids, Benzamide+Benzoic acid, 
Sucrose+Raffinose, [Weissbuch 2001] Triglycine sulfate + L-alanine [Aravazhi 
1997], Phenytoin + 3-acetoxymethyl-5,5-diphenyl hydantoin [Chow 1991], and 
Phenytoin+ 3-butanoyloxymethyl-5,5-diphenyl hydantoin [Chow 1995a]. Thirdly, 
the impurities can selectively displace host atoms, molecules or ions from their 
lattice points and thereby change the unit cell dimensions. While such 
substitutions are common among inorganic crystals, the substitutional point 
defects are seldom seen in pharmaceutically relevant crystals as reflected in the 
published literature. Instead, other zero and first order defects are frequent in 
organic crystals, perhaps through interstition of small molecules both within and 
outside the lattice. The basic criterion, however in either case is that the topology 
of networks should be complementary [Biradha 1999]. The interstition of 
impurities is reported to most frequently lead to lower dimensional defects such as 
point defects or edge and screw dislocations, resulting in an overall reduction in 
symmetry [Duddu 1995]. Finally, non-specific inclusion as observed in channeled 
impurities is another means by which impurities can induce crystal defects in the 
hosts. In a recent publication, Zhang and Grant evaluated eight guest-host systems 
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to report that the guest molecules most commonly exist in a solid solution rather 
than in liquid inclusions [Zhang 1999]. 
Depending on the differential rates at which the host and guest are 
precipitated out of a supersaturated solution and the specificity of interactions 
between them, the guest molecules either form a homogenous dispersion within 
the host matrix or are limited to surface sites as adsorbates . Several analytical 
techniques such as adsorption measurements, surface washing, progressive 
dissolution etc are currently in place to distinguish surface adsorption from solid 
solutions [Zhang 1999] . A solid solution can be viewed as the homogenous 
dispersion of the guest molecules at specific sites of the host during the early 
nucleation step, which subsequently get occluded as the growth of crystals 
continues. The presence of guest molecules therefore leads to the formation of 
defective crystals composed of mosaic blocks with totally different local 
symmetries and energies compared to pure crystals (Weisinger-Lewin 1989]. The 
implications of altered surface and bulk energies are profound in crystal 
dissolution [Burt1981], wetting [Chow 1995b] and reactivity [Duddu 1995] 
among other biopharmaceutical properties. Given the complexity of the 
crystallization process and the inadequacy of current analytical techniques to 
specify the exact location of impurity within lattices, the selection of doping 
agents has mostly been by trial and error. A direct correlation between the nature 
of the impurity and its role on the crystallization process is yet to be established, 
although significant inroads have been made towards this goal [Weissbuch 2001 ]. 
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The defects in the crystals can spread, change their nature and at times 
may vanish depending on the molecular mobility and diffusivity of the impurities 
in the host crystals and other external stress factors. Given that such properties are 
orders of magnitude lower when dealing with solid substances, the 
thermodynamic instability of the defective crystals can be sustained throughout 
the typical shelf life of pharmaceutical actives. 1n theory, the stabilization of 
defective crystals requires similarity in the morphological, chemical and 
thermodynamic properties of the guest and host molecules. This theoretical 
intuition is substantiated in several model host/guest systems where similarity in 
molecular size, shape, melting point and solubility are found to be important 
[York 1985, Pikal 1987]. Also, large supersaturation aiding in fast nucleation and 
growth is demonstrated to be critical in locking the guest molecules into the 
lattices of the host [Burt 1981]. 1n this context, the RESS process (Rapid 
Expansion from Supercritical Solutions) appears particularly attractive, owing to 
the uniforn1 and large supersaturation implicit in RESS aided crystallizations. 
Other factors such as vapor sorption, residual solvents and external stress can 
adversely mediate conversion of doped crystals to their thermodynamically stable 
forms. The RESS process proves viable even in this respect, as it involves neither 
the use of liquid solvents nor any large mechanical stresses in producing uniform 
sized crystals. 
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2.B. EFFECTS OF DOPING ON THE PROPERTIES OF CRYSTALS AND 
THEIR PHARMACEUTICAL APPLICATIONS: 
A number of properties of the crystals are affected as a result of doping host 
molecules with impurities. The various properties are broadly classi tied based on 
their specific influence on the morphology and energy of the crystals. They are 
further subclassified into surface and bulk effects. This section covers the various 
modifications in the properties induced by doping of crystals with illustrated 
examples excerpted from the published literature. Possible applications of each of 
these modifications are also addressed wherever applicable. 
Habit modification in the host crystals as a result of the incorporation of 
an impurity translates into changes in such properties as particle size, aspect ratio, 
density, specific surface area and surface roughness. The effects on particle size 
are based on the impurity effects on supersaturation and hence the crystallization 
kinetics, besides being habit related. A decrease in the particle size of phenytoin 
crystals is reported when doped with 3-propanoyloxymethyl-5,5-diphenyl 
hydantoin, which the authors attributed to habit thinning [Gordon 1992). Changes 
in the aspect ratio of host crystals are frequently observed owing to the 
differential inhibition of growth in specific directions by the impurity. Chow and 
Grant investigated the influence of p-acetoxyacetanilide on the aspect ratios of 
acetaminophen [Chow I 989a) and further correlated such influence to the 
aqueous dissolution rates of acetaminophen [Chow 1989b). True density of the 
crystals was found to be sensitive to the presence of impurities and is claimed to 
97 
be a sensitive indicator in quantifying the extent of crystal disruption. The 
influence of impurities on crystal densities has been experimentally verified using 
adipic acid/o leic acid and acetaminophen/p-acetoxyacetanilide as host/guest 
systems. [Duncan-Hewitt 1986] Another habit related property that was shown to 
be largely influenced by the doping process is specific surface area. Significant 
increases in the surface areas of acetaminophen [Chow 1985] and phenytoin 
[Gordon 1992, Chow 1995a] were observed when doped with impurities. Part of 
this enhancement has been attributed to the surface irregularities arising from the 
dislocation sites during measurements by gas adsorption techniques [Chow 1985]. 
As a result of crystal doping, surface irregularities have also been reported in few 
instances that significantly contribute to enhanced dissolution rates [Chow 1991]. 
A majority of the above mentioned properties are habit dependent. Inducing 
changes in habit, for exan1ple from acicular prisms to long thin plates as observed 
in phenytoin [Chow 1991] and from columnar to plate-like in acetaminophen 
[Prasad 2001] can have potential implications in processes such as wetting, 
dissolution, compaction etc. Another means of altering the properties of 
pharmaceutical actives is though the conversion of polymorphs & isomers [Kopp 
1989, Laihanen 1996, Bosela 1997, Badawi 1997]. In theory, polymorphism 
arising from differences in conformation and packing can both be controlled using 
tailor made impurities. Reported proof of concept studies substantiating this fact 
include impurity induced crystallization of the polar polymorph of N(2-
acetamido-4-nitrophenyl)pyrolidene (PAN) [Staab 1990] and a-form of L-
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glutamic acid [Sano 1997). Resolution of equi-energetic conglomerates was also 
made possible utilizing tailor made impurities [Addadi 1982). 
Doped crystals in general have lower crystallinity, melting point, enthalpy 
of fusion and higher entropy, free energy and disruption index compared to 
perfect crystals. The energy related effects of crystal doping originate from the 
lattice defects and other secondary manifestations in the host crystals. The defects 
in the crystals are stated to be associated with higher localized energies compared 
to the regions of normal configuration [Burt 1981]. These high-energy pockets are 
composed of the excess energy resulting from lattice strain and the core potential 
energy stored in the dislocation sites [Burt 1981, Weisinger 1989). The higher 
energy of the system contributed by such pockets is slightly compensated by 
increased entropy of the disordered solids. In effect, impurities thereby render 
higher free energy to the imperfect crystals. Consequently, an increase in 
chemical potential and thermodynamic instability results in such crystals. The 
combined effects of loss of symmetry and increased activity lead to increased 
wettability, intrinsic dissolution rates and crystal reactivity in general [Chow 
l 995b]. This has been unambiguously proven using model systems like phenytoin 
[Chow 1995b) and adipic acid [Chan 1989] as hosts and a number of structurally 
related impurities as guests. Dissolution enhancement utilizing such subtle crystal 
modifications appears particularly attractive in the wake of recent amorphization 
efforts of a number of active pharmaceuticals [Yu 200 l]. 
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2.C. CHARACTERIZATION OF CRYSTAL DOPING: 
The various techniques for evaluating the nature and magnitude of crystal 
disruption can be broadly classified into ones that characterize modifications in 
crystal morphologies and others that quanify the crystal energetics. Among the 
spectroscopic and microscopic techniques that study the primary morphological 
changes following crystal doping include optical microscopy [Burt 1981 ,Chow 
1985,Prasad 2001], SEM [Chow 1991 , Gordon 1992, Chow 1995a, Prasad 2001], 
atomic force microscopy [Li 2000], single crystal x-ray diffraction, [Bettinetti 
2000, Williams-Seton 2000, Prasad 2001, Lynch 2000, Atencio 2000, Foxman 
2001) powder x-ray diffraction [Burt 1981 , Chow 1985, Gordon 1992, Chow 
l 995a], neutron X-ray diffraction, [Weisinger-Lewin 1989], IR [Aravazhi 1997, 
Bondar 2000) and solid state NMR [Yatsenko 1997, Bauer 2001, Gustafsson 
1998] . Secondary manifestations that are sensitive to morphology changes such 
as density [Duncan-Hewitt 1986, Chow 1991) and thermal expansivity [Duncan-
Hewitt 1986] are also used as indicators in evaluating crystal disruption. As 
reported by Burt [Burt 1981 ), Chow [Chow 1985] and Prasad [Prasad 2001] in 
their studies involving doped potassium perchlorate and acetaminophen crystals, 
optical microscopy aids in characterizing the aspect ratios, habit and dislocation 
sites such as etch pits in the doped crystals. In addition, changes in birefringence 
of the doped crystals can also be studied using polarizing optical microscopy. 
While gross structural changes are easily detectable using this technique, subtle 
crystal modifications are rather difficult to study and require further sensitive 
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techniques such as x-ray topography, scanning electron microscopy and atomic 
force microscopy. By contributing to the sensitivity, these techniques can also aid 
in locating the impurity in the doped crystals . Differentiation of surface 
adsorption from lattice incorporation of impurities is clearly demonstrated 
utilizing these techniques [Chow 1991 , Gordon 1992, Chow !995a, Prasad 2001, 
Li 2000]. 
Whenever growth of sufficiently large crystals is attainable, single crystal 
X-ray diffraction is most frequently used in typifying the structure of doped 
crystals. Although not simple in nature, this technique provides the knowledge of 
even minute changes in the cell dimensions of the defective crystals. Twinning 
and disordering in adipic acid crystals doped with different monoalkanoic acids 
was studied utilizing this technique [Williams-Seton 2000]. In a recent study, 
Prasad et al. analyzed p-acetoxyacetanilide doped acetan1inophen crystals using 
single crystal x-ray diffraction [Prasad 2001]. The authors reported an increase in 
the mosaic spread as a result of the high lattice strain induced by the impurity. 
Similarly, neutron diffraction analysis of the asparagine/aspartic acid system 
afforded knowledge of a reduction in symmetry of host crystals as a result of 
doping [Weisinger-Lewin 1989]. Excepting situations involving gross structural 
changes, powder x-ray diffraction (XRPD) does not appear to be sensitive to 
subtle changes in the doped crystals. A review of the pharmaceutical literature on 
crystal doping substantiates this fact as no significant changes in the diffraction 
patterns or the ct-spacings were observed in a majority of doped crystals. On the 
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other hand, peak broadening and a change in the peak intensities were seen in IR 
and solid state NMR spectra with increasing disorder in the crystals. Aravazhi et 
al found broadening of the peaks in the IR spectra of doped crystals of triglycine 
sulfate [Aravazhi 1997]. Similar observations were reported in Gustafsson et al's 
study where the crystalline disorder in lactose is quantified using solid state NMR 
and confirmed with solution microcalorimetry [Gustafsson 1998]. 
Given that the impurities in the crystals bring about a variety of changes 
and by different means, it is not always possible to characterize the doping 
process by any one particular method. The complexity of identifying subtle 
morphological changes prompted researchers into quantifying the manifestations 
of such changes. In this context, density and thermal expansivity were found to 
closely vary with the disruption of the crystals by impurities. Duncan-Hewitt and 
Grant developed and evaluated different experimental techniques for the 
determination of these properties in doped adipic acid crystals. A comparative 
evaluation of these properties in quantifying the crystal disruption revealed that 
thermal expansivity is a more reliable indicator of crystallinity than density at a 
fixed temperature [Duncan-Hewitt 1986]. 
Crystal dissolution rate is another indicator frequently used in evaluating the 
doping process. The mixed effects of habit and the energy modifications on the 
intrinsic dissolution rates of the doped crystals, however need to be individually 
addressed in such evaluations. For example, the impurities can act as poisons in 
inhibiting dissolution from specific surfaces and locations [Burt 1981]. Other 
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habit related effects like crystal anisotropy, shape and size could also adversely 
affect crystal dissolution. On the other hand, the increased thermodynamic 
activity of these high energy-metastable crystal forms lends the driving force for 
enhanced dissolution of these crystals. Other means of dissolution enhancement 
following crystal doping are based on the surface irregularity and the solid 
solution mediated effects. The isolation and quantification of each of these effects 
is therefore very critical in controlling the final dissolution rates. To this 
objective, Chan and Grant developed methods that distinguish habit-related 
effects from the energy effects and successfully demonstrated it in two host/guest 
systems [Chan 1989). 
Calorimetric techniques are commonplace to pharmaceutical laboratories, 
applications of which are constantly evolving with the advancements in 
instrumentation. Also, crystal energies are more sensitive to doping as compared 
to the morphological changes and are relatively easier to quantify. Owing to these 
reasons, the characterization of crystal doping in the pharmaceutical field is 
frequently based on the energy changes in the crystals. Doped crystals in general 
have lower crystallinity, melting point, enthalpy of fusion, heats of solution and 
higher entropy and free energy compared to pure crystals. Calculation of 
crystallinity values based on a single parameter or a technique often was found to 
result in different values [Pikal 1987). This prompted academicians to develop 
scales to measure disruption based on the thermodynamic analysis of crystalline 
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solids. Accordingly, two indices were defined namely disruption index (d.i) [York 
1986) and excess entropy index (e.e.i). [Pikal 1987). 
The dimensionless disruption index compares the disorder created in the 
solid with that created in the liquid host by incorporation of guest molecules. It is 
defined as rate of change of the difference between the entropy of the solid and 
that of the liquid, with respect to the ideal entropy of mixing. For impurity mole 
fractions (x2) less than 0.05, a plot of the entropy change following solid to liquid 
transition of the doped crystals (l'>S) versus the ideal entropy of mixing (l'>Smideol) 
was experimentally found to give a straight line according to the equation: 
l'>S = 6S0 - (b-c) . i'>Smideol. 
where (b-c) is defined as the disruption index. This behavior has been 
experimentally verified in several host guest systems [York 1986] and used it to 
develop a thermodynamic basis for such behavior. A number of assumptions have 
been made in the theoretical development of disruption index such as : (i) Excess 
entropies of solid hosts as a result of the incorporation of guests are proportional 
to the ideal entropes of mixing and (ii) The concepts of ideal entropy of mixing, 
often used in gas and liquid mixtures are applicable to the compressed states also. 
Although the validity of these assumptions is arguable to a degree, the concept of 
disruption index is simple, of practical interest and experimentally substantiated 
by various host/guest systems at x2 < 0.05 [Pikal 1987). The values of disruption 
index in the experimental systems evaluated thus far were found to range from 5 
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to 800 [Duddu 1995]. A correlation between the d.i values and the dissimilarty in 
the properties of the host and the guest has also been established [York 1986]. 
The change in entropy (t.S ) as a result of the phase change can be 
obtained from either the entropy of fusion (Sr) or the entropy of solution (S,). 
Following thermal analysis of the doped crystals, the entropy of fusion can be 
calculated from the values of the heat of fusion and the melting temperature 
according to the equation: 
t.G =Aff r-T mL'>Sr 
Here, the Gibbs free energy term becomes zero at the equilibrium fusion 
temperature implying 1'.Sr=L'>H rl Tm . 
At times, the thermal history of the doped crystals during DSC/DT A 
analysis can induce relaxation oflattice strain and/or changes in their crystallinity. 
Also, partial decomposition might be evident as a result of heating the samples. 
Large errors in the experimental determination of the entropy of fusion values can 
occur in these cases. In such instances, entropy of solution, S,= (t.H-11.G)/T can be 
used as an alternative approach. While the free energy of solution process (1'.G) 
can be obtained from the solubility/intrinsic dissolution experiments, solution 
calorimetry can be used to determine heat of solution values (11.H) at a fixed 
temperature. [Simonelli 1976, Grant 1986, Aki 2001]. 
The ideal entropy of mixing quantifies the disorder induced in any host 
substance (irrespective of its state) by the simple mixing of guest molecules so as 
to form a solution of guest+host. It explicitly disregards any other interactions 
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between the guest and the host. It can be calculated from the knowledge of the 
composition of the doped crystals following the equation: 
il.Sm;doal = -R Xj lnxj 
where Xj is the mole fraction of component j in the solid mixture. 
With the current state of the art analytical instrumentation and the 
advances in separation science, isolation & quantification of impurities in the host 
crystals is not outside the scope of the analytical chemist. Such analytical data can 
then be used in the calculation of the ideal entropy of mixing of doped crystals. 
Knowledge of the entropy change following fusion or dissolution of the doped 
crystals along with the ideal entropy of mixing thus allows calculation of the 
disruption index at low levels of impurities. The invalidity of thermodynamic 
assumptions at higher levels of impurities coupled with other developing 
interactions between the host and the guest (eg-Eutectic formation) at such levels 
limits the concept of disruption index to impurity mole fractions of less than 0.05. 
In an attempt to theoretically strengthen the concept of disruption index 
while questioning the validity of its assumptions, Pikal and Grant developed an 
analogous index to quantify crystal disruption called the 'excess entropy index' 
(S2 E JR) [Pikal 1987). According to this development, the pure entropy change of 
doped crystal as a result of the solid to liquid phase change was redefined 
following a more rigorous thermodynamic treatment and the limitations of the 
earlier assumptions were identified and compensated. Also, the disruption index 
was expressed in tem1s of limiting partial molar excess entropy of the guest. The 
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changes in the entropies of the doped crystals during the fusion and solution 
processes are expressed as quadratic functions of the mole fraction of guests as, 
ti.Sr=6Sro _ (SE2)0 x2 + K x/ 
6S, =6S'o - 6Sm;deat - [ (Sa·02- s•2) +( S E2)0] x2 + K xz2 
where (SE2) 0 =Partial molar excess entropy of the guest 
x2 is the mole fraction of the guest 
6Sr0 is the entropy change during fusion of the pure crystalline host 
6S' 0 is the entropy of solution of the pure crystalline host 
s a·
0
2 is the entropy of the guest in standard solution phase 
s· 2 is the entropy of the guest in pure liquid state 
K is a positive constant 
The partial molar excess entropy of the guest is converted into a dimensionless 
number after dividing by the universal gas constant and tenned excess entropy 
index. While this is considered a more exact approach to quantify crystal 
disruption, it does not necessarily negate the concept of disruption index. 
Moreover, a correlation was established (d.i=0.35[( SE2)0 ]P, p=0.912) between the 
two indices, within the limitations of the assumptions made in Pikal and Grant' s 
analysis [Pikal 1987]. Disruption index is therefore most frequently used in view 
of the simplicity of the model and its ease of detennination, notwithstanding the 
limitations in its assumptions. 
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3. MATERIALS AND METHODS 
3.A. Materials: 
Aspirin (Sigma, St.Louis.MO Lot# 88H041 l), Benzoic acid (JT Baker, NJ, Lot# 
Nl0603), Caffeine (JT Baker, NJ, Lot# T06596), Chloramphenicol, (Sigma, 
St.Louis,MO,Lot# 48H0570), Chlorpropamide (Sigma, St.Louis,MO, Lot# 
3 IH0722), lndomethacin (Sigma, St. Louis, MO, Lot# 60K0745), a-Naphthalene 
acetic acid (Sigma, St.Louis.MO, Lot# 99H3253), Naprpoxen (Sigma, 
St.Louis,MO, Lot# 79H3685), Phenytoin (Lot#, Pfizer, NJ) Piroxicam (Sigma, 
St.Louis.MO, Lot# 126H0820), Salicylic acid (Sigma, St.Louis.MO, Lot# 
49H3435), Theobromine (Sigma, St.Louis.MO, Lot#50K2503), Theophylline 
(Sigma, St.Louis,MO, Lot# 30K0939, Lot# 68H0610), Tolbutamide (Sigma, 
St.Louis.MO, Lot# 47Hl030), Urea (JT Baker, NJ, Lot# N37340). 
All the solvents used were bought from JT Baker and are ofHPLC grade. 
3.B. Methods: 
3.B. I. Crystallization from supercrtical solvent: 
The Rapid Expansion of Supercritical Solution (RESS) process was used in the 
co-crystallization of solid active pharmaceuticals and their structurally related 
impurities. In the RESS process, the solutes of interest were dissolved in 
supercritical carbon dioxide (SC C02), forming a homogenous supercritical 
solution. Nucleation of solutes was then induced by rapidly reducing the solution 
density through expansion to atmospheric conditions. A rapid decrease in solvent 
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strength results in high supersaturation that leads to very high nucleation rates 
[Mohamed 1989]. The time for nucleation and growth is very limited {typically 
10·5 to 10·6 seconds), resulting in very small particles [Debenedetti 1993, Turk 
1999]. Also, the rapid nucleation and growth aids in locking the impurities into 
the crystal domains of the hosts by not providing sufficient time for the impurities 
to segregate. Absence of residual liquid solvents in the RESS produced crystals 
further reduces the possibility for segregation effects in the solid state. 
In addition, the rapid decompression of SCF generates mechanical 
perturbation within the so lution that travels at the speed of sound. Consequently, 
very uniform conditions are reached within the nucleating media. Uniform 
conditions in the nucleation media assist in homogenous dispersion of impurities 
in the crystal domains of the hosts. The crystal disruption following such uniform 
and rapid co-crystallization can be expected to be controlled and large. All the 
above factors contributed to the special interest in RESS aided crystal doping and 
formed the rationale for its choice. Further, the concept is fairly nascent as 
reflected by the number of SCF aided crystal doping studies reported in the 
published literature [Weber 1997, York 1995]. 
The commercially availab le supercritical fluid extraction equipment 
(SFT150, Supercritical Fluid Technologies lnc., Delaware) was reconfigured to 
produce co-crystals of drugs and impurities by the rapid expansion of supercritical 
solution process. The modified design for the RESS process is schematically 
represented in Figure 8 and shown in Figure 9. 
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Figure 8. Schematic of RESS Process for Crystal Doping 
Figure 9. RESS Equipment used in Crystal Doping 
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Liquid C02 from a tank is pressurized using an air driven Haskel pump. The 
pump head is enclosed in a chiller-can through which a coolant at -10°C is 
continuously circulated. The coolant compensates for heat generation in the pump 
and prevents cavitation by maintaining C02 in the liquid state at all times. The 
pressurized liquid is then fed to the preheater at a controlled flow rate. The 
function of the preheater is to serve as a heat exchanger and raise the temperature 
of the pressurized liquid to the supercritical region. The preheater used was a five-
metered stainless steel coil wrapped with Omegalux rope heaters (FGR, Omega 
Engineering Inc., Stamford, CT). The temperature of the preheater was controlled 
using a Glas-Col temperature controller (Glas-Col, Terre Haunte, IN). The 
supercritical C02 from the preheater then flows into the 100 ml reaction vessel 
that contains the solutes to be recrystallized. 
The reaction vessel was typically packed with 90 g of 3 mm glass beads and 
10 g of solutes. The glass beads assist in improving the extraction efficiency of 
the SC C02 by providing better fluid contact with solutes while also serving to 
buffer the turbulent flow of the fluid through the vessel. The starting mixture in 
the reaction vessel consisted of a physical blend of 80% drug and 20% impurity. 
Placing glass wool at both ends of the reaction vessel supported the powder bed 
and also prevented the entrainment of solutes. Depending on the selectivity of 
extraction of the supercritical solvent, saturated solutions form in the reaction 
vessel with fixed compositions of the host and impurity. The saturated 
supercritical fluid solution from the reaction vessel flows through a 0.5 µ frit into 
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the pre-expansion chamber. It can be treated in the pre-expansion chamber to 
control the supersaturation prior to expansion. For the purposes of consistency in 
the crystal doping studies, the preexpansion chamber was maintained at 50°C 
above the extraction temperature. The presence of cold spots and abrupt 
temperature drop in the lines were found to cause premature precipitation of 
solutes, which in tum lead to plugging of lines. All the lines and connectors 
therefore were heated using Omega rope heaters controlled by a common Glas-
Col temperature controller. 
The saturated solution from the preexpansion chamber then passed through a 
heated restriction device maintained at 1OO-l50°C prior to rapid expansion. The 
heated restriction valve compensates for the Joule-Thompson cooling that occurs 
as a result of rapid expansion. The expansion device used was a stainless steel 
capillary with an aspect ratio of 100 (5" L I 0.05" ID) that is securely inserted 
through the snap cap of a 40 ml glass vial (Daigger, Lincolnshire, IL). Given that 
the interest here is in the crystal morphology of the pharmaceutical actives rather 
than their particle size, a 40ml particle collection vial is best suited for these 
purposes. Use of a 40 ml glass vial also improved yields by preventing losses 
from the particle collection typically observed with larger vessels. C02 gas after 
deposition of the solids was exhausted through a custom filter and passed through 
lengthy tubing (5meters) prior to feeding to the thermo mass flow meter (Porter 
Instruments, Hatfield, PA). The gas flow rates were further measured (Infinity 
Rate Totalizer, Newport Electronics, Santa Ana, CA) over the course of the 
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experiment to get a more reliable estimate of the average C02 flow rates though 
the system. Typical flow rates of C02 through the system were between 5-10 
SLPM. At the end of each run, yields of the recrystallized materials were recorded 
and the vials stored in low humidity plastic bags at ambient temperature until 
further use. 
Following the above method, a number of drug-impurity mixtures (Table 10) 
were recrystallized and the efficiency of SCF aided crystal doping was evaluated. 
The supercritical region investigated in these studies included a temperature 
regime of 45-100°C and pressures between 2000-8000 psi. 
3.B. 2. Differential Scanning Calorimetry: 
DSC analysis was performed using a Perkin-Elmer DSC-7 equipped with an 
intercooler. Accurately weighed milligram samples were scanned in pin-holed 
aluminum pans (TA Instruments, Dupont) under a dry nitrogen purge. Various 
heating rates of 1,3,5 and 10°C/min were used to scan the different temperature 
regimes that were of interest to the samples under consideration. The instrument 
was calibrated for temperature and enthalpy using high purity Indium and USP 
Water. 
3.B. 3. Thermogravimetric Analysis: 
Thermal decomposition, moisture and residual solvent contents of the 
recrystallized materials were investigated using Perkin-Elmer TGA-7 at a heating 
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Table I 0. Drug-Impurity Mixtures Evaluated in RESS Recrystallization 
Studies 
APl Dopant 
Salicylic acid Aspirin 
Salicylic acid Benzoic acid 
Aspirin Benzoic acid 
Tolbutamide Chlorpropamide 
Tolbutamide Urea 
Piroxicam Theophylline 
Piroxicam Benzoic acid 
Theophylline Caffeine 
Theophylline Theobromine 
Phenytoin Caffeine 
Indomethacin Salicylic acid 
Naproxen a-Naphthalene-acetic acid 
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rate of 5°C/min. Samples were heated in an open platinum pan with the nitrogen 
purge at 60 mL/min. The temperature scale was calibrated by measuring the Curie 
point (354°C) of standard PE ferromagnetic Nickel, while standard weights were 
used to calibrate the weight scale. 
3.B. 4. Powder X-ray diffractometry: 
XRPD was performed using a Rigaku-Geigerflex KD-2660-N X-ray 
diffractometer controlled by the D-Max B controller and Datascan MDI software. 
The diffractometer is equipped with a copper target, yielding X-rays of 
wavelength l.54° A. Diffractograms were obtained over the 28 range 3° to 50° and 
analyzed using MDI Jade-5 software. Depending on amounts of the samples 
available for XRPD analysis, the powders are either packed into the 0.2 mm 
groove of a glass slide (Regular Method) or sprinkled onto a thin film of Apiezon 
grease applied onto the glass slide (Grease Method). The operating conditions 
included: scan speed 3°/minute, sampling interval 0.020° and X-ray power (tube 
input) of 40kV/40mA. The path ofx-rays is controlled utilizing standard slits such 
as: Y2 divergence, Y2 scatter slits, 0.3mm receiving and 0.6mm receiving 
monochromator slits, in that order. The instrument is routinely calibrated under 
these operating conditions using Rigaku Quartz as standard. 
3.B. 5. Polarizing Optical Microscopy: 
The bulk particle morphology and the crystalline birefringence behavior of the 
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samples were investigated using a polarizing optical microscope (Leitz Lab 12 
Pol S) with a tungsten lamp as the light source. The objects are viewed and 
photomicrographs developed utili zing such accessories as a Sony video camera, 
Boeckeler Via-70 Video marker and Sony 5600MD Video printer. A first order 
red compensator was used to enhance the clarity of the photomicrographs. 
Untreated powders or powders dispersed in suitable media were placed on a glass 
slide and covered with a cover slip, prior to staging them in the path of brightfield 
light. The objects were viewed in the magnification range 200-BOOX, calibrated 
using an Olympus calibration slide. 
3.B. 6. HPLC Analysis: 
The quantities of host and guest m theophylline+caffeine and 
theophylline+theobromine co-crystals were assayed by liquid chromatography 
(LC). Jsocratic, reversed phase LC separation methods were developed and 
validated following modifications to the respective USP methods for the hosts and 
using external standards. Specific details of the methods are summarized in 
Tables 11 and 13, while the representative chromatograms of these mixtures are 
shown in Figures I 0 and 11 . The results of the validation experiments of 
theophylline+caffeine and theophylline+theobromine are respectively 
summarized in Tables 12 and 14. Calibrated HP 1100 series LC system equipped 
with a diode array detector was used in these analyses. 
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Table 11. HPLC Method of Assay for Theophylline & Caffeine 
Column Supelco C-18 column, 4.6mm x 15cm 
Mobile Phase 15% Acetonitrile + 85% Sodium acetate buffer (pH of mix= 3.97) 
Flow rate 1.0ml/min 
Runtime 6 minutes 
Injection Volume 20 µL 
Detector HP Diode array, 280nm 
System HP 1100 series 
Retention times 2.5 min (Theophylline) and 3.5 min(Caffeine) 
Table 13. Validation Results ofHPLC Method of Analysis ofTheophylline 
And Caffeine 
Parameter* Theophylline Caffeine 
Range 40-240 µg/ml 2-60 µg/ml 
Precision 0.22-0.37% 0.2-0.54% 
Accuracy 98-100% 97-102% 
Linearity 0.07% 0.05% 
Reproducibility -----Demonstrated over 1 week-----
Theoretical Plates >15000 >18000 
Resolution - 7 
*Refer USP 24/NF 19, 200 I for the definitions of validation parameters and their significance. 
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Table 12. HPLC Method of Assay for Theophvlline & Theobromine 
Column Supelco C-18 column. 4.6mm x 15cm 
Mobile Phase 5% Tetrahydrofuran + 95% USP Water 
Flow rate 1.0ml/min 
Runtime 10 minutes 
Injection Volume 20 µL 
Detector HP Diode array, 280nm 
System HP 1100 series 
Retention times 2.4 min {Theobromine) and 3.7 min{Theophylline) 
Table 14. Validation Results ofHPLC Method of Analysis ofTheophylline & 
Theobromine 
Parameter* Theophylline Theobromine 
Range 10-300 µg/ml 2-160 µg/ml 
Precision 0.08-0.40% 0.06-0.34% 
Accuracy 98-101 % 98.5-100% 
Linearity 0.02% 0.07% 
Reproducibility -----Demonstrated over 1 week-----
Theoretical Plates >16000 >14000 
Resolution - 8.5 
*Refer USP 24/NF 19, 2001 for the definitions of validation parameters and their significance. 
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4. RESULTS AND DISCUSSION 
4.A. Habit modification and Solubility enhancement: 
Qualitative observations of the phase behavioral events of Salicylic acid +Aspirin 
in supercritical C02 revealed that the three component mixture exists in a single 
phase at 75°C, 4000 psi (Chapter 5). The solvent power of SC C02 (30 ml) at 
these P,T conditions is therefore sufficiently high to dissolve salicylic acid (4 mg) 
and aspirin (I mg) and form a clear solution. Knowledge from the phase 
behavioral studies provided the ability to perform rapid co-crystallizations from 
the homogenous supercritical solutions of host + impurity in SC C02. The 
presence of aspirin as an impurity was found to affect the crystallization of 
salicylic acid in two different ways. Firstly, the bulk morphology of recrystallized 
salicylic acid changed from long needles to short dense network in the presence of 
aspirin. (Figures l 2a and l 2b) The effects of varying supersaturation on the 
crystallization kinetics and hence the particle size were observed by changing the 
pressure conditions prior to expansion. As can be seen from Figures 13a to 13e, 
the crystal size appears to be increasing as a combined effect of the lowered 
supersaturation and increased time for growth upon lowering the pressure from 
4500 psi to 750 psi. The use of ethanol as a cosolvent with SC C02 promoted 
selective extraction of salicylic acid while reducing the impurity effects on the 
crystal morphology of salicylic acid (Figure 13 f). Particle size reduction, however 
was still evident even in this case that is implicit in RESS processing. 
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12a. Salicylic acid recrystallized from SC C02 at 75°C, 4000psi 
12b. Salicylic acid recrystallized in the presence of Aspirin from SC C02 at 75°C, 4000psi 
Figure 12. Change in the Crystal Morphology of Salicylic acid Upon Doping 
with Aspirin 
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c.Recrystallized from SC C02 at 75°C, 750psi f. Recrystallized from SC C02+EtOH at 45°C, 3000psi 
Figure 13. Effect of Precipitation Conditions On the Morphologv of 
Salicylic Acid + Aspirin Co-Crystals 
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The effects on the crystallinity of pure salicylic acid recrystallized by RESS were 
investigated using DSC and XRPD. The results of DSC analysis of SCF 
recrystallized salicylic acid are shown in Figure 14 and summarized in Table 15. 
As can be seen from Table 15, no significant differences in the melting 
temperature or the enthalpy of fusion values are observed in salicylic acid 
recrystallized from SC C02 compared to the original material. These results are 
consistent with the XRPD observations where no changes in the crystallinity of 
salicylic acid were seen as a result of supercritical recrystallization. However, as 
can be seen from Figure 15, the crystal habit was significantly altered from plates 
to acicular needles, depending on the expansion conditions. Supercritical fluid 
recrystallization herein provides the independent ability to change the crystal 
habit while not altering the polymorphic form of the APL In addition to the 
changes in the crystal habit, particle size reduction was also apparent in RESS 
produced salicylic acid the extent of which depended on the expansion conditions. 
The secondary effects of the presence of a co-solute in the crystallization 
medium included enhancement of the yields. For example, a five-fold increase in 
the salicylic acid yield was observed in the presence of aspirin. While 
crystallization of pure salicylic acid at the same conditions of pressure and 
temperature yielded 390 mg of product, the presence of aspirin increased the yield 
up to 2050 mg per JOO L of recrystallizing solvent C02 used (at STP) (see 
Appendix A, sections I B and 28 for further details). Co-solute mediated 
enhancement of salicylic acid solubil ity in SC C02 in the presence of aspirin is 
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Figure 14. DSC Thermograms of RESS Recrvstallized Salicylic Acid 
Table 15. Thermal Analysis of RESS Recrystallized Salicylic acid 
Material Melting Onset End Melting Delta H 
Point Range 
oc oc oc oc Jig 
Pure Salicylic acid as obtained from Sigma 161.3 158.7 163. 1 4.5 188.3 
Recrystallized from SC C02 at [45°C, 3000psi] 160.3 158.6 161.4 2.7 175.6 
Recrysta ll ized from SC C02 at [65°C, 3000psi] 159.8 158 .3 160.4 2. 1 175.4 
Recrysta ll ized from SC C02 at [75°C, 4000psi] 160.8 157.5 161.9 4.4 169.9 
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expected be the cause for improved yields. In a similar study, the effect of trace 
amounts of methanol and acetone on the solubility of theophylline+caffeine was 
also investigated. The results of these studies are summarized in Figure 16. As 
can be seen from figure 16, acetone appears to significantly enhance the solute 
uptake by SC C02 at lower temperatures. Higher temperatures, on the other hand 
reduced the solute uptake, perhaps because of a reduction in the solvent density. 
The results of the effects of methanol were inconclusive owing to the difficulty in 
preventing MeOH from condensing in the collection vial during particle 
formation. 
4.B. Eutectic Formation: 
Addition of aspirin as an impurity to the crystallization media of salicylic acid 
resulted in the formation of a low melting mixture. As can be seen from Figure 
17, recrystalllization from pure SC C02 at 75°C and 4000 psi formed a low 
melting mixture that melted at l l 5°C. On the other band, use of SC C02 + ethanol 
at 45°C and 3000 psi as the solvent system resulted in the formation of a similar 
low melting mixture as a minor component and pure salicylic acid as the major 
component. Selective salicylic acid crystallization is evident in the latter case. 
Although no eutectic formation between salicylic acid and aspirin has been 
reported to date, similar melting point depressions were observed in these 
mixtures by Mroso et al. [Mroso 1982). Depression in the melting point depended 
on the amount of aspirin present as can be seen from Figure 17. 
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Figure 17. DSC of Salicylic acid +Aspirin Mixtures Figure 18. DSC of Salicvlic acid+ Benzoic Acid Mixtures 
Thennal analysis of RESS produced mixtures revealed that a constant 
composition mixture that melted at l I 5°C was fonned at the various conditions 
studied. Similar melting depressions were seen in RESS recrystallized mixtures of 
salicylic acid+benzoic acid (Figure 18), aspirin+benzoic acid (Figure 19), 
tolbutamide+ chlorpropamide (Figure 20) as compiled in Table 16. Such 
reproducibly large shifts in the melting temperatures indicate the fonnation of low 
melting compositions of drugs and impurities and possibly eutectic fonnation. 
4.C. Reduction in Crystallinity/Amomhous Conversion: 
Depending on the affinity of the impurity to the host and the relative rates of 
nucleation and growth, solid solutions or solid dispersions of the impurity in the 
host matrix are fonned. A reduction in the crystallinity and subsequent amorphous 
conversion of a number of host crystals was affected by this means following the 
RESS aided co-crystallization of host and the impurity (Table 17). Weber et al 
reported a similar study involving the co-precipitation of chloramphenicol+urea 
and ascorbic acid+aspirin systems by the PCA (precipitation from compressed 
antisolvent) process [Weber 1997] . Following the NMR analysis, the authors 
stated that a general reduction in crystallinity and an increase in the amorphous 
content was seen in these co-crystals. The authors further expressed the difficulty 
in detecting modest changes in the crystallinity of doped crystals, when NMR 
revealed no specific infonnation in the ascorbic acid+aspirin co-crystals. In view 
of this fact, a number of complementary techniques discussed in section D were 
128 
AtplrlrttBeruole Acid 
-191Pi.re,._., -lbl"""9S.-Acid -1e1~Pl"Y... -!di~.~) 
-fel~40D0p9il -(llf4K.aooop.;J -1o1f12C.2<XlllJi9ol -11111S2C."°°°""'I 
Figure 19. DSC Thermograms of Aspirin+ Benzoic Acid Mixtures 
Tolbutamldi9•Chlorpropamlde 
d 
c 
b 
a 
!c!!IOC.5000poo! 
Figure 20. DSC Thermograms ofTolbutamide + Chlorpropamide Mixtures 
129 
Table 16. Formation of Low Melting Mixtures of Drugs + Impurities Upon 
RESS Recrystallization 
Drug( 1 )+lmpurity(2) Tm1 T mi Tm1•2 RESS Co-Crystals 
(OC) (OC) (OC) 
Salicylic acid+Aspirin 161.3 142.9 11 5 
Salicylic acid+Benzoic acid 161.3 123 .7 112 
Aspirin+Benzoic acid 142.9 123 .7 90, 105 
Tolbutamide+Chlorpropamide 130.5 121.5 108 
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Table 17. Summa sta llization Studies of Various Dru2-In11rn ritv Mixtures 
API 
Salicy li c acid 
Salicy lic acid* 
Aspirin* 
Tolbutamide 
Tolbutamide 
Pi roxicam 
Piroxicam 
Theophylline 
Theophylline* 
Phenytoin 
I ndomethaci n 
Naproxen 
Dopant 
Aspirin 
Benzoic acid* 
Benzoic acid* 
Chlorpropamide 
Urea 
Theophylline 
Benzo ic acid 
Caffeine* 
Theo bromine 
Caffeine* 
Salicylic acid* 
a-Naphthalene-acetic acid 
Observation• 
Habit modification, Improved Yield, Low melting Mixture 
Low melting Mixture, Selective extraction 
Low melting Mixture, Selective extraction 
Polymorphic Conversion 
Polymorphic Conversion 
Amorphous Conversion 
Amorphous Conversion 
Selective Extraction, Hydrate Formation 
Selective Extraction 
Amorphous Conversion, Selective extraction 
Amorphous Conversion, Selective extraction 
Amorphous Conversion 
•Reduction in Crystallinity seen in all the doped crystals. 
·component Preferentially Extracted. 
utilized in this study. XRPD analysis served as a very powerful tool in monitoring 
the sensitive changes in the crystallinity of doped crystals. The initial examination 
of the diffraction patterns of the recrystallized materials and physical blends 
revealed no gross differences in a majority of the drug-impurity mixtures studied. 
Exhaustive analysis of the raw XRPD data was then undertaken following which 
the FWHM (full width at half maximum) values were calculated for individual 
peaks. Sections C of Appendix A tabulates the analyzed XRPD data of all the 
drug-impurity mixtures reported in this chapter. Although no crystallinity scales 
were developed from these values, a comprehensive evaluation of the crystallinity 
was made based on such factors as the intensity of diffraction, peak shifts and 
FWHM values. Comparison of the intensity of reflections from doped crystals 
with those of the pure crystals and the physical mixtures indicated a general 
reduction in the crystallinity in all the drug-impurity mixtures studied (Section C, 
Appendix A) . Figures 21 and 22 illustrate this fact where a drastic reduction in the 
intensity of salicylic acid was seen upon co-crystallizing with aspirin and benzoic 
acid respectively. Polarizing optical microscopy of salicylic acid doped with 
aspirin indicated a loss in the birefringence further validating the reduction in 
crystallinity (Figure 23). This reduction in crystallinity may be mediated through 
the eutectic formation between SA and aspirin reported in section-B. 
Reduction in crystallinity, in theory, reduces the extent to which different 
planes diffract x-rays while also causing the broadening of peaks. On the other 
hand, an impurity can also influence the crystal geometry by not only altering the 
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SA recrystall ized from SC C02 at 32'C, 1400psi 
lattice parameters but also the order in which they pack. Such crystal disruption 
translates into a shift in the angle of diffraction and/or broadening and subsequent 
splitting of the peaks. Crystal disruption upon recrystallizing a number of drugs 
from SC C02 in the presence of structurally related impurities was also confirmed 
based on the broadening and shifts of the major x-ray diffi-action peaks. A 
complete list of the altered major diffi-action peaks from the XRPD analyses of 
several SCF recrystallized mixtures are tabulated in bold and italicized fonts 
(refer to sections C of Appendix for details). 
Illustrative examples are excerpted from Appendix A to represent the 
broadening and shifts of XRPD peaks and are shown in Tables 18a to l 8c and 
Figures 24 to 26. Tables I 8a to 18c respectively list the major diffraction peaks 
and their FWHM values for aspirin+benzoic acid, tolbutamide+urea and 
naproxen+a-naphthalene acetic acid co-crystals recrystallized at various 
conditions. As can be seen from Tables I 8a to I 8c, systematic shifts in the 20 
values are evident in various co-crystals. The possibility of preferred orientation 
to have caused the above reported peak shifts was excluded by establishing a 
single reproducible peak in each case. On the other hand, peak broadening 
indicated by the increased FWHM values can be seen in Figures 24 to 26. Of 
particular interest here is the broadening of consistently selective peaks that in 
part depended on the extraction conditions. From a crystallographer's standpoint, 
it is possible to identify the specific faces of the crystal that are likely to be 
attacked by the impurity utilizing the above data. 
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Table 18. Representative XRD Peaks Showing Peak Shifts and Peak 
Broadening Upon Doping Crvstals with Impurities 
T bl 18 A . . B .d a e a. i!]: mn + e nzo1c ac1 
Condition 
[ 46C, 2000psi] 
[46C, 4000psi] 
[46C, 8000psi] 
[62C, 2000psi] 
[ 62C, 4000psi] 
[61C, 8000psi] 
[7SC, 2000psi] 
[76C, 4000psi] 
[76C, 8000psi] 
Phy Mix 
20(FWHM) Values 
3. 16(0.38) 7.88(0.S3) 16.22(0.3 1) 17. 14(0.2 1) I 9. 12(0.2S) 23.78(0.21) 
8. 16(0.3S) JS.62(0.3) 16.3(0.28) 17.22(0.28) 19. 18(0.3) 27. 16(0.37) 
8.08(0.3 1) I S.64(0.27) 16. 16(0.23) 17. 12(0.26) 19.06(0.36) 27. 18(0.4 1) 
7.42(0.13) 7.8(0.39) 8.08(0.28) 16. 16(0.2) 19.03(0.28) 30. 12(0.17) 
7.84(0.46) 8. 1(0.44) J S.62(0.28) 19.06(0.32) 20.72(0.44) 21.16(0.S4) 
3.22(0.34) 7.8(0.26) 16.74(0.32) 17. 18(0.3S) 22.66(0.2S) 27.14(0.39) 
3.2 1(0.27) JS.64(0.28) 22.72(0.3 1) 2S.23(0.38) 2S.3(0.47) 27.2(0.2S) 
J S.62(0.24) 17.24(0.2) 23.26(0.36) 2S(0.4) 27. 16(0.37) 36.1 6(0.SS) 
IS.62(0.22) 16. 78(0.23) 21(0.69) 22.7(0.26) 23.28(0.4 1) 27.16(0.38) 
7.86(0.18) 8. 14(0.2 1) IS.66(0.1 9) 16.32(0.12) 17.24(0. JS) 19.2(0.21 ) 
20.76(0.2S) 2 1.06(0.28) 22.76(0. 16) 27.04(0.3) 30.3(0.17) 36.02(0. 13) 
T able I 8 b Tolbutamide + U rea 
Condition 20(FWHM) Values 
[49C, 4000psi] 10.3(0.24) I 0.65(0.18) 11.38(0.22) 15.02(0.5 1) 19.64(0.36) 21.38(0.3 1) 23.12(0.32) 
(48C, 8000psi] I 0.36(0.23) 10.61(0. 18) 11.42(0.2) 15.62(0.32) 19.66(0.32) 21.4(0.4) 23.2(0.44) 
[63C, 4000psi] I 0.34(0.23) 10.62(0.23) 11.42(0.22) 15.62(0.3) 19.66(0.33) 21.44(0.27) 23.2(0.28) 
[64C, 8000psi] I 0.28(0.22) 11.34(0.15) 18.06(0.22) 19.62(0.26) 19.96(0.37) 26.38(0.26) 23.16(0.2) 
[7SC, 4000psi] 10.34(0.23) I 0.34(0.23) 11.42(0.22) 19.64(0.35) 20.98(0.33) 2 1.3(0.44) 23. 16(0.27) 
[76C, 8000psi] 10.36(0.26) I 0.36(0.26) 11.46(0.23) 19.62(0.36) 20.04(0.60 20.94(0.42) 21.52(0.44) 
!Phy Mix 15.62(0. 17)119.6(0.2 1)119.98(0.26)120.94(0.18)1 21.5(0. 16)1 23. 18(0. 18)1 26.4(0.21)1 
T a ble I 8c. Na.Qroxen +a-N hhl !!Pl t a ene a cetic ac1 
Condition 20(FWHM) Values 
[SOC, 4000psi] 6.69(0.S7) 11 .82(0.22) 13.96(0.24) 19.06(0.3 1) 22.3(0.37) 27 .86(0.6 1) 
[SOC, 8000psi] 6.76(0.44) 11.86(0.23) 18.68(0.6 1) 19. 12(0.36) 22.36(0.44) 27.9(0.44) 
(63C, 2000psi] 6.7(0.42) 13.96(0.23) 18.64(0.7 1) 19.08(0.3) 22.3S(0.33) 22.06(0.34) 
[62C, 4000psi] 6.7(0.38) 6.94(0.48) 18. 7S(0.36) 19. 1(0.3 1) 22.34(0.3) 27 .42(0.38) 
[63C, 8000psi] 6.73(0.28) 7.04(0.28) 18.69(0.67) 19.08(0.22) 22.38(0.3S) 23.78(0. 16) 
[78C, 4000psi] 6.68(0.18) 11.8(0.04) 12.69(0.08) 19.1(0.23) 22.44(0.28) 22.64(0.4) 
[76C, 8000psi] 3.4(0.44) 3.54(0.4) 6.64(0.3 1) J 9.04(0.2S) 22.66(0.39) 27.47(0.44) 
Phy Mix 6.68(0.2S) 11.84(0.09) 12.74(0.2) 13.94(0. IS) 18.66(0.48) 19. 1(0.2) 
22.4(0.37) 27.53(0.27) 
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While crystal doping for the most part resulted in a general reduction in the 
crystallinity, extreme situations were also identified where major loss of 
crystallinity and amorphous conversion ensued. For example, a drastic reduction 
in the crystallinity was seen upon SCF recrystalli zation of naproxen+a-
naphthalene acetic acid (Figure 27). As can be seen from the figure, both the 
increases in the pressure and temperature for extraction appeared to significantly 
reduce the crystallinity of the mixtures, perhaps by controlling the levels of the 
impurity in the host crystals. Piroxicam+theophylline co-crystals recrystallized 
from [65°C, 6000 psi] represent another example where drastic reduction in 
crystallinity occurred upon crystal doping (Figure 28). Similarly, reprecipitation 
ofpiroxican1+benzoic acid mixtures at low temperature conditions of (49°C, 2000 
psi] and (50°C, 4000 psi] formed weakly crystalline, low melting mixtures 
(Figures 29 and 30). Further increases in the temperature and pressure during the 
extraction of these mixtures resulted in amorphous conversion. As indicated by 
Figures 29 and 30, complete amorphization is confirmed following the powder x-
ray diffraction and DSC analyses of these mixtures. Analogous amorphous 
conversion was also evident in mixtures of indomethacin+salicylic acid extracted 
at higher temperature and pressure conditions as can be seen from Figure 31. 
Phenytoin+caffeine extracted from (76°C, 2000 psi] also formed an amorphous 
mixture while other extraction conditions selectively crystallized caffeine (Figure 
32). All the above studies indicate that the composition of the mixtures prior to 
the rapid expansion in RESS process is the limiting factor in controlling the 
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crystallinity of the particles formed. Rapid recrystallization conditions of RESS 
process represent the far from equil ibrium conditions during crystallization. In 
addition to the existing thermodynamic instability of the highly supersaturated 
SCF solution, the presence of impurity in the crystallizing medium of the host 
might have disfavored the formation of the most stable form of the host. 
Apparently, a reduction in the crystallinity was seen in all the drug-impurity 
mixtures recrystallized from SC C02. In instances where the impurity levels are 
adequate to cause severe crystal disruption, drastic reduction in crystallinity and 
subsequent amorphization conversion might have occurred. 
4.D. Hydrate Formation: 
In RESS, the saturated supercritical solution in the pre-expansion chamber at a 
significantly high pressure is rapidly expanded through a micrometering valve 
into a collection vial at atmospheric conditions. Owing to the large pressure drop 
across the micrometering valve, Joule-Thompson cooling occurs that has the 
potential to plug the valve and the lines downstrean1 of it. The micrometering 
valve is therefore maintained at 1OO-l50°C to compensate for the cooling effect. 
The effect of the temperature of the micrometering valve on the particles formed 
is often disregarded so long as the flow of supercritical solution through it is 
uniform. An extreme case where this norm does not hold was identified while 
dealing with the RESS of theophylline+caffeine mixtures. Figure 33 shows the 
XRPD patterns oftheophylline +caffeine co-crystals produced by the RESS 
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process. The micrometering valve in this case was maintained at I 00°C. As can 
be seen from the figure, the diffraction patterns of the RESS recrystallized 
mixtures extracted from lower temperatures were significantly altered. 
Comparison of these patterns to the various crystal forms oftheophylline revealed 
that the end product was the monohydrate form. Although no significant 
temperature drop was evidenced during the expansion, RESS produced 
theophylline appeared to have picked up moisture from the atmosphere and 
instantly formed a hydrate. Similar conversion from anhydrous to hydrous form 
of theophylline has been reported during the wet granulation and pelletization of 
theophylline. [Herman 1989] Further, Rodriguez-Homedo and Wu investigated 
the crystallization kinetics of the monohydrate form and reported that mechanism 
for the growth is defect mediated. This mechanism is of particular interest while 
dealing with doping of theophylline crystals. As can be seen from Figure 33, 
recrystallization of theophylline+caffeine from higher temperature conditions did 
not allow this conversion. Extending the mechanism proposed by Rodriguez-
Homedo and Wu, it is possible that higher levels of caffeine may have competed 
with water molecules during the crystallization step and disallowed the 
conversion. To further validate this hypothesis, Theophylline+Caffeine mixtures 
were recrystallized from SCC02+ MeOH and SCC02+Acetone with the 
micrometering valve set at I 00°C. As can be seen from Figures 34 and 35, altered 
proportions of drug and impurity as a result of modified solvent systems did not 
allow the water molecules to be doped into the crystals and form a hydrate. 
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Figure 34. Recrvstallization ofTheophvlline+Caffeine from SCC02+MeOH 
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Figure 35. Recrystallization ofTheophylline+Caffeine From SCC02+Acetone 
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Increase in the temperature of the micrometering valve to l 50°C (Figure 36) also 
did not allow the conversion to a hydrate, perhaps by raising the temperature of 
the particles to the extent where no condensation from the atmosphere occurred. 
4.E. Polymorph Conversion: 
The commercially available polymorph ofTolbutamide is the orthorhombic form 
I that crystallizes as rectangular prisms [Leary 1981). DSC thermogram and 
powder x-ray diffractogram of this form are distinctively different from form II as 
can be seen in Figures 37 and 38. Polymorph I was utilized for RESS 
recrystallization from three different supercritical fluid conditions viz. [45°C, 
5000 psi] , [60°C, 5000 psi] and [75°C, 5000 psi]. Recrystallization at all the three 
conditions resulted in the conversion of form I to form II as reflected by the shift 
in melting points (Figure 37). As can be seen from the figure, form I exhibits a 
melting endotherm at l 30.5°C. The endotherm occurring at 40°C was reported to 
be due to the enthalpic relaxation from the rearrangement of hydrogen bonds in 
the molecule [Leary 1981 ]. On the other hand, the RESS recrystallized materials 
showed melting endotherms between l l8°C and l23°C. The melting temperature 
of polymorph II could not be exactly determined due to the simultaneous 
conversion of form II to I during the heating step. In addition, this transformation 
was reported to occur in the solid state and not from the melt of fom1 II, making 
the events rather difficult to distinguish [Kimura 1999]. A possible reason for this 
may be because of the spontaneous transformation from polymorph U to I, 
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Figure 38. XRPD Patterns Tolbutamide Polvmorpbs I and II 
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dependent on the free energy difference between the two fonns. Published 
literature however indicated that polymorph II is a low melting metastable fonn 
[Kimura 1999). Reduction in the melting temperatures of RESS recrystallized 
materials is therefore ascribed to the conversion of fonn I to fonn II. The true 
identity of RESS recrystallized material is established from their x-ray diffraction 
behavior. XRPD results from Figure 38 confinn a polymorphic conversion from I 
to U, consistent with the results from thennal analysis. The conversion to a 
metastable fonn II upon RESS recrystallization can be attributed to the altered 
kinetics of nucleation and growth. These results are in agreement with Kimura et 
al's study [Kimura 1999) where polymorph II was produced from a spray dried 
intennediate (fonn IV). 
It is noteworthy that polymorphs III and IV closely resemble fonns I and 11 
respectively, with negligible free energy differences within each pair [Rowe 
1984) . It is therefore possible that reversible transfonnations between these fonns 
may occur during the analytical characterization. The XRPD patterns of 
Tolbutamide+Urea mixtures recrystallized from SC C02 exemplifies this fact 
where a mixture of fonns II and IV resulted at few extraction conditions (see 
Figure 38 and Section C, Appendix B). Conversion of fonn I to II following 
RESS recrystallization was evident even in the presence of urea as impurity. 
XRPD and DSC results of RESS mixtures summarized in Figures 39 and 40 
validate the conversion to fonn 11. In addition, a reduction in the crystallinity of 
tolbutamide was seen following doping with urea (refer to section C for details). 
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Reduction of the crystallinity in an already existing metastable form can be 
expected to enhance the dissolution rates, and thereby the bioavailability of the 
otheiwise poorly soluble tolbutamide. Utilizing dog as the animal model, Kimura 
et al reported a two-fold enhancement in the bioavalability from polymorph II 
compared to form I. Dissolution is identified as the rate limiting step in achieving 
therapeutic bioavailability values for this compound. Producing a metastable form 
coupled with the impurity-induced crystal disruption is therefore particularly 
attractive from the standpoint of improving the dissolution rates. Results of 
tolbutamide studies in summary, served as the proof of concept for utilizing SCF 
aided crystal doping toward improving the bioavailability of poorly soluble 
compounds. 
Among the other mixtures that also exhibited polymorphic conversions upon 
recrystallization from SC C02 included Tolbutamide+Chlorpropamide. The 
XRPD results of these mixtures are summarized in Figure 42. As can be seen, 
both the sulfonylrea compounds in this case were found to undergo polymorphic 
changes, making the study rather complex. Interestingly, DSC analyses of these 
mixtures revealed the formation of a low melting composition between these two 
hypoglycemic agents. (Figure 41). A rational extension to this study would be to 
test the bioavailability of the low melting composition of this metastable mixture 
and forms the scope for future research. 
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4.F. Selective Extraction: 
The potential for SCF based crystal doping was demonstrated in Sections A to E. 
Rapid nucleation and the growth implicit to RESS based crystallizations were 
taken advantage in doping the drug crystals with impurities. While supercritical 
fluid based crystal doping offers great promise in this regard, it has also been 
found to have a few shortcomings. This section addresses some of the limitations 
encountered in doping crystals by the RESS process. Firstly, the yields from 
crystallization are low due to the poor solubility of a majority of APls in 
supercritical C02. The utility of co-solutes and co-so lvents in improving the 
yields have been addressed in section A. Techniques to enhance the solubility of 
active pharmaceutical ingredients in SC C02 are of particular interest in this 
regard and are still at inception. Alternatively, supercritical antisolvent processes 
can be used to overcome this limitation of poor yields, although the advantages of 
liquid solvent-free RESS process maybe compromised to some extent. 
Another shortcoming associated with RESS based crystal doping arises from 
the selective solvent nature of supercritical fluids. The high resolution capability 
of supercritical solvents is widely taken advantage in chiral separations and forms 
the basis for supercritical fluid chromatography [Wong 1993, Hoke 2000]. In an 
exact contrast to such applications, SCF aided crystal doping relies on extracting 
both the host and the impurity at equal rates and forming a homogenous mixture. 
The efficiency of SCF crystal doping therefore depends on the relative rates of 
solubilization and recrystallization. While an optimum between these two kinetic 
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processes was attempted by probing a wide domain of supercritical region, 
selective extraction of components appeared to have overtaken in a majority of 
the cases. Theophylline+Caffeine represents a classic example of the selective 
extraction by SC C02 and has been studied in detail. 
The compositions of various co-crystals of theophylline and caffeine were 
determined by HPLC analysis and the results reported in Tables 19-20 and 
Figures 43-44. As can be seen from Figure 45, the relative amounts of 
theophylline and caffeine in the co-crystals formed are highly dependent on the 
supercritical extraction conditions. A general trend of increase in theophylline 
levels was found both with the increase in temperature and pressure. Within the 
constraints of the pressures and temperatures achievable with RESS equipment, it 
is therefore possible to control the levels of host and impurity in the co-crystals by 
changing the extraction conditions. For example, a 50/50 mixture of theophylline 
and caffeine was produced at I 00°C, 8000psi. In a further study, the effect of 
impurity on the extraction efficiency of the host was evaluated by using two 
different starting mixtures viz. 80/20 and 20/80. Comparison of Figures 43 and 44 
illustrates that the compositions of resultant co-crystals are dependent on that of 
the starting mixture. The presence of impurity therefore does play a role on the 
composition and the supersaturation of the supercritical solution prior to 
expansion. These results support the earlier findings that showed a reduction in 
crystallinity of the host induced by the impurity. 
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Table 19. Composition of Co-Crystals Produced from 80/20 Mixture of 
Theophylline +Caffeine 
Condition % Theophylline* o/oCaffeine* 
[46.5°C, 4000psi] 1.80 98.20 
[48°C, 8000psi] 4.58 95.42 
63°C, 2000psif 1.51 98.49 
[62 .5°C, 4000psi] 6.92 93.08 
[64°C, 8000psi] 17.6 1 82.39 
[76.5°C, 2000psi] 4.46 95.54 
[76°C, 4000psi] 12.05 87.95 
[75.1 °C, 8000psi] 32.99 67.01 
[100.1°C, 2000psi] 12.40 87.60 
[ 100°C, 4000psi] 25.11 74.89 
[ 100°C, 8000psi] 45 .98 54.02 
Physical Mixture 81.49 18.51 
Table 20. Composition of Co-Crystals Produced from 20/80 Mixture of 
Theophylline +Caffeine 
Condition % Theophylline* 0/oCaffeine* 
[47.7°C, 2000psi] 1.74 98.26 
[48.2°C, 4000psi) 1.03 98.97 
[ 4 7°C, 8000psi] 1.62 98.38 
[63°C, 2000psi] 1.43 98.57 
[63.2°C, 4000psi] 1.57 98.43 
[62.2C, 8000psi] 2.76 97.24 
[75.8°C, 2000psi] 3.2 1 96.79 
[74.5°C, 4000psi] 2.93 97.07 
[76.4°C, 8000psi] 4.79 95 .21 
[ 100.9°C, 4000psi] 4.42 95.58 
[98. 7°C, 8000psi] 7.02 92.98 
Physical Mixture 20.35 79.65 
•Values reported are average of two runs with no significanl differences belwcen runs & within each HP LC analysis. 
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Fi1rnre 45. Effect of Process Conditions on the Comoositions of RESS Produced Co-C 
In summary, the composition of the recrystallization media is not only dependent 
on the RESS extraction conditions, but also on the relative amounts of drug and 
impurity in the reaction vessel. Similar conclusions were reached in theophylline 
+ theobromine co-crystals as summarized in Figure 46. As can be seen from the 
figure, theophylline appears to be more soluble in SC C02 than theobromine at all 
the conditions studied. A general trend of increased theobromine levels at higher 
temperatures and higher pressures of extraction can be seen. The use of methanol 
as a co-solvent in a further series of studies reversed this trend, exemplifying the 
tunable solvent power of supercritical solvents. 
Other drug impurity mixtures that also exhibited selective extraction upon 
RESS processing include salicylic acid+benzoic acid, aspirin+benzoic, 
indomethacin+salicylic acid and phenytoin+caffeine. Selectivity of extraction in 
these systems was not quantified and is only derived on the basis of the qualitative 
observations of their XRPD patterns and DSC therrnograms. For example, refer to 
Figures 47A and 47B that respectively show the XRPD patterns and DSC 
therrnograms of salicylic acid+benzoic acid mixtures recrystallized from various 
extraction conditions. As can be seen from Figure 47A, the peaks occurring at 29 
values of 8.16° and 11.1 ° are distinct diffraction peaks of benzoic acid and 
salicylic acid respectively. Comparison of the patterns of recrystallized materials 
with particular attention to these 29 values indicates that benzoic acid is 
selectively extracted at lower temperature conditions. As the temperatures 
increase above 65°C, selective extraction of salicylic acid is evident. 
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The above observations from XRPD analysis are consistent with the thermal 
behavior of the mixtures, as can be seen from Figure 47B. Interestingly, an 
intermediary condition was found at [45°C, 8000 psi] where significant amounts 
of both the components are extracted as can be seen from its diffraction pattern. 
This perhaps led to a significant reduction in crystallinity of the co-crystals 
(Figure 47A), which upon subjecting to DSC analysis did not exhibit any melting 
endotherms (Figure 4 7B). Aspirin+benzoic acid is another such system that 
exhibited selective extraction of benzoic acid at lower extraction temperatures, 
while aspirin was preferentially extracted at temperatures higher than 62°C (see 
figures 48A and 48B). Qualitative analysis of the XRPD and DSC data was 
performed analogous to salicylic acid+benzoic system discussed above. The DSC 
analysis in this case, however could not be performed above temperatures higher 
than 130°C as significant sublimation of the mixtures occurred. 
Salicylic acid+indomethacin (Figure 49) and phenytoin+caffeine (Figure 50) 
are two other systems that exhibited selective extraction at most of the 
supercritical extraction conditions investigated. Preferential extraction of salicylic 
acid and caffeine occurred at a majority of the conditions from these two systems. 
Increases in the amounts of second component in these mixtures resulted in 
amorphous conversions as was discussed in section C. In summary, the 
composition of the recrystallization media is not only dependent on the RESS 
extraction conditions, but also on the relative amounts of drug and impurity in the 
reaction vessel. 
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ln summary, supercritical solvents are extremely selective in nature, which is a 
feature not favored in crystal doping. Notwithstanding this fact, SCF conditions 
were identified where significant amounts of impurity can still be doped into drug 
crystals. This was made possible by modifying the extraction conditions and 
through the use of co-solvents. Rapid nucleation and growth from such modified 
recrystallization media provide the ability to lock the impurities into the lattices of 
the drug hosts. Varying levels of crystallinities ranging from pure crystals to 
amorphous mixtures can thus be achieved by changing the relative amounts of 
drug and impurity in the co-crystals. 
S. CONCLUSIONS 
The presence of an impurity in the crystallization medium exhibits varied effects 
depending on the phase in which it is present prior to nucleation and its affinity to 
the host relative to the crystallizing solvent. This in turns dictates the rate at which 
it nucleates and grows in relation to that of the host. The domain of effects that 
these kinetics dictate on one extreme includes the formation of a solid solution or 
a solid dispersion of the impurity in the host lattice. On the other hand, selective 
extraction of each of the components with respect to time can also occur, the 
extent of which primarily depends on the resolution factor of the recrystallizing 
solvent. While the former mechanism is largely aided by the rapid nucleation and 
growth implicit to supercritical fluid recrystallizations, the latter forms the scope 
of supercritical fluid chromatography. An optimal compromise between these 
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extremes can be reached by utilizing the adjustable so lvent power of supercritical 
fluids. This hypothesis was tested utilizing a number of host/guest systems and 
SC C02 as the recrystallizing medium. In this process, various interesting 
phenomena were identified (Table 17). 
The presence of aspirin as an impurity was found to alter the habit of 
salicylic acid crystals from avicular to fibrous form. Supercritical fluid 
recrystallization herein provided the independent ability to change the crystal 
habit while not altering the polymorphic form of the APL On the other hand, the 
polymorphic conversion to a metastable form of tolbutamide was seen upon SCF 
recrystallization. Doping tolbutamide with urea not only promoted such 
conversion, but also induced a reduction in the overall crystallinity. Loss of 
crystallinity in an already existing metastable form can be expected to enhance the 
dissolution rates, and thereby the bioavailability of the otherwise poorly soluble 
tolbutamide. 
Utilizing a co-solute and a co-solvent to alter the solvent power of SC C02, 
enhancement in the solid solubility in SC C02 was demonstrated in SA+aspirin 
and theophylline+caffeine systems respectively. In addition, a general reduction 
in crystallinity was seen in all the doped crystals. This manifested as a reduction 
in the heat of fusion values, melting point depressions and eutectic formation in 
salicylic acid+aspirin, salicylic acid+benzoic acid, aspirin+benzoic acid, 
tolbutamide+ chlorpropamide. In the drug-impurity systems that did not permit 
the use of thermal analysis, crystallinity was evaluated based on the XRPD 
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studies. Consistent broadening and shifts of XRPD peaks were seen in 
aspirin+benzoic acid, tolbutamide+urea and naproxen+u-naphthalene acetic acid 
co-crystals, reiterating a loss in crystallinity. While crystal doping resulted in such 
reductions in crystallinity for the most part, extreme situations were also 
identified where major loss of crystallinity and amorphous conversion ensued. For 
example, a drastic reduction in the crystallinity and amorphous conversion were 
seen upon SCF recrystallization of piroxicam+theophylline, piroxicam+benzoic 
acid, indomethacin+salicylic acid phenytoin+caffeine mixtures. By adjusting the 
solvent power of SC C02 through changes in temperature and pressure, conditions 
were identified in the above systems that promoted incorporation of high levels of 
impurity in the drug. In addition to this, the rapid precipitation conditions of 
RESS may have led to the formation of a solid dispersion or a solid solution and 
consequently, the amorphous conversion. In a further series of investigations, the 
effect of the presence of caffeine as an impurity on the crystal form of 
theophylline was tested. It was found that higher levels of caffeine competed with 
water molecules during the crystallization step and disallowed the conversion 
from anhydrous to monohydrate fom1 oftheophylline. 
Among the systems that exhibited pronounced selectivity of extraction of a 
particular component include theophylline+caffeine, theophylline+theobromine, 
salicylic acid+benzoic acid, aspirin+benzoic, indomethacin+salicylic acid and 
phenytoin+caffeine. The solvent power of supercritical C02 was modified in these 
systems either by changing the temperature and pressure of the SCF or through 
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the use of a co-solvent. By adjusting the solvent power of the recrystallizing 
solvent, conditions were found where higher levels of impurity could be extracted 
along with the active. The crystallinity and the morphology of such co-crystals 
can thus be altered by controlling the levels of impurity in the host matrix. In 
viewing each of these phenomena from the standpoint of pharmaceutical 
development, the studies reported here serve as a proof of concept for altering the 
physicochemical properties of API's by supercritical fluid crystal doping. 
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CHAPTER FOUR 
Title: Crystal Doping aided by Rapid Expansion of Supercritical Solutions. 
Abstract: This body of work is intended to serve as a proof of concept for the 
application of supramolecular chemistry in drug development. More specifically, 
this work is designed to evaluate crystal doping by recrystallization from 
supercritical media. The rapid nucleation and growth implicit to supercritical fluid 
based crystallizations were advantageously used in doping drug crystals with 
structurally related impurities. Polymorph conversion and crystal disruption of a 
model AP! viz. chlorpropamide were accomplished in this work. Several 
metastable forms of the drug were formed by utilizing the tunable solvent nature 
of SC C02. Crystal disruption in chlorpropamide was induced by controlled co-
crystallization in the presence of urea. Based on the results from these studies, 
two different mechanisms of crystal disruption are proposed. In a further series of 
investigations, comparative evaluation of RESS versus solvent based crystal 
doping was performed. Rapid crystallization kinetics proved vital in making 
RESS superior to conventional solvent based crystallizations. Finally, a particle 
size reduction of about an order magnitude was seen following RESS processing. 
In providing the ability to control both the particle and crystal morphology of 
AP!s, RESS proved potentially advantageous to crystal engineering. 
Key words: Rapid expansion of supercritical solutions; RESS; Crystal doping; 
Co-Crystallization; Chlorpropamide; Urea. 
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I. INTRODUCTION: 
The role of residual impurities on the bulk physical properties of a crystalline 
substance has long been identified and is generally regarded to be adverse. The 
residual impurities often include unused reactants, catalysts, synthetic byproducts, 
chiral isomers, solvates, hydrates, surfactants, monomers, etc. that develop during 
the synthesis, extraction, recrystallization and storage. Although often 
challenging, the cleanup task is achieved by secondary recrystallization methods 
or by alternative methods of synthesis. ln instances where purification beyond a 
certain level is far fetched, the effects of the presence of impurities on the 
efficacy, safety and stability profi les of the active pharmaceutical ingredient (API) 
have been established. Such studies have revealed a domain of effects that an 
impurity can have on the crystal morphology and crystal energetics of an AP!. 
While this awareness of the role of impurities manifested as an additional burden 
to the traditional synthetic chemist, it also opened up a realm of new science 
called 'Supramolecular chemistry'. Broadly defined as the science that deals with 
anything outside the scope of covalent chemistry, it involves selective 
incorporation of tailor made additives and impurities into the crystal lattice of a 
host substance. Incorporation of the additives is based on interactions such as H-
bonding, ion pairing, van der Waals attractive forces, hydrophobic interactions, 
beta-stacking, non-specific inclusion, etc. [Cram 1988, Klamer 200 1]. Design of 
composite materials with altered bulk properties is made possible through such 
crystal modification. Supramolecular chemistry combines the features of 
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contemporary stereochemistry and biological enzyme-ligand systems in 
engineering crystal morphologies. Crystal engineering based on this science 
afforded among other applications a considerable promise in habit modification, 
racemate isolation, doping mediated induction of crystal defects & amorphous 
conversion, preferential crystallization of favored polymorph and synthesis of 
new molecular complexes. 
A theoretical basis for the role of additives at molecular and bulk levels 
that will allow precise control over tailoring crystals still remains to be 
established. Efforts at such an understanding have mostly been limited to 
inorganics and other small molecules like (adipic acid, acetaminophen and 
algine). The complexity of multiple conformations while dealing with 
pharmaceutically relevant molecules lends extension of such theories to 
pharmaceuticals rather difficult and may be the cause for limited progress in this 
area. While the advancement of supramolecular chemistry in disciplines such as 
ceramics, photography and semiconductor industries has therefore been 
significant to achieve commercialization, the concept is still at its inception in 
pharmaceuticals and only restricted to few research labs [Grant, Chow, Sherwood, 
Weissbuch 1991]. This body of work is intended to serve as a proof of concept for 
the application of supramolecular chemistry in drug development. More 
specifically, this work is designed to evaluate crystal doping by recrystallization 
from supercritical media. The rapid nucleation and growth implicit to supercritical 
fluid based crystallizations provided the motivation for choosing the Rapid 
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Expansion of Supercritical Solution (RESS) process. The ultimate motive in 
producing doped crystals is to add functionality to APis at early stages of 
chemical synthesis. For example, producing low energy forms of the crystals can 
enhance the dissolution rates of poorly soluble drugs. Alternatively, 
crystallization of the most favored polymorph can be induced through doping. 
Such studies can prove particularly viable and timely in the context of the recent 
emphasis on the integration of the discovery and development research in 
pharmaceutical industry. For the purposes of this study, Chlorpropamide (CPD) 
was chosen as a model API and urea as the model dopant. The rationale for the 
selection of this APl-dopant mixture was based on the structural similarity 
between the API and the dopant (Figure 51 ). In addition, doping is more 
controllable with a small molecule such as urea and in theory will reduce the 
propensity for segregation and associated stability problems. 
Chlorpropamide belongs to the sufonyl urea class of oral hypoglycemics. 
It is known to be practically insoluble in water and belongs to class n of 
biopharmaceutical classification (BCS). Five different polymorphs of CPD are 
identified to date, of which three are most commonly referred to in the published 
literature [Burger 1975, Aal-Saieq 1982, Simmons 1973, De Villiers 1999]. As is 
often the case with APls exhibiting multiple conformations, the nomenclature of 
various fom1s of CPD is very confusing. For the purposes of consistency, the 
notation defined by Simmons [Simmons 1973] is used in this study. Even after the 
three decades since it was discovered, it is interesting to note that polymorphism 
188 
Chlororopamide 
0 
Cl -0 so, NH -~ - NHCH,CH,CH, 0 11 
H N- C - NH 2 2 
Figure 51. Chemical Structures of Cblorpropamide and Urea 
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in CPD has not been completely characterized. The specific objectives of this 
study are therefore to characterize the various polymorphs of Chlorpropamide 
prior to evaluating the efficacy of RESS process in doping CPD with urea. 
2. MATERIALS AND METHODS: 
2.A. Materials: 
Chlorpropamide (Sigma, St.Louis,MO, Lot# 31 H0722), Urea (JT Baker, NJ, Lot# 
N37340). All the solvents used were bought from JT Baker and are of HPLC 
grade. 
2.B. Methods: 
2.B. l . Crystallization from supercrtical solvent: 
Rapid Expansion of Supercritical Solution (RESS) process was used in the co-
crystallization of solid active pharmaceuticals and their structurally related 
impurities. In the process, the solutes of interest were dissolved in supercritical 
C02, forming a homogenous supercritical solution. Nucleation of solutes was then 
induced by rapidly reducing the solution density through expansion to 
atmospheric conditions. A rapid decrease in solvent strength results in high 
supersaturation that leads to very high nucleation rates [Mohamed 1989). The 
time for nucleation and growth is very limited (typically 10·5 to 10-6 seconds), 
resulting in very small particles [Debenedetti 1993, Turk 1999). Also, the rapid 
nucleation and growth aids in locking the impurities into the crystal domains of 
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the hosts by not providing sufficient time for the impurities to segregate. Absence 
of residual liquid solvents in the RESS produced crystals further reduces the 
possibility for segregation effects in the solid state. 
In addition, the rapid decompression of SCF generates mechanical 
perturbation within the solution that travels at the speed of sound [Debenedetti 
1993]. Consequently, very uniform conditions are reached within the nucleating 
media. Uniform conditions in the nucleation media assist in homogenous 
dispersion of impurities in the crystal domains of the hosts. The crystal disruption 
following such uniform and rapid co-crystallization can be expected to be 
controlled and large [Burt 1981 ]. All the above factors contributed to the special 
interest in RESS aided crystal doping and formed the rationale for its choice. 
Further, the concept is fairly nascent as reflected by the number of SCF aided 
crystal doping studies reported in the published literature [Weber 1997, York 
1995]. 
The commercially available supercritical fluid extraction equipment 
(SFT150, Supercritical Fluid Technologies Inc., Delaware) was reconfigured to 
produce co-crystals of drugs and impurities by the rapid expansion of supercritical 
solution process. The modified design for the RESS process is schematically 
represented in Figure 8 and shown in Figure 9 (Chapter-3). Liquid C02 from a 
tank is pressurized using an air driven Haskel pump. The pump head is enclosed 
in a chiller-can through which a coolant at - 10°C is continuously circulated. The 
coolant compensates for heat generation in the pump and prevents cavitation by 
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maintaining C02 in the liquid state at all times. Pressurized liquid was then fed to 
the preheater at a controlled flow rate. The function of the preheater is to serve as 
a heat exchanger and raise the temperature of the pressurized liquid to the 
supercritical region. The preheater used was a five metered stainless steel coil 
wrapped with Omegalux rope heaters (FGR, Omega Engineering lnc., Stamford, 
CT). The temperature of the preheater was controlled using Glas-Col temperature 
controller (Glas-Col, Terre Haunte, IN). Supercritical C02 from the preheater then 
flows into the 1 OOml reaction vessel that contains the solutes to be recrystallized. 
The reaction vessel was typically packed with 90 g of 3 mm glass beads and 
10 g of solutes. The glass beads assist in improving the extraction efficiency of 
SC C02 by providing better fluid contact with solutes while also serving to buffer 
the turbulent flow of the fluid through the vessel. The starting mixture in the 
reaction vessel consisted of a physical blend of 80% drug and 20% impurity. 
Placing glass wool at either ends of the reaction vessel supported the powder bed 
and also prevented the entrainment of solutes. Depending on the selectivity of 
extraction of the supercritical solvent, saturated solutions form in the reaction 
vessel with fixed compositions of the host and impurity. The saturated 
supercritical fluid solution from the reaction vessel flows through a 0.5µ frit into 
the pre-expansion chamber. It can be treated in the pre-expansion chamber to 
control the supersaturation prior to expansion. For the purposes of consistency in 
the crystal doping studies, the preexpansion chamber was maintained at 50°C 
above the extraction temperature. Presence of cold spots and abrupt temperature 
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drop in the lines were found to cause premature precipitation of solutes, which in 
tum lead to plugging of lines. All the lines and connectors therefore were heated 
using Omega rope heaters controlled by a common Glas-Col temperature 
controller. 
The saturated solution from the preexpansion chamber then passes through a 
heated restriction device maintained at I 00-I 50°C prior to rapid expansion. The 
heated restriction valve compensates the Joule-Thompson cooling that occurs as a 
result of rapid expansion. The expansion device used was a stainless steel 
capillary of aspect ratio 100 (5" L I 0.05" ID) that is securely inserted through the 
snap cap of a 40ml glass vial (Daigger, Lincolnshire, IL). Given that the interest 
here is in the crystal morphology of the pharmaceutical actives rather than their 
particle size, a 40 ml particle collection vial is best suited for these purposes. Use 
of 40 ml glass vial also improved yields by preventing losses from the particle 
collection typically observed with larger vessels. C02 gas after deposition of the 
solids was exhausted through a custom filter and passed through lengthy tubing (5 
meters) prior to feeding to the thermo mass flow meter (Porter Instruments, 
Hatfield, PA). The gas flow rates were further totalized (Infinity Rate Totalizer, 
Newport Electronics, Santa Ana, CA) over the course of the experiment to get a 
more reliable estimate of the average C02 flow rates though the system. Typical 
flow rates of C02 through the system were between 5-10 SLPM. At the end of 
each run, yields of the recrystallized materials were recorded and the vials stored 
in low humidity plastic bags at ambient temperature until further use. 
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Following the above method, Chlorpropamide + Urea mixtures were 
recrystallized and the efficiency of SCF aided crystal doping was evaluated. The 
supercritical region investigated in these studies included a temperature regime of 
45-100°C and pressures between 2000-8000 psi. The yields of co-crystals 
extracted at pressure less than 4000psi Were very low to perform further 
characterization work and hence are not reported in this manuscript. 
2.B. 2. Crystallization from Organic Solvents: 
The role of the rapid crystallization kinetics in the supercritical fluid aided crystal 
doping can be best evaluated by comparing the doped crystals from RESS process 
to the ones crystallized at a much slower rate, for example by evaporative 
crystallization. Toward this objective, evaporative crystallization of 
chlorpropamide in the presence of varying amounts of urea as the impurity was 
undertaken. Other solvent related effects were in part normalized by choosing 
hexane (8=7.24 Hildebrand units) and ethyl acetate (8=9. 10 Hildebrand units) as 
recrystallizing solvents, which are reported to closely correspond to supercritical 
C02 in their solubility behavior [Hyatt 1984, Dandge 1985, Dobbs 1987]. In 
addition, recrystallization from a relatively polar ethyl alcohol solvent was also 
performed in order to investigate the effect of the solvent polarity on the crystal 
doping of chlorpropamide+urea. 
Evaporative crystallization experiments were carried out using a nitrogen 
analytical evaporator (The Myer N-Evap, Organomation Associates Inc., MA) 
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placed in a fume hood. One gram of chlorpropamide/urea mixtures in varying 
proportions (100/0, 80/20, 90/ 10, 9911, 99.510.5 and 99.9/0.1, percent w/w basis) 
were accurately weighed into 40ml glass vials. !Oml of warm recrystallizing 
solvents at 45°C were added to these vials and the solutions thoroughly shaken. 
The open vials were securely fastened with clamps and immersed to fixed lengths 
into the 45°C temperature bath of the nitrogen evaporator. Needles connected to a 
common nitrogen source were inserted into the head space of the vials and fixed 
at standard heights such that uniform conditions prevailed in the different vials. 
The flow of nitrogen gas was controlled using a pressure regulator attached to the 
nitrogen tank. A Spsi pressure differential (20psi at the regulator to atmospheric 
pressure) was found to maintain suitable nitrogen flow rates into the vials. While 
solvent evaporation was complete in the case of hexane and ethyl acetate within 
12 hours, recrystallization from ethyl alcohol took up to 24 hours owing to the 
lower vapor pressure of the hydralcoholic solution. At the end of the experiment, 
the recrystallized materials were spread in individual petri dishes, oven dried at 
45°C overnight and sieved through a #60 (250µ) screen. The screened materials 
were subsequently filled into vials, tightly capped and stored in low humidity 
plastic bags at ambient temperature until needed for further use. 
2.B. 3. Differential Scanning Calorimetry: 
DSC analysis was performed using a Perkin-Elmer DSC-7 equipped with an 
intercooler. Accurately weighed milligram samples were scanned in pin-holed 
195 
aluminum pans (TA Instruments, Dupont) under dry nitrogen purge. Various 
heating rates of 1,3,5 and 10°C/min were used to scan the different temperature 
regimes that are of interest to samples under consideration. The instrument was 
cal ibrated for temperature and enthalpy using high purity Indium and USP Water. 
2.B. 4. Modulated DSC: 
mDSC was used in an attempt to distinguish the kinetic events from the 
thermodynamic events in the thermal analyses of chlorpropamide+urea mixtures. 
About 10 mg of sample mixtures were accurately weighed (MTS, Mettler Toledo) 
and thermally scanned in the pin-holed, crimped aluminum pans (TA Instruments, 
Dupont) using TA Instruments Modulated DSC 2920. Samples were analyzed in 
the temperature range of25°C-l40°C. The scanning conditions included a heating 
ramp of l °C/min with the modulation amplitude of 1°C in a 60sec period. 
Sapphire and Indium were used as calibration standards. The instrument was 
within the calibration period at all times when the reported analyses were 
performed. 
2.B. 5. Hot Stage Microscopy: 
Thermomicroscopy of these samples was performed using a Mettler FP82-HT Hot 
stage attached to the Mettler FP80-HT Controller and a Video System. Untreated 
samples were sprinkled onto a glass microscope slide, covered with a cover slip 
and placed on the hotstage. Changes in the particle and crystal morphologies, 
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among other thermal events that occur during the heating and cooling cycles were 
observed using Leitz Ortholux polarized optical microscope and recorded using a 
Sony 5600MD Video printer. The accuracy of the hot stage was routinely checked 
against USP melting standards. 
2.B. 6. Thermogravimetric Analysis: 
Thermal decomposition, moisture and residual solvent contents of the 
recrystallized materials were investigated using Perkin-Elmer TGA-7 at a heating 
rate of 5°C/min. Samples were heated in an open platinum pan with the nitrogen 
purge at 60 mUmin. The temperature scale was calibrated by measuring the Curie 
point (354°C) of standard PE ferromagnetic Nickel, while standard weights were 
used to calibrate the weight scale. 
2.B. 7. Powder X-ray diffractometry: 
XRPD was performed using a Rigaku-Geigerflex KD-2660-N X-ray 
diffractometer controlled by the D-Max B controller and Datascan MDI software. 
The diffractometer is equipped with a copper target, yielding X-rays of 
wavelength 1.54° A. Diffractograms were obtained over the 20 range 3° to 50°and 
analyzed using MDI Jade-5 software. Depending on amounts of the samples 
available for XRPD analysis, the powders were either packed into the 0.2mm 
groove of a glass slide (Regular Method) or sprinkled onto a thin film of Apiezon 
grease applied onto the glass slide (Grease Method). The operating conditions 
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included: scan speed 3°/minute, sampling interval 0.020° and X-ray power (tube 
input) of 40kV/40mA. The path of x-rays was controlled utilizing standard slits 
such as: Yi divergence, 'Ii scatter slits, 0.3mm receiving and 0.6mm receiving 
monochromator slits, in that order. The instrument was routinely calibrated under 
these operating conditions using Rigaku Quartz as standard. 
2.8. 8. Polarizing Optical Microscopy: 
Bulk particle morphology and the crystalline birefringence behavior of the 
samples were investigated using polarizing optical microscope (Leitz Lab 12 Pol 
S) with tungsten lamp as the light source. The objects are viewed and 
photomicrographs developed utilizing such accessories as Sony video camera, 
Boeckeler Via-70 Video marker and Sony 5600MD Video printer. A first order 
red compensator was used in enhancing the clarity of the photomicrographs. 
Untreated powders or powders dispersed in suitable media were placed on a glass 
slide and covered with a cover slip, prior to staging them in the path of bright field 
light. The objects were viewed in the magnification range 200-800X, calibrated 
using an Olympus calibration slide. 
2.8. 9. Scanning Electron Microscopy: 
The morphology and surface characteristics of the samples were observed by 
scanning electron microscopy (SEM). Samples were mounted on an aluminum 
SEM stub and gold coated for 90 seconds at 45 mA with a Denton Vacuum Desk 
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II sputter coater (SIN 13156). SEM (Cambridge Stereoscan S360) examination 
was performed at 5-10 kV, 20 pA probe current, 100-4000x, and a working 
distance of 6-9 mm. Calibration is performed annually by LEO associates for 
morphological use only. 
2.B. IO. HPLC Analysis: 
The amounts of host and guest in chlorpropamide+urea co-crystals were assayed 
by liquid chromatography (LC). Isocratic, reversed phase LC separation methods 
were developed and validated using external standards following modification in 
USP method for the hosts. Specific details of the method are summarized in Table 
21, while the representative chromatogram of these mixtures is shown in Figure 
52. A calibrated HP 1100 series LC system equipped with a diode array detector 
was used in this analysis. Absence of chromophores in urea limited its detection 
by the diode array detector in both the UV and visible ranges. The separation 
however was accomplished by HPLC method and the interference from urea in 
the detection of CPD was established to be negligible. In the validation of this 
method of analysis, stock solutions of CPD and urea in the mobile phase were 
made at a concentration of 0.05% w/v each. Known aliquots of these solutions 
were then mixed to obtain varying proportions ofCPD+Urea in the final mixture. 
These solutions were then subjected to HPLC analysis and the calibration curve 
was developed. Similar procedure was repeated at two other dilutions of stock 
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Table 21. HPLC Method of Assay for Chlorpropamide and Urea 
Column Supelco C-18 column, 4.6mm x 15cm 
Mobile Phase 60% Dilute Acetic acid + 40% Acetonitrile 
Flow rate 1.5ml/min 
Runtime 10 minutes 
Injection Volume 10 µL 
Detector HP Diode array, 240nm 
System HP 1100 series 
Retention times 4.94 min {Chlorpropamide) 
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solutions, viz. 0.025% and 0.005% w/v. The results of the above validation 
method are reported in Figure 53 . As can be seen from the figure, urea in the 
mixture does not appear to interfere with the detection of CPD at any dilution. 
The amounts of urea in a mixture can thus be confidently calculated from the 
CPD levels in the mixture. 
3. RESULTS AND DISCUSSION 
3.A. POLYMORPHISM IN CHLORPROPAMIDE: 
The commercially available form of CPD is obtained by crystallization from 
ethanol-water mixture and is called form-A. It is the most thermodynamically 
stable fom1 at room temperature and has the lowest dissolution rate. Melt 
recrystallization of this form results in polymorph-B, which is monotropic with 
fom1-A (Yu 1995). This form is unstable at all the temperatures and is stated to 
convert into form-A through multiple transformations [De Villerrs 1999). 
Polymorph C is obtained by heating form-A at l 20°C for 4 hours. Taken as a pair, 
fom1s A and C are enantiotropically related, form C being the thermodynamically 
stable form at higher temperatures while form A is stable at lower temperatures. 
The transition temperature for this conversion, however is not reported to date. 
DeVilliers and Wurster determined the heats of solution of these fom1s in DMF at 
25°C [De Villerrs 1999). The difference in the heats of solution between these 
forms was found significant (- 4kJ/mol) in this study. This did not reflect in the 
DSC analysis, which did not show any endotherms corresponding to this heat of 
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transition even at heating rates as low as 0.5°C/min (Figure 54). Conversion fo r 
form-A to form-C was seen during the analysis, that did not permit calculation of 
individual melting data for these forms. The thermal behavior of polymorph A 
was therefore investigated in detail. As can be seen from Figure 54, subjecting 
form-A to DSC analysis at different heating rates revealed some interesting 
results. The endotherm at 12 l °C corresponds to the melting of form-A, while the 
one at l 29°C to that of form-C. The transition from A to C was found to occur 
gradually with increase in temperature and was most rapid at temperatures 
nearing the melting point of A. Apparently, the melting endotherms overlap, 
making the heat of fusion values for these polymorphs indeterminable. Efforts at 
reso lving these melting endotherms by reducing the heating rates revealed 
intermediate recrystallization that was hidden before at higher heating rates. 
Thermomicroscopy, simulating the heating ramps used in the above DSC analysis 
revealed that the transition from A to C is rapid around melting point of A, but 
does not necessarily occur from the melt. Apparent change in the particle 
morphology was seen upon gradually heating from 100°C to l 20°C. TGA 
analysis of polymorph A (Figure 55a and 55b) did not indicate any weight loss 
around this temperature, excluding the possibility of solvent/water mediated 
transition. From the discussion above, it can be stated that the transition from A to 
C occurs in a solid state with no change in the composition of the solid. It is 
hoped that the intermediary recrystallization exotherm can be separated as a 
kinetic event, utilizing the modulations in heating by mDSC. 
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The results of mDSC performed at heating rates of 5°C/min and I °C/min are 
shown in Figures 56 and 57. As can be seen from the reversing (enthalpy related) 
curves in the figures, even this method failed to isolate the two endotherms. This 
indicates that a reversible transformation between forms A and C occurs just 
before form-A melts. Calculation of the heat of fusion value of form-A, to be 
utilized in evaluating its crystallinity is therefore not possible by direct DSC 
analysis. For the purposes of this study, this value was calculated from the LiHr of 
form C in a manner analogous to Behme and Brooke ' s study [Behme 1991 J. 
Unlike in the case of carbamazepine, the transition from one polymorph to other 
however did not occur during the DSC analysis of Chip. For the purposes of this 
study, this heat of transition was estimated to be 4 kJ/mol (or 14.45 Jig), the 
difference in the heats of so lution values reported by DeVilliers at 25°C. This 
estimation was made on the basis that a linear relationship exists between the heat 
of solution and the heat of fusion for the same polymorph with fixed chemical 
structure [Yoshihashi 2000]. Such an estimation is further supported by Hess 
Law that states that the energy associated with a transition depends on the final 
states and is independent of the path. Assuming that this difference is constant 
over the temperature range of 30- I 20°C, the heat of fusion of form-A can be 
estimated to be 85.77+ 14.45= 100.22 Jig. This assumption was validated when 
the heat capacity values (Cp) of polymorphs A and C were found to vary similarly 
in this temperature range (notice the parallel baselines for various polymorphs in 
Figures 58-60). The Li Hr values of polymorphs B and C are obtained from the 
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DSC analysis, given that these polymorphs can be produced in pure form and no 
concurrent phase changes occur during their thermal analysis. The melting data 
for polymorphs A, B and C, following the above discussion is summarized in 
Table 22. 
Two other means of characterizing the various polymorphs of Chip were also 
developed. The first used polarizing optical microscopy. As can be seen from 
Figures 61 a to 61 c,the crystal habit of the various polymorphs appear to be 
distinctly different. Polymorph A seemed to crystallize in tabular habit, while the 
metastable forms B and C appear as blades and plates respectively. In addition, 
XRPD serves as a very powerful tool in distinguishing these polymorphs. The 
diffraction patterns of the three forms are shown in Figure 62. The major 
diffraction peaks distinguishing the various polymorphs are shown in Table 23 . In 
summary, polymorphs A, B and C are characterized by various analytical 
techniques and the results are tabulated in Table 23 . Also, the thermodynamic 
data useful in evaluating the crystallinity of these polymorphs in the later doping 
studies is developed. 
3.B. RESS OF PURE CHLORPROPAMIDE: 
Pure Chip was recrystallized from varying RESS conditions shown in Table 24. 
As can be seen from Figure 63, increased yields from crystallization are achieved 
both upon increasing the extraction pressure and also, the temperature of 
supercritical C02. Recrystallization of polymorph A from supercritical C02 at 
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Figure 61. Photomicrographs of Various Polvmorphs of Chlorpropamide 
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Table 22. Meltini: data and Heat of Solutions of Different Pol):'.mOrl!hS of 
Chlorl!rol!amide 
Polymorph Tm(°C) /'i. Hr, Jig H, at 25°C Jig 
A 121.5 100.22 21.25 
B 125.35 77.03 15 .22 
c 128.85 85.77 36.07 
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Figure 62. XRPD Patterns of Various Polvmorphs ofChlorpropamide 
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Table 23. Nomenclature/Properties of Reported Chlorpropamide Polymorphs 
Polymorph Source Tm(' C) 6 Hr 6. Hs i Characteristic Habit 
(Jig) (KJ/11101) XRPD peak(20) 
A / III/IV Commercial 12 1- 122 100.22 5.88 6.62, 11.78 Tabu lar 
B / II / V Recrystallized from melt 124- 127 77.03 4.2 1 12 .36 Blades 
C I I /1 Heat A @ l20°C for 3 hrs 128- 130 85.77 9.98 15.18 Plates 
IV Crystallized from CC I, 122- 123 
"' 
"' v Desolvat ion of Solvate of benzene < I 18 
II Rapid evaporation from Chloroform 
Ill Rapid cooling from Hexanol 
Simmons, Canad ian Joumal of Pharmaceutical Sciences, 8(4), 1973 
Burger, Sc i. Pharm 1975 
Saieq, Phann Acra Helvetica, 57(/). 1982 
Table 24. Summary of RESS Recrvstallization Of Chlorpropamide 
Ex pt JP,T conditions! Weight Collection Collection 
Collected, mg Time, min Rate, mg/min 
I [46°C, 4000psi] 356.0 240 1.48 
2 [48°C, 8000psi] 618. I 90 6.87 
3 [60°C, 4000psi] 445.2 210 2.12 
4 [61 °C, 8000psi] 400.4 30 13.35 
5 [75°C, 4000psi] 411.6 30 13.72 
6 [75.5°C, 8000psi] 750.2 30 25.01 
7 [101 °C, 4000psi] 1266.4 60 21.11 
8 [ 100°c, 8000psi] 1389.5 45 30.88 
ol-~~~~~~~~~--'--~~~~~~~~~~~-1 
' 
Figure 63. Yields from RESS Recrvstallization of Cblorpropamide 
As a Function of Temperature and Pressure 
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different P,T conditions resulted in the formation of several metastable 
polymorphs (Table 25). Of interest here in view of enhancing the dissolution 
performance is the formation of polymorph C (Figure 64).While complete 
polymorph conversion from A to C was seen at certain conditions, the original 
form remained at other extraction temperatures and pressures (Table 25). The 
polymorphic identity of the RESS recrystallized materials was positively 
confirmed from their XRPD data (Figure 65). On the other hand, thermal behavior 
of RESS recrystallized materials as determined by DSC exhibited inconsistency 
with the XRPD results in certain cases. The melting temperatures, however 
exactly match Burgers polymorphs denoted by the Roman nomenclature (Table 
25) [Burger 1975]. XRPD data for these polymorphs has not been reported in 
Burgers study and hence no definitive matches can be made. 
The results of RESS recrystallizations of pure Chip indicate the ability of the 
RESS process to form different polymorphs from the same solvent by mere 
changes in the temperature and pressure conditions. The polymorphic conversion 
from form A to C can be explained based on the individual effects of temperature 
and pressure on the Chip crystallites during their nucleation and growth. The 
effect of temperature on this conversion was addressed in detail in section A. This 
conversion upon recrystallization from SC C02 is consistent with the reported 
effects of temperature and compression pressure during the tabletting of 
Chlorpropamide [Matsumoto 1995]. It appears from these studies that these forms 
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Table 25. Polymorph Convers ion ofChlorpropamide by RESS Recrystallization 
Conditions of Rxn Vessel Tm Delta H, Polymorph 
[Tin °C, P in psi] °C (RSD) (Jig) (RSD) Identity (XRPD) 
[46, 4000] 112.43 (1 .51) 23.67 (8.99) c 
[48, 8000] 122.05 (1 .01) 49.97 (1 .31) c 
N 
"' [60, 4000] 111 .58 (0.47) 32.99 (5.70) A+C 
[61 , 8000] 11750 (0.43) 54.14 (1 .82) A+C 
[75, 4000] 126.58 (0.23) 68.63 (2.06) A+C 
[75,8000] 127 08 (0.30) 70.72 (3.66) c 
[101 , 4000] 124.56 (0.95) 60.43 (1 .18) A+C 
[100, 8000] 125.58 (0.41) 62.62 (1 08) c 
( 
z 
0 
.... 
:::> 
_, 
0 
"' 
"' 0 
90 
~ 60 
w 
u 
a: 
w 
... 
30 FORM I • 
FORM II o 
FORM II I • 
FORM IV • 
FORMV 
100 
TIME IN MINUTES 
150 
Figure 64. Dissolution Profiles of Various Polymorphs of Chlorpropamide 
Reproduced from Saieq, Phann Acta Helvetica, 1982 
220 
( 
2000 
1800 
1400 . 
... ; ... 
IZ08 331 .MDIJ :Chlorpropamlde :RESS il OOC, 8000psl) : 
10 JO 40 
2-Theta(1 
Figure 65. XRPD Patterns of RESS Produced Chlorpropamide 
2-Thetan 
Figure 66. XRPD Patterns of RESS Produced Co-Crvstals of 
Chlorpropamide +Urea 
221 
differ in the manner of their packing that is easily influenced by the temperature 
and pressure during SCF crystallization. 
Scanning electron microscopy of recrystallized materials indicated a change 
in the habit and also, a general reduction in the particle size of the recrystallized 
materials (Figure 67). Agglomeration of the particles arising from bouncing with 
each other and with the walls of the smaller collection vial can be seen in relation 
to rather distinct crystals collected in a larger vessel (compare Figures 67.b-e vs. 
67f). While a tabular habitat can be seen in the commercially available material, 
all the RESS recrystallized samples attained the shape of blades that is typical of 
form-C. Consistent with the XRPD results, Chlp recrystallized from selective 
RESS conditions contained both the forms A and C reflected as a mix of tabular 
and plate like crystals. (Figure 67-b, c, d). Also, the particle size reduction was 
significant at the 75°C condition, perhaps due to higher supersaturations attained 
at this temperature versus the 60°C condition. As can be seen from Figures 67a to 
67f, submicron to few micron sized particles were produced by RESS 
recrystallization. 
3.C. RESS OF CHLORPROPAMIDE+ UREA: 
The presence of urea in the crystallizing medium of Chlorporpamide reduced the 
yields as can be seen from Table 26. The solubility of Chip appears to be 
significantly higher than urea in SC C02 at the various conditions studied. An 
apparent reduction in the overall yields can therefore be expected in the presence 
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Table 26. Summary Of RESS Recrystallization Of Chlorpropamide+ Urea 
COMPOSITION OF STARTING MIXTURE: 80% Chlorpropamide + 20% Urea 
CONTENTS OF REACTION VESSEL: IOg Chlorporoamide + 2.5g Urea (12.5g of blend) 
Ex pt IP,T conditions I Weight collected Collection time min Collection Rate 
mg mg/min 
1 [ 48°C, 4000psi] 292 180 1.62 
2 [ 48°C, 8000psi] 325 180 1.8 1 
3 [60°C, 4000psi] 507.6 120 4.23 
4 [60.5°C, 8000psi] 361.7 30 12.06 
5 [75°C, 4000psi] 465 .9 60 7.77 
6 [77°C, 8000psi] 1467.3 60 24.46 
7 [I 00.5°C, 4000psi] 724.9 90 8.05 
8 [I 03°C, 8000psi] 900.4 90 10.00 
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of a less soluble component like urea. The binary phase behavior of Chip+ Urea 
mixtures was reported by Ford and Rubenstein (Ford 1977) and is shown in 
Figure 68. As can be seen, a mixture containing 89% Chip+ I I %Urea forms a 
eutectic that melts at 89°C. Compositions containing >90% Chlorporpan1ide can 
be seen to form solid solutions. This region is of particular interest in the context 
of crystal doping. Co-crystallization of chlorpropamide in the presence of urea 
resulted in the formation of eutectic mixtures and solid solutions depending on the 
composition of the mixtures formed (Tables 27 and 28). A agreement between the 
thermal behavior of the co-crystals and their compositions can be seen from 
Tables 27 and 28. 
Formation of the solid solutions of urea in chlorpropamide resulted in the 
crystal disruption of the host and eventually in amorphous conversion at urea 
levels higher than 40% w/w (Figure 66). Peak broadening and peak shifts in the x-
ray diffraction patterns were seen in all the doped crystals (Tables 29 and 30). 
Two mechanisms are proposed that caused this consistent broadening and shifts in 
the XRPD peaks and illustrated in Figure 69. Firstly, as shown in mechanism-I , 
urea may have been adsorbed onto selective faces of the crystals of Chip that 
apparently changed the way it packs. This leads to altered symmetry and 
increased mosaic spread mirroring in the manner in which different planes reflect 
x-rays. Apparently, peak broadening and a shift in the XRPD peaks is evident. 
Another fact that further validates this mechanism is the preferential 
crystallization of polymorph C in the presence of urea. 
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Table 27. Selectivitv of Extraction as a function of TIP of SC C02 
Extraction Conditions C02 Density Average RSD %Urea 
[T in °C, P in psi] glee Chlorpropamide% (n=3) 
[48, 4000] 0.8631 
[48, 8000] 0.9852 85.87 1.07 14. 13 
[60, 4000] 0.8109 93.09 3.43 6.91 
[61, 8000] 0.9509 93.55 3.12 6.45 
[75, 4000] 0.7431 98.38 0.82 1.62 
[77, 8000] 0.9055 85 .61 5.48 14.39 
[IOO, 4000] 0.6287 60.57 4.84 39.43 
[103, 8000] 0.8355 42.08 0.95 57.92 
Table 28. Results of Doping Chlorpropamide with Urea 
Conditions of Rxn Vessel Tm &H,(RSD) Polymorph 
[T in °C, P in psi] °C(RSD) (Jig), n=3 Identity 
(48, 4000] 123.42 (0.23) 47.40(7.03) c 
[48, 8000]° No Drug Peak c 
(60, 4000]° 118.29 (0.66) 44.96 (5.17) A+C 
[61 , 8000]° 121.08 (1.33) 54.80 (5.45) c 
[75, 4000] 121.57 (0.23) 40.0 I ( 4.30) c 
(77, 8000] 119.58 (0.97) 26.39 (I 1.34) c 
[100,4000] No Drug Peak Cl Amorphous 
(103,8000] No Drug Peak Amorphous 
• Eutectic Mixture Formed 
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Table 29. Peak Shifts and Peak Broadening in Doped Chlorpropamide Crystals 
I 
[48C. 400QE!q [75C, 400~;] [60.5C, 800QE!U [60C, 4000psq [48C, 8000ps;] [77C, 8000psq [ IOOC, 4000psq [I 03C, 8000psq 
2111c1a Pure %Urea=O % Urea=l.62 %Urca:=6.45 % Urea=6.9 1 %Urca= l4.13 % Urca.,,. 14 .39 % Urca=.J9.43 % Urea=57.92 
:r 0.31 A 
6.89 0.2& 0.31 0.24 
9.08 0 1& 02 0.27 M 
0 19 0 23 
0.29 0 
13.04 0. 18 0.43 0.51 0.38 0.4 1 0.48 0.41 0.41 
15. 18 0.15 0.19 0.2 0.25 0.46 0.27 0.25 0.21 R 
16 27 0. 15 0 15 
18.04 0. 19 0 21 0.16 0.29 0.33 0.28 0.32 p 
19.6 0.15 O.ll 0.18 0.22 
20.68 0.18 0.25 0.25 0.22 0.21 0.29 0.27 H 
21.76 0.17 0.27 0.27 0.25 0.25 0.29 0.24 0.26 
N ~ 23.84 0.19 0.24 0.24 0.14 0.17 0.27 0 ~ 24.78 0.14 0.35 0.16 
25 64 0.15 0.29 0.41 0.15 018 0.34 u 
26.66 0.18 0.22 0.23 0.24 0.31 0.23 0.13 
27.46 0.17 0.18 0.27 0 13 0.08 s 
27.9 0.19 0.28 0.17 0.19 0.19 
29.7 0. 18 0.48 0.4 0.35 0.34 0.2 
30.42 0. 15 0.21 0.22 0.29 0.33 0.24 
31.34 0.18 0.64 0.48 0.37 0.3 
3236 0.17 0.3 0.38 0.11 0.41 
0.22 
38.02 0.17 0. 18 
39.62 0.39 034 0.25 
43.S 0.4 1 0.29 
0.15 
Bold font Broadened Peaks 
Italic font Shifted Peaks 
"' 
"' 
"' 
Condition 
Pure Fom1-C 
f48°C, 4000psi] 
[75°C, 4000psi] 
[61 °C, 8000psi] 
[60°C, 4000psi] 
[48°C, 8000ps i] 
[77°C, 8000ps i] 
f 100°C, 4000psi] 
[ 103°C, 8000psi) 
Table 30. Peak Broadening as a function of impurity levels in the doped crystals 
Percent Urea FWHM Values 
2 =13.04 2 = 15.18 2= 18.04 2 =20.68 2 =21.76 2 =26.66 2 =29.7 2 =30.42 
0 0. 18 0.15 0. 19 0.18 0.17 0. 18 0.18 0. 15 
0.00 0.43 0.19 0.21 0.25 0.27 0.22 0.48 0.21 
1.62 0.51 0.2 0.16 0.25 0.27 0.23 0.4 0.22 
6.45 0.38 0.25 0.29 0.22 0.25 0.24 0.35 
6.9 1 0.41 0.46 0.33 0.21 0.25 0.31 
14. 13 0.48 0.27 0.28 0.29 0.29 0.34 0.29 
14 .39 0.41 0.25 0.32 0.24 0.23 0.33 
39.43 0.41 0.21 0.27 0.26 0. 13 0.2 0.24 
57.92 AMORPHOUS CONVERSION 
2 =3 1.34 2 =32.36 
0. 18 0.17 
0.64 0.3 
0.38 
0.48 0.11 
0.37 0.4 1 
0.3 
( 
Mechanism- I: Selective Adsorption of different faces 
Mechanism-2: 
Inclusion -7 Volumetric Expansion-7 Loss ofSymmetry-7 Amorphous Conversion 
Figure 69. Illustration of the Proposed Mechanisms of Crystal Disruption 
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By adsorbing onto selective faces, urea may have mediated crystallization of 
polymorph C while stunting the growth of A. The second mechanism involves the 
inclusion of urea into the lattice of Chip, increasing the volume of the crystal 
lattice, and thereby increasing the d-spacings. Increased volume as a result of the 
distortion induced by a foreign molecule thus also results in the shift of XRPD 
peaks. Interestingly, this is reflected in the majority of the peaks shifting toward 
lower 29's. A combination of these two mechanisms is also possible where the 
levels of impurity are high, culminating in the eventual loss of symmetry and 
subsequent amorphous conversion. Although, single crystal data of the doped 
crystals will provide more insight into such mechanisms, single crystals are 
difficult to grow to tangible sizes using SCF recrystallization. On the other hand, 
the XRPD data generated in this study can be utilized in deducing the lattice 
parameters and other crystallographic data by iterative computer simulations. 
Published single crystal data however is only available for form A [Koo 1980] 
and such studies could not be performed for polymorph C, which is frequently 
formed in these studies. The evidence of crystal disruption was also confirmed by 
the lowering of the melting points and the heat of fusion values of the doped 
crystals compared to pure crystal of the same polymorph (Table 28). Melting 
point reductions up to 9°C were seen upon doping with urea. Also, significant 
reductions in the LI.Hr values of Chip up to 50% were seen as a result of doping 
with urea. By imparting a strain in the lattices of chlorpropamide crystals that was 
observed in XRPD results, urea may have reduced the symmetry in the original 
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crystals and hence a reduction in the heat of fusion values were seen. Such 
reductions manifest in significant increases in the initial dissolution rates owing to 
the ease with which the solvent can destroy the crystal structure for subsequent 
dissolution. Following the log-linear relationship observed between these entities 
by Yoshihashi [Yoshihashi 2000], projected enhancement in the initial dissolution 
rates can be expected to be significant. 
Scanning electron microscopy of the doped crystals indicated surface 
adsorption of urea onto Chip crystals. Also, the particles appeared severely 
agglomerated owing to the use of a smaller collection vial. Given that the interest 
here is in the crystalline morphology of the RESS produced crystals of Chip, no 
exhaustive attempts were made to restore the microcrystals formed by SCC02 
from agglomeration. To prove the concept of agglomeration arising from the 
bouncing of particles coming at high velocities into the collection vessel ( 40 ml), 
a larger collection vessel was used (I L). Owing to the altered dynamic of jet 
expansion in this case, agglomeration was significantly reduced (compare Figure 
70f versus Figures 70b-e). The SEMS shown in figure 70f indicate that the 
particle size of the primary RESS produced particles is in the range of 1-2 µ while 
that of the starting material was around I 0 µ. A particle size reduction of up to an 
order of magnitude was therefore produced upon RESS processing. 
The efficiency of RESS process in doping was evaluated by direct 
comparison to the doped crystals produced from liquid organic solvents. 
Polymorphic conversion was not seen in Chip recrystallized from ethanol, ethyl 
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[d]Recrystallized from SCC02 at [75°C, 4000psi] [e]Recrystallized from SCC02 at [77°C, 8000psi] [f]Recrystallized from SCC02 at [77°C, 8000psi]• 
Figure 70. Scanning Electron Micrographs of RESS Produced Chlorpropamide+Urea Co-Crystals 
• IL Collection Vessel Used 
acetate or hexane. As can be seen from Figures 71 to 73, polymorph A was 
formed in all the solvent systems, irrespective of their polarities. 
Although minor reductions in the melting temperatures and the heat of 
fusion values of Chip were seen upon doping with urea {Tables 31 A-C), no 
significant disruption in the crystallinity was evident from XRPD results. A 
possible cause for this may be due to the limited amounts of urea that actually got 
incorporated into the lattice of Chip. On the other hand, the fast nucleation and 
growth from a supercritical solution may have locked rather high levels of urea 
into the crystal lattice of the host, causing large reductions in the crystallinity. The 
ability to adjust the level of impurity in this context provides the ability to control 
the levels of crystallinity of Chip. This feature of RESS based crystal doping 
coupled with the polymorph conversion and particle size reduction ability may all 
be advantageously utilized towards enhancing the dissolution rates of poorly 
soluble drugs. 
4. CONCLUSIONS 
Towards the objective of enhancing the dissolution characteristics of poorly 
soluble drugs, amorphization of AP!s is increasingly popular in the present day 
developmental research. A more subtle crystal modification approach toward the 
same goal if applied early on in the development process may ease subsequent 
development work. It is with this objective that the polymorph conversion and 
crystal disruption of a model AP! viz. Chlorpropamide were investigated in this 
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Figure 71. XRPD Patterns ofCblorpropamide+Urea Co-Crystals 
Recrystallized from Ethanol 
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Figure 72. XRPD Patterns of Cblorpropamide+Urea Co-Crystals 
Recrystallized from EtAc 
Figure 73. XRPD Patterns ofCblorpropamide+Urea Co-Crystals 
Recrystallized from Hexane 
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Table 31. Thermal Analysis ofChlorpropamidc+Urca mixtures Recrystallized from Liquid Organic Solvents 
[A] Recrystallized from EtOH 
- -
Sa mple ID E.ndothcrm-1 iHlrl Endoth erm-2 <1.Hr2 
(OC) Jig (oC) Jig 
80% Chip+ 20% Urea (2) 98.63(0.33) 54.8 1 (2.80) 122.67(0.92) 3.88(2.36) 
90% Ch ip+ I 0% Urea (3) 96.07(0.5 1) 56.80( 19.92) 
99.5% Chip+ 0.5% Urea (5) 11 7.20(0.85) 5.90(32.99) 126.33(0.54) 54.34(4 .19) 
99.9% Chip+ 0.1% Urea 11 2.95(0.62) 60.73(12.95) 
[BJ Recrystallized from EtAc 
Sa mple ID Endotherm- t <I.Hr I Endoth erm-2 <1.Hr2 
(OC) Jig (OC) Jig 
Pure Chlorpropamide (7) 119.97(0.65) 8.41 (4.63) 128.95(0.4 1) ]16.97(2.20) 
80% Ch ip+ 20% Urea (8) 95.83(0.40) 68. 11 (19. 14) 125 .42(0.23) 3.97(25.03) 
90% Ch ip+ I 0% Urea(9) I 06.1 1 (0.24) 87 .55(2.30) 
99% Ch ip+ 1% Urea(IO) 116.38(0.34) 2 1.19(58.34) 124.43(0.50) 53.35(9.68) 
99.5% Chip+ 0.5% Urea( ! I) 11 7.38(0.48) 22. 13(73.28) 126.63(0.52) 70.39(2.43) 
99.9% Chip+ 0.1% Urea(l2) 11 8.56(0. 13) 17.59(8.2 1) 127.86(0. 12) 72.44( 1.20) 
[CJ Recrystallized from Hexane 
Sample ID Endotherm-1 <1.Hrl Endotherm-2 <l. Hr 2 Endotherm-3 <1. Hr3 
(OC) Ji g coq Jig (OC) Ji g 
Pure Chlorpropamide, F 122.83(0.42) 16.25( I I. 72) 129.58(0.11 ) 82.596( 1.83) 
80% Chip+ 20% Urea, G 99 .00(0.25) 77.48(3.52) 11 5.50(0.75) 9.90(8.69) 
99% Chip+ 1% Urea, H I 00.92(0. 14) 7.92( 100) 11 5.33(0.25) 31.10(8.3 6) 120.92(0.43) 32.57(5.3 1) 
99.5% Chip+ 0.5% Urea, I 121.08(0.66) 9.77(20.6) 129.25(0.5 1) 75 .95(3.62) 
99.9% Chip+ 0.1% Urea, J 11 8.67(0.49) 9.8 1(12. 13) 127.42(0.4 1) 66.95(2.22) 
work. The utility of rapid co-crystallizations using the RESS process was tested 
for these purposes. Toward this objective, three different means of characterizing 
the various polymorphs of Chip were developed in this study. Following 
polarizing optical microscopy, it was found that polymorph A crystallizes in 
tabular habit, while the metastable forms B and C appear as blades and plates 
respectively. The major XRPD diffraction peaks distinguishing the various 
polymorphs were also identified. Thirdly, the melting data useful in evaluating the 
crystallinity of these polymorphs was developed following thermal analysis by 
DSC. 
RESS recrystallizations of pure Chip indicate the ability of the RESS process 
to form different polymorphs from the same solvent by mere changes in the 
temperature and pressure conditions. Scanning electron microscopy of 
recrystallized materials showed a change in the habit and also, a general reduction 
in the particle size of the recrystallized materials. 
The presence of urea in the crystallizing medium of chlorporparnide 
reduced the yields of crystallization. Co-crystallization studies also revealed the 
formation of eutectic mixtures and solid solutions depending on the composition 
of the mixtures formed. Formation of the solid solutions of urea in 
chlorpropamide resulted in the crystal disruption of Chip and eventually in 
amorphous conversion at urea levels higher than 40% w/w. Consistent with these 
results were the reductions in melting point (up to 9°C) and in the ti.Hr values of 
Chip (up to 50%). By imparting a strain in the lattices of chlorpropamide crystals, 
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urea may have reduced the symmetry in the original crystals and subsequently 
destroyed the crystal structure. Scanning electron microscopy of the doped 
crystals indicated surface adsorption of urea onto Chip crystals. SEMS also 
revealed a particle size reduction of up to an order of magnitude upon RESS 
processing. Unlike RESS, recrystallizations from liquid organic solvents lacked 
the ability to affect polymorphic conversions. Also, incorporation of urea into the 
lattice of Chip was found inadequate. The efficiency of RESS process in doping 
therefore was reported to be superior to organic solvent-based recrystallizations. 
In summary, the results reported in this manuscript reflect the potential for 
RESS aided crystal doping in not only controlling the crystallinity levels in AP!s, 
but also tailor the polymorphism and particle morphology. 
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CHAPTER FIVE 
Title: Solubility and Phase Behavior of Pharmaceutical Solids in Supercritical 
Carbon dioxide. 
Abstract: 
Purpose. To study the phase behavior of selected pharmaceutical sol ids as a 
function of temperature, pressure and composition of the supercritical solvent. 
Methods. A phase monitor was employed to characterize the phase behavior of6 
pharmaceutical solids in supercritical carbon dioxide. The basic design of the 
phase monitor includes a variable volume syringe pump fitted with a quartz view 
cell and a light source. The events occurring in the high pressure cell are observed 
by projecting the view onto a TV monitor through a variable focus camera 
attached to the view cell. The pharmaceutical solids studied included ketoprofen, 
piroxicam, tolbutamide, chlorpropamide, chloramphenicol and salicylic acid. The 
P,T region probed in this study included 0.1-55.2 MPa and 40-I00°C. The effect 
of the presence of a second component (cosolute/cosolvent) on the behavior of 
solids in SC C02 was also studied. Results. By continuously tuning the solvent 
power of SC C02, regions were located that exhibited enhanced so lubilization of 
the so lids studied. Upon depressurization from these regions, a characteristic 
turbidity was seen that subsequently lead to recrystallization of the solids. ln a 
further series of investigations involving low melting solids, reduction of melting 
temperatures was seen in the presence of SC C02. In some cases, the presence of 
a second component resulted in a shill in the conditions, while also affecting the 
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morphology of the reprecipitated crystals. Conclusions. Qualitative observations 
from such phase behavioral studies can assist in choosing the optimum extraction 
conditions for subsequent RESS processing. The melting point depression of 
solids in the presence of SC C02 may have potential implications in studies 
involving other supercritical fluid based processing techniques. 
Key words: Supercritical C02, Phase Behavior, Solubility, Phase Monitor. 
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1. INTRODUCTION 
Control over supercritical fluid (SCF) based crystallization processes depend on 
the knowledge of the mechanism of solute nucleation, supersaturation levels and 
the phase of the solution from which solutes nucleate and grow [Turk 1999, 
Palakodaty 1999, Bristow 2001, Diefenbacher 2002). An understanding of the 
so lubility and phase behavior of the solids in SCFs is therefore essential in 
optimizing the crystallization conditions. For example, the crystallization yields 
from Rapid Expansion of Supercritical Solution (RESS) process primarily depend 
on the solute solubilities in the supercritical solvent. The knowledge of the 
solubility behavior of the so lute as a function of pressure and temperature of the 
SCF would allow to choose optimum extraction conditions. Similarly, 
establishing the phase behavior of a three component solid + cosolvent + SCF can 
assist in crystallizing the solute from the desired phase. Further, solvent removal 
can be eased by following appropriate path on the phase diagram. While the 
knowledge of such behavior is regarded to be vital in particle formation studies, 
very little has been accomplished to date in the pharmaceutical area [Mc Hugh 
1994, Kordikowski 2002). This stems from the inherently complex behavior of 
supercritical fluids, which is rather difficult to trace and model. Research efforts 
at such an understanding, even in a qualitative sense can serve as the basis for a 
yet larger goal that remains to be accomplished. It is with this objective that the 
solubility and phase behavior of different pharmaceutical solids were studied in 
supercritical C02. 
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2. DESIGN OF PHASE MONITOR 
A Phase Monitor provides direct, visual observation of materials under SCF 
conditions, which may be controlled precisely. Depending on the supercritical 
fluid under consideration and the range of data desired, several designs of the 
phase monitors can be used, ranging from a simple Jerguson gauge to a complex 
diamond anvil cell (Zhen 1999). For the purposes of thi s study, a simple phase 
monitor was purchased from Supercritical Fluid Technologies Inc, DE. The basic 
design of this apparatus (Figure 74) includes a 30ml capacity syringe pump, a 
high pressure vessel with quartz windows, a mixer, and a variable focus video 
camera. Pressures up to 10,000 psi are attainable with the sensor accuracy of ±2 
psi. The mantle heaters equipped with the temperature control system can heat the 
vessel up to 300°C. Temperature control is provided by a PID attached to a 
temperature sensing RTD that provides ±0.5°C temperature sensing accuracy and 
precise control. The solute is introduced through a port in the top of the 
horizontally oriented pump and carefully placed within the custom designed 
sample holder. Liquid C02 from a tank is delivered through the same port into the 
syringe pump. Upon pressurization and equilibration of the temperature, C02 
changes to the supercritical fluid state. An additional module is also included 
using which a cosolvent can be co-introduced with C02• The events in the high 
pressure vessel are viewed through a quartz window using a variable focus 
camera. The view is projected onto a TV NCR monitor that provides the ability 
to record experiments for future review. 
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Figure 74. Schematic of SFT Phase Monitor 
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3. EXPERIMENT AL 
3.1 Materials: 
Aspirin (Sigma, Lot# 88H041 l), Chloramphenicol, (Sigma, Lot# 48H0570), 
Chlorpropamide (Sigma, Lot# 31H0722), Ketoprofen (Sigma, Lot# 28H0344), 
Piroxicam (Sigma, Lot# 126H0820), Salicylic acid (Sigma, Lot# 49H3435), 
Tolbutamide (Sigma, Lot# 47Hl 030), Ethanol (190 Proof, Lot# 01 D24QB, Aaper 
Alcohol Company). 
3.2 Sample preparation: 
About 50 mg of sample was introduced into the sample holder of the Phase 
Monitor. C02 from the tank was introduced and allowed to equilibrate at the set 
temperature for 5 minutes. Using the syringe pump, C02 was pressurized to the 
maximum value. Rapid depressurization of the supercritical solution from this 
stage allowed formation of crystals onto the quartz window and in the direct view 
of the camera. 
3.3 Co-solvent addition: 
Predetermined amount of a co-solvent was pumped using a liquid metering pump 
and co-introduced along with C02. Mixing of the two fluids was affected in a low 
dead volume-T as they are delivered into the syringe pump. 
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The reproducibility of the solvent effects of SCC02 upon repeated pressurization 
and depressurization was initially confirmed. This was stru1ed with broad sweeps 
up and down in pressure hundreds of psi to characterize the significant events. 
Following this, the oscillat ions were attenuated with each pass until the degree of 
resolution was attained and the events were then recorded. In instances where the 
occurrence of an event is gradual , the onset and the endpoints are noted and the 
event was continuously recorded over a broad pressure range. A similar procedure 
was then repeated at a different temperature setting. 
4. RESULTS AND DISCUSSION 
The phase behavior of salicylic acid in SC C02 as a function of temperature and 
pressure is shown in Figure 75. Solid salicylic acid can be seen as needles at 
75°C, 2300 psi condition. As can be seen from the figure, continuous 
pressurization of the supercritical solvent resulted in the dissolution of these 
crystals. Complete dissolution of the crystals at 75°C was evident when the 
pressure reached 4300 psi. Similar trend was seen at 100°C, although the pressure 
needed to completely dissolve the salicylic acid in this case was found to be 
2700psi. Figures 76 and 77 represent the results from a simi lar study to identify 
the temperature and pressure conditions required for complete dissolution of 
chloramphenicol and chlorpropamide respectively. The optimum conditions for 
the maximum solubi lity of the various solids studied are summarized in Table 32. 
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[75°C, 2300psi) [75"C, 2700psi) 
[75' C, 3100ps~ [75°C, 4300psi) 
....... \ . 
[100°C, 1900psi) [100°C, 2350psi) [100°C, 2700psi) 
Figure 75. Phase Behavior of Salicylic acid + SCC02 
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[35°C, 9000psi) 
[60'C, <4500psi) [60°C, 4500psij 
[75°C, <3800psij [75' C, 3800psi] 
( 
' t 
[100' C, <2500psi] [100°C, >2500psi] 
"Melting point of Ch1orpropamide=121°C 
Figure 76. Phase Behavior of Chlorpropamide + SCC02 
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(60°C , <3000psi] [60' C, >3500psi] 
[75°C, <3000psij [75' C, >3500psi] 
[100' C, <3000psl) [100' C, >3500psi] 
·Melting point of Chloramphenicol=154°C 
Figure 77. Phase Behavior of Chloramphenicol + SCC02 
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Table 32. Supercritica l Fluid Conditions for Enhanced Solubilization 
Salicylic acid 
Piroxicam 
Chlorpropamide' 
Tolbutamide' 
Ketoprofen' 
Chloramphenicol ' 
[75°C, 4300psi]; [100°C, 2700psi) 
[40°C,4500psi) ; [60°C, 3500psi) 
[60°C,4500psi] ; [75°C, 3800psi]; (I 00°C, 2500psi) 
[60°C,3800psi]; [75°C, 6000psi] ; [100°C, 2500psi) 
[55°C, I 400psi) 
[75°C, 3500psi); [100°C, 3500psi) 
• Exh ibited melting point depression 
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Depressurization of these supercritical solutions resulted in a characteristic 
turbidity that subsequently led to the fomiation of crystals. While this event is 
very responsive to small pressure changes in the case of chlorpropamide (Figure 
76), other solids showed a gradually increasing turbidity with reduction in 
pressure. Identification of the significant events therefore should take into account 
both the pressurization and depressuri zation cycles for a more comprehensive 
understanding of the solid behavior in supercritical solvents. 
The influence of a second component on the solubility behavior of 
salicylic acid in SC C02 was studied using aspirin as a cosolute and ethanol as a 
co-solvent. Results of these studies are respectively shown in Figures 78 and 79. 
The presence of aspirin changed the morphology of the recrystallized salicylic 
acid from needles to fibrous habitat (Figures 75, 78). Comparison of these figures 
also reveals that aspirin allowed complete dissolution of salicylic acid at a lower 
pressure condition by mediating in solubility enhancement. These results are 
consistent with the increased yields of RESS recrystallization for salicylic acid+ 
aspirin mixture, reported in chapter three. 
The 75°C, 2400 psi condition in Figure 79 shows a 3-component, biphasic 
mixture of salicylic acid+ethanol (droplets) and SC C02 (continuous phase). 
Continuous pressurization from this stage resulted in a single phase when the 
pressure of SCF reached 3200psi. Again, a shift in the solubilization conditions 
was evident in the presence of ethanol as cosolvent (Figures 75, 79). 
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[75°C. 2400psi) [75°C, 3200psi) 
Figure 78. Phase Behavior of Salicylic acid + Aspirin + SCC02 
[75°C. 2400psi) [75°C, 3200psi) 
Figure 79. Phase Behavior of Salicylic acid + EtOH + SCC02 
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In a different series of investigations involving low melting solids such as 
chlorpropamide (Figure 76) and chloramphenicol (Figure 77), a reduction in the 
liquefaction temperature of these solids was seen. The appearance of melt droplets 
of chlorpropamide and chloramphenicol can be seen in these figures at I 00°C and 
75°C respectively. Contrary to the effect of static pressure on the melting 
temperatures of solids, the presence of SCF in fact caused a reduction in the 
melting points. This behavior is attributed to the diffusion of supercritical fluid 
into the drug crystals in a manner analogous to the plasticization effects in 
amorphous polymers. While the former manifests as a reduction in melting point, 
the latter results in softening & lowered glass transition temperatures. The 
implications of such effects can be expected to be profound while dealing with 
processes such as PGSS and supercritical fluid extrusion. 
5. RECOMMENDATIONS TO IMPROVE THE UTILITY OF PHASE 
MONITOR 
5.A. Design of Equipment: 
I) The view of the camera is too narrow and appears to represent only about 
1 percent of the total volume in the view cell. 
2) Areas where solids would tend to settle, dissolve and recrystallize/ 
reprecipitate typically are outside the scope of the camera. The design of 
the view cell needs to be corrected so that the camera is directed towards a 
larger area where solids would tend to be deposited. 
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3) The extension from the piston pump needs to be redesigned so that no 
portions are hidden from the view of the camera. A possible solution is to 
remove the circular extension at the end and instead have the same 
dimensions as the cylindrical piston pump, fitted with a larger diameter 
quartz window. 
4) The magnetic stir bar under current design often is displaced from its 
position into the piston. The magnetic stir bar should be designed so that 
it stays in its only circular extension and does not get knocked out by the 
currents of liquid entering and exiting the cell. 
5) Even when the magnetic stir bar stays in place, the mixer is not powerful 
enough for good mixing within the cell. Therefore, the motor needs to be 
more powerful and the magnet in the stir bar stronger to have complete 
mixing in the phase equilibrium monitor. 
6) Another solution to the mixing problem would be to introduce a stir bar 
without a magnet and the view cell made capable of tilting about 45 
degrees. The stir bar in this case can be made to slide from one end to the 
other end of the view cell, causing additional stirring. 
7) There appears to be a design flaw in the standard configuration of the light 
source being 90 degrees from the view of the camera. The depth of the 
camera appears to be good and the resolution is reasonable for up to l 
foot, which is the length of the piston pump. The amount of light entering 
the view cell, however is limited by the position of the light source, 
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leaving the cell only dimly lit. On the other hand, increasing the wattage 
of the light source blurs the overall view due to excessive brightness. The 
light needs to be directed from the same direction as the camera or at 180 
degrees from the camera to light up the whole cell . This would be 
beneficial for observing the critical opalescence since the refraction of 
light through the cell is required to observe this phenomenon. The present 
design only partially lights the cell that makes it difficult for the human 
eye to pick up the critical opalescence phenomenon. By positioning the 
light source in the same plane as the camera (by reflecting light off the 
fluid versus transmitting light in the current design), the visual effects can 
be enhanced. The intensity of the light being reflected back into the 
camera would also be much greater and would allow for a much more 
accentuated transition from a bright red color to a dark color when 
entering the critical fluid region. This might assist in a more precise 
determination of the critical points of fluid mixtures. It would also make 
for a much more powerful visual display when demonstrating the unit. 
8) For polymer applications, the capability to determine the extent of 
polymer swelling in supercritical fluids is essential. To do this, the 
standard phase equilibrium system must be modified so that a) a polymer 
can be held in position in front of the camera at a fixed position and b) and 
a micrometer for optical measurements be placed next to the polymer to 
determine the degree of swelling. A correlation needs to be made between 
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the size of the particle on the TV screen and the size of the particle in the 
view cell. 
9) For applications where the refractive index of the supercritical fluid and 
the solute are very close, use of a different colored light source may be 
advantageous. The contrast between the supercritical fluid and the solute 
can be accentuated by eliminating one wavelength (analogous to using a 
compensator in optical microscopy). An easier and cheaper solution, 
however is to use a different light source like a neon or sodium lamp. 
I 0) In place of the camera in the back, a photo multiplier tube or a detector 
can be placed to quantitatively determine the solubility of solids in 
supercritical fluids. 
5.8. Operation of the Equipment 
I) Start off with broad sweeps up and down in pressure lOOs of psi to get an 
approximate idea of where the solute is precipitating out of solution. Then 
attenuate the oscillations with each pass until the degree of resolution is 
attained. 
2) Introduce the solute into the view cell. The current setup does not allow 
for accurate placement of quantitative amounts of solute, which is required 
to get quantitative data out of this instrument. If the system can be 
redesigned so that an exact weight of solute can be placed in the view of 
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the camera, semi quantitative investigations of solute solubilities as 
functions of pressure and temperature of SCF solvent can be made. 
6. CONCLUSIONS 
By continuously tuning the solvent power of SC C02, regions were located 
that exhibited enhanced solubilization of the solids tested. Upon 
depressurization from these regions, a characteristic turbidity was seen that 
subsequently lead to the recrystallization of solids. A general trend of 
increased solubilization with increasing pressures was seen in all the cases. 
Qualitative observations from such phase behavioral studies can assist in 
choosing the optimum extraction conditions for subsequent RESS processing. 
The melting point depression of solids in the presence of SC C02 may have 
potential implications in studies involving other supercritical fluid based 
processing techniques. Finally, the limitations of the commercially available 
design are identified and recommendations made in the design and operation 
for better performance of the phase monitor. 
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APPENDIX 
INTRODUCTION : 
This appendix compiles the data generated in the recrystallization of pure drugs and 
drug-impurity mixtures by RESS process. Excerpts from this appendix are utilized 
in Chapter-3 to comprehensively report the various phenomena observed during the 
supercritical fluid recrystallizations. For clarity purposes, the data associated with 
each RESS study is divided into several individual sections. Section A in each 
study gives the chemical structures of the API and the dopant. The RESS 
conditions used in the recrystallization experiments are summarized in Section B. 
Section C compiles the thermal analysis data by differential scanning calorimetry. 
The data from XRPD analyses is divided into two subsections, DI and D2. While 
the XRPD patterns in each analysis are shown in DI, the analyzed data 
demonstrating peak shifts and peak broadening is tabulated under D2. Broadened 
peaks in this subsection are shown in bold font and peak shifts in italicized font. 
Optical microscopy and HPLC analysis was performed only for a selective set of 
compounds. Wherever available, results from these studies are documented in 
sections E and F respectively. 
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Index for Appendix 
Drugi Drug-Impurity Mixture Page Numbers 
Pure Salicylic acid 263-264 
Sahcyhc acicH Aspmn :Z-6>-270 
Salicylic acid + Benzoic acid 27 1-278 
Aspirin + Benzoic acid 279-287 
Pure Tolbutamide 288-289 
Tolbutamide + Chlorpropamide 290-294 
Tolbutamide +Urea 295-303 
Piroxicam + Theophylline 303 
Piroxjcam + Benzoic acid 304-306 
Theophylline + Caffeine 307-318 
Theophylline + Theobromine 3 19-32 1 
Phenytoin + Ca !Teine 322-327 
lndomethacin +Salicylic acid 328-336 
Naproxen + a-Naphthalene-acetic acid 337-343 
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1. PURE SALICYLIC ACID: 
I A. CHEMICAL STRUCTURE: 
0 
II 
C-OH A oH 
lJ 
Salicylic Acid 
IB. SUMMARY OF RESS RECRYSTALLlATION: 
CONTENTS OF REACTlON VESSEL: 5g of Salicylic acid 
Experiment jP,T conditions I Weight Collection CO, Used 
collected time Lat STP 
mg min 
I [45°C, 900psi] 25 10 24.58 
2 [45°C, 3000psi] 158 10 36.28 
3 [60°C, 4000psi] 48 1 20 99.92 
4 [65°C, 3000psi] 152 10 44.02 
5 [75°C, 4000psi] 436 20 11 2.27 1 
Solubility 
mg/IOOL 
C02 atSTP 
101.71 
435.50 
48 1.39 
345.30 
388.35 
6 [60°C, 750-4000psi] Collected on glass slides using phase monitor. 
263 
1 C. DSC ANALYSIS: 
i:;/ ~ 
...L 
----..__J 
I"' 
.b '-.. 
.... J ~ 
Material Melting Onset End Melting DeltaH 
Point range 
•c •c •c •c Jig 
Pure Salicylic acid as obtained from Sigma 161.3 158.7 163.1 4.5 188.3 
Recrystallized from SC C02 at [45°C, 3000psi] 160.3 158.6 161.4 2.7 175.6 
Recrystallized from SC C02 at [65°C, 3000psi] 159.8 158.3 160.4 2.1 175.4 
Recrystallized from SC C02 at [75°C, 4000psi] 160.8 157.5 161.9 4.4 169.9 
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2. SALICYLIC ACID+ ASPIRIN: 
2A. CHEMICAL STRUCTURE: 
0 
II 
C-OH 
ArOH 
v 
Salicylic Acid 
0 
II 
C-OH 
CH,J-o{) 
28. SUMMARY OF RESS RECRYSTALLIATION: 
COMPOSITION OF STARTING MIXTURE: 80% Salicylic acid + 20% Aspirin 
CONTENTS OF REACTION VESSEL: 4g Salicylic acid + lg Aspirin (5g of blend) 
Experiment IP,T conditions] 
I [75C, 4000psi] 
2 [45C, 3000psi] 
2C. DSC ANALYSIS : 
f 
' 
,., .... ..,.,,, 
-141SCC02•EIOl1f'!Cfl!lll<Zed 
Weight collected,mg 
2511 
265 
Collection time, min Recrystallizing 
Solvent 
20SCC02 
Jct~10Ptrjol.b 
-inacmP!!fu.. 
- SC CO,+EtOH 
20.l. XRPD ANALYSIS: 
45 .0 . 
40.0 -
35.0 . 
30.0 
w § 25.0 . 
" i! 
~ 20.0 . 
i i 
15.0 . 1Z07ii7S~ ·~~·~k:Yik edd ; ·~;a~· t;.;i~· ~;;g· ~;,i::O.ih.--·· 
10.0 
s.o 
Xl0A3 
10 20 30 40 
2-Theu.(1 
is .a~---------~-----~------~-----~ 
10.0 
5.0 . 
(Z07234 .MOI) Ptryslal Millfturt of Sallcylk Kid (l®+Asplr1n(20llQ <PJ~.0> 
1207237.MOll Sallcylk .cld +Aspirin :RESS {75,4000) d'll• O.O> 
2-Thetan 
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2D.2. XRPD ANALYSIS: 
Peak Search Report (21 Peaks, Max PIN = 46. 7) 
[Z07009.MDI] Ground Aspirin pure, Lot#88H041 l-Sigma, Grinded for 2 min 
PEAK: 23-pts/Parabolic Fi lter, Threshold=3.0, CutofT=0. 1%, BG=3/ 1.0, Peak-Top=Summit 
2-Theta d(A) BG Height 1% Area 1% FWHM 
7.72 11.443 43 4049 45.8 49590 41.9 0.21 
15.52 5.705 60 8845 100 118408 100 0.23 
16.66 5.3 18 54 280 3.2 3442 2.9 0.26 
18.08 4.903 41 169 1.9 2 192 1.9 0.29 
20.54 4.321 54 677 7.7 1376 1 11 .6 0.38 
2 1.42 4.145 102 153 1.7 480 0.4 0.16 
22.56 3.938 98 1567 17.7 28701 24.2 0.33 
23. 14 3.841 64 1015 11.5 20475 17.3 0.37 
24.84 3.581 69 160 1.8 143 1 1.2 0.27 
26.88 3.3 14 80 1655 18.7 4038 1 34. 1 0.44 
28.8 3.097 83 171 1.9 1423 1.2 0.27 
29.46 3.029 74 176 2 1759 1.5 0.29 
30.08 2.968 75 186 2.1 141 6 1.2 0.22 
3 1.6 2.829 75 685 7.7 8727 7.4 0.24 
32 .5 2.753 69 437 4.9 6309 5.3 0.29 
33 .76 2.653 6 1 140 1.6 1316 I.I 0.28 
34.38 2.606 55 165 1.9 1999 1.7 0.31 
35.86 2.502 60 184 2.1 3980 3.4 0.55 
39. 14 2.3 43 144 1.6 1287 I.I 0.22 
40.44 2.229 48 122 1.4 1566 1.3 0.36 
41.96 2.151 51 165 1.9 3679 3. 1 0.55 
Peak Search Report (2 1 Peaks, Max PIN = 93.6) 
[Z07075.MDI] Pure Salicylic acid, after 2 min Grinding <Psi=O.O> 
PEAK: 19-pts/Parabolic Filter, Threshold=3.0, CutofT=0.1%, BG=3/l.O, Peak-Top=Summit 
2-Theta d(A) BG Height 1% Area 1% FWHM 
10.98 8.051 41 35122 100 296650 100 0.14 
15.28 5.793 41 1085 3. 1 13023 4.4 0.21 
15.74 5.625 46 667 1.9 6681 2.3 0.18 
17.22 5.145 44 11620 33. 1 142907 48.2 0.21 
17.5 5.063 44 1237 3.5 30708 10.4 0.44 
17.96 4.935 37 159 0.5 1286 0.4 0.18 
19.62 4.52 36 259 0.7 2584 0.9 0.2 
25.26 3.523 49 2452 39357 13.3 0.28 
28.04 3.179 59 1790 5.1 21209 7. 1 0.2 1 
28.7 3. 108 74 11 72 3.3 14462 4.9 0.22 
30.68 2.912 59 886 2.5 14469 4.9 0.3 
31.82 2.8 1 53 294 0.8 2853 1 0.2 
32.76 2.73 1 61 168 0.5 101 3 0.3 0. 16 
33.34 2.685 48 244 0.7 3240 I.I 0.28 
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33.7 2.657 53 245 0.7 2968 I 0.26 
34.86 2.571 52 161 0.5 1069 0.4 0.17 
35.52 2.525 46 366 4493 1.5 0.24 
38 2.366 48 226 0.6 2645 0.9 0.25 
39.92 2.256 46 289 0.8 5969 2 0.42 
44 2.056 46 149 0.4 1481 0.5 0.24 
46.78 1.94 45 251 0.7 3900 1.3 0.32 
Peak Search Report (22 Peaks, Max PIN = 5 1.5) 
(207234.MDI] Physical Mixture of Salicylic acid (80%)+Aspirin(20%) <Psi=O.O> 
PEAK: 17-pts/Parabolic Filter, Threshold=3.0, Cutoff=0.1 %, BG=3/ 1.0, Peak-Top=Surnmit 
2-Theta d{A) BG Height 1% Area 1% FWHM 
7.88 11.211 43 603 5.6 4912 6.3 0.15 
11.04 8.007 48 7968 73.9 67631 86.9 0.15 
15.48 5.7 19 73 407 3.8 6268 8.1 0.32 
15.78 5.612 78 10780 100 77791 100 0.12 
17.34 5.11 94 3921 36.4 38173 49. 1 0.1 7 
17.62 5.029 97 409 3.8 7536 9.7 0.41 
18.06 4.907 118 263 2.4 1096 1.4 0.13 
19.8 4.48 102 389 3.6 2568 3.3 0.15 
22.72 3.91 92 2848 26.4 22318 28.7 0.14 
25.44 3.499 87 1271 11.8 17393 22.4 0.25 
28.16 3.166 83 647 6 5274 6.8 0.16 
28.88 3.089 82 829 7.7 6794 8.7 0.15 
30.46 2.932 72 164 1.5 1667 2.1 0.31 
30.82 2.899 73 509 4.7 6424 8.3 0.25 
31.58 2.83 1 71 121 I.I 598 0.8 0.2 
32.9 2.72 65 145 1.3 775 0.16 
33.82 2.648 59 150 1.4 1024 1.3 0.19 
35.6 2.52 52 114 I.I 1010 1.3 0.28 
38.16 2.356 44 156 1.4 1526 2 0.23 
40.08 2.248 47 199 1.8 2586 3.3 0.29 
40.52 2.224 45 93 0.9 772 0.27 
46.88 1.936 37 107 1201 1.5 0.29 
Peak Search Report (23 Peaks, Max PIN = 11 .8) 
[Z07237.MDI] Salicylic acid +Aspirin :RESS (75,4000) <Psi=O.O> 
PEAK: 19-pts/Parabolic Filter, Threshold=3.0, CutofT=0.1%, BG=3/ l.O, Peak-Top=Summit 
2-Theta d(A) BG Height 1% Area 1% FWHM 
3.16 27.968 114 287 40.9 4289 53.1 0.42 
3.3 26.763 107 265 37.8 320 1 39.6 0.34 
5.75 15 .362 7 1 106 15 . I 392 4.9 0.19 
7.89 11.19 69 161 23 1346 16.7 0.25 
11.06 7.993 75 701 100 8082 100 0.22 
15.42 5.74 106 197 28.1 1103 13.6 0.21 
15.7 5.641 110 337 48.1 3420 42.3 0.26 
l 17.32 5.11 5 146 526 75 5203 64.4 0.23 
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17.7 5.008 148 207 29.5 2580 31.9 0.74 
18.1 4.896 163 2 11 30. 1 433 5.4 0. 15 
19.73 4.497 148 243 34 .7 13 11 16.2 0.23 
20.71 4.284 138 20 1 28.7 765 9.5 0.21 
21.45 4. 14 130 187 26.7 730 9 0.22 
22.72 3.9 11 11 7 181 25 .8 576 7. 1 0. 15 
23.87 3.725 11 4 162 23. 1 432 5.3 0. 15 
25 .44 3.499 97 552 78.7 709 1 87.7 0.26 
27.08 3.29 94 14 1 20. 1 799 9.9 0.29 
27.22 3.274 92 149 21.3 800 9.9 0.24 
28.22 3.159 88 140 20 678 8.4 0.22 
28.86 3.09 1 85 214 30.5 1649 20.4 0.22 
30.8 2.901 75 140 20 1352 16.7 0.35 
38.26 2.35 1 48 81 11.6 3 11 3.8 0. 16 
40. 18 2.243 44 83 11.8 790 9.8 0.34 
( 
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2E. OPTICAL MICROSCOPY: 
... -IOOu 
80/20 Physical Mixture of SA + Aspirin 
>HB• 670J•h•l31 ;15001)S! ll 
Recrystallized from SC C02 at 75°C, l 500psi 
• 
• N8 • 61QJ<l•IJ I :750psl { a ) 
Rccrysiallized from SC CO, at 75°C, 750psi 
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3. SALICYLIC ACID+ BENZOIC ACID: 
3A. CHEMICAL STRUCTURE: 
0 
II 
C-OH 
~OH 
u 
Salicylic Acid 
3B. SUMMARY OF RESS RECRYSTALLIATION: 
0 
II 
C-OH 
6 
Benzoic Acid 
COMPOSITION OF STARTING MIXTURE: 80% Salicylic acid + 20% Benzoic acid 
CONTENTS OF REACTION VESSEL : 4.8g Salicylic acid + l .2g Benzoic acid (6g of blend) 
Experiment (P,T conditions! Weight collected,mg Collection time, min 
1 (45C, 2000psi] 168 20 
2 (47C, 4000psi] 235 5 
3 (47C, 8000psi] 409 5 
4 [65C, 2000psi] 40 10 
5 [65C, 4000psi] 128 3 
6 [65C, 8000psi] 185 1 
7 [75C, 2000psi] 98 20 
8 [75C, 4000psi) 194 5 
9 [76C, 8000psi) 183 I 
3C. DSC ANALYSIS: 
) 
~ ~ 
I 
j_ ~ l .. 
-111t>s,- -1,uooc -
!l!!SP"ft' 
271 
( 
3D.l. XRPD ANALYSIS: 
35. 
30.0 ···········-····· '-······-···················-···---:.---
25.0 
I 
~ 20.0 
~ 15.0 
10. 
s.o 
l()QA) 
10 
2-ThetaO 
10.0 ········-······ ....... ~ ..... . i. - .. ~ .. 
8.0 
. . 
~ § 6.0 
~ I\: ~ 
4.0 
(Z11.MO<( Sol...,lk K~ + .. ,,.k Kid •Phy/kol " '""" <1'>~0. 0> 
!'----"--'.', l___M.) ~·~-"- v..."'-' "---~-----~ 
···-···············j·j_··-···············-·A ··- ...... Ji... ······· 1201216.MOll S.llcylk acid+ &t~ acid :RESS(76C, SOOOpsl) <PJI 
·.....A [207275.MOIJ Salicylic ..::Id+ le~ Kid :RESS C7SC. •OOOP.SI) <N 
' _),,_ (2~7274.MOI) Sallcylk Kid+ ~nzolc add :RESS (7SC,~ <p,;I 
2.0 
:..A [207213.MOIJ Salicylk Kid+ e,nzok acid :Rf.SS (65C.i000Pso cl'I 
.. j-;__j._... . .. [207272 .MOIJS.lkytklCld+~acld :lESS(65C,4000psl)<l's 
Ji. -.A . II. IZ07271 .MOIJ S.lKylk ICld. ~ru:ok ICld :RESS(65C.zooofs1) <Ps 
~ A .J\. [207270.MOIJ s.lkylk iKld + '!nzok Kid :RESS (-47C,8000psf) <l's 
-1- 0 A ~ [Z07269.MOl] SaHcylkKid+8!MOk.Kld:RCSS(47C.•O"oOi l)<PI 
_A V\.. ....J\. [Z07261.MOI) s.allcyllc ICld + ~ ICld :RESS (45C,2000v.sl) <1'11 
10 20 30 40 
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3D.2. XRPD ANALYSIS: 
Peak Search Report (2 1 Peaks, Max PIN = 93.6) 
[Z07075.MD!) Pure Salicylic ac id, after 2 min Grinding <Psi~.O> 
PEAK: 19-pts/Parabolic Fi lter, Threshold=3.0, CutotT--0.1%, BG=3/ l.O, Peak-Top=Summit 
2-Theta d(A) BG Height 1% Area 1% FWHM 
10.98 8.051 41 35 122 100 296650 100 0.14 
15.28 5.793 41 1085 3. 1 13023 4.4 0.21 
15.74 5.625 46 667 1.9 6681 2.3 0.18 
17.22 5.145 44 11620 33. 1 142907 48.2 0.21 
17.5 5.063 44 1237 3.5 30708 10.4 0.44 
17.96 4.935 37 159 0.5 1286 0.4 0.18 
19.62 4.52 36 259 0.7 2584 0.9 0.2 
25.26 3.523 49 2452 39357 13.3 0.28 
28.04 3.179 59 1790 5.1 2 1209 7. 1 0.21 
28.7 3. 108 74 1172 3.3 14462 4.9 0.22 
30.68 2.912 59 886 2.5 14469 4.9 0.3 
3 1.82 2.8 1 53 294 0.8 2853 I 0.2 
32.76 2.73 1 61 168 0.5 101 3 0.3 0.16 
33.34 2.685 48 244 0.7 3240 I.I 0.28 
33.7 2.657 53 245 0.7 2968 0.26 
34.86 2.571 52 161 0.5 1069 0.4 0.17 
35.52 2.525 46 366 I 4493 1.5 0.24 
38 2.366 48 226 0.6 2645 0.9 0.25 
39.92 2.256 46 289 0.8 5969 0.42 
44 2.056 46 149 0.4 1481 0.5 0.24 
46.78 1.94 45 251 0.7 3900 1.3 0.32 
Peak Search Report (20 Peaks, Max PIN = 43.8) 
[Z07339.MDI] Pure Benzoic acid <Psi=O.O> 
PEAK: 17-pts/Parabolic Filter, Threshold=3.0, Cutoff=0. 1%, BG=3/ 1.0, Peak-Top=Summit 
2-Theta d(A) BG Height 1% Area 1% FWHM 
6.88 12.838 55 95 1.2 236 0.3 0.1 
8.16 10.825 73 7805 100 84984 100 0.19 
16.34 5.42 1 162 2908 37.3 25687 30.2 0.16 
17.34 5.11 189 3054 39.1 31514 37.1 0.19 
17.84 4.967 205 318 4.1 943 I.I 0.14 
19.18 4.625 200 644 8.3 5468 6.4 0.2 1 
21.32 4.164 163 424 5.4 3169 3.7 0.2 1 
23.94 3.7 14 125 1233 15.8 12036 14.2 0.18 
24.58 3.6 18 129 329 4.2 1226 1.4 0.1 
25.96 3.429 102 621 8 6324 7.4 0.2 1 
26.94 3.307 94 214 2.7 1224 1.4 0.17 
27.9 3. 196 90 470 6 3836 4.5 0.17 
30.2 2.957 79 378 4.8 3690 4.3 0.2 1 
31.42 2.845 73 168 2.2 807 0.9 0.14 
32.92 2.7 18 69 401 5.1 3623 4.3 0.19 
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34.92 2.567 66 320 4.1 2547 0.17 
38.88 2.315 61 211 2.7 1525 1.8 0.17 
39.32 2.289 60 235 2255 2.7 0.22 
40.91 2.204 55 94 1.2 347 0.4 0.15 
42.84 2.109 54 110 1.4 948 I.I 0.29 
Peak Search Report (28 Peaks, Max PIN = 36.9) 
[Z07277.MDI] Salicylic acid+ Benzoic acid :Physical Mixture <Psi=O.O> 
PEAK: 17-pts/Parabolic Filter, Threshold=3.0, Cutoff=O. l %, BG=3/ 1.0, Peak-Top=Summit 
2-Theta d(A) BG Height 1% Area 1% FWHM 
3. 14 28.142 69 178 3.2 2014 3.9 0.3 1 
8.24 10.724 55 206 3.7 2119 4.1 0.24 
11.06 7.993 66 5565 100 5 1782 100 0.16 
15.43 5.736 116 382 6.9 2680 5.2 0.17 
15.86 5.583 124 297 5.3 2169 4.2 0.21 
17.34 5.11 157 4511 81.1 38998 75.3 0.15 
17.64 5.024 164 578 10.4 6499 12.6 0.27 
18.14 4.887 170 274 4.9 751 1.5 0.12 
19.78 4.484 157 381 6.8 2079 4 0.16 
21.48 4.134 129 210 3.8 779 1.5 0.16 
24 3.705 103 185 3.3 1388 2.7 0.29 
25.42 3.501 91 1113 20 15257 29.5 0.25 
27.98 3.186 94 470 8.4 365 1 7. 1 0.17 
28.18 3.1 64 84 562 IO. I 6227 12 0.22 
28.86 3.091 95 391 7 2516 4.9 0.14 
30.82 2.899 74 288 5.2 3262 6.3 0.26 
32.02 2.793 65 131 2.4 656 1.3 0.17 
32.9 2.72 66 11 8 2.1 469 0.9 0.15 
33.5 1 2.672 60 Ill 1139 2.2 0.38 
33 .82 2.648 62 135 2.4 968 1.9 0.23 
35.07 2.556 57 94 1.7 423 0.8 0.19 
35.62 2.518 53 161 2.9 1129 2.2 0.18 
36.82 2.439 47 107 1.9 965 1.9 0.27 
38. 18 2.355 48 Ill 2 89 1 1.7 0.24 
40.12 2.246 52 160 2.9 1556 0.24 
44.23 2.046 44 76 1.4 494 I 0.26 
46.9 1.936 43 106 1.9 893 1.7 0.24 
49.4 1.844 41 72 1.3 356 0.7 0.2 
Peak Search Report (15 Peaks, Max PIN = 9.8) 
[Z07268.MDI] Salicylic acid+ Benzoic acid :RESS (45C,2000psi) <Psi=0.0> 
PEAK: 19-pts/Parabolic Filter, Threshold=3.0, Cutoff=0.1%, BG=3/ l.O, Peak-Top=Summit 
2-Theta d(A) BG Height 1% Area 1% FWHM 
8.18 10.803 Ill 586 93.2 6885 100 0.25 
I I.I 7.962 116 173 27.S 708 10.3 0.21 
16.24 5.452 232 438 69.6 2355 34.2 0.19 
17. 12 5.174 265 629 100 4643 67.4 0.22 
274 
r 
18.93 4.684 282 352 56 1700 24.7 0.4 1 
19. 18 4.624 283 383 60.9 1546 22.5 0.26 
21.27 4.175 216 278 44.2 1071 15.6 0.29 
21.46 4.136 208 297 47.2 1124 16.3 0.21 
23.86 3.726 144 5 18 82.4 3893 56.5 0. 18 
25.92 3.434 120 339 53.9 2436 35.4 0. 19 
27.86 3.2 96 188 29.9 1535 22.3 0.28 
30. 16 2.96 1 87 154 24.5 946 13.7 0.24 
32.1 5 2.782 73 106 16.9 143 2.1 0.07 
32.1 5 2.782 73 106 16.9 143 2.1 0,07 
39.1 2 2.30 1 53 85 13.5 420 6.1 0.22 
Peak Search Report (17 Peaks, Max PIN = 8.6) 
[Z07269.MD1] Salicylic acid+ Benzoic ac id :RESS (47C,4000psi) <Psi=O.O> 
PEAK: 19-pts/Parabolic Fi lter, Threshold=3.0, CutofT=0. 1%, BG=3/1.0, Peak-Top=Summit 
2-Theta d(A) BG Height 1% Area 1% FWHM 
3.26 27. 119 71 182 44.8 1969 38.4 0.3 
8. 16 10.825 61 406 100 5 13 1 100 0.25 
11.16 7.923 61 164 40.4 1316 25.6 0.22 
16.28 5.44 1 105 280 69 22 11 43. 1 0.2 1 
17.18 5. 158 11 8 40 1 98.8 4963 96.7 0.3 
19.2 4.6 19 134 200 49.3 101 5 19.8 0.26 
21.3 4. 168 11 5 173 42 .6 9 19 17.9 0.27 
21.56 4.119 113 156 38.4 957 18.7 0.38 
22.24 3.995 104 142 35 396 7.7 0.18 
23.93 3.7 15 98 303 74.6 3315 64.6 0.27 
25.46 3.496 96 163 40.1 1605 31.3 0.41 
25.96 3.429 95 309 76.1 3523 68.7 0.28 
27.86 3.2 84 192 47.3 1510 29.4 0.24 
28.9 3.087 81 120 29.6 188 3.7 0.08 
30. 18 2.959 75 162 39.9 1087 2 1.2 0.2 1 
42.58 2. 12 1 41 68 16.7 229 4.5 0.14 
42.58 2. 12 1 4 1 68 16.7 229 4.5 0.1 4 
Peak Search Report (22 Peaks, Max PIN = 9.0) 
[Z07270.MD1] Salicylic acid+ Benzoic ac id :RESS (47C,8000psi) <Psi=O.O> 
PEAK: 17-pts/Parabolic Fil ter, lbreshold=3.0, CutofT=O. l %, BG=3/1.0, Peak-Top=Summit 
2-Theta d(A) BG Height 1% Area 1% FWHM 
8.13 10.872 82 177 35.7 1365 25.2 0.24 
10.63 8.3 14 85 129 26 530 9.8 0.2 
11.1 7.963 88 483 97.4 5426 100 0.23 
15.4 5.748 139 189 38. 1 37 1 6.8 0. 13 
16.02 5.528 147 190 38.3 1404 25.9 0.56 
16.26 5.445 157 215 43.3 851 15.7 0.25 
17.18 5.157 179 295 59.5 2956 54.5 0.43 
17.4 5.093 185 496 100 4699 86.6 0.26 
19.4 1 4.569 196 248 50 607 11 .2 0.2 
275 
19.8 4.481 195 277 55.8 608 11.2 0.13 
21.43 4. 144 160 227 45.8 577 10.6 0.15 
23.88 3.723 11 8 236 47.6 1525 28.1 0.22 
25.46 3.496 105 402 81 4976 91.7 0.28 
25.95 3.431 124 182 36.7 168 3.1 0.05 
27.84 3.202 90 127 25.6 243 4.5 0.11 
28.88 3.089 83 181 36.5 1280 23.6 0.22 
30. 15 2.962 79 113 22.8 418 7.7 0.21 
30.62 2.917 72 109 22 1778 32.8 0.82 
30.77 2.904 78 118 23.8 1077 19.8 0.46 
30.88 2.893 78 139 28 828 15.3 0.23 
40.27 2.238 49 77 15.5 373 6.9 0.23 
47.28 / .921 37 68 13.7 149 2.7 0.08 
Peak Search Report (14 Peaks, Max PIN = 13.1) 
[Z07271.MDI] Salicylic acid+ Benzoic acid :RESS (65C,2000psi) <Psi=0.0> 
PEAK: 17-pts/Parabolic Filter, Threshold=3.0, Cuto!F0.1%, BG=3/l.0, Peak-Top=Summit 
2-Theta d(A) BG Height 1% Area 1% FWHM 
8.06 10.959 103 883 100 9064 100 0.2 
11.02 8.021 104 549 62.2 5440 60 0.21 
16.14 5.487 190 427 48.4 2636 29.1 0.19 
17.1 5.181 215 438 49.6 6115 67.5 0.47 
17.3 5.121 221 493 55.8 6117 67.5 0.38 
21.26 4.176 178 229 25.9 814 9 0.27 
21.42 4.145 174 241 27.3 815 9 0.21 
23.76 3.741 126 304 34.4 1934 21.3 0.18 
25.34 3.5 12 109 225 25 .5 1819 20.1 0.27 
25.88 3.44 116 199 22.5 455 5 0.09 
27.8 3.207 86 145 16.4 925 10.2 0.27 
28.13 3.17 84 118 13.4 1083 11.9 0.54 
34.5 2.598 56 85 9.6 500 5.5 0.29 
40.07 2.248 48 81 9.2 196 2.2 0.1 
Peak Search Report (14 Peaks, Max PIN = 7.9) 
[Z07272.MDI] Salicylic acid+ Benzoic acid :RESS (65C,4000psi) <Psi=O.O> 
PEAK: 17-pts/Parabolic Filter, Threshold=3.0, Cutoff=0. 1%, BG=3/l.O, Peak-Top=Summit 
2-Theta d(A) BG Height 1% Area 1% FWHM 
9.72 9.093 62 92 24.7 185 4.9 0.1 
9.72 9.093 62 92 24.7 185 4.9 0.1 
11.08 7.98 69 373 100 3762 100 0.21 
17.4 5.094 139 347 93 3105 82.5 0.25 
17.69 5.01 143 186 49.9 1551 41.2 0.61 
18.06 4.908 157 204 54.7 370 9.8 0.13 
19.8 4.481 150 200 53.6 698 18.6 0.24 
23.83 3.731 119 165 44.2 245 6.5 0.09 
25.38 3.506 98 333 89.3 3417 90.8 0.25 
28.86 3.09 1 86 179 48 610 16.2 0.11 
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( 
30.83 2.897 75 122 32.7 572 15.2 0.21 
36.89 2.435 44 76 20.4 320 8.5 0. 17 
38. 14 2.357 43 73 19.6 3 16 8.4 0. 18 
40.2 2.241 43 72 19.3 359 9.5 0.21 
Peak Search Report ( 12 Peaks, Max PIN = 8.4) 
(207273.MDl] Salicylic acid + Benzoic ac id :RESS (65C,8000psi) <Psi=O.O> 
PEAK: 17-pts/Parabolic Filter, Threshold=3.0, CutofT=O. l %, BG=3/ l .0, Peak-Top=Summit 
2-Theta d(A) BG Height 1% Area 1% FWHM 
10.54 8.387 70 112 26.9 648 13.8 0.26 
11.06 7.993 73 416 100 4681 100 0.23 
15.4 5.749 107 160 38.5 656 14 0.2 1 
17.32 5. 11 5 152 382 9 1.8 2729 58.3 0.2 
17.99 4.927 152 198 47.6 1178 25.2 0.44 
18.04 4.914 152 209 50.2 1126 24.1 0.34 
19.8 4.481 149 211 50.7 838 17.9 0.23 
23.84 3.73 100 168 40.4 787 16.8 0.2 
24.96 3.565 92 129 31 514 II 0.24 
25 .4 3.504 90 355 85.3 3725 79.6 0.24 
28.92 3.085 79 163 39.2 832 17.8 0. 17 
30.76 2.904 70 11 8 28.4 498 10.6 0. 18 
Peak Search Report ( 11 Peaks, Max PIN = 7. 1) 
(207274.MD!] Salicylic ac id + Benzoic ac id :RESS (75C,2000psi) <Psi=0.0> 
PEAK: 17-pts/Parabolic Fil ter, Threshold=3.0, CutofT=0. 1%, BG=3/1.0, Peak-Top=Summit 
2-Theta d(A) BG Height 1% Area 1% FWHM 
I t.t 7.963 120 407 96.7 3237 96.5 0.19 
17.38 5.099 248 421 100 2059 61.4 0.2 
19.62 4.52 252 309 73.4 810 24.1 0.24 
19.88 4.463 244 304 72.2 672 20 0.19 
21.5 4.13 189 278 66 510 15.2 0.1 
23 .84 3.73 134 248 58.9 1236 36.8 0.18 
24.99 3.56 110 149 35.4 444 13.2 0.19 
25.44 3.498 109 349 82.9 3355 100 0.24 
28.86 3.09 1 88 163 38.7 823 24.5 0. 19 
30.82 2.899 79 120 28.5 774 23.1 0.32 
37.83 2.376 52 80 19 280 8.3 0. 17 
Peak Search Report ( 15 Peaks, Max PIN = 8.0) 
[207275.MDI] Salicylic acid + Benzoic acid :RESS (75C, 4000psi) <Psi=O.O> 
PEAK: 17-pts/Parabolic Filter, Threshold=3.0, CutofT=0. 1%, BG=3/ I.O, Peak-Top=Summit 
2-Theta d(A) BG Height 1% Area [o/o FWHM 
3.18 27.779 147 346 80.5 4205 92.8 0.36 
10.7 8.262 IOI 139 32.3 585 12.9 0.26 
It.I 7.966 97 430 JOO 4531 100 0.23 
16.67 5.313 187 237 55. l 146 3.2 0.05 
17.34 5.109 226 428 99.5 2399 52.9 0.2 
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( 
19.69 4.506 232 289 67.2 498 II 0.15 
21.44 4.141 175 280 65.1 687 15.2 0. 11 
23.84 3.73 121 228 53 1312 29 0.21 
25.44 3.498 107 322 74.9 3084 68.1 0.24 
28.86 3.091 81 139 32.3 1301 28.7 0.38 
30.4 2.938 77 11 3 26.3 532 11.7 0.25 
30.8 2.9 77 141 32.8 744 16.4 0.2 
36.8 1 2.44 49 85 19.8 249 5.5 0.12 
38.38 2.343 45 74 17.2 333 7.3 0.2 
38.38 2.343 45 74 17.2 333 7.3 0.2 
Peak Search Report ( 12 Peaks, Max PIN = 8.0) 
(207276.MDI] Salicylic acid+ Benzoic acid :RESS (76C, 8000psi) <Psi=O.O> 
PEAK: 17·pts/Parabolic Filter, Threshold=3.0, Cutoff=0.1%, BG=3/ l.O, Peak-Top=Summit 
2-Theta d(A) BG Height 1% Area 1% FWHM 
3.23 27.335 168 537 100 5785 100 0.27 
3.7 23.872 119 273 50.8 3109 53.7 0.34 
8.67 10. 193 74 106 19.7 322 5.6 0.17 
11.08 7.981 77 394 73.4 3899 67.4 0.21 
17.36 5.104 157 383 71.3 2736 47.3 0.21 
21.42 4.145 135 176 32.8 354 6.1 0.15 
23.82 3.732 109 170 31.7 686 11.9 0.19 
25.42 3.501 95 371 69. 1 3858 66.7 0.24 
28.86 3.091 80 171 31.8 1045 18.1 0.2 
30.83 2.898 75 128 23.8 427 7.4 0.14 
38 .26 2.35 44 75 14 293 5.1 0.16 
40.14 2.244 41 72 13.4 344 5.9 0.19 
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4. ASPIRIN+ BENZOIC ACID: 
4A. CHEMICAL STRUCTURE: 
0 
II 
C - OH 
CH,J-o-O 
Aspirin 
0 
II 
C-OH 
6 
Benzoic Acid 
4B. SUMMARY OF RESS RECRYSTALLIATION: 
COMPOS ITION OF STARTING MIXTURE: 80% Aspirin + 20% Benzoic acid 
CONTENTS OF REACTION VESSEL : 4.8g Aspirin + l.2g Benzoic acid (6g of blend) 
Experiment (P,T conditions! 
I [46C, 2000psi] 
2 [ 46C, 4000psi] 
3 [ 46C, 8000psi] 
4 [ 62C, 2000psi] 
5 [62C, 4000psi] 
6 [61 C, 8000psi] 
7 [75C, 2000psi] 
8 [76C, 4000psi] 
9 [76C, 8000psi] 
4C. DSC ANALYSIS: 
Weight collected,mg 
' 
' 
116 
253 
450 
73 
108 
160 
64 
302 
682 
279 
Collection time, min 
10 
5 
3 
20 
20 
5 
50 
20 
3 
( 4D.l. XRPD ANALYSIS: 
10.0 . 
10 20 30 
2-Thetan 
10.0 . 
.. 
6.0 
§ 
I 
2. 
1207HS.M0tl Aspirin + ~ok Kid : AES5 ('46C, 
)<> 
1 (Z0721J .MDtl Aspirin+ ~ ldd : IU'SS (46C,2 
10 20 30 40 
2·Thtta0 
280 
( 
4D.2. XRPD ANALYSIS: 
Peak Search Repon (21 Peaks, Max PIN = 46. 7) 
[Z07009.MDI] Ground Aspirin pure, Lot#88H041 I-Sigma, Grinded for 2 min 
PEAK: 23-pts/Parabolic Filter, Threshold=3.0, CutofT=0.1 %, BG=3/ l.O, Peak-Top=Summit 
2-Theta d(A} BG Height 1% Area 1% FWHM 
7.72 11.443 43 4049 45.8 49590 41.9 0.21 
15.52 5.705 60 8845 100 118408 100 0.23 
16.66 5.318 54 280 3.2 3442 2.9 0.26 
18.08 4.903 41 169 1.9 2192 1.9 0.29 
20.54 4.321 54 677 7.7 13761 11.6 0.38 
21.42 4.145 102 153 1.7 480 0.4 0.16 
22.56 3.938 98 1567 17.7 28701 24 .2 0.33 
23.14 3.841 64 1015 11.5 20475 17.3 0.37 
24.84 3.581 69 160 1.8 1431 1.2 0.27 
26.88 3.314 80 1655 18.7 40381 34.1 0.44 
28.8 3.097 83 171 1.9 1423 1.2 0.27 
29.46 3.029 74 176 1759 1.5 0.29 
30.08 2.968 75 186 2.1 1416 1.2 0.22 
31.6 2.829 75 685 7.7 8727 7.4 0.24 
32.5 2.753 69 437 4.9 6309 5.3 0.29 
33.76 2.653 61 140 1.6 1316 I.I 0.28 
34.38 2.606 55 165 1.9 1999 1.7 0.31 
35.86 2.502 60 184 2.1 3980 3.4 0.55 
39.14 2.3 43 144 1.6 1287 I.I 0.22 
40.44 2.229 48 122 1.4 1566 1.3 0.36 
41.96 2.151 51 165 1.9 3679 3.1 0.55 
Peak Search Repon (20 Peaks, Max PIN = 43.8) 
[Z07339.MDI] Pure Benzoic acid <Psi=O.O> 
PEAK: 17-pts/Parabolic Filter, Threshold=3.0, CutofT=0.1 %, BG=3/ 1.0, Peak-Top=Summit 
2-Theta d(A) BG Height 1% Area 1% FWHM 
6.88 12.838 55 95 1.2 236 0.3 0.1 
8.16 10.825 73 7805 JOO 84984 JOO 0.19 
16.34 5.421 162 2908 37.3 25687 30.2 0.16 
17.34 5.11 189 3054 39.I 31514 37.1 0.19 
17.84 4.967 205 318 4. 1 943 I.I 0.14 
19.18 4.625 200 644 8.3 5468 6.4 0.21 
21.32 4.164 163 424 5.4 3169 3.7 0.21 
23.94 3.714 125 1233 15.8 12036 14.2 0.18 
24.58 3.618 129 329 4.2 1226 1.4 0.1 
25.96 3.429 102 621 6324 7.4 0.21 
26.94 3.307 94 214 2.7 1224 1.4 0.17 
27.9 3.196 90 470 6 3836 4.5 0.17 
30.2 2.957 79 378 4.8 3690 4.3 0.21 
3 1.42 2.845 73 168 2.2 807 0.9 0.14 
32.92 2.71 8 69 401 5.1 3623 4.3 0.19 
28 1 
( 
34.92 
38.88 
39.32 
40.91 
42.84 
2.567 
2.315 
2.289 
2.204 
2.109 
66 
61 
60 
55 
54 
320 
211 
235 
94 
110 
Peak Search Report (37 Peaks, Max PIN = 33.6) 
4.1 
2.7 
3 
1.2 
1.4 
2547 
1525 
2255 
347 
948 
[Z07292.MDI] Physical Mixture of Aspirin + Benzoic acid <Psi=O.O> 
1.8 
2.7 
0.4 
I.I 
PEAK: 17-pts/Parabolic Filter, Threshold=3.0, Cutotf=0.1%, BG=3/ l.O, Peak-Top=Summit 
0.17 
0.17 
0.22 
0.1 5 
0.29 
2-Theta d(A) BG Height 1% Area 1% FWHM 
7.4 11.932 45 265 5.8 4182 8.8 0.32 
7.86 11.238 39 4586 100 47486 100 0.18 
8.14 10.854 41 1536 33.5 18765 39.5 0.21 
15.66 5.654 111 2915 63.6 31280 65.9 0.19 
16.32 
16.84 
17.24 
19.2 
20.76 
21.06 
21.4 
22 .76 
23.4 
23.82 
24.56 
25 .1 2 
25 .98 
27.04 
27.9 
30.3 
31.56 
31.8 
32.76 
32.92 
33 .9 
34.68 
34.92 
36.02 
36.6 
37.58 
39.34 
40.89 
41.85 
42.78 
43.79 
46.24 
48.76 
5.428 
5.262 
5.14 
4.618 
4.276 
4.215 
4.148 
3.904 
3.798 
3.733 
3.622 
3.542 
3.426 
3.295 
3.195 
2.948 
2.832 
2.811 
2.732 
2.719 
2.642 
2.584 
2.567 
2.491 
2.453 
2.391 
2.288 
2.205 
2.157 
2.112 
2.066 
1.962 
1.866 
147 
143 
145 
142 
132 
124 
126 
175 
109 
93 
92 
88 
84 
94 
96 
71 
67 
68 
66 
65 
63 
59 
58 
56 
58 
58 
59 
55 
59 
59 
51 
46 
47 
826 
364 
807 
309 
416 
722 
248 
633 
1633 
326 
134 
201 
143 
557 
292 
50 1 
212 
213 
453 
288 
114 
224 
140 
87 
242 
150 
115 
126 
131 
115 
93 
73 
100 
282 
18 
7.9 
17.6 
6.7 
9.1 
15.7 
5.4 
13.8 
35.6 
7.1 
2.9 
4.4 
3.1 
12.1 
6.4 
10.9 
4.6 
4.6 
9.9 
6.3 
2.5 
4.9 
3.1 
1.9 
5.3 
3.3 
2.5 
2.7 
2.9 
2.5 
1.6 
2.2 
4751 
1591 
5693 
2020 
4257 
9813 
2877 
4290 
20493 
3561 
305 
738 
519 
8127 
1849 
4404 
2238 
1993 
5085 
4569 
467 
2506 
1172 
235 
1980 
851 
557 
945 
1354 
504 
604 
405 
601 
10 
3.4 
12 
4.3 
9 
20.7 
6.1 
43.2 
7.5 
0.6 
1.6 
I.I 
17.1 
3.9 
9.3 
4.7 
4.2 
10.7 
9.6 
I 
5.3 
2.5 
0.5 
4.2 
1.8 
1.2 
2 
2.9 
I.I 
1.3 
0.9 
1.3 
0.12 
0.12 
0.15 
0.2 1 
0.25 
0.28 
0.4 
0.1 6 
0.23 
0.26 
0.1 2 
0.11 
0.15 
0.3 
0.16 
0.17 
0.26 
0.23 
0.22 
0.35 
0.1 6 
0.26 
0.24 
0.13 
0.18 
0.16 
0.17 
0.23 
0.32 
0.15 
0.24 
0.25 
0.19 
Peak Search Report ( 13 Peaks, Max PIN = 7 .0) 
(Z07283 .MDI] Aspirin + Benzoic acid: RESS (46C,2000psi) <Psi=0.0> 
PEAK: 17-pts/Parabolic Filter, Threshold=3.0, Cutoff=0. 1%, BG=3/1.0, Peak-Top=Summit 
2-Theta d(A) BG Height 1% Area 1% FWHM 
3.16 27.948 155 41 1 95.6 5672 100 0.38 
7.88 It.2I 90 I78 41.4 2727 48.I O.S3 
8.08 10.932 9 1 352 81.9 3724 65.7 0.24 
15.6 5.676 154 205 47.7 243 4.3 0.08 
I6.22 S.46I IS8 272 63.3 2062 36.4 0.3I 
I7.14 S.169 I80 430 IOO 3112 54.9 0.2I 
19.12 4.639 194 27 1 63 1113 19.6 0.25 
21.41 4.146 162 231 53.7 395 7 0.1 
23 .78 3.738 120 309 71.9 2294 40.4 0.21 
25 .86 3.443 100 239 55.6 1490 26.3 0.18 
26.86 3.3 16 93 135 3 1.4 406 7.2 0. 16 
27 .76 3.211 91 169 39.3 720 12.7 0.16 
30.16 2.961 79 126 29.3 565 10 0.2 
Peak Search Report ( 17 Peaks, Max PIN = 13.3) 
[Z07284.MD!] Aspirin + Benzoic acid: RESS (46C,4000psi) <Psi=O.O> 
PEAK: 21-pts/Parabolic Filter, Threshold=3.0, Cutoff=0.1 %, BG=3/1.0, Peak-Top=Sumrnit 
2-Theta d(A) BG Height 1% Area 1% FWHM 
8.16 10.827 64 832 98.2 IS83S IOO 0.3S 
IS.62 S.668 92 406 47.9 SS76 3S.2 0.3 
16.3 S.433 IS8 467 SS.I Sl54 32.S 0.28 
17.22 S.14S 166 847 100 III8I 70.6 0.28 
19.18 4.624 147 3 10 36.6 2886 I8.2 0.3 
20.74 4.28 144 200 23.6 826 5.2 0.25 
21.3 4.I68 I33 237 28 2373 IS 0.39 
22.66 3.92 1 127 210 24.8 1167 7.4 0.24 
23.88 3.723 123 616 72.7 8008 50.6 0.28 
2S.94 3.432 I04 S69 67.2 739S 46.7 0.27 
26.9 3.311 119 2 15 25.4 1607 IO. I 0.28 
27.16 3.28 I 120 I93 22.8 1599 IO.I 0.37 
27.82 3.204 II3 329 38.8 3014 I9 0.24 
30.18 2.9S9 77 249 29.4 3090 I9.S 0.31 
32.76 2.732 66 108 12.8 652 4.1 0.26 
34.98 2.S63 S8 104 12.3 870 s.s 0.32 
38.83 2.317 54 94 II.I I06I 6.7 0.4S 
Peak Search Report ( 15 Peaks, Max PIN = 12. 7) 
[Z07285.MDI] Aspirin+ Benzoic acid: RESS (46C,8000psi) <Psi=O.O> 
PEAK: 21-pts/Parabolic Filter, Threshold=3.0, Cutoff=0.1%, BG=3/1.0, Peak-Top=Summit 
2-Theta d(A) BG Height 1% Area 1% FWHM 
8.08 I0.93 IOI 832 IOO 13471 100 0.31 
IS.64 S.662 I9S 482 S7.9 4619 34.3 0.27 
283 
( 
16.16 5.48 225 569 68.4 4729 35.1 0.23 
17.12 5.175 257 782 94 8002 59.4 0.26 
19.06 4.652 248 375 45.1 2658 19.7 0.36 
20.71 4.285 217 278 33.4 1712 12.7 0.48 
21.44 4. 141 206 296 35.6 948 7 0.18 
22.7 3.915 173 242 29.l 652 4.8 0.16 
23.8 3.735 156 574 69 5179 38.4 0.21 
25.88 3.44 116 493 59.3 52 18 38.7 0.24 
26.96 3.305 120 211 25.4 1544 11.5 0.29 
27.18 3.278 123 187 22.5 1539 11.4 0.41 
27.8 3.207 119 294 35.3 1894 14.1 0.18 
30.16 2.961 87 210 25.2 2108 15.6 0.29 
37. 12 2.42 61 97 11.7 279 2.1 0.13 
Peak Search Report ( 12 Peaks, Max PIN = 18.8) 
[Z07286.MDI] Aspirin+ Benzoic acid: RESS (62C,2000psi) <Psi~.O> 
PEAK: 17-pts/Parabolic Filter, Threshold=3.0, Cutoff~. ! %, BG=3/ 1.0, Peak-Top=Summit 
2-Theta d(A) BG Height 1% Area 1% FWHM 
7.42 11.91 80 115 6.7 259 1.8 0.13 
7.8 11.324 74 159 9.3 1961 13.5 0.39 
8.08 10.934 76 272 15.9 3283 22.5 0.28 
15.58 5.682 129 170 IO 132 0.9 0.05 
16.16 5.48 133 3 12 18.3 2108 14.5 0.2 
17.1 5.181 152 1707 100 14575 100 0. 16 
19.03 4.659 166 212 12.4 745 5.1 0.28 
22.83 3.892 11 7 162 9.5 384 2.6 0.15 
23 .76 3.741 110 197 11.5 1229 8.4 0.24 
27.8 3.206 84 164 9.6 653 4.5 0.14 
30. 12 2.965 73 Ill 6.5 382 2.6 0.17 
34.58 2.592 54 117 6.9 839 5.8 0.23 
Peak Search Report ( 17 Peaks, Max PIN = 8.8) 
[Z07287.MDI] Aspirin + Benzoic acid: RESS (62C,4000psi) <Psi~.O> 
PEAK: 21-pts/Parabolic Filter, Threshold=3.0, Cutoff=0. 1%, BG=3/ 1.0, Peak-Top=Summit 
2-Theta d(A) BG Height 1% Area 1% FWHM 
7.84 11.269 77 373 67.5 7955 87.4 0.46 
8.1 10.904 81 429 77.6 9106 100 0.44 
15.62 5.668 139 553 100 6721 73.8 0.28 
16.22 5.46 164 346 62.6 2729 30 0.25 
17.12 5.175 177 485 87.7 4641 51 0.26 
19.06 4.653 174 243 43.9 1319 14.5 0.32 
20.72 4.284 161 240 43.4 2067 22.7 0.44 
21.16 4.196 157 204 36.9 1492 16.4 0.54 
21.34 4.16 154 224 40.5 151 1 16.6 0.37 
22.7 3.9 15 160 274 49.5 1337 14.7 0.2 
23.78 3.738 144 368 66.5 2326 25.5 0.18 
25.88 3.44 106 337 60.9 2805 30.8 0.2 1 
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27.1 6 3.281 105 249 45 34 14 37.5 0.4 
27.74 3.2 13 115 216 39. I 926 10.2 0.16 
30.2 2.957 83 156 28.2 1113 12.2 0.26 
32.63 2.742 75 Ill 20. 1 284 3.1 0.13 
Peak Search Report (21 Peaks, Max PIN = 12.7) 
[Z07288.MDI] Aspirin+ Benzoic acid : RESS (6 1C,8000psi) <Psi=O.O> 
PEAK: 19-pts/Parabolic Filter, Threshold=3.0, Cutoff.=0. 1%, BG=3/ l.O, Peak-Top=Summit 
2-Theta d{A) BG Height 1% Area 1% FWHM 
3.22 27.411 139 322 37.9 3689 36.2 0.34 
3.36 26.285 128 283 33.3 3174 31.1 0.35 
3.98 22. 194 88 200 23.5 2116 20.8 0.32 
3.98 22.194 88 200 23.5 2116 20.8 0.32 
7.26 12.159 67 103 12./ 706 6.9 0.33 
7.8 I 1.326 65 442 52 5835 57.2 0.26 
8.63 10.24 1 58 89 10.5 90 0.9 0.05 
8.63 10.241 58 89 10.5 90 0.9 0.05 
15.62 5.669 110 850 100 10193 100 0.23 
16.74 5.29 124 180 21.2 1040 10.2 0.32 
17.18 5.157 127 178 20.9 1040 10.2 0.35 
18.2 4.871 137 182 21.4 855 8.4 0.32 
20.7 4.288 148 266 31.3 1844 18.I 0.27 
2 1.46 4.138 152 200 23.5 284 2.8 0.1 
22.66 3.921 143 347 40.8 3035 29.8 0.25 
23.21 3.829 158 217 25.5 486 4.8 0.14 
23.83 3.731 129 183 21.5 162 1.6 0.05 
25.82 3.447 96 133 15.6 310 3 0.14 
27.14 3.283 97 316 37.2 5077 49.8 0.39 
32.56 2.748 7 1 104 12.2 425 4.2 0.22 
32.76 2.73 1 70 105 12.4 447 4.4 0.22 
Peak Search Report ( 12 Peaks, Max PIN = 6.2) 
[Z07289.MDI] Aspirin + Benzoic acid : RESS (75C,2000psi) <Psi=O.O> 
PEAK: 19-pts/Parabolic Filter, Threshold=3.0, Cutoff.=0. 1%, BG=3/1.0, Peak-Top=Summit 
2-Theta d(A) BG Height 1% Area 1% FWHM 
3.21 27. 525 128 367 100 3852 JOO 0.27 
3.6 24.538 IO I 24 1 65.7 2425 63 0.29 
7.78 11.355 66 152 41.4 1254 32.6 0.25 
II 8.039 63 150 40.9 995 25.8 0.19 
15.64 5.662 93 217 59.1 2026 52.6 0.28 
17.28 5. 128 13 1 173 47.1 449 I 1.7 0.18 
20.64 4.299 124 171 46.6 269 7 0.1 
21.46 4.138 I 14 158 43.1 972 25.2 0.38 
22.72 3.91 I 109 162 44.1 955 24.8 0.31 
25.23 3.527 92 138 37.6 1020 26.5 0.38 
25.3 3.517 92 128 34.9 997 25.9 0.47 
27.2 3.276 88 137 37.3 724 18.8 0.25 
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Peak Search Report (23 Peaks, Max PIN = 19.7) 
[Z07290.MD!] Aspirin + Benzoic acid : RESS (76C,4000psi) <Psi=O.O> 
PEAK: 21-pts/Parabolic Filter, Threshold=3.0, Cutoff=0.1 %, BG=3/ 1.0, Peak-Top=Summit 
2-Theta d(A) BG Height 1% Area 1% FWHM 
7.84 11.269 84 791 42.2 11399 48.2 0.27 
9.3 1 9.495 89 131 358 1.5 0./4 
11.04 8.01 I II 287 15.3 2022 8.6 0.2 
15.62 5.668 170 1873 100 23642 JOO 0.24 
16.78 5.28 2 12 307 16.4 926 3.9 0.17 
17.24 5.139 222 356 19 1583 6.7 0.2 
19.2 4.619 229 283 15.I 477 0.15 
20.68 4.291 229 533 28.5 4573 19.3 0.26 
22.7 3.9 14 195 7 12 38 7742 32.7 0.25 
23.26 3.821 179 348 18.6 3624 15.3 0.36 
23.76 3.741 174 229 12.2 270 l.l 0.08 
25 3.559 131 195 10.4 1510 6.4 0.4 
25.34 3.512 129 265 14.1 2374 10 0.3 
27.16 3.281 122 639 34.1 11384 48.2 0.37 
28.76 3.102 102 149 8 694 2.9 0.25 
30.25 2.952 95 136 7.3 704 3 0.29 
3 1.49 2.838 91 148 7.9 592 2.5 0.18 
32.68 2.738 83 165 8.8 1304 5.5 0.27 
34.54 2.595 68 112 6 759 3.2 0.29 
36.16 2.482 64 118 6.3 1753 7.4 0.55 
36.57 2.455 69 118 6.3 1241 5.2 0.43 
40.62 2.2 19 59 102 5.4 732 3.1 0.29 
42.04 2.148 61 106 5.7 1223 5.2 0.46 
Peak Search Report (19 Peaks, Max PIN = 19.2) 
[Z07291.MDI] Aspirin + Benzoic acid : RESS (76C,8000psi) <Psi=O.O> 
PEAK: 19-pts!Parabolic Filter, Threshold=3.0, Cutoff=0.1 %, BG=3/ l.O, Peak-Top=Summit 
2-Theta d(A) BG Height 1% Area 1% FWHM 
7.82 11.297 89 780 43.2 10500 49.7 0.26 
15.62 5.668 176 1807 100 21142 100 0.22 
16.78 5.278 206 299 16.5 1236 5.8 0.23 
18.33 4.837 231 287 15.9 596 2.8 0.18 
20.7 4.288 220 5 11 28.3 4685 22.2 0.27 
21 4.227 210 292 16.2 3337 15.8 0.69 
21.41 4. 148 220 297 16.4 608 2.9 0.13 
22.7 3.914 194 678 37.5 7266 34.4 0.26 
23.28 3.818 181 324 17.9 3449 16.3 0.41 
23.79 3.738 170 239 13.2 483 2.3 0.12 
25 3.559 126 191 10.6 1149 5.4 0.3 
25.37 3.508 126 176 9.7 941 4.5 0.32 
27.16 3.281 115 585 32.4 10521 49.8 0.38 
30.26 2.951 97 147 8.1 427 0.15 
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31.44 2.843 85 140 7.7 840 4 0.26 
32.72 2.734 81 174 9.6 1245 5.9 0.23 
36.04 2.49 77 118 6.5 382 1.8 0.16 
36.56 2.456 66 108 6 674 3.2 0.27 
42.04 2.147 57 107 5.9 1385 6.6 0.47 
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5. TOLBUTAMIDE: 
SA. CHEMICAL STRUCTURE: 
0 0 O ii II CH S - NH -C-NHCH CH CH CH 3 It 2 2 2 3 0 
Tolbutam.ide 
SB . SUMMARY OF RESS RECRYSTALLIATION: 
CONTENTS OF REACTION VESSEL : 3g ofTolbutamide 
Experiment f P,T conditions] Weight collected C~llection time J 
mg mm 
1 [ 45C, 900psi] 136 30 
2 (60°C, 5000psi] 76 2~ 
3 [75°C, 4000psi] 36 1 1~ 
SC . DSC ANALYSIS: 
DSC Thermograms of Tolbutamld• Polymorphs 
fl 
288 
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50.1 XRPD ANALYSIS: 
140 
1200 
1000 
~ i so1o-l'. .... ,.....,.1""' .... d 
~ 
10 
2-Theta(") 
a-Commercial-Form I b-[45°C, 5000psi) c-[60°C, 5000psi] d-[75°C, 5000psi] 
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6. TOLBUTAMIDE + CHLORPROPAMlDE: 
6A. CHEMICAL STRUCTURE: 
0 0 
-011 II CH S -NH- C -NHCHCHCHCH 3 H 2 2 2 J 0 
Tolbutamide Chlorpropamide 
6B. SUMMARY OF RESS RECRYSTALLIATION: 
CONTENTS OF REACTION VESSEL: 80% Tolbutamide + 20% Chlorpropamide 
CONTENTS OF REACTION VESSEL: 2g Tolbutamide + 0.5g Chlorpropamide (2.5g of blend) 
Experiment IP,T conditions I Weight collected,mg Collection time, min 
I [ 45C, 5000psi] 165 5 
2 [60C, 5000psi] 125 20 
3 [75C, 8000psi] 261 20 
6C. DSC ANALYSIS : 
,/ 
l!I Pl"C!OO!oo1 [ 
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60.1 XRPO ANALYSIS: 
3000 . 
2·Theta(1 
60.2 XRPO ANAL YSJS: 
Peak Search Repon (32 Peaks, Max PIN = 22.2) 
[Z07034.MDI] 2 min ground Chlorpropamide, NB# 67034x44-Stage []] 
PEAK: 19-pts/Parabolic Filter, Threshold=3.0, CutofP0.1 %, BG=3/1.0, Peak-Top=Summit 
2-Theta d(A) BG Height 1% Area 1% FWHM 
6.64 13.307 19 20 16 100 21465 100 0.18 
11.76 7.5 18 23 1177 58.4 12954 60.3 0. 19 
13.26 6.67 1 18 90 4.5 1205 5.6 0.28 
16.45 5.386 19 72 3.6 435 0. 14 
18.22 4.866 23 243 12. 1 245 1 11.4 0.19 
19.52 4.544 23 1234 61.2 14406 67. 1 0.2 
19.98 4.441 49 200 9.9 2770 12.9 0.31 
20.7 4.288 52 167 8.3 1416 6.6 0.21 
21.6 4.111 45 929 46.I 12135 56.5 0.23 
22 4.037 25 3 16 15.7 6325 29.5 0.37 
23.78 3.738 29 665 33 8958 41.7 0.24 
25.76 3.456 27 395 19.6 6342 29.5 0.29 
26.22 3.396 40 103 5.1 2070 9.6 0.56 
26.82 3.322 5 1 154 7.6 1347 6.3 0.22 
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f 
28.08 
28.96 
29.26 
30.28 
30.6 
31.77 
33.36 
34.78 
35.06 
35 .76 
40.32 
41.1 8 
42.24 
42.96 
44.02 
45.43 
46.28 
48.68 
3. 175 
3.08 
3.05 
2.95 
2.919 
2.814 
2.684 
2.577 
2.558 
2.509 
2.235 
2.19 
2.138 
2.104 
2.055 
1.995 
1.96 
1.869 
40 
40 
37 
3 1 
28 
25 
27 
44 
48 
46 
34 
33 
37 
39 
34 
31 
28 
24 
326 
221 
181 
91 
246 
54 
122 
127 
125 
11 8 
72 
76 
106 
69 
60 
60 
64 
78 
Peak Search Report (35 Peaks, Max PIN = 18. 1) 
16.2 
II 
9 
4.5 
12.2 
2.7 
6.1 
6.3 
6.2 
5.9 
3.6 
3.8 
5.3 
3.4 
3 
3.2 
3.9 
[Z07031.MDI] 2 min ground Tolbutamide, NB#67034x43-Stage lII 
369 1 
3673 
2510 
727 
3606 
369 
1092 
18 14 
18 11 
1256 
957 
387 
774 
23 1 
185 
707 
685 
9 13 
17.2 
17. 1 
11.7 
3.4 
16.8 
1.7 
5. 1 
8.5 
8.4 
5.9 
4.5 
1.8 
3.6 
I.I 
0.9 
3.3 
3.2 
4.3 
PEAK: 2 1-pts/Parabolic Filter, Threshold=3.0, CutofT=0. 1%, BG=3/ 1.0, Peak-Top=Summit 
0.22 
0.34 
0.3 
0.21 
0.28 
0.22 
0.2 
0.37 
0.4 
0.3 
0.43 
0. 15 
0.19 
0.13 
0.12 
0.41 
0.32 
0.29 
2-Theta d(A) BG Height 1% Area 1% FWHM 
3.88 22.777 97 179 12.9 2241 8.7 0.46 
3.96 22.301 95 165 11.9 2252 8.7 0.55 
8.7 
10.29 
12.06 
13.06 
14.22 
15.48 
17.3 
19.5 
19.88 
20.84 
21.4 
23.04 
24.24 
24.7 
26.26 
28.18 
28.74 
30.44 
31.7 
32.96 
34.36 
35.06 
10. 156 
8.59 1 
7.332 
6.775 
6.222 
5.719 
5. 122 
4.548 
4.462 
4.259 
4. 149 
3.857 
3.669 
3.60 1 
3.39 1 
3. 164 
3. 104 
2.934 
2.82 1 
2.715 
2.608 
2.557 
27 
29 
38 
58 
51 
49 
42 
46 
55 
50 
51 
51 
57 
53 
49 
57 
58 
45 
4 1 
35 
49 
39 
13 11 
54 
1389 
1108 
628 
342 
419 
1274 
11 35 
1153 
35 1 
675 
14 1 
169 
580 
198 
534 
212 
I ll 
136 
84 
146 
292 
94.4 
3.9 
100 
79.8 
45.2 
24.6 
30.2 
91.7 
8 1.7 
83 
25.3 
48.6 
10.2 
12.2 
41.8 
14.3 
38.4 
15.3 
8 
9.8 
10.5 
15805 
283 
20133 
12668 
7493 
4670 
7080 
19399 
25742 
17062 
4682 
9 151 
13 15 
19 18 
9355 
3020 
7437 
3 101 
1004 
1639 
235 
2950 
61.4 
I.I 
78.2 
49.2 
29.I 
18. I 
27.5 
75.4 
100 
66.3 
18.2 
35.5 
5. 1 
7.5 
36.3 
11.7 
28.9 
12 
3.9 
6.4 
0.9 
11.5 
0.2 1 
0. 19 
0.25 
0.2 1 
0.22 
0.27 
0.32 
0.27 
0.41 
0.26 
0.27 
0.25 
0.27 
0.28 
0.3 
0.36 
0.27 
0.32 
0.24 
0.28 
0.11 
0.47 
35.44 2.53 1 47 11 3 8. 1 956 3.7 0.25 
36.79 2.44 1 45 82 5.9 323 1.3 0.1 5 
38.66 2.327 44 I ll 8 1228 4.8 0.3 1 
39.98 2.253 45 93 6.7 9 19 3.6 0.33 
40.47 2.227 47 84 6 845 3.3 0.39 
41.08 2. 196 48 89 6.4 596 2.3 0.25 
41.65 2. 167 42 8 1 5.8 320 1.2 0. 14 
42.42 2. 129 38 68 4.9 326 1.3 0. 18 
43.7 2.07 40 113 8. 1 1190 4.6 0.28 
45.84 1.978 39 74 5.3 653 2.5 0.32 
46.5 1.95 1 41 67 4.8 257 0. 17 
Peak Search Report (20 Peaks, Max PIN = 10.2) 
(20725 1.MDI] Tolbutamide +Chlorpropamide by RESS( 45,5000) <Psi=O.O> 
PEAK: 19-pts/Parabolic Filter, Threshold=3.0, Cutoff.=0. 1%, BG=3/ 1.0, Peak-Top=Summit 
2-Theta d(A) BG Height 1% Area 1% FWHM 
8.86 9.973 75 355 53.5 2909 42.2 0.18 
12.22 7.236 105 402 60.6 3960 57.5 0.23 
12.48 7.086 108 469 70.7 6886 100 0.32 
13.2 6.70 1 11 0 613 92.5 5254 76.3 0.1 8 
14.6 6.061 129 280 42.2 2716 39.4 0.31 
15.78 5.6 12 154 225 33.9 732 10.6 0. 18 
17.67 5.0 15 208 3 14 47.4 1599 23.2 0.26 
19.62 4.52 214 663 100 5733 83.3 0.22 
20.22 4.388 2 12 566 85.4 5746 83 .4 0.28 
21.2 4.188 187 429 64.7 4330 62.9 0.3 
2 1.52 4. 125 175 396 59.7 27 18 39.5 0.2 1 
23.28 3.818 129 267 40.3 184 1 26.7 0.23 
23.86 3.726 131 2 11 31.8 845 12.3 0. 18 
26.48 3.363 89 222 33.5 1982 28.8 0.25 
26.9 3.312 89 163 24.6 949 13.8 0.22 
28.98 3.079 8 1 177 26.7 1668 24.2 0.3 
29.42 3.033 78 138 20.8 1182 17.2 0.33 
30.62 2.917 70 114 17.2 1064 15.5 0.41 
3 1.93 2.801 63 98 14.8 439 6.4 0.2 1 
38.37 2.344 46 8 1 12.2 305 4.4 0.15 
Peak Search Report (27 Peaks, Max PIN = 10.4) 
[Z07252.MDI] Tolbutamide +Chlorpropamide by RESS(75,5000) <Psi=O.O> 
PEAK: 19-pts/Parabolic Filter, Threshold=3 .0, Cutoff.=0. 1 %, BG=3/ l .O, Peak-Top=Summit 
2-Theta d(A} BG Height 1% Area 1% FWHM 
8.9 9.931 38 201 33.6 3 129 38.4 0.33 
9.47 9.327 47 76 12.7 264 3.2 0. 15 
12.4 7. 133 39 504 84. I 8 158 100 0.3 
13.22 6.69 68 442 73.8 5476 67. 1 0.25 
14.54 6.087 61 271 45.2 29 11 35.7 0.24 
15.86 5.584 76 172 28.7 1329 16.3 0.24 
293 
17.54 5.052 97 224 37.4 2055 25.2 0.28 
19.7 4.503 121 599 100 7060 86.5 0.25 
20.2 4.392 124 53 1 88.6 7634 93.6 0.32 
21.12 4.203 123 402 67.1 5343 65.5 0.33 
21 .58 4.115 109 258 43.1 2663 32.6 0.3 
23.3 3.8 15 89 236 39.4 2375 29. 1 0.27 
24.46 3.636 87 125 20.9 608 7.5 0.27 
26.62 3.346 70 227 37.9 2956 36.2 0.32 
26.7 3.336 70 180 30.1 2950 36.2 0.46 
26.78 3.327 70 162 27 2945 36.1 0.54 
28.43 3.137 65 102 17 453 5.6 0.2 1 
29.26 3.05 62 148 24.7 2 148 26.3 0.42 
30.47 2.932 56 87 14.5 811 9.9 0.44 
30.86 2.895 56 11 5 19.2 11 48 14.1 0.33 
31.94 2.8 53 88 14.7 389 4.8 0.19 
33.21 2.696 48 86 14.4 353 4.3 0. 16 
35.32 2.539 46 80 13.4 658 8. 1 0.33 
38.86 2.3 15 40 71 11.9 335 4.1 0. 18 
42.27 2. 136 37 63 10.5 545 6.7 0.36 
47.6 1.909 36 62 10.4 11 2 1.4 0.07 
47.6 1.909 36 62 10.4 11 2 1.4 0.07 
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7. TO LB UT AMIDE + UREA: 
7 A. CHEMICAL STRUCTURE: 
0 0 0 11 II CH S-NH-C-NHCH CH CH CH 3 ll 2 2 2 3 0 
Tolbutamide 
0 
I I 
H N- C - NH 2 2 
7B. SUMMARY OF RESS RECRYSTALLIATION: 
COMPOSITION OF STARTING MIXTURE: 80% Tolbutanlide + 20% Urea 
CONTENTS OF REACTION VESSEL: 3.2g Tolbutanlide + 0.8g Urea (4g of blend) 
Experiment IP,T conditions I Weight collected,mg Collection time, min 
I [ 48C, 2000psi] 34 30 
2 [48.5C, 4000psi] 11 8 20 
3 [48C, 8000psi] 135 5 
4 [64C, 2000psi] 28 30 
5 [62C, 4000psi] 230 22 
6 [ 62C, 8000psi] 11 7 5 
7 [76C, 2000psi] 37 30 
8 [75C, 4000psi] 325 20 
9 [75C, 8000psi] 344 6 
10 [90C, 2000psi] 34 30 
11 [90C, 4000psi] 430 22 
12 [9 1C, 8000psi] 326 5 
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7C. DSC ANALYSIS: 
Tolbutamlde +Urea 
_L_ ~ ' ,. 
_j,,_ ./ 
_!L ) 
q 
-j( ]l 
• :-n: f ~ c ! (\ 
85 105 
"' "' 
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70.1. XRPD ANALYSIS: 
7500 ............. ·····--······ 
~ 5000 
§ 
f [Z07316.MOIJ Tot~t&mldt+Uru. ; Physlc&l Ml~turt (80/20) <PslooO.O> 
10 20 30 40 
2-Thetan 
3500 ·····-:· 
3000 ········-···········i··· 
~ 
. . 8 2000 .... /Z07315.MDI/ T~bv1amld0Uru. : RESS 176c'. 8000psl) <Psl•0.0> .. 
~ 
~ 1500 
(Z073 I 3.MOll ~olbuL1mide+Urto1 : RESS (&4y, 8000psi) <Psl-0.0> 
fZ073 12.,.1Dl(Tolbut1mlde.Urn ; RESS (63C. 4000psl) <Psl-0.0> 
500 1~07311 :~~~~'.olbur~-~-~Urn.'..~-~~-~~ :_8~~!~ <~ ~ O·?.~ 
IZ07310.MOIJ;Tolbutamlde+Uru : RESS (<I~ 4000psl) <Psl-0.0> 
10 20 30 40 
Z·The1an 
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70.2. XRPD ANALYSIS: 
Peak Search Report (29 Peaks, Max PIN = 18. 7) 
[Z07030.MDI] I min ground Tolbutamide, NB#67034x43-Stage II 
PEAK: 19-pts/Parabolic Filter, Threshold=3.0, Cutotr-0.1%, BG=3/ 1.0, Peak-Top=Sumrnit 
2-Theta d(A) BG Height 1% Area 1% FWHM 
8.68 10.176 27 1256 83. l 14684 69.4 0.2 
12.08 7.322 56 1511 100 18153 85.8 0.21 
13.06 6.775 42 1211 80.l 13 17 1 62.3 0. 19 
14.24 6.214 45 762 50.4 8386 39.6 0.2 
14 .85 5.962 49 77 5.1 295 1.4 0.18 
15.54 5.699 40 393 26 4511 21.3 0.22 
17.28 5.1 28 35 463 3Q.6 7537 35.6 0.3 
19.52 4.544 44 1234 81.7 17157 81.1 0.25 
19.88 4.462 88 1284 85 21157 100 0.3 
20.84 4.259 83 1449 95.9 16857 79.7 0.21 
21.38 4.152 49 322 21.3 4558 21.5 0.28 
23.04 3.857 48 754 49.9 9649 45.6 0.23 
24.26 3.665 49 152 IO.I 1226 5.8 0.2 
24.68 3.604 45 192 12.7 2 189 10.3 0.25 
26.26 3.391 46 632 41.8 9567 45.2 0.28 
28.12 3.17 50 241 15 .9 2845 13.4 0.25 
28.78 3. 1 52 637 42.2 8 169 38.6 0.24 
30.4 2.938 41 249 16.5 3697 17.5 0.3 
3 1.68 2.822 36 128 8.5 1303 6.2 0.24 
32.92 2.718 31 144 9.5 1951 9.2 0.29 
34.38 2.607 45 78 5.2 403 1.9 0.21 
35.04 2.559 40 170 11.3 3492 16.5 0.46 
35.42 2.532 48 129 8.5 1156 5.5 0.24 
36.84 2.438 42 85 5.6 438 2. 1 0.17 
38.64 2.328 41 145 9.6 1703 8 0.28 
39.96 2.254 51 84 5.6 349 1.6 0.18 
41.06 2.196 47 105 6.9 951 4.5 0.28 
43.66 2.07 1 38 129 8.5 1525 7.2 0.28 
45.9 1.976 36 82 5.4 930 4.4 0.34 
Peak Search Report ( 14 Peaks, Max PIN = 41.8) 
[Z07347.MDI] Pure Urea <Psi=O.O> 
PEAK: 19-pts/Parabolic Filter, Threshold=3.0, Cutoff=0.1%, BG=3/1.0, Peak-Top=Sumrnit 
2-Theta d(A) BG Height 1% Area 1% FWHM 
18.51 4.79 164 217 1568 2.2 0.5 
18.92 4.687 169 247 3.4 1485 2.1 0.32 
21.38 4.153 146 221 3.1 959 1.3 0.22 
22.34 3.976 133 7237 100 71195 100 0.17 
23.76 3.741 114 176 2.4 676 0.9 0.19 
24.76 3.593 101 1549 21.4 14259 20 0.17 
29.4 3.035 77 740 10.2 7773 10.9 0.2 
298 
31.76 2.815 71 368 5. 1 4553 6.4 0.26 
35 .66 2.516 64 787 10.9 10303 14.5 0.24 
37.2 2.415 59 266 3.7 2765 3.9 0.23 
40.62 2.2 19 56 160 2.2 1039 1.5 0. 17 
41.64 2.167 56 570 7.9 4340 6. 1 0.14 
44.78 2.022 51 83 I.I 18 1 0.3 0.1 
45.56 1.99 48 106 1.5 72 1 0.21 
Peak Search Report (29 Peaks, Max PIN = 14.3) 
(Z073 l 6.MDI] Tolbutamide+Urea : Physical Mixture (80120) <Psi=O.O> 
PEAK: 17-pts/Parabolic Filter, Threshold=3.0, Cutoff=0. 1%, BG=3/l .0, Peak-Top=Sumrnit 
2-Theta d(A) BG Height 1% Area 1% FWHM 
8.8 10.043 60 519 52 5195 55.6 0.19 
12.18 7.26 1 94 999 100 9342 100 0.18 
13. 16 6.722 97 828 82.9 7306 78.2 0.17 
14.36 6.162 115 491 49. l 3915 41.9 0.18 
15.62 5.668 142 398 39.8 2624 28 .l 0.17 
17.42 5.087 193 419 41.9 2998 32.1 0.23 
19.6 4.525 2 10 943 94.4 9179 98.3 0.21 
19.98 4.44 224 752 75.3 8 132 87 0.26 
20.94 4.238 184 73 1 73.2 5890 63 0.18 
21.5 4.13 179 380 38 1864 20 0.16 
22 .38 3.97 144 500 50. l 2901 3 1.1 0.14 
23 .18 3.834 130 446 44.6 3414 36.5 0. 18 
23.8 3.736 126 202 20.2 557 6 0.12 
24.42 3.643 11 2 166 16.6 5 18 5.5 0.16 
24.72 3.599 106 242 24.2 1832 19.6 0.23 
26.4 3.373 86 358 35.8 3334 35 .7 0.21 
28.26 3. 155 79 141 14.1 937 IO 0.26 
28.86 3.091 76 339 33.9 3370 36. l 0.22 
29.45 3.03 76 120 12 340 3.6 0.13 
30.24 2.953 69 118 11 .8 554 5.9 0.19 
30.5 2.928 68 166 16.6 1454 15.6 0.25 
3 1.86 2.806 64 257 25.7 1996 2 1.4 0. 18 
33.09 2.705 63 122 12.2 506 5.4 0.15 
35.16 2.55 63 11 5 11 .5 657 7 0.21 
35.6 2.519 61 233 23.3 1606 17.2 0.16 
38.27 2.35 57 154 15.4 832 8.9 0.15 
38.67 2.326 56 98 9.8 406 4.3 0.16 
40.57 2.222 56 171 17.1 1431 15.3 0.2 1 
43.88 2.062 49 93 9.3 554 5.9 0.21 
Peak Search Report (23 Peaks, Max PIN = 8.6) 
[Z073 10.MDI] Tolbutamide+Urea: RESS (49C, 4000psi) <Psi=O.O> 
PEAK: 19-pts/Parabolic Filter, Threshold=3.0, CutofF0.1 %, BG=3/l.0, Peak-Top=Summit 
2-Theta d(A) BG Height 1% Area 1% FWHM 
8.78 10.065 7 1 196 29.6 1505 16.2 0.2 
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10.3 
10.65 
11.38 
12.16 
13. 14 
14. 12 
14.35 
15.02 
15.6 
16.27 
17.33 
19.64 
20 
20.96 
21.38 
23.1 2 
23.84 
25. 93 
26.36 
28.24 
28.9 
36.9 
8.578 
8.3 
7.769 
7.274 
6.732 
6.268 
6. 165 
5.895 
5.677 
5.444 
5.11 3 
4.516 
4.437 
4.235 
4.152 
3.844 
3.73 
3.434 
3.378 
3. 157 
3.087 
2.434 
89 
95 
106 
109 
106 
130 
138 
146 
165 
162 
204 
222 
220 
197 
180 
132 
126 
107 
110 
85 
83 
so 
288 
143 
269 
3 15 
334 
173 
258 
210 
284 
227 
253 
663 
356 
316 
322 
198 
2 16 
155 
170 
124 
145 
82 
Peak Search Report (25 Peaks, Max PIN = 9.0) 
43.4 
21 .6 
40.6 
47.5 
50.4 
26. 1 
38.9 
31.7 
42.8 
34.2 
38.2 
100 
53.7 
47.7 
48.6 
29.9 
32.6 
23.4 
25.6 
18.7 
2 1.9 
12.4 
(2073 11 .MDI] Tolbutamide+Urea : RESS ( 48C, 8000psi) <Psi=O.O> 
2775 
508 
2110 
2067 
2426 
363 
1735 
1931 
11 62 
263 
332 
9303 
5968 
2559 
2619 
1223 
809 
314 
574 
466 
884 
282 
29.8 
5.5 
22.7 
22 .2 
26. 1 
3.9 
18.6 
20.8 
12.5 
2.8 
3.6 
100 
64.2 
27.5 
28.2 
13.l 
8.7 
3.4 
6.2 
5 
9.5 
3 
PEAK: 2 1-pts/Parabolic Filter, Threshold=3.0, Cutoff=0. 1%, BG=3/ 1.0, Peak-Top=Summit 
0.24 
0.18 
0.22 
0.17 
0. 18 
0. 14 
0.25 
0.51 
0. 17 
0.07 
0.12 
0.36 
0.75 
0.37 
0.31 
0.32 
0. 15 
0. 11 
0. 16 
0.2 
0.24 
0.15 
2-Theta d(A) BG Height 1% Area 1% FWHM 
3.28 26.93 61 178 24 2179 23.7 0.32 
7.12 
8.82 
10.36 
10.61 
11.42 
12. 16 
13.2 
14.37 
15.62 
16.42 
17.45 
18.85 
19.66 
20.22 
20.9 
20.97 
21.4 
23.2 
23.82 
12.409 
10.0 18 
8.535 
8.328 
7.742 
7.272 
6.704 
6. 157 
5.67 
5.394 
5.077 
4.704 
4.512 
4.389 
4.247 
4.234 
4.148 
3.831 
3.732 
65 
77 
110 
120 
125 
11 9 
11 6 
152 
166 
181 
2 15 
259 
253 
270 
225 
221 
197 
138 
130 
97 
141 
33 1 
203 
310 
249 
3 15 
23 1 
307 
231 
277 
3 18 
741 
334 
290 
307 
338 
186 
239 
300 
13.I 
19 
44.7 
27.4 
41.8 
33.6 
42.5 
3 1.2 
41.4 
31.2 
37.4 
42.9 
100 
45.I 
39.1 
41.4 
45.6 
25.1 
32.3 
394 
795 
2944 
888 
2183 
1404 
2089 
841 
2676 
306 
985 
572 
9206 
967 
1554 
1637 
3331 
1238 
1236 
4.3 
8.6 
32 
9.6 
23.7 
15.3 
22.7 
9.1 
29.l 
3.3 
10.7 
6.2 
100 
10.5 
16.9 
17.8 
36.2 
13.4 
13.4 
0.21 
0.21 
0.23 
0. 18 
0.2 
0. 18 
0. 18 
0. 18 
0.32 
0.1 
0.27 
0.16 
0.32 
0.26 
0.41 
0.32 
0.4 
0.44 
0. 19 
25.92 3.435 109 155 20.9 567 6.2 0.2 1 
26.48 3.363 99 175 23.6 1857 20.2 0.42 
28. 19 3. 163 9 1 126 17 533 5.8 0.26 
28 .88 3.089 93 140 18.9 175 1.9 0.06 
31.6 2.829 73 111 15 383 4.2 0.17 
Peak Search Report (24 Peaks, Max PIN = I 1.0) 
[Z073 12.MDl] Tolbutamide+Urea : RESS (63C, 4000psi) <Psi=O.O> 
PEAK: 19-pts/Parabolic Filter, Threshold=3.0, Cutoff=O. l %, BG=3/l .O, Peak-Top=Summit 
2-Theta d(A) BG Height £% Area 1% FWHM 
7. 18 12.299 59 90 9.6 369 2.8 0.2 
8.82 10.021 70 252 26.8 2409 18.5 0.23 
10.34 8.548 97 298 31.7 2739 21. / 0.23 
10.62 8.322 104 172 18.3 903 6.9 0.23 
11.42 7.741 122 280 29.8 2083 16 0.22 
12.18 7.259 126 480 51.1 3929 30.2 0.1 9 
13.18 6.7 11 123 527 56.1 4456 34.3 0.1 9 
14.42 6. 139 155 301 32. 1 1700 13.1 0.2 
15.05 5.881 160 241 25.7 1818 14 0.38 
15.62 5.669 169 368 39.2 3526 27.1 0.3 
17.4 5.093 226 338 36 1237 9.5 0.19 
19.66 4.512 264 939 100 13008 100 0.33 
20.04 4.427 265 505 53.8 5972 45.9 0.42 
20.94 4.239 226 408 43.5 3133 24.1 0.29 
21.44 4.141 201 377 40.1 2806 21.6 0.27 
22.84 3.89 154 201 21.4 733 5.6 0.27 
23 .2 3.83 1 143 282 30 2305 17.7 0.28 
23.84 3.73 143 265 28.2 1188 9.1 0. 17 
26 3.424 108 152 16.2 843 6.5 0.33 
26.46 3.366 106 255 27.2 2471 19 0.28 
28.9 3.087 85 198 21. 1 1648 12.7 0.25 
30.18 2.958 78 118 12.6 920 7.1 0.39 
30.52 2.926 78 126 13.4 1001 7.7 0.35 
31./ 2.873 76 115 12.2 334 2.6 0.15 
Peak Search Report (26 Peaks, Max PIN = 9.1 ) 
[Z073 l 3.MDI] Tolbutamide+Urea : RESS (64C, 8000psi) <Psi=0.0> 
PEAK: 17-pts/Parabolic Filter, Threshold=3.0, Cutoff=0. 1%, BG=3/1.0, Peak-Top=Summit 
2-Theta d(A) BG Height 1% Area 1% FWHM 
8.78 10.064 64 287 43.8 2828 40.2 0.22 
10.28 8.596 73 150 22.9 975 13.8 0.22 
11.34 7.794 96 20 1 30.6 953 13.5 0. 15 
12.14 7.283 100 489 74.5 4599 65.3 0.2 
13.14 6.732 100 500 76.2 4403 62.5 0.19 
14.32 6.178 11 3 287 43.8 1714 24.3 0.17 
15.56 5.69 131 296 45. I 2230 31.7 0.23 
17.38 5.098 177 274 41.8 933 13.2 0. 16 
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( 
17.64 
18.06 
19.62 
19.96 
20.75 
20.94 
21.46 
23. 16 
23 .8 
24.8 
25.94 
26.38 
28.3 
28.86 
30.54 
33.03 
33 .03 
33.14 
5.024 
4.909 
4.521 
4.444 
4.278 
4.239 
4.137 
3.837 
3.735 
3.587 
3.432 
3.376 
3. 151 
3.09 1 
2.925 
2.71 
2.71 
2.701 
177 
178 
188 
194 
182 
171 
155 
121 
121 
104 
96 
93 
81 
78 
73 
62 
62 
61 
232 
234 
656 
416 
247 
365 
277 
249 
202 
142 
136 
207 
122 
182 
106 
97 
97 
92 
Peak Search Report (27 Peaks, Max PIN = 12.0) 
35.4 
35 .7 
100 
63.4 
37.7 
55.6 
42.2 
38 
30.8 
21.6 
20.7 
31.6 
18.6 
27.7 
16.2 
14.8 
14.8 
14 
[Z07314.MDIJ Tolbutamide+Urea: RESS (75C, 4000psi) <Psi=0.0> 
753 
74 1 
7043 
4895 
8 10 
2850 
1688 
1541 
591 
338 
361 
1722 
561 
1652 
495 
292 
292 
306 
10.7 
10.5 
100 
69.5 
11.5 
40.5 
24 
21.9 
8.4 
4.8 
5.1 
24.4 
8 
23.5 
4.1 
4.1 
4.3 
PEAK: 23-pts/Parabolic Filter, Threshold=3.0, Cutoff=0.1 %, BG=3/ l.O, Peak-Top=Summit 
0.23 
0.22 
0.26 
0.37 
0.21 
0.25 
0.24 
0.2 
0.12 
0.15 
0.15 
0.26 
0.23 
0.27 
0.25 
0.14 
0.14 
0.17 
2-Theta d(A} BG Height 1% Area 1% FWHM 
7.J6 J2.339 49 JOO J0.9 664 4.4 0.22 
8.78 10.063 56 227 24.7 1956 13. 1 0.19 
9.75 9.066 65 100 J0.9 603 4 0.29 
10.34 
11.08 
J J.42 
12.14 
13.14 
14.34 
J5.38 
15.62 
J6.26 
17.38 
J9.64 
20.06 
20.98 
21.3 
22.74 
23.16 
23.78 
26 
26.4 
28.34 
28.88 
8.55 
7.977 
7.742 
7.282 
6.731 
6.172 
5.755 
5.669 
5.447 
5.098 
4.5J7 
4.423 
4.231 
4.168 
3.907 
3.837 
3.739 
3.425 
3.374 
3.147 
3.089 
76 
90 
96 
96 
91 
121 
J30 
129 
J38 
166 
192 
J98 
177 
163 
112 
114 
115 
98 
94 
86 
87 
342 
J33 
289 
402 
410 
272 
244 
298 
J90 
251 
9J8 
404 
364 
324 
J5J 
243 
176 
J64 
210 
125 
164 
302 
37.3 
J4.5 
3J.5 
43.8 
44.7 
29.6 
26.6 
32.5 
20.7 
27.3 
JOO 
44 
39.7 
35.3 
J6.4 
26.5 
19.2 
J7.9 
22.9 
13.6 
17.9 
36J9 
940 
25JO 
3538 
3709 
2676 
3J45 
3156 
5J8 
919 
J4970 
7458 
3610 
4130 
748 
2059 
871 
1184 
2809 
755 
1167 
24.2 
6.3 
J6.8 
23.6 
24.8 
17.9 
2J 
21.1 
3.5 
6.1 
JOO 
49.8 
24.1 
27.6 
5 
13.8 
5.8 
7.9 
18.8 
5 
7.8 
0.23 
0.37 
0.22 
0.2 
0.2 
0.3 
0.47 
0.32 
O.J7 
0.18 
0.35 
0.62 
0.33 
0.44 
0.33 
0.27 
0.24 
0.3 
0.41 
0.33 
0.26 
30.23 2.954 80 113 12.3 697 4.7 0.36 
30.52 2.927 78 115 12.5 647 4.3 0.3 
31.62 2.827 72 105 11.4 360 2.4 0. 19 
Peak Search Report (23 Peaks, Max PIN = 13.9) 
[Z073 15.MDI] Tolbutamide+Urea : RESS (76C, 8000psi) <Psi=O.O> 
PEAK: 23-pts/Parabolic Filter, Threshold=3.0, CutofT=0. 1%, BG=3/1.0, Peak-Top=Summit 
2-Theta d(A) BG Height 1% Area 1% FWHM 
8.8 10.038 42 271 25. 1 3062 15.9 0.23 
10.36 8.534 53 225 20.8 2581 13.4 0.26 
I 1.46 7.716 86 245 22.7 2136 JI.I 0.23 
12.2 7.25 9 1 567 52.5 5864 30.5 0.2 1 
13.1 6 6.72 1 80 602 55.7 6 193 32.2 0.2 
14.34 6.17 1 97 305 28.2 2975 15.5 0.24 
15.04 5.885 106 146 13.5 720 3.7 0.31 
15.64 5.662 IOI 323 29.9 4219 21.9 0.32 
16.34 5.42 114 152 14. J 245 1.3 0. 11 
17.4 5.092 130 272 25.2 2252 11.7 0.27 
18.42 4.8 12 143 20 1 18.6 495 2.6 0. 15 
19.62 4.521 165 1080 100 19253 100 0.36 
20.04 4.427 182 487 45.1 10838 56.3 0.6 
20.94 4.238 163 448 41.5 7116 37 0.42 
21.52 4.126 143 288 26.7 3728 19.4 0.44 
23 .1 6 3.837 104 324 30 3320 17.2 0.26 
23.84 3.73 111 177 16.4 674 3.5 0. 17 
25.94 3.432 97 140 13 836 4.3 0.33 
26.44 3.368 90 284 26.3 3723 19.3 0.33 
28.32 3.149 74 130 12 1238 6.4 0.38 
28.88 3.089 76 2 12 19.6 2258 11.7 0.28 
30.6 2.919 69 125 11.6 1122 5.8 0.34 
35.18 2.549 50 82 7.6 1134 5.9 0.6 
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8. PLROXICAM + THEOPHYLLINE: 
8A. CHEMICAL STRUCTURE: 
Piroxicam Theophylline 
8B. SUMMARY OF RESS RECRYSTALLIATION: 
COMPOSITION OF STARTING MIXTURE: 80% Piroxicam + 20% Theophylline 
CONTENTS OF REACTION VESSEL: 2g Piroxicam + 0.5g Theophylline (2.5g of blend) 
Experiment (P,T conditions) Weight collected,mg Collection time, min 
l [65C, 6000psi] 91 10 
8D. I. XRPD ANALYSIS: 
304 
9. PIROXICAM + BENZOIC ACID: 
9A. CHEMICAL STRUCTURE: 
Piroxicam 
9B. SUMMARY OF RESS RECRYSTALL!ATION: 
0 
II 
C-OH 
6 
Benzoic Acid 
COM POSITION OF ST ART!NG MIXTURE: 80% Piroxicam + 20% Benzoic acid 
CONTENTS OF REACTION VESSEL : I .6g Piroxicam + 0.4g Benzoic acid (2g of blend) 
Experiment iP,T Weight collected,mg Collection time, min 
condition& 
I [48.SC, 2000psi] 8S 30 
2 [SOC, 4000psi] 70 IO 
3 [SOC, 8000psi] 8S s 
4 [66C, 2000psi] 41 30 
S [67C, 4000psi] S9 IO 
6 [6SC, 8000psi] 34 s 
7 [78C, 2000psi] 31 30 
8 [7SC, 4000psi] 38 IO 
9 [74C, 8000psi] 46 s 
30S 
9D. l. XRPD ANALYSIS : 
10.0======= =======----=======···"'···"'···"·· -c.::: ...:;:.,.::: ...=====::i 
8.0 
6.0 
4.0 
2.0 
10 
5000 . 
4000 ... 
~ i 3000 r-..._ ___ Jo~_..,_,.._,.._~ 
~ 
~ 
10 
20 
20 
. ' 
i ! 
· · · · · · ··· rio;;3 38.M-o.i· ;;~~k~:.:~~~~k ~~ki ~ · p.;;~k~ ·Mi~~-~~~ ~~~o:o; · -· 
t ! 
i (Z07339.MDIJ Punt &mzok: 1ckl <Psl-0.0> 
(Z070~3 . MDI) 2 min ground Plf'O)I~, N816703'4x46· S~e II 
30 40 
2·Theta{') 
. . 
[Z07336.MDl1.''lrodcam+Btnzolc .cld : ~ (7SC,4000psl) <Psi-0.0> 
1207333.MOI) ~ro1tkam+Btnzok acid : R~ (SOC,8-000psO <Pslo-0.0> 
[Z07332.MDl) Ptro11lu.m+8enzolc add : ~ (SOC,4000psl) <Psl-0.0> 
(207331 .MDIJ Pl_roxlam+km'ok «Id : R£SS,(48.SC,2000p~ <PSl-0.0> 
30 40 
2-Theta(l 
306 
( JO. THEOPHYLLINE +CAFFEINE: 
JOA. CHEMICAL STRUCTURE: 
Theophylline 
!OB. SUMMARY OF RESS RECRYSTALLIATION: 
COMPOSITION OF STARTING MIXTURE: 80% Theophylline + 20% Caffeine 
CONTENTS OF REACTION VESSEL: 4.8g Theophylline+ I .2g Caffeine (6g of blend) 
TEMPERATURE OF MICROM ETERING v ALVE: I 50°C 
RECRYSTALLIZING SOLVENT: Pure SCC02 
Experiment IP,T conditions I Weight Collection time, min 
collecled,~ 
I [47.5C, 2000psi] 3 1 30 
2 [46.5C, 4000psi] 195 35 
3 [48C, 8000psi] 131 15 
4 [63C, 2000psi] 35 30 
5 [62.5C, 4000psi] 86 30 
6 [64C, 8000psi] 127 30 
7 [76.5C, 2000psi] 30 30 
8 [76C, 4000psi] 32 30 
9 [75.1 C, 8000psi] 62 20 
10 [100.IC, 2000psi] 21 30 
11 [IOOC, 4000psi] 34 30 
12 [I OOC, 8000psi] 127 30 
COMPOSITION OF ST AR TING MIXTURE: 20% Theophylline + 80% Caffeine 
CONTENTS OF REACTION VESSEL: 2g Theophyll ine+ 8g Caffeine (IOg of blend) 
TEM PERATURE OF MICROMETERJNG v ALVE: I 50°C 
RECRYSTALLIZING SOLVENT: Pure SCC02 
307 
Experiment [P,T conditions[ Weight collccted,mg Collection time, min Ref 
I [47.7°C, 2000psi] 68 60 NB 72656xl37 
2 (48.2°C, 4000psi] 357 20 NB 72656x 138 
3 (47°C, 8000psi] 263 IO NB 72656x l38 
4 [63°C, 2000psi] 50 30 NB 72656xl37 
5 [63.2°C, 4000psi] 279 20 NB 72656x 138 
6 [62.2C, 8000psi] 203 30 NB 72656x 139 
7 (75.8°C, 2000psi] 61 30 NB 72656x 139 
8 (74 .5°C, 4000psi] 160 25 NB 72656xl40 
9 [76.4°C, 8000psi] 296 15 NB 72656x l40 
JO [J 00.4°C, 2000psi] 58 20 NB 72656x l40 
I I [I 00.9°C, 4000psi] 136 30 NB 72656x l40 
I 2 [98. 7°C, 8000psi] 282 30 NB 72656x l41 
COMPOSITION OF STARTfNG MIXTURE: 80% Theophylline + 20% Caffeine 
CONTENTS OF REACTION VESSEL: 4.8g Theophylline+ I .2g Caffeine (6g of blend) 
TEMPERATURE OF MICROMETERfNG v ALVE: 100°C 
RECRYSTALLIZfNG SOLVENT: SCC02 + MeOH 
Experiment [P,T conditions[ Weight collected,mg Collection time, min 
I [53C, 2000psi] 79 30 
2 [53.6C, 4000psi] 123 30 
3 [52.6C, 8000psi] 43 30 
COMPOSITION OF STARTfNG MIXTURE: 80% Theophylline + 20% Caffeine 
CONTENTS OF REACTION VESSEL: 8g Theophylline+ 2g Caffeine ( IOg of blend) 
TEMPERATURE OF MICROM ETERING v ALVE: 100°C 
RECRYSTALLIZfNG SOLVENT: SCC02 + Acetone 
Experiment [P,T conditions) Weight collected,mg Collection time, min 
I [52C, 2000psi] 90 30 
2 [57C, 4000psi] 381 10 
3 [54.8C, 8000psi] 157 IO 
4 [62.2C, 2000psi] 22 32 
5 [ 60.3C, 4000psi] 44 60 
6 (60.6C, 8000psi] 108 30 
7 [76.2C, 2000psi] 25 60 
8 [75C, 4000psi] 27 60 
9 [74.8C, 8000psi] 28 15 
I 0 [I 0 I.SC, 2000psi] 24 60 
11 [I 02C, 4000psi] 27 30 
12 [99. IC, 8000psi] 18 IO 
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10.D.2 XRPD ANALYSIS: 
Peak Search Report (25 Peaks, Max PIN = 46.4) 
[Z07020.MDI] Ground Theophylline, 2 min grinding time, NB#67034x39, Stage II 
PEAK: 23-pts/Parabolic Fi lter, Threshold=3.0, CutofP0.1%, BG=3/ l.O, Peak-Top=Summit 
2-Theta d(A} BG Height 1% Area 1% FWHM 
7.16 12.342 31 2135 24.6 30012 25.5 0.24 
12.6 7.019 47 8695 100 11 79 14 100 0.23 
14.34 6.171 36 1119 12 .9 14900 12.6 0.23 
17.78 4.986 28 150 1.7 1555 1.3 0.22 
20.86 4.255 43 234 2.7 2051 1.7 0.18 
21.6 4.11 47 294 3.4 3363 2.9 0.23 
22.08 4.022 48 146 1.7 1231 0.21 
23.44 3.792 43 476 5.5 6331 5.4 0.25 
24.04 3.699 76 846 9.7 15583 13.2 0.34 
25.58 3.479 82 1969 22.6 41091 34.8 0.37 
26.48 3.363 153 11 35 13. l 13875 11.8 0.24 
27.36 3.257 112 1024 11.8 24518 20.8 0.46 
27.68 3.22 103 924 10.6 14304 12.1 0.3 
29.36 3.04 70 1029 11.8 15361 13 0.27 
30.24 2.953 67 143 1.6 794 0.7 0.18 
30.92 2.89 60 256 2.9 3 121 2.6 0.27 
3 1.4 2.847 60 190 2.2 2663 2.3 0.35 
33.32 2.687 49 169 1.9 1976 1.7 0.28 
34.84 2.573 45 146 1.7 1259 1.1 0.21 
36.04 2.49 42 144 1.7 1642 1.4 0.27 
36.44 2.464 41 150 1.7 2003 1.7 0.31 
38.96 2.31 50 200 2.3 3260 2.8 0.37 
42.4 2.13 44 108 1.2 2077 1.8 0.55 
43 .36 2.085 45 230 2.6 3895 3.3 0.36 
45.5 1.992 35 94 1.1 1105 0.9 0.32 
Peak Search Report (12 Peaks, Max PIN = 28.l} 
[Z07346.MDI) Pure Caffeine <Psi=0.0> 
PEAK: 21-pts/Parabolic Filter, Threshold=3.0, CutofT=O. I%, BG=3/l .O, Peak-Top=Summit 
2-Theta d(A} BG Height 1% Area 1% FWHM 
8.36 10.57 83 155 4.6 1041 1.6 0.25 
11.88 7.443 118 3399 100 64100 100 0.33 
14.39 6.148 133 179 5.3 141 0.2 0.05 
18.07 4.904 212 263 7.7 1276 2 0.43 
20.58 4.312 201 278 8.2 1170 1.8 0.26 
21.36 4.156 176 263 7.7 714 I.I 0.14 
23.82 3.733 126 3 19 9.4 4125 6.4 0.36 
24.08 3.692 123 288 8.5 3221 5 0.33 
26.46 3.365 114 6 11 18 11256 17.6 0.39 
27.1 3.288 147 468 13.8 4362 6.8 0.23 
28.48 3.132 99 186 5.5 1635 2.6 0.32 
312 
29.67 3.009 87 129 3.8 516 0.8 0.21 
Peak Search Report (28 Peaks, Max PIN = 3 1.6) 
(207689.MDI] Theophylline+CafTeine:Physical Mixture; Sample weight=l4.2mg <Psi=O.O> 
PEAK: 19-ptsfParabolic Filler, Threshold=3.0, Cutoff=0. 1%, BG=3/ 1.0, Peak-Top=Summit 
2-Theta d(A) BG Height 1% Area 1% FWHM 
7.2 12.266 54 1076 26. 3 11616 27 0.19 
11.96 7.394 49 1044 25.5 21497 50 0.37 
12.7 6.964 53 4091 100 43027 100 0.18 
14.44 6.129 56 506 12.4 4658 10.8 0.18 
17.84 4.968 90 142 3.5 339 0.8 0.11 
20.6 4.308 99 140 3.4 429 I 0.18 
20.96 4.235 102 179 4.4 782 1.8 0.17 
21.72 4.088 98 188 4.6 757 1.8 0.14 
22.2 4 .00 1 93 139 3.4 250 0.6 0.09 
23.58 3.77 91 246 6 2436 5.7 0.27 
24.14 3.684 88 361 8.8 5653 13.1 0.35 
24.4 3.645 94 276 6.7 2988 6.9 0.28 
25.76 3.456 114 738 18 9692 22.5 0.26 
26.58 3.351 141 565 13.8 4995 11.6 0.2 
27.1 3.288 112 245 6 2073 4.8 0.26 
27.48 3.243 126 375 9.2 3682 8.6 0.25 
27.84 3.202 109 386 9.4 2902 6.7 0.18 
29.46 3.029 80 397 9.7 3793 8.8 0.2 
30.4 2.938 72 105 2.6 241 0.6 0.12 
31.01 2.881 7 1 133 3.3 1148 2.7 0.31 
31.74 2.8 17 70 110 2.7 622 1.4 0.26 
32.51 2.752 65 104 2.5 99 0.2 0.04 
33.44 2.678 59 94 2.3 537 1.2 0.26 
34.9 2.568 5 1 85 2.1 3 13 0.7 0.1 6 
36.54 2.457 44 85 2.1 841 2 0.35 
39. 12 2.301 42 78 1.9 913 2.1 0.43 
42.06 2.147 41 68 1.7 489 I.I 0.3 1 
43.5 2.079 42 109 2.7 79 1 1.8 0.2 
Peak Search Report (6 Peaks, Max PIN = 10.7) 
(207363.MDI] Theophylline+CafTeine : RESS (47.5C,2000psi); Sample weight=0.7mg <Psi=0.0> 
PEAK: 19-ptsfParabolic Filter, Threshold=3.0, Cutoff--0. 1%, BG=3/ 1.0, Peak-Top=Summit 
2-Theta d(A) BG Height 1% Area 1% FWHM 
11.88 7.443 133 70 1 100 8032 100 0.24 
21.47 4.135 2 15 317 45.2 608 7.6 0.1 
23.82 3.732 150 264 37.7 1378 17.2 0.21 
26.68 3.338 109 216 30.8 2811 35 0.45 
27.08 3.29 Ill 157 22.4 1250 15.6 0.46 
Peak Search Report (I I Peaks, Max PIN = 19.3) 
(207673.MDI] Theophylline+CafTeine:RESS (46.5C, 4000psi]; Sample weight =5.lmg <Psi=0.0> 
313 
PEAK: 21-pts/Parabolic Filter, Thresbold=3.0, CutofP0.1 %, BG=3/1.0, Peak-Top=Summit 
2-Theta d(A} BG Height 1% Area 1% FWHM 
3.77 23.387 121 163 9.2 889 2.6 0.36 
11.94 7.407 153 1779 100 33998 100 0.36 
20.56 4.317 259 317 17.8 810 2.4 0.24 
21.39 4.151 238 323 18.2 422 1.2 0.08 
23.84 3.73 138 325 18.3 3631 10.7 0.33 
24.16 3.68 1 143 223 12.5 11 57 3.4 0.25 
24.16 3.681 143 223 12.5 1157 3.4 0.25 
26.6 3.348 122 476 26.8 8586 25.3 0.41 
27.16 3.281 140 372 20.9 4200 12.4 0.31 
28.44 3.1 36 106 164 9.2 1034 3 0.3 
28.62 3.116 104 173 9.7 1050 3.1 0.26 
Peak Search Report (9 Peaks, Max PIN = 16. l) 
(207676.MDI] Theophylline+Caffeine:RESS [48C, 8000psi], Sample weight=3.3mg <Psi=O.O> 
PEAK: 23-pts/Parabolic Filter, Threshold=3.0, Cutoff=0.1%, BG=3/ 1.0, Peak-Top=Summit 
2-Theta d(A} BG Height 1% Area 1% FWHM 
11.94 7.406 79 1196 100 23257 100 0.35 
20.63 4.302 139 185 15.5 115 0.5 0.04 
21.48 4.134 127 167 14 134 0.6 0.06 
23.78 3.739 103 160 13.4 1216 5.2 0.36 
24.2 3.675 99 151 12.6 1503 6.5 0.49 
26.6 3.349 97 305 25.5 5331 22.9 0.44 
27.12 3.285 110 257 21.5 2690 11.6 0.31 
28.58 3.12 1 85 126 10.5 610 2.6 0.25 
29.7 3.005 74 106 8.9 750 3.2 0.4 
Peak Search Report (3 Peaks, Max PIN = 4.2) 
(207679.MDl] Theophylline+Caffeine:RESS [63C, 2000psi] ; Sample weight=0.2mg <Psi=O.O> 
PEAK: 19-pts/Parabolic Filter, Threshold=3.0, Cutoff=0.1%, BG=3/ 1.0, Peak-Top=Summit 
2-Tbeta d(A} BG Height 1% Area 1% FWHM 
I 1.9 7.43 1 45 145 100 1519 100 0.26 
26.69 3.337 80 116 80 726 47.8 0.34 
26.69 3.337 80 116 80 726 47.8 0.34 
Peak Search Report (8 Peaks, Max PIN = 14.8) 
(207681.MDI] Theophylline+Caffeine:RESS [62.5C, 4000psi] ; Sample weight=3.2mg <Psi=O.O> 
PEAK: 25-pts/Parabolic Filter, Threshold=3.0, Cutoff=O. 1%, BG=3/1.0, Peak-Top=Summit 
2-Theta d(A} BG Height 1% Area 1% FWHM 
11.94 7.406 62 1000 100 20489 100 0.37 
20.73 4.282 113 152 15.2 395 1.9 0.1 7 
23.86 3.726 101 154 15.4 1397 6.8 0.45 
24.15 3.683 103 150 15 1110 5.4 0.4 
26.58 3.351 97 337 33.7 7001 34.2 0.5 
27.1 3.287 112 252 25.2 2582 12.6 0.31 
28.44 3.136 89 133 13.3 643 3.1 0.25 
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28.68 3.11 86 121 12./ 667 3.3 0.32 
Peak Search Report (8 Peaks, Max PIN = 11.4) 
[Z07682.MDl) Theophylline+Caffeine:RESS [64C, 8000psi] ; Sample weight=l .8mg <Psi=O.O> 
PEAK: 25-pts/Parabolic Filter, Threshold=3.0, Cutoff=0.1%, BG=3/ l.O, Peak-Top=Summit 
2-Theta d(A) BG Height 1% Area 1% FWHM 
7.24 12.196 38 72 11.7 502 4.7 0.25 
11.94 7.406 49 615 100 10694 100 0.32 
12.66 6.985 64 150 24.4 887 8.3 0.18 
23.94 3.714 90 130 21.1 954 8.9 0.41 
26.58 3.351 91 210 34.1 3630 33.9 0.52 
27.11 3.286 96 180 29.3 1596 14.9 0.32 
31.18 2.866 66 99 16.l 79 0.7 0.04 
47.89 1.898 26 48 7.8 261 2.4 0.2 
Peak Search Report (4 Peaks, Max PIN = 7.9) 
[Z07683.MD!) Theophylline+Caffeine:RESS [76.5C, 2000psi) ; Sample weight=0.6mg <Psi=O.O> 
PEAK: 19-pts/Parabolic Filter, Threshold=3.0, Cutoff=0. 1%, BG=3/ 1.0, Peak-Top=Summit 
2-Theta d(A) BG Height 1% Area 1% FWHM 
11.86 7.455 63 364 100 4433 100 0.25 
23.8 3.735 101 141 38.7 264 6 0.11 
26.7 3.336 86 137 37.6 679 15.3 0.23 
26.94 3.307 84 123 33.8 729 16.4 0.32 
Peak Search Report (3 Peaks, Max PIN = 8.0) 
[Z07684.MD!) Theophylline+Caffeine:RESS (76C, 4000psi] ; Sample weight=0.5mg <Psi=0.0> 
PEAK: 23-pts/Parabolic Filter, Threshold=3.0, Cutoff=0. 1%, BG=3/ 1.0, Peak-Top=Summit 
2-Theta d(A) BG Height 1% Area 1% FWHM 
11.84 7.469 54 357 100 4589 100 0.26 
26.46 3.366 94 153 42.9 1200 26.1 0.35 
26.93 3.308 88 123 34.5 1450 31.6 0.7 
Peak Search Report (8 Peaks, Max PIN = 10.7) 
[Z07685 .MDI) Theophylline+Caffeine:RESS (75.1 C, 8000psi] ; Sample weight=2.0mg <Psi=0.0> 
PEAK: 23-pts/Parabolic Filter, Threshold=3.0, Cutoff=0.1%, BG=3/1.0, Peak-Top=Summit 
2-Theta d(A) BG Height 1% Area 1% FWHM 
7.27 12.146 61 116 19 662 6.6 0.2 
11.96 7.394 81 609 100 10057 100 0.32 
12.76 6.934 90 255 41.9 2184 21.7 0.23 
23.89 3.721 107 158 25.9 1076 10.7 0.36 
26.58 3.351 108 214 35.1 2574 25.6 0.41 
27.1 3.287 105 166 27.3 1196 11.9 0.33 
31.03 2.88 70 104 17.1 290 2.9 0.14 
Peak Search Report (7 Peaks, Max PIN = 7.9) 
[Z07686.MD!) Theophylline+Caffeine:RESS [100.l C, 200Qpsi); Sample weight=0.3mg <Psi=O.O> 
PEAK: 17-pts/Parabolic Filter, Threshold=3.0, Cutoff=0.1 %, BG=3/ l .0, Peak-Top=Summit 
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2-Theta d(A) BG Height 1% Area 1% FWHM 
3.J3 28.2J6 J3J 369 JOO 3874 JOO 0.28 
3.27 27.0J5 112 322 87.3 3J59 81.5 0.26 
3.55 24.872 93 204 55.3 J924 49.7 0.29 
11.88 7.444 51 343 93 3870 99.9 0.23 
23.23 3.825 90 J27 34.4 537 J3.9 0.25 
26.66 3.341 89 136 36.9 578 14.9 0.21 
42.08 2.145 34 62 16.8 163 4.2 0.1 
Peak Search Report (11 Peaks, Max PIN = 8.6) 
[Z07687.MDI] Theophylline+Caffeine:RESS [IOOC, 4000psi] ; Sample weight=0.7mg <Psi=O.O> 
PEAK: 19-pts/Parabolic Filter, Threshold=3.0, Cutoff=0.1 %, BG=3Jl.O, Peak-Top=Summit 
2-Theta d(A) BG Height 1% Area 1% FWHM 
3.J2 28.3J9 75 202 49.3 2700 48. 6 0.36 
3.22 27.427 63 J87 45.6 2086 37.6 0.29 
3.54 24.945 54 J29 3J.5 1184 2J.3 0.27 
7.2 12.268 44 79 19.3 333 6 0.16 
11.88 7.443 63 410 100 5554 100 0.27 
12.68 6.975 69 158 38.5 408 7.3 0.08 
J9.2 4.6J8 J02 J4J 34.4 50J 9 0.22 
25.73 3.459 97 135 32.9 351 6.3 0.16 
26.56 3.353 95 181 44.1 1603 28.9 0.32 
27.0 1 3.298 90 136 33.2 1330 23.9 0.49 
36.34 2.47 42 69 16.8 252 4.5 0. 16 
Peak Search Report ( 14 Peaks, Max PIN = I 0.0) 
[Z07688.MD1] Theophylline+Caffeine:RESS [IOOC, 8000psi]; Sample weight=2.2mg <Psi=O.O> 
PEAK: 23-pts/Parabolic Filter, Threshold=3.0, Cutoff=0.1 %, BG=3Jl.O, Peak-Top=Summit 
2-Theta d(A) BG Height 1% Area 1% FWHM 
3.32 26.602 75 206 4J 2 J56 24. J 0.28 
3.4 25.974 75 J86 37 J703 J9 0.26 
7.18 12.305 54 132 26.2 1227 13.7 0.27 
11.92 7.418 56 503 100 8945 100 0.34 
12.68 6.976 61 447 88.9 5985 66.9 0.26 
14.34 6.172 66 109 21.7 622 0.25 
J6.47 5.377 84 J2J 24.J 22J 2.5 0.J 
17.97 4.933 106 148 29.4 34 1 3.8 0.14 
23.67 3.756 98 138 27.4 1250 14 0.53 
23.82 3.732 97 143 28.4 1238 13.8 0.46 
25 .76 3.456 IOI 176 35 1147 12.8 0.26 
26.6 3.349 104 215 42.7 2084 23.3 0.32 
27.1 3.288 98 158 31.4 1663 18.6 0.47 
29.5 3.025 78 115 22.9 540 6 0.25 
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10.F. HPLC ANAL YSJS: 
RUN-1 
Condition % Theophylline 0/oCaffeine o/oExtracted 
[ 46.5C, 4000psi] 1.76 98.24 96.74 
[ 48C, 8000psi] 4.45 95.55 96.95 
(63C, 2000psi] 2.22 97.78 101.23 
(62.5C, 4000psi] 6.87 93. 13 96.83 
[64C, 8000psi] 17.44 82.56 97.73 
(76.SC, 2000psi] 4.82 95. 18 96.87 
[76C, 4000psi] 12.18 87.82 95.61 
(75. IC, 8000psi] 33.43 66.57 98. 11 
[JOO. IC, 2000psi] 12.91 87.09 97.02 
[I OOC, 4000psi] 25. 19 74.8 1 96.35 
(IOOC, 8000psi] 46.04 53 .96 98.97 
Physical Mixture 81.96 18.04 102.83 
Run-2 
Condition % Theophylline o/oCaffeine 0/oExtracted 
[ 46.5C, 4000psi] 1.84 98. 16 95.98 
(48C, 8000psi] 4.71 95.29 98.83 
[63C, 2000psi] 0.80 99.20 95.88 
[62.5C, 4000psi] 6.98 93.02 95.67 
[64C, 8000psi] 17.79 82.21 97. 16 
(76.5C, 2000psi] 4. 10 95.90 95.11 
[76C, 4000psi] 11.92 88.08 95.47 
(75. 1 C, 8000psi] 32.54 67.46 98.39 
[JOO. IC, 2000psi] I 1.89 88.11 92.90 
[I OOC, 4000psi] 25 .03 74.97 95 .95 
[I OOC, 8000psi] 45 .9 1 54.09 99.43 
Physical Mixture 81.02 18.98 102.43 
RUN-3 
Condition % Theophylline %1Caffeine 0/oExtracted 
(47.7C, 2000psi] 1.69 98.3 1 97 .97 
[48.2C, 4000psi] 1.04 98.96 102.82 
(47C, 8000psi] 1.54 98.46 I 04.42 
(63C, 2000psi] 1.37 98.63 102.74 
[63 .2C, 4000psi] 1.57 98.43 101.99 
[62.2C, 8000psi] 2.78 97.22 102.94 
(75.8C, 2000psi] 3.17 96.83 103.93 
(74.5C, 4000psi] 2.96 97.04 100.22 
[76.4C, 8000psi] 4 .80 95.20 102.79 
3 17 
[ 100.9C, 4000psi] 4.47 95.53 103.14 
[98.7C, 8000psi] 6.99 93.01 102.68 
Physical Mixture 20.42 79.58 103.1 7 
RUN-4 
Condition % Theophylline o/oCaffeine 0/oExtracted 
[47.7C, 2000psi] 1.80 98.20 97.91 
[ 48.2C, 4000psi] 1.02 98.98 104.3 1 
[47C, 8000psi] 1.70 98.30 96.14 
[63C, 2000psi] 1.49 98.5 1 102.5 1 
[63.2C, 4000psi] 1.57 98.43 99.74 
[62.2C, 8000psi] 2.73 97.27 103.26 
[75 .8C, 2000psi] 3.25 96.75 102.48 
[74.SC, 4000psi] 2.91 97.09 103.75 
[76.4C, 8000psi] 4.79 95.21 101.73 
[ 100.9C, 4000psi] 4.37 95.63 103.22 
(98.7C, 8000psi] 7.06 92.94 102.57 
Physical Mixture 20.28 79.72 103.75 
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11 . THEOPHYLLlNE + THEOBROMINE: 
11 A. CHEMICAL STRUCTURE: 
Theophylline Theobromine 
1 IB. SUMMARY OF RESS RECRYSTALLIATION: 
COMPOSITION OF STARTING MIXTURE: 80% Theophylline + 20% Theobromine 
CONTENTS OF REACTION VESSEL: 8g Theophylline+ 2g Theobromine (IOg of blend) 
TEMPERATURE OF MICROMETERING v ALVE: 150°C 
RECRYSTALLIZING SOLVENT: Pure SCC02 
Experiment jP,T conditions! Weight collected,mg Collection time, min Ref 
I [44°C, 2000psi] 43 45 NB 729I7x 17 
2 [48°C, 4000psiJ 26 55 NB 72917x 18 
3 [49.2°C, 8000psi] 28 30 NB 729 17x 18 
4 [62.8°C, 2ooopsi] 21 90 NB 72917x 18 
5 [62°C, 4000psi] 25 60NB 72917x I8 
6 [62.5°C, 8000psi] 43 60 NB 72917x I9 
7 [76°C, 2000psi) 15 60 NB 72917x 19 
8 [76°C, 4000psi] 26 60 NB 72917x I9 
9 [75.2°C, 8000psi] 92 45 NB 72917x I9 
IO [IO l.4°C, 2000psi] 19 60 NB 729 17x 20 
11 [Io l.5°C, 4000psi] 36 60 NB 729 17x 20 
12 [JO l.5°C, 8000psi] 116 40 NB 72917x 20 
COMPOSITION OF STARTING MIXTURE: 80% Theophylline + 20% Theobromine 
CONTENTS OF REACTION VESSEL: 8g Theophylline+ 2g Theobromine ( IOg of blend) 
TEMPERATURE OF MICROMETERING v ALVE: 150°C 
RECRYSTALLIZING SOLVENT: SCC02 + MeOH 
3 I9 
Experiment [P,T conditions] Weight collected,mg Collection time, min Ref 
I [99.7C, 2000psi] 25 60 NB 72917x 27 
2 [IOl.5C, 4000psi] 52 30 NB 72917x 27 
3 [IO I.IC, 8000psi] 166 3 NB 72917x 27 
11 C. DSC ANALYSIS: 
Ttwophylline + Theobromine 
... 200 220 2'<1 
"' TempenluN ("Cl 
-(OIJP\.w'e~ -11>1Pt#eTheobtm*le -1c181YlOPh)'Mix 
-1&1i«:.~1 -1f)f49C,80l>Oplll -!gl(63C. 2000psi] 
- ""· 
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I ID. I . XRPD ANALYSIS: 
llO---·---(lt•K.-+ lllnci---·-1···.K.- r 
llO,.._._.,_._r•••..:.-~ 
~·-------· .. ~--+­""'-·--·'-;<OOll>tC.-~· 
llO>M•.-- · .._~IPK.~.., • llO•-.--·-.- ...  K.-. .;.... 
llt1nl--·T--.po -IUC.-.-11'1---·- IEUIU-K.1-" . 
....,... ____ ~
32 1 
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12. PHENYTOIN +CAFFEINE: 
12A. CHEMICAL STRUCTURE: 
Phenvtoin 
12B. SUMMARY OF RESS RECRYSTALLIATION: 
COMPOSITION OF STARTING MIXTURE: 80% Phenytoin + 20% Caffeine 
CONTENTS OF REACTION VESSEL : 4.8g Phenytoin+ l.2g Caffeine (6g of blend) 
Experiment [P,T \Veight collected,mg Collection time, min 
conditions I 
I [ 49C, 2000psi] 75 
2 [ 48.SC, 4000psi] 78 
3 ( 4 7C, 8000psi] I57 
4 [62.5C, 2000psi] 35 
5 [62C, 4000psi] 46 
6 (62C, 8000psi] 48 
7 (76.5C, 2000psi] 28 
8 [76C, 4000psi] 43 
9 (75C, 8000psi] 43 
322 
60 
20 
IO 
60 
IO 
5 
64 
30 
IO 
( 
12.D. l. XRPD ANALYSIS: 
4500 .......... .. . ········-! · ·· ... ···········i --·--·· ..... ................... ! ··-······-······ .. ··-··········-~---
4000 . 
3500 . 
~ 8 2500''-'==_. .... _, .ll,,ll.--'--' -''···· ···'--'""' 
;; 
~ 
~ 2000,l ······················ ·+···-ll .. , .. .... ....... ... ...... .... ........ .• .. .... ... ··· ······· ·· .........•... 
· · ····-··*·Q.U~,~l -~.~-"ff~~- ~-.Q?': ... 
30 40 
f : 
6000 . . ······· ··················· ............ . 
: : 
! 1207421 .MDII Phenytoln+c~fft!lne :Phy$1ul Mixture; Sample• 
jZ~7420.MOIJ Phenvtoln+Caff~lne : RESS (7SC,8000psl); Sa pit 1 
' ' 
! 4000 . 
~ i : 
1~7-419.MOI] Phi=nvtoln+e.atr'.elne : R!SS(76C,4000psl); pie 
[20; 418.MDtl F>ti.nytoln+Ciofftl~ : RESS (76.5c.2000psl}; Sample 1 
j 3000 . 
1----Ji~--~-~_, ...... _ _ __ --'_'----___j 
[2074 16.MOll Phtmytoln+C4ffeine : RESS (62C,4000psl); Sa pie "' 
' ' 
······ ······ (Z07417 .MOil Phtnytoln+Uff•!n• : Rill (62C,8000psl); Sample.., 
2000·-'·-~.,,._,~_.. 
1207.41 S.MOIJ Phenytoln+Ca!Mn:t : RESS (62.SC,2000psl); S..mple.,. 
1000 
10 20 40 
2·Theta(l 
323 
12.D.2. XRPD ANALYSIS: 
Peak Search Report (27 Peaks, Max PIN = 20.3) 
[Z07422.MDI] Pure Phenytoin; Sample weight=l2.7mg <Psi=0.0> 
PEAK: 19-pts/Parabolic Filter, Threshold=3.0, Cutoff.=0. 1 %, BG=3/l .O, Peak-Top=Summit 
2-Theta d(A) BG Height 1% Area 1% FWHM 
8.68 10.18 65 550 29.1 5480 3 1.2 0.19 
11.42 7.742 69 1719 91 17180 98 0.18 
13 .06 6.772 73 655 34.7 5545 3 1.6 0.16 
16.7 5.304 122 1889 100 17539 100 0.17 
17.36 5.103 148 698 37 5080 29 0.16 
18.3 4.844 143 974 51.6 7602 43.3 0.16 
19.44 4.563 147 322 17 1632 9.3 0. 16 
20.46 4.337 131 105 1 55.6 980 1 55.9 0.18 
21.49 4.131 123 169 8.9 635 3.6 0.23 
22.52 3.945 11 7 101 5 53.7 8935 50.9 0.17 
22.92 3.877 114 287 15.2 2161 12.3 0.21 
23.29 3.8 16 116 156 8.3 164 0.9 0.07 
25.98 3.427 98 373 19.7 4980 28.4 0.31 
26.28 3.389 96 543 28.7 776 1 44.2 0.3 
27.06 3.292 95 210 II.I 1227 7 0.18 
27.9 3. 195 87 302 16 1979 11.3 0.16 
29.94 2.982 81 178 9.4 1090 6.2 0.19 
30. 17 2.96 84 122 6.5 290 1.7 0.13 
30.96 2.886 77 112 5.9 275 1.6 0.13 
3 1.7 2.82 1 73 125 6.6 613 3.5 0.2 
33 .54 2.67 70 157 8.3 1143 6.5 0.22 
35.04 2.559 55 105 5.6 1106 6.3 0.38 
35.47 2.529 59 Ill 5.9 251 1.4 0.08 
37.44 2.4 47 Ill 5.9 1128 6.4 0.3 
41.58 2.17 42 84 4.4 803 4.6 0.33 
43.21 2.092 45 76 4 327 1.9 0. 18 
44.09 2.052 44 92 4.9 509 2.9 0.18 
Peak Search Report ( 12 Peaks, Max PIN = 28. 1) 
[Z07346.MDI] Pure Caffeine <Psi=0.0> 
PEAK: 21-pts/Parabolic Filter, Threshold=3.0, Cutoff.=0. 1 %, BG=3/ l .O, Peak-Top=Summit 
2-Theta d(A) BG Height 1% Area !% FWHM 
8.36 10.57 83 155 4.6 1041 1.6 0.25 
11.88 7.443 118 3399 100 64100 JOO 0.33 
14.39 6.148 133 179 5.3 141 0.2 0.05 
18.07 4.904 212 263 7.7 1276 0.43 
20.58 4.312 20 1 278 8.2 1170 1.8 0.26 
21.36 4.156 176 263 7.7 7 14 I.I 0.14 
23.82 3.733 126 319 9.4 4125 6.4 0.36 
24.08 3.692 123 288 8.5 322 1 5 0.33 
26.46 3.365 114 61 1 18 11256 17.6 0.39 
324 
27.1 3.288 147 468 13.8 4362 6.8 0.23 
28.48 3.132 99 186 5.5 1635 2.6 0.32 
29.67 3.009 87 129 3.8 516 0.8 0.21 
Peak Search Report (27 Peaks, Max PIN = 17.6) 
[Z07421.MDI] Phenytoin+CafTeine :Physical Mixture; Sample weighc=I0.8mg <Psi=O.O> 
PEAK: 17-pts/Parabolic Filter, Threshold=3.0, Cutoff=0.1%, BG=3/J .0, Peak-Top=Summit 
2-Theta d(A) BG Height 1% Area 1% FWHM 
8.68 10.18 79 412 28.7 3987 27.1 0.2 
11.42 7.742 102 1438 100 14721 100 0.19 
11.88 7.444 109 863 60 14381 97.7 0.32 
13.06 6.773 106 474 33 3564 24.2 0.16 
16.7 5.304 187 1430 99.4 11892 80.8 0.16 
17.38 5.098 202 630 43.8 3612 24.5 0. 14 
18.3 4.844 212 767 53.3 5145 35 0.16 
19.44 4.563 207 373 25.9 1564 10.6 0.16 
20.46 4.337 182 907 63.1 7751 52.7 0.18 
21.4 4.148 155 241 16.8 914 6.2 0.18 
22.54 3.941 138 786 54.7 6920 47 0.18 
22.92 3.877 136 264 18.4 1227 8.3 0.16 
23.78 3.739 125 208 14.5 1333 9.1 0.27 
24.13 3.686 121 165 11.5 467 3.2 0. 18 
25.96 3.429 118 309 21.5 2258 15.3 0.2 
26.28 3.389 116 460 32 7265 49.4 0.36 
26.46 3.366 102 286 19.9 6157 41.8 0.57 
27.12 3.286 124 256 17.8 1147 7.8 0.15 
27.88 3.197 IOI 262 18.2 1376 9.3 0.15 
29.9 2.985 91 141 9.8 661 4.5 0.22 
31.64 2.826 78 116 8.1 518 3.5 0.23 
33.52 2.672 70 136 9.5 765 5.2 0.2 
35.05 2.558 65 103 7.2 521 3.5 0.23 
37.38 2.404 55 113 7.9 780 5.3 0.23 
41.62 2.168 47 97 6.7 677 4.6 0.23 
43.28 2.089 51 79 5.5 305 2.1 0.19 
44.12 2.051 48 83 5.8 505 3.4 0.25 
Peak Search Report (8 Peaks, Max PIN = 18.9) 
[Z074 12.MDI] Phenytoin+CafTeine: RESS (49C,2000psi); Sample weighc=5.2mg <Psi=O.O> 
PEAK: 23-pts/Parabolic Filter, Threshold=3.0, Cutoff=0.1%, BG=3/1.0, Peak-Top=Summit 
2-Theta d(A) BG Height 1% Area 1% FWHM 
11.88 7.443 118 1656 100 25452 100 0.28 
21.44 4.141 189 298 18 1189 4.7 0.19 
23.82 3.733 13 1 271 16.4 2262 8.9 0.27 
26.72 3.334 117 414 25 7430 29.2 0.43 
27.04 3.295 117 241 14.6 3588 14.1 0.49 
28.52 3. 127 97 135 8.2 520 2 0.23 
39.55 2.277 52 81 4.9 3 14 1.2 0.18 
325 
( 
43.62 2.073 46 75 4.5 354 1.4 
Peak Search Report (5 Peaks, Max PIN = 10.0) 
[Z07413.MDl] Phenytoin+Catfeine: RESS (48.5C,4000psi); Sample weight=l.9mg <Psi=O.O> 
PEAK: 23-pts/Parabolic Filter, Threshold=3.0, Cutoff=0.1%, BG=3/ 1.0, Peak-Top=Summit 
0.21 
2-Theta d(A) BG Height 1% Area 1% FWHM 
11.96 7.395 137 642 100 9551 100 0.32 
21.46 4.137 195 270 42.1 628 6.6 0.14 
23.8 3.735 133 246 38.3 1274 13.3 0.19 
26.56 3.354 I 13 212 33 2269 23.8 0.39 
27.12 3.285 105 180 28 1847 19.3 
Peak Search Report (6 Peaks, Max PIN = I 3.6) 
[Z07414.MD!] Phenytoin+Catfeine : RESS (47C,8000psi); Sample weight=2.7mg <Psi=O.O> 
PEAK: 25-pts/Parabolic Filter, Threshold=3.0, Cutoff=O. l %, BG=3/ I .0, Peak-Top=Summit 
0.42 
2-Theta d(A) BG Height 1% Area 1% FWHM 
11.92 7.418 153 1019 100 17916 100 0.35 
21.44 4.142 237 363 35.6 1014 5.7 0.14 
23.78 3.738 155 351 34.4 2058 11.5 0.18 
26.54 3.356 118 274 26.9 4080 22.8 0.44 
27.08 3.29 124 228 22.4 2010 11.2 0.33 
28.38 3.142 103 145 14.2 412 2.3 
Peak Search Report (6 Peaks, Max PIN = 6.7) 
[Z074 l 5.MDI] Phenytoin+Catfeine : RESS (62.5C,2000psi); Sample weight=0.9mg <Psi=O.O> 
PEAK: 21-pts/Parabolic Filter, Threshold=3.0, Cutoff=O. l %, BG=3/ 1.0, Peak-Top=Summit 
0.17 
2-Theta d(A) BG Height !% Area 1% FWHM 
3.29 26.835 114 272 78.8 2185 48.7 0.24 
11.9 7.43 97 345 100 4490 100 
21.42 4.145 150 208 60.3 552 12.3 
23.8 3.735 Ill 181 52.5 1378 30.7 
26.56 3.354 96 160 46.4 1387 30.9 
27.12 3.286 94 149 43.2 793 17.7 
Peak Search Report (5 Peaks, Max PIN = 12.2) 
[Z07416.MDI] Phenytoin+Catfeine: RESS (62C,4000psi); Sample weight=l.4mg <Psi=O.O> 
PEAK: 23-pts/Parabolic Filter, Threshold=3.0, Cutoff=0.1 %, BG=3/ 1.0, Peak-Top=Summit 
0.31 
0.16 
0.33 
0.37 
0.25 
2-Theta d(A) BG Height 1% Area !% FWHM 
11.88 7.443 152 872 I 00 13068 I 00 0.31 
21.4 1 4.147 237 324 37.2 498 3.8 0.1 
23.78 3.738 147 278 31.9 1730 13.2 0.22 
26.54 
27.12 
3.356 
3.286 
119 
108 
247 
193 
Peak Search Report (6 Peaks, Max PIN = 14.5) 
28.3 
22.1 
3322 
2673 
25.4 
20.5 
[Z07417.MDI] Phenytoin+Catfeine: RESS (62C,8000psi); Sample weight=2.8mg <Psi=O.O> 
PEAK: 27-pts/Parabolic Filter, Threshold=3 .0, Cutotf=0.1 %, BG=3/ 1.0, Peak-Top=Summit 
326 
0.44 
0.53 
( 
2-Theta d(A) BG Height 1% Area 1% FWHM 
8.33 10.606 57 87 8.9 706 4.2 0.4 
11.86 7.455 72 975 100 16802 100 0.32 
21.42 4.146 118 157 16.1 266 1.6 0.12 
23.86 3.727 101 161 16.5 945 5.6 0.27 
26.6 3.348 96 246 25.2 4836 28.8 0.55 
27.08 3.29 103 195 20 2042 12.2 0.38 
Peak Search Report (7 Peaks, Max PIN = 3.4) 
[Z07418.M DI] Phenytoin+Caffeine: RESS (76.5C,2000psi); Sample weight=0.3mg <Psi=O.O> 
PEAK: 17-pts/Parabolic Filter, Threshold=3.0, Cutoff-=0.1 %, BG=3/ l.O, Peak-Top=Summit 
2-Theta d(A) BG Height 1% Area 1% FWHM 
4.2 21.027 107 146 57.3 539 57 0.23 
11.67 7.574 113 154 60.4 410 43.4 0.17 
11.82 7.479 114 157 61.6 470 49.7 0.19 
11.82 7.479 114 157 61.6 470 49.7 0.19 
21.42 4.144 179 255 100 613 64.9 0.14 
23.74 3.744 129 232 91 945 100 0.16 
27.26 3.269 86 124 48.6 137 14.5 0.06 
Peak Search Report (4 Peaks, Max PIN = 9.5) 
[Z07419.MD!] Phenytoin+Caffeine: RESS (76C,4000psi); Sample weight=l.4mg <Psi=O.O> 
PEAK: 23-pts/Parabolic Filter, Threshold=3.0, CutofT=O. l %, BG=3/l .O, Peak-Top=Summit 
2-Theta d(A) BG Height 1% Area 1% FWHM 
11.94 7.405 110 560 100 9578 100 0.36 
21.44 4.142 172 220 39.3 394 4.1 0.14 
23.82 3.733 133 210 37.5 799 8.3 0.18 
26.62 3.346 104 189 33.8 2226 23.2 0.45 
Peak Search Report ( 11 Peaks, Max PIN = 11.2) 
[Z07420.MDI] Phenytoin+Caffeine : RESS (75C,8000psi); Sample weight=2.2mg <Psi=O.O> 
PEAK: 21-pts/Parabolic Filter, Threshold=3.0, CutofT=0.1%, BG=3/ 1.0, Peak-Top=Summit 
2-Theta d(A) BG Height 1% Area 1% FWHM 
3.23 27.34 160 340 48.9 3353 28.6 0.32 
5.53 15.96 IOI 138 19.9 113 0.05 
8.65 10.212 82 116 16.7 517 4.4 0.26 
8.65 10.212 82 116 16.7 517 4.4 0.26 
11.94 7.406 106 695 100 11713 100 0.34 
16.79 5.275 176 233 33.5 734 6.3 0.22 
20.58 4.311 176 223 32.1 1196 10.2 0.43 
21.39 4.151 160 212 30.5 414 3.5 0.14 
23.82 3.733 117 185 26.6 1340 11.4 0.34 
26.64 3.343 99 236 34 4495 38.4 0.56 
27.16 3.28 112 175 25.2 1027 8.8 0.28 
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13. INDOMETHACIN + SALICYLIC ACID: 
13A. CHEMICAL STRUCTURE: 
0 
II 
3 ~ I I CH 0 W CH2 - C - OH 
~ CH3 
!-O-c1 
lndomethacin 
13B. SUMMARY OF RESS RECRYSTALLIATION: 
0 
I I 
C-OH 
A OH 
v 
Salicylic Acid 
COMPOSITION OF STARTING MIXTURE: 80% lndomethacin + 20% Salicylic acid 
CONTENTS OF REACTION VESSEL : 4.8g lndomethacin+ l .2g Salicylic acid (6g of blend) 
Experiment (P,T conditions) Weight collected,mg Collection time, min 
I [ 4 7C, 2000psi] 175 56 
2 [ 4 7C, 4000psi] 103 10 
3 [47.5C, 8000psi] 46 5 
4 [63C, 2000psi] 67 30 
5 [62.5C, 4000psi] 107 10 
6 [64C, 8000psi] 63 3 
7 [77C, 2000psi] 35 30 
8 [76C, 4000psi] 33 10 
9 [77C, 8000psi] 29 3 
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13.D.I. XRPD ANALYSIS: 
35.0 
30.0 
25.0 
20.0 
x10"3 
4SOO 
4000 
HOO ·· 
3000 
g 
8 2500 
~ 
~ 2000 
1000 
500 
a-Physical Mixture; b-[47"C, 2000psi]; c-[47°C, 4000psi}; d-[47 .5°C, 8000ps i] ;e -(63°C, 2000psi ] 
f-(62.5°C, 4000psi] ; g-(64°C, 8000psij ; h·(77°C. 2000psi j; i·(76°C, 4000psi]i·[77°C, 8000psij 
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13.D.2. XRPD ANALYSIS : 
Peak Search Report ( 41 Peaks, Max PIN = I 8.4) 
[Z07408.MDI] Pure lndomethacin, Sample weight= l5.2mg <Psi~.O> 
PEAK: 19-pts/Parabolic Filter, Threshold=3.0, Cutof'P0. 1%, BG=3/1.0, Peak-Top=Summit 
2-Theta d(A) BG Height 1% Area 1% FWHM 
9.8 9.014 44 117 8.1 764 6.3 0.18 
10.26 8.616 46 241 16.6 2697 22 .3 0.24 
11.7 
12.88 
15.85 
16.76 
17.08 
17.4 
18.64 
19.42 
19.68 
20.5 
20.96 
21.47 
21.9 
22.94 
23.3 
24.16 
25.79 
26.29 
26.7 
27 
27.54 
28 .37 
29.42 
30.52 
30.86 
3 1.68 
32.76 
33.66 
34.28 
35 
35.52 
35.8 
37.56 
39.72 
41.66 
43.4 1 
43.9 
47.56 
48.78 
7.557 
6.868 
5.587 
5.285 
5.1 87 
5.093 
4.757 
4.567 
4.507 
4.329 
4.235 
4.136 
4.055 
3.873 
3.8 15 
3.68 1 
3.452 
3.388 
3.336 
3.3 
3.236 
3.144 
3.033 
2.927 
2.895 
2.822 
2.732 
2.661 
2.613 
2.562 
2.525 
2.506 
2.393 
2.267 
2. 166 
2.083 
2.061 
1.91 
1.865 
48 
56 
86 
IOI 
105 
115 
130 
129 
130 
123 
119 
11 3 
101 
88 
91 
82 
75 
75 
9 1 
73 
78 
71 
70 
64 
62 
59 
57 
55 
53 
49 
46 
47 
42 
42 
42 
41 
41 
40 
33 
1450 
185 
126 
725 
588 
3 16 
287 
323 
900 
345 
303 
152 
775 
199 
183 
380 
120 
181 
372 
206 
325 
149 
553 
152 
125 
89 
93 
158 
106 
128 
77 
11 5 
122 
70 
72 
81 
72 
74 
63 
330 
100 
12.8 
8.7 
50 
40.6 
21.8 
19.8 
22.3 
62.1 
23.8 
20.9 
10.5 
53.4 
13.7 
12.6 
26.2 
8.3 
12.5 
25.7 
14.2 
22.4 
10.3 
38.l 
10.5 
8.6 
6. 1 
6.4 
10.9 
7.3 
8.8 
5.3 
7.9 
8.4 
4.8 
5.6 
5.1 
4.3 
12078 
1238 
373 
7870 
6942 
2141 
1473 
3508 
7497 
1561 
1575 
899 
6425 
1195 
11 77 
3208 
674 
1959 
4603 
1727 
1951 
675 
4847 
1164 
742 
198 
231 
822 
994 
1339 
340 
720 
974 
556 
321 
861 
253 
364 
330 
100 
10.3 
3.1 
65.2 
57.5 
17.7 
12.2 
29 
62. 1 
12.9 
13 
7.4 
53.2 
9.9 
9.7 
26.6 
5.6 
16.2 
38. 1 
14.3 
16.2 
5.6 
40.1 
9.6 
6. 1 
1.6 
1.9 
6.8 
8.2 
II.I 
2.8 
6 
8. 1 
4.6 
2.7 
7. 1 
2.1 
3 
2.7 
0.15 
0.16 
0.16 
0.21 
0.24 
0.18 
0.16 
0.31 
0.17 
0.12 
0.15 
0.39 
0.16 
0.18 
0.22 
0.18 
0.25 
0.31 
0.28 
0.22 
0.13 
0.15 
0. 17 
0.22 
0.2 
0.11 
0.11 
0.14 
0.32 
0.29 
0.19 
0.18 
0.21 
0.34 
0.18 
0.37 
0. 14 
0.18 
0.19 
( 
Peak Search Report (21 Peaks, Max PIN = 93.6) 
[207075.MD!] Pure Salicylic acid, afier 2 min Grinding <Psi=O.O> 
PEAK: 19-pts!Parabolic Filter, Threshold=3.0, Cutoff=0.1 %, BG=3/ l .O, Peak-Top=Surnmit 
2-Theta d{A) BG Height 1% Area 1% FWHM 
10.98 8.051 4 1 35122 100 296650 100 0.14 
15.28 5.793 4 1 1085 3. 1 13023 4.4 0.2 1 
15.74 5.625 46 667 1.9 668 1 2.3 0.18 
17.22 5.145 44 11620 33.1 142907 48.2 0.21 
17.5 5.063 44 1237 3.5 30708 10.4 0.44 
17.96 4.935 37 159 0.5 1286 0.4 0. 18 
19.62 4.52 36 259 0.7 2584 0.9 0.2 
25.26 3.523 49 2452 39357 13.3 0.28 
28.04 3. 179 59 1790 5. 1 2 1209 7.1 0.2 1 
28.7 3. 108 74 1172 3.3 14462 4.9 0.22 
30.68 2.9 12 59 886 2.5 14469 4.9 0.3 
3 1.82 2.81 53 294 0.8 2853 1 0.2 
32.76 2.731 61 168 0.5 1013 0.3 0.16 
33.34 2.685 48 244 0.7 3240 I.I 0.28 
33.7 2.657 53 245 0.7 2968 0.26 
34.86 2.571 52 161 0.5 1069 0.4 0.17 
35.52 2.525 46 366 1 4493 1.5 0.24 
38 2.366 48 226 0.6 2645 0.9 0.25 
39.92 2.256 46 289 0.8 5969 0.42 
44 2.056 46 149 0.4 148 1 0.5 0.24 
46.78 1.94 45 25 1 0.7 3900 1.3 0.32 
Peak Search Report ( 46 Peaks, Max PIN = 17 .6) 
[207407.MDI] Indornethacin+ Salicylic acid; Physical Mixture; Sample weight=19.9mg 
<Psi=O.O> 
PEAK: 19-pts/Parabolic Fi lter, Threshold=3.0, Cutoff=O. l %, BG=3/ 1.0, Peak-Top=Summit 
2-Theta d{A) BG Height 1% Area 1% FWHM 
9.93 8.9 54 117 7.9 295 2.6 0.08 
10.26 8.615 61 217 14.7 1936 16.8 0.21 
11.03 8.012 61 565 38.3 4748 41.3 0.16 
11.72 7.546 78 1071 72.5 8283 72 0.14 
12.88 6.867 52 215 14.6 1633 14.2 0. 17 
15.4 1 5.743 76 138 9.3 694 6 0.19 
15.76 5.617 81 194 13.1 940 8.2 0.14 
16.76 5.284 101 612 41.4 5729 49.8 0.19 
17.1 5.181 103 710 48.1 9343 81.2 0.26 
17.3 5.121 112 528 35.7 8605 74.8 0.35 
18.64 4.755 125 232 15.7 1256 10.9 0.2 
19.34 4.585 128 3 12 2 1.1 5804 50.4 0.54 
19.68 4.507 126 1477 100 11509 100 0.14 
20.46 4.337 120 197 13.3 785 6.8 0.17 
20.92 4.242 114 323 21.9 1554 13.5 0.13 
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21.44 4.14 108 180 12.2 1056 9.2 0.25 
21.9 4.055 IOI 881 59.6 7863 68.3 0.17 
23.03 3.858 94 492 33.3 3446 29.9 0.15 
23.3 3.815 95 198 13.4 1227 10.7 0.2 
23.8 3.736 86 136 9.2 1102 9.6 0.37 
24.09 3.692 86 219 14.8 1510 13.1 0.19 
25.38 3.507 78 274 18.6 2920 25.4 0.25 
25.88 3.439 83 127 8.6 86 1 7.5 0.33 
26.32 3.384 83 218 14.8 1125 9.8 0.14 
26.7 3.336 82 416 28.2 4486 39 0.23 
27 3.299 79 275 18.6 1960 17 0.17 
27.68 3.22 76 231 15 .6 1638 14.2 0.18 
28.18 3.164 77 123 8.3 705 6.1 0.26 
28.42 3.138 75 163 II 1027 8.9 0.2 
28.8 3.097 73 157 10.6 1253 10.9 0.25 
29.42 3.033 69 554 37.5 4828 41.9 0.17 
30.52 2.926 65 359 24.3 3490 30.3 0.2 
30.9 2.892 64 136 9.2 1382 12 0.33 
32.81 2.727 62 96 6.5 83 0.7 0.04 
33.1 1 2.704 64 99 6.7 132 I.I 0.06 
33.66 2.66 68 127 8.6 499 4.3 0.14 
34.22 2.618 61 177 12 1785 15.5 0.26 
34.57 2.593 68 101 6.8 690 6 0.36 
35.51 2.526 47 89 6 738 6.4 0.3 
35.86 2.502 46 95 6.4 843 7.3 0.29 
36.78 2.442 45 72 4.9 229 0.14 
37.58 2.391 44 114 7.7 1367 11.9 0.33 
38.16 2.357 47 75 5.1 201 1.7 0.12 
39.72 2.268 48 81 5.5 459 4 0.24 
43.28 2.089 49 86 5.8 218 1.9 0.1 
44.12 2.051 40 68 4.6 375 3.3 0.23 
Peak Search Report (16 Peaks, Max PIN = 12.3) 
[Z07398.MDl) lndomethacin+ Salicylic acid: RESS ; Sample weight=l.3mg 
<Psi~.O> 
PEAK: 17-pts/Parabolic Filter, Threshold=3.0, CutofT=0.1%, BG=3/ l.O, Peak-Top=Summit 
2-Theta d(A) BG Height 1% Area 1% FWHM 
11.04 8.008 76 754 100 9348 100 0.23 
15.36 5.764 130 184 24.4 449 4.8 0.14 
17.32 5.1 15 182 598 79.3 5046 54 0.21 
17.62 5.029 171 255 33.8 3360 35.9 0.68 
18.05 4.911 193 251 33.3 600 6.4 0.18 
19.44 4.562 176 232 30.8 1667 17.8 0.51 
19.78 4.485 185 283 37.5 892 9.5 0.15 
21.41 4.146 153 209 27.7 440 4.7 0.13 
23.84 3.73 118 194 25.7 540 5.8 0.12 
25.42 3.501 110 645 85.5 7173 76.7 0.23 
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28. 12 3. 17 90 140 18.6 406 4.3 0. 14 
28.88 3.089 85 238 31.6 1767 18.9 0.2 
30.78 2.903 76 160 21.2 1579 16.9 0.32 
36.84 2.437 5 1 80 10.6 246 2.6 0.1 4 
38.1 2.36 49 88 11.7 48 1 5. 1 0.2 1 
40.l 2.247 46 85 11.3 672 7.2 0.29 
Peak Search Report (20 Peaks, Max PIN = 13.7) 
[Z07399.MDl] lndomethacin+ Salicylic acid: RESS ; Sample weight=5.3mg 
<Psi=O.O> 
PEAK: 19-pts/Parabolic Filter, Threshold=3.0, Cutoff=0. 1%, BG=3/1.0, Peak-Top=Summit 
2-Theta d(A) BG Height 1% Area 1% FWHM 
8.44 10.472 89 129 13.4 294 2.8 0. 12 
11.04 8.007 112 965 100 10430 100 0.21 
15.36 5.764 178 263 27.3 1327 12.7 0.27 
15.86 5.584 19 1 253 26.2 96 1 9.2 0.26 
17.32 5.116 253 818 84.8 6585 63 . l 0.2 
17.64 5.025 245 356 36.9 3851 36.9 0.59 
18.06 4.907 276 356 36.9 822 7.9 0. 17 
19.74 4.494 249 360 37.3 1486 14.2 0.23 
21.39 4. 15 1 196 278 28.8 1036 9.9 0.2 1 
23.84 3.73 136 253 26.2 1269 12.2 0. 18 
24.97 3.564 124 186 19.3 792 7.6 0.22 
25.38 3.506 119 74 1 76.8 8584 82.3 0.23 
28.16 3. 166 90 150 15.5 8 17 7.8 0.23 
28.88 3.089 94 267 27.7 2078 19.9 0.2 
30.76 2.904 81 186 19.3 1752 16.8 0.28 
33.87 2.644 66 102 10.6 528 5. 1 0.25 
35.9 1 2.498 58 88 9. 1 206 0. 12 
36.89 2.434 55 88 9. 1 370 3.5 0. 19 
38. 16 2.356 54 103 10.7 538 5.2 0. 19 
40.09 2.247 57 99 10.3 586 5.6 0.24 
Peak Search Report (7 Peaks, Max PIN = 8.6) 
[Z07400.MD l) lndomethacin+ Salicylic acid: RESS(47.5C,8000psi) ; Sample weight=l mg 
<Psi=O.O> 
PEAK: 17-pts/Parabolic Fi lter, Threshold=3.0, Cutoff=0. 1%, BG=3/1.0, Peak-Top=Summit 
2-Theta d(A} BG Height 1% Area 1% FWHM 
11.02 8.022 65 4 18 100 3567 100 0.17 
12.52 7.067 63 95 22.7 239 6.7 0.13 
17.3 5.122 133 328 78.5 1870 52.4 0. 16 
19.75 4.492 139 183 43.8 718 20. 1 0.28 
25.34 3.5 11 93 293 70.1 250 1 70. I 0.2 1 
28.8 3.097 80 148 35.4 600 16.8 0. 15 
30.76 2.904 7 1 111 26.6 484 13.6 0.2 1 
Peak Search Report ( 15 Peaks, Max PIN = 9.9) 
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[Z07401.MD!] Indomethacin+ Salicylic acid: RESS(63C,2000psi); Sample weight=4. lmg 
<Psi=O.O> 
PEAK: 19-pts/Parabolic Filter, Threshold=3.0, CutofT=0.1 %, BG=3/ I.O, Peak-Top=Summit 
2-Theta d(A) BG Height 1% Area 1% FWHM 
11.04 8.008 96 569 93.7 5689 JOO 0.2 
15.43 5.739 151 204 33.6 211 3.7 0.07 
17.34 5.111 212 607 100 4288 75.4 0.18 
19.76 4.489 202 274 45.1 1750 30.8 0.41 
21.4 4.149 166 216 35.6 596 10.5 0.2 
23.8 3.735 124 191 31.5 737 13 0.19 
25.4 3.504 99 426 70.2 5040 88.6 0.26 
28. 14 3.168 87 146 24.1 495 8.7 0.14 
28.84 3.094 82 200 32.9 1453 25.5 0.21 
30.8 2.901 69 142 23.4 1487 26.I 0.35 
36.76 2.443 48 76 12.5 276 4.9 0.17 
38. 19 2.354 45 78 12.9 537 9.4 0.28 
40.07 2.249 50 90 14.8 187 3.3 0.08 
40.07 2.249 50 90 14.8 187 3.3 0.08 
43 .27 2.089 42 70 11.5 344 6 0.2 1 
Peak Search Report (14 Peaks, Max PIN = 10.5) 
[Z07402.MD!] Indomethacin+ Salicylic acid: RESS(62.5C,4000psi) ; Sample weight=2.9mg 
<Psi=0.0> 
PEAK: 17-pts/Parabolic Filter, Threshold=3.0, Cutoff--0.1%, BG=3/ 1.0, Peak-Top=Sumrnit 
2-Theta d{A) BG Height 1% Area 1% FWHM 
11.04 8.009 95 620 100 5987 100 0.19 
11.63 7.603 96 134 21.6 286 4.8 0.13 
15.84 5.591 158 207 33.4 595 9.9 0.21 
17.32 5.116 194 540 87.1 4445 74.2 0.22 
17.58 5.041 203 267 43. I 1563 26.I 0.42 
19.74 4.494 207 273 44 515 8.6 0.13 
21.38 4.152 159 236 38.1 793 13.2 0.18 
23.8 3.736 126 222 35.8 696 11.6 0.12 
25.34 3.5 12 IOI 449 72.4 50 17 83.8 0.25 
28.12 3. 17 87 132 21.3 514 8.6 0. 19 
28.85 3.092 83 190 30.6 1336 22.3 0.21 
30.78 2.903 73 155 25 1080 18 0.22 
38. 12 2.359 45 84 13.5 507 8.5 0.22 
40.11 2.246 44 75 12.1 521 8.7 0.29 
Peak Search Report ( 13 Peaks, Max PIN = 8.1) 
(Z07403.MD!] lndomethacin+ Salicylic acid: RESS(64C,8000psi) ; Sample weight=2.7mg 
<Psi=O.O> 
PEAK: 19-pts/Parabolic Filter, Threshold=3.0, CutofT=0.1%, BG=3/ 1.0, Peak-Top=Summit 
2-Theta d(A) BG Height 1% Area 1% FWHM 
11.02 8.024 129 485 86.8 4004 100 0.19 
11.63 7.603 133 190 34 577 14.4 0.17 
13.02 6.793 135 178 31.8 229 5.7 0.09 
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17.31 5.117 283 559 100 3146 78.6 0.19 
19.72 4.498 276 342 61.2 1764 44.1 0.45 
21.39 4.151 224 300 53.7 895 22.4 0.2 
21.86 4.063 201 252 45 . I 244 6.1 0.08 
23.82 3.733 138 263 47 1763 44 0.24 
25.36 3.509 123 366 65.5 2961 74 0.21 
28.8 3.097 95 179 32 914 22.8 0.18 
30.73 2.907 86 130 23 .3 371 9.3 0.14 
35.73 2.511 57 86 15.4 457 11.4 0.27 
38.24 2.352 54 83 14.8 537 13.4 0.31 
Peak Search Report (10 Peaks, Max PIN = 3.6) 
[Z07404.MD!] lndomethacin+ Salicylic acid: RESS(77C,2000psi) ; Sample weight=0.2mg 
<Psi=0.0> 
PEAK: 15-pts/Parabolic Filter, Threshold=3.0, Cutoff=O. I%, BG=3/ l .O, Peak-Top=Summit 
2-Theta d(A) BG Height 1% Area 1% FWHM 
11.06 7.996 107 212 67.l 1288 100 0.21 
15.I 5.861 152 204 64.6 203 15.8 0.07 
16.I 5.5 186 238 75.3 253 19.6 0.08 
16.1 5.5 186 238 75.3 253 19.6 0.08 
17.32 5.115 227 316 JOO 647 50.2 0.12 
21.41 4.146 177 232 73.4 342 26.6 0.11 
23.84 3.73 122 211 66.8 1137 88.3 0.22 
25.36 3.509 109 192 60.8 726 56.4 0.15 
28.9 3.087 88 125 39.6 247 19.2 0.11 
35.5 2.526 52 80 25.3 250 19.4 0.15 
Peak Search Report (10 Peaks, Max PIN = 3.5) 
[Z07405 .MDI] lndomethacin+ Salicylic acid: RESS(76C,4000psi) ; Sample weight=0.3mg 
<Psi=O.O> 
PEAK: 17-pts/Parabolic Filter, Threshold=3.0, CutotT=O. I%, BG=3/l .O, Peak-Top=Summit 
2-Theta d(A} BG Height 1% Area 1% FWHM 
II 8.035 100 198 66.4 955 100 
17.11 5.178 192 241 80.9 596 62.4 
17.28 5.128 198 298 100 853 89.3 
18.68 4.746 212 273 91.6 703 73.6 
18.68 4 .746 212 273 91.6 703 73.6 
21.49 4.132 160 205 68.8 501 52.5 
23.78 3.738 121 188 63.1 845 88.5 
24.05 3.697 119 160 53.7 819 85.8 
25.38 3.507 104 187 62.8 885 92.7 
28.12 3.171 82 119 39.9 809 84.7 
Peak Search Report (7 Peaks, Max PIN= 5.7) 
[Z07406.MDl] lndomethacin+Salicylic acid: RESS(77C,8000psi); Sample weight=l .7mg 
<Psi=O.O> 
PEAK: 23-pts/Parabolic Filter, Threshold=3.0, Cutoff=O. I%, BG=3/ I .0, Peak-Top=Summit 
0.17 
0.21 
0.15 
0.2 
0.2 
0.19 
0.21 
0.34 
0.18 
0.37 
2-Theta d(A) BG Height 1% Area 1% FWHM 
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7.68 11.496 79 11 4 29.8 366 6.6 0. 18 
18.34 4.833 185 232 60.6 792 14.3 0.29 
19.47 4.556 19 1 256 66.8 1145 20.7 0.3 
19.47 4.556 19 1 256 66.8 11 45 20.7 0.3 
2 1.8 4.074 160 383 100 5536 100 0.42 
23.84 3.73 130 202 52.7 2618 47.3 0.62 
24.2 3.675 121 208 54.3 2970 53.6 0.58 
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14. NAPROXEN +a-NAPHTHALENE ACETIC ACID: 
l4A. CHEMICAL STRUCTURE: 
CH H 0 3 ~ ; II 0 
II 
c~o 
O)C-C - OH ~ ~-C-OH 
~ 
a-Naphthalene acetic acid 
14B. SUMMARY OF RESS RECRYSTALLIATION : 
COMPOSITION OF STARTING MIXTURE: 80% Naproxen + 20% a-Naphthalene acetic ac id 
CONTENTS OF REACTION VESSEL: 4.8g Naproxen+ J .2g a-Naphthalene acetic acid (6g of blend) 
Experiment IP,T conditions I Weight collected,mg Collection time, min 
I [SOC, 2000psi] 28 
2 [49.5C, 4000psi] 69 
3 [50.5C, 8000psi] 56 
4 [63C, 2000psi] 31 
5 [62C, 4000psi] 60 
6 [63C, 8000psi] 57 
7 [82C, 2000psi] 37 
8 [78C, 4000psi] 102 
9 [76C, 8000psi] 280 
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45 
JO 
45 
30 
JO 
30 
30 
20 
14.D.l. XRPD ANALYSIS: 
2000 . 
1500 . 
IZ073S7 MDI] Phy:i?J mlxturt of Naproicen+alp~a-NM <Psl-0.0> 
10 •o 
2-Thuan 
350 
IZ07lSl.MOIJ Naproxtn+•lpha·NM : RESS {62C, 4000psl) <Psl•O.O> 
. . 
IZ07lS2.MOIJ .NaproxtMalpha-NM ; R.£SS_ {63C. 2000psl) .cPsl-0.0> 
1207351 .MOIJ Nl4)nlXtn+alpM.NM ; RESS (50.SC, 8000psl) <~0.0> 
(Z07l50.MOI! NaproxenuJpM-NM : R~ (49.SC, 4000psl) <Psl-0.0> 
10 20 30 40 
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14.D.2. XRPD ANALYSIS: 
Peak Search Report (21 Peaks, Max PIN = 15.9) 
[Z07349.MDI] Pure Naproxen <Psi=O.O> 
PEAK: 19-pts/Parabolic Filter, Threshold=3.0, Cutoff=0.1 %, BG=3/1.0, Peak-Top=Summit 
2-Theta d(A) BG Height 1% Area 1% FWHM 
6.68 13.221 92 688 47.6 7047 52.1 0.2 
12.72 6.953 126 521 36. l 4079 30.2 0.18 
13.42 6.593 132 217 15 1107 8.2 0.22 
16.94 5.231 203 413 28.6 3416 25.3 0.28 
18.08 4.902 236 348 24. 1 1038 7.7 0.16 
19.08 4.647 239 1444 100 13519 100 0.19 
20.06 4.422 223 289 20 1197 8.9 0.31 
20.46 4.337 211 470 32.5 3810 28.2 0.25 
21.43 4.143 185 269 18.6 298 2.2 0.06 
22.38 3.969 168 373 25.8 2762 20.4 0.23 
22.7 3.914 162 551 38.2 5718 42.3 0.25 
23.84 3.73 136 436 30.2 4477 33.1 0.25 
24.06 3.696 133 273 18.9 1798 13.3 0.22 
27.5 3.241 IOI 243 16.8 2 11 3 15.6 0.25 
27.94 3.191 100 238 16.5 1972 14.6 0.24 
28.7 3. 108 98 188 13 1296 9.6 0.24 
30 2.976 83 138 9.6 563 4.2 0.17 
31.49 2.838 73 123 8.5 1061 7.8 0.36 
33.79 2.65 70 102 7.1 3 15 2.3 0.17 
37.36 2.405 56 86 6 123 0.9 0.07 
38.81 2.319 56 96 6.6 427 3.2 0.18 
Peak Search Report (22 Peaks, Max PIN = 11.7) 
[Z07348.MD!] Pure alpha-naphthalene acetic acid <Psi=O.O> 
PEAK: 19-pts/Parabolic Filter, Threshold=3.0, CutofT=0.1%, BG=3/ l.O, Peak-Top=Summit 
2-Theta d(A) BG Height 1% Area 1% FWHM 
6.96 12.686 92 570 69.4 8370 86.5 0.3 
11.84 7.468 117 549 66.9 6034 62.3 0.24 
13.96 6.339 148 82 1 100 9680 100 0.24 
18.04 4.914 280 659 80.3 6233 64.4 0.28 
18.68 4.747 268 649 79 6278 64.9 0.28 
19.68 4.508 250 468 57 3628 37.5 0.28 
21.42 4.146 195 292 35.6 1048 10.8 0.18 
22.06 4.026 188 435 53 5730 59.2 0.39 
22.3 3.984 188 651 79.3 7355 76 0.27 
22.98 3.867 184 345 42 2695 27.8 0.28 
23.22 3.827 175 309 37.6 2879 29.7 0.37 
23 .78 3.739 162 368 44.8 1907 19.7 0.16 
24.5 3.63 139 383 46.7 3327 34.4 0.23 
25.72 3.461 11 3 156 19 33 1 3.4 0.13 
27.34 3.26 105 150 18.3 561 5.8 0.21 
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27.84 3.202 102 207 25.2 1826 18.9 0.3 
29.59 3.016 91 128 15.6 293 3 0.13 
30.22 2.955 88 130 15.8 368 3.8 0.15 
32.42 2.759 73 167 20.3 1275 13.2 0.23 
35.01 2.561 69 108 13.2 368 3.8 0.16 
37.02 2.426 64 96 I 1.7 725 7.5 0.39 
37.44 2.4 58 91 I I.I 896 9.3 0.46 
Peak Search Report (24 Peaks, Max PIN = 14.0) 
[Z07357.MDl) Physical nlixture ofNaproxen+alpha-NAA <Psi=O.O> 
PEAK: 19-pts/Parabolic Filter, Threshold=3.0, CutofT=0.1 %, BG=3/ J.O, Peak-To~Sununit 
2-Theta d{A) BG Height 1% Area 1% FWHM 
6.68 13.219 88 72 1 58.9 94 16 79.9 0.25 
I 1.84 7.467 108 199 16.2 470 4 0.09 
12.74 6.943 I 19 459 37.5 3960 33.6 0.2 
13.48 6.563 128 232 18.9 1498 12.7 0.24 
13.94 6.347 132 211 17.2 696 5.9 0.15 
16.86 5.253 199 388 3 1.7 3044 25.8 0.27 
18.1 4.898 239 388 31.7 1615 13.7 0. 18 
18.66 4.751 237 320 26.1 2361 20 0.48 
19.1 4.643 245 1225 JOO I 1788 100 0.2 
20.05 4.425 228 292 23.8 804 6.8 0.21 
20.48 4.333 2 18 457 37.3 2833 24 0.2 
21.44 4.142 184 255 20.8 440 3.7 0.11 
22.4 3.966 159 377 30.8 4747 40.3 0.37 
22.7 3.914 154 503 41.1 6039 51.2 0.29 
23.84 3.73 133 423 34.5 4589 38.9 0.27 
24.08 3.693 128 272 22.2 2847 24.2 0.34 
27.53 3.237 103 225 18.4 1936 16.4 0.27 
27.94 3.191 95 238 19.4 1944 16.5 0.23 
28.66 3.1 12 JOO 181 14.8 I 186 JO.I 0.25 
29.96 2.98 80 154 12.6 53 I 4.5 0.12 
3 1.4 2.846 78 120 9.8 552 4.7 0.22 
33.78 2.652 68 103 8.4 235 0.11 
38.78 2.32 56 89 7.3 343 2.9 0.18 
45.68 1.985 40 75 6.1 369 3.1 0.18 
Peak Search Report (24 Peaks, Max PIN = 8.9) 
[Z07350.MDI) Naproxen+alpha-NAA : RESS (49.5C, 4000psi) <Psi=O.O> 
PEAK: 19-pts/Parabolic Filter, Threshold=3.0, CutofT=O. I%, BG=3/ J .0, Peak-Top=Sununit 
2-Theta d{A) BG Height 1% Area 1% FWHM 
3. 12 28.3 1 157 590 100 10133 100 0.4 
3.65 24.201 142 316 53.6 1897 18.7 0. 19 
6.69 13.21 101 217 36.8 3873 38.2 0.57 
6.86 12.867 102 234 39.7 3603 35.6 0.46 
7 12.616 JOI 257 43.6 3604 35.6 0.39 
I 1.82 7.48 125 304 51.5 2302 22.7 0.22 
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12.74 6.94 140 201 34.1 476 4.7 0.13 
13.96 6.339 157 405 68.6 3446 34 0.24 
17.92 4.945 280 444 75.3 1913 18.9 0.2 
18.74 4.731 308 419 71 1788 17.6 0.27 
19.06 4.652 296 521 88.3 4159 41 0.31 
19.67 4.51 280 388 65.8 1439 14.2 0.23 
20.51 4.326 237 303 51.4 574 5.7 0.15 
21.42 4.144 218 311 52.7 638 6.3 0. 12 
22.1 4.019 224 312 52.9 1565 15.4 0.3 
22.3 3.983 208 421 71.4 4637 45.8 0.37 
22.98 3.867 216 269 45.6 470 4.6 0.15 
23 .8 3.736 168 298 50.5 1736 17.1 0.23 
24.5 3.63 154 221 37.5 619 6.1 0.16 
27.35 3.258 124 167 28.3 141 1.4 0.06 
27.86 3.2 102 167 28.3 2319 22.9 0.61 
28.69 3.109 100 142 24.1 Ill I.I 0.04 
30.99 2.883 79 114 19.3 480 4.7 0.23 
32.31 2.769 78 119 20.2 550 5.4 0.23 
Peak Search Report (22 Peaks, Max PIN = 5.6) 
[Z0735 l .MD!] Naproxen+alpha-NAA : RESS (50.5C, 8000psi) <Psi=0.0> 
PEAK: 2 1-pts/Parabolic Filter, Threshold=3.0, CutofT=0.1%, BG=3/ 1.0, Peak-Top=Summit 
2-Theta d(A) BG Height 1% Area 1% FWHM 
6.76 13.066 IOI 216 44.9 3007 64.9 0.44 
7 12.622 99 251 52.2 3079 66.5 0.34 
11.86 7.455 119 242 50.3 1672 36.1 0.23 
12.76 6.933 128 209 43.5 891 19.2 0.19 
13.57 6.519 139 186 38.7 719 15.5 0.26 
13.94 6.347 147 359 74.6 2806 60.6 0.23 
17.98 4.928 286 394 8/.9 999 21.6 0.16 
18.68 4.747 276 395 82.1 4244 91.6 0.61 
19.12 4.638 274 481 100 4438 95.8 0.36 
20.53 4.323 229 293 60.9 321 6.9 0.09 
21.4 1 4.147 194 264 54.9 440 9.5 0.11 
22 4.036 187 258 53.6 1505 32.5 0.36 
22.36 3.973 175 355 73.8 4631 100 0.44 
22.64 3.924 168 247 51.4 3761 81.2 0.81 
23 3.864 188 252 52.4 472 10.2 0.1 3 
23 .8 3.735 150 299 62.2 1499 32.4 0.17 
24.52 3.628 135 192 39.9 520 11.2 0.16 
27.34 3.26 99 145 30.1 1600 34.5 0.59 
27.6 3.23 IOI 141 29.3 1313 28.4 0.56 
27.9 3.195 100 153 31.8 1368 29.5 0.44 
32.32 2.768 74 120 24.9 510 II 0.19 
32.47 2.755 73 108 22.5 489 10.6 0.24 
Peak Search Report ( 12 Peaks, Max PIN = 3.8) 
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[Z07352.MDI) Naproxen+alpha-NAA : RESS (63C, 2000psi) <Psi=0.0> 
PEAK: 21-pts/Parabolic Filter, Threshold=3.0, Cutotf=0.1%, BG=3/1.0, Peak-Top=Summit 
2-Theta d(A) BG Height 1% Area 1% FWHM 
6.7 13.176 106 189 48.3 2070 56.1 0.42 
6.94 12.722 109 201 51.4 1560 42.3 0.29 
11.78 7.503 136 218 55.8 663 18 0.14 
13.96 6.339 162 290 74.2 1722 46.7 0.23 
17.94 4.94 306 384 98.2 603 16.3 0.13 
18.36 4.828 288 359 91.8 3691 100 0.88 
18.64 4.755 291 378 96.7 3658 99.1 0.71 
19.08 4.649 305 391 100 1538 41.7 0.3 
21.47 4.135 221 289 73 .9 353 9.6 0.09 
22.06 4.026 191 250 63.9 1188 32.2 0.34 
22.35 3.974 182 258 66 1465 39.7 0.33 
23.76 3.741 152 272 69.6 1411 38.2 0.2 
Peak Search Report (21 Peaks, Max PIN = 4.6) 
[Z07353.MDJ) Naproxen+alpha-NAA : RESS (62C, 4000psi) <Psi=O.O> 
PEAK: 21-pts/Parabolic Filter, Threshold=3.0, Cutotf=0.1%, BG=3/ l.O, Peak-Top=Summit 
2-Theta d(A) BG Height 1% Area 1% FWHM 
6.7 13.181 115 220 44.3 2320 61.9 0.38 
6.94 12.719 111 206 41.4 2679 71.5 0.48 
10.67 8.287 121 165 33.2 302 8.1 0.12 
11.81 7.49 130 218 43.9 897 23.9 0.17 
12.7 6.962 138 230 46.3 913 24.4 0.17 
13.55 6.532 149 195 39.2 648 17.3 0.24 
13.92 6.356 157 302 60.8 1776 47.4 0.21 
17.98 4.93 303 375 75.5 567 15. / 0.13 
18.75 4.728 307 372 74.8 1393 37.2 0.36 
19.1 4.643 293 497 100 3748 100 0.31 
20.02 4.431 269 324 65.2 759 20.3 0.23 
20.49 4.33 252 307 61.8 406 10.8 0.13 
21.43 4.144 214 292 58.8 442 11.8 0.1 
22.34 3.977 190 293 59 1812 48.3 0.3 
23.84 3.73 151 305 61.4 2047 54.6 0.23 
24.43 3.64 142 185 37.2 276 7.4 0.11 
27.42 3.25 99 147 29.6 1082 28.9 0.38 
27.86 3.199 98 149 30 974 26 0.32 
28.62 3.116 93 142 28.6 447 11.9 0.16 
Peak Search Report ( 13 Peaks, Max PIN = 6.5) 
[Z07354.MDI) Naproxen+alpha-NAA : RESS (63C, 8000psi) <Psi=0.0> 
PEAK: 17-pts/Parabolic Filter, Threshold=3.0, Cutotf=O. I%, BG=3/J .0, Peak-Top=Summit 
2-Theta d(A) BG Height 1% Area 1% FWHM 
3.1 28.493 162 431 82.6 6305 100 0.4 
3.27 27.003 155 370 70.9 3712 58.9 0.29 
6.73 13. 114 123 212 40.6 1484 23.5 0.28 
342 
( 7.04 12.552 121 162 31 679 10.8 0.28 
12.76 6.935 159 216 41.4 405 6.4 0.12 
13 .96 6.337 171 251 48.l 535 8.5 0.11 
18.69 4.744 308 375 71.8 2637 41.8 0.67 
19.08 4.647 311 522 100 2761 43.8 0.22 
20.11 4.411 276 338 64.8 656 10.4 0.18 
21.38 4.152 236 297 56.9 216 3.4 0.06 
22.38 3.969 189 247 47.3 11 83 18.8 0.35 
23 .78 3.738 154 316 60.5 1536 24.4 0.16 
47.67 1.906 38 63 12.1 167 2.6 0.11 
Peak Search Report ( 11 Peaks, Max PIN = 5.8) 
[Z07355.MDIJ Naproxen+alpha-NAA : RESS (78C, 4000psi) <Psi=O.O> 
PEAK: 23-pts/Parabolic Filter, Threshold=3.0, Cutoff=O. l %, BG=3/ l .O, Peak-Top=Summit 
2-Tbeta d(A) BG Height 1% Area 1% FWHM 
3.28 26.934 149 373 JOO 4020 JOO 0.3/ 
6.68 13.212 87 175 46.9 955 23 .8 0.18 
11.8 7.497 84 124 33.2 104 2.6 0.04 
12.69 6.968 94 141 37.8 233 5.8 0.08 
19.l 4.643 181 317 85 1832 45.6 0.23 
22.3 3.983 135 201 53 .9 923 23 0.24 
22.44 3.959 136 192 5 1.5 908 22.6 0.28 
22.64 3.924 128 184 49.3 1302 32.4 0.4 
23.8 3.736 117 190 50.9 898 22.3 0.21 
24.17 3.679 110 156 41.8 556 13.8 0.21 
27.36 3.257 86 131 35.I 700 17.4 0.26 
Peak Search Report (13 Peaks, Max PIN = 6.0) 
[Z07356.MDl] Naproxen+alpha-NAA : RESS (76C, 8000psi) <Psi=O.O> 
PEAK: 21-pts/Parabolic Filter, Threshold=3.0, Cutoff=0. 1%, BG=3/ l.O, Peak-Top=Summit 
2-Theta d(A) BG Height 1% Area 1% FWHM 
3.4 25.983 162 348 66.5 483J JOO 0.44 
3.54 24.948 153 332 63.5 42J7 87.3 0.4 
3.64 24.25 J4/ 3J8 60.8 3628 75./ 0.35 
3.83 23.067 J24 303 57.9 3045 63 0.29 
6.64 13.298 101 226 43.2 2256 46.7 0.31 
12.76 6.932 125 203 38.8 1081 22.4 0.24 
16.8 5.273 208 263 50.3 983 20.3 0.3 
19.04 4.657 247 523 100 4127 85.4 0.25 
21.35 4.159 18 1 242 46.3 374 7.7 0.1 
22.66 3.921 145 229 43.8 1925 39.8 0.39 
23.76 3.742 128 271 51.8 185 1 38.3 0.22 
24.04 3.699 125 170 32.5 556 11.5 0.21 
27.47 3.245 89 137 26.2 1236 25.6 0.44 
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